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Fusobacterium necrophorum, a Gram negative, anaerobic bacterium, is a common cause of acute
pharyngitis and tonsillitis and a rare cause of more severe infections of the head and neck. At the
beginning of the project, there was no available genome sequence for F. necrophorum. The aim of
this project was to sequence the F. necrophorum genome and identify and study its putative
virulence factors contained using in silico and in vitro analysis. Type strains JCM 3718 and JCM 3724,
F. necrophorum subspecies necrophorum (Fnn) and funduliforme (Fnf), respectively, and strain ARU
01 (Fnf), isolated from a patient with LS, were commercially sequenced by Roche 454 GS-FLX+ next
generation sequencing and assembled into contigs using Roche GS Assembler. Sequence data was
annotated semi-automatically, using the xBASE pipeline, BLASTp and Pfam. The F. necrophorum
genome was determined to be approximately 2.1 – 2.3 Mb in size, with an estimated 1,950 ORFs
and includes genes for a leukotoxin, ecotin, haemolysin, haemagglutinin, haemin receptor, adhesin
and type Vb and Vc secretion systems. The prevalence of the leukotoxin gene was investigated in
strains JCM 3718, JCM 3724 and ARU 01, as well as a clinical collection of 25 Fnf strains, identified
using biochemical and molecular tests. The leukotoxin operon was found to be universal within the
strain collection by PCR. HL-60 cells subjected to aliquots of concentrated high molecular weight
culture supernatant, predicted to contain the secreted leukotoxins of strains JCM 3718, JCM 3724
and ARU 01, were killed in a dose-dependent manner. The cytotoxic effect of the leukotoxin against
human donor white blood cells was also tested to validate the HL-60 assay. The differences in the
results between the two assays were not statistically significant. Ecotin, a serine protease inhibitor,
was found to be present in 100 % of the strain collection and had a highly conserved sequence with
primary and secondary binding sites exposed on opposing sides of the protein. During enzyme
inhibition studies, a purified recombinant F. necrophorum ecotin protein inhibited human
neutrophil elastase, a protease that degrades bacteria at inflammation sites, and human plasma
kallikrein, a component of the host clotting cascade. The recombinant ecotin also prolonged human
plasma clotting times by up to 7-fold for the extrinsic pathway, and up to 40-fold for the intrinsic
pathway. The genome sequence data provides important information about F. necrophorum type
strains and enables comparative study between strains and subspecies. Results from the leukotoxin
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1.1.1 The Fusobacterium genus
The Fusobacterium genus contains Gram negative, non-motile, non-sporulating, rod-shaped
bacteria that are obligate anaerobes. They can be found in association with both humans and
animals, particularly in mucous membranes. In humans they can be found in the oral cavity,
gastrointestinal tract, female genital tract, periurethral areas and in necrotic lesions. In animals
such as cattle, horses, sheep, pigs, cats and dogs, they can be found in the gastrointestinal tract,
oral cavities and necrotic lesions. The genus contains three species clades: F. nucleatum, F.
periodonticum, F. russi, F. simiae and F. canifelinum, which form a group of oral species; F.
necrophorum, F. equinum and F. gonidiaformans which form a second clade which are
genealogically related, as are species F. varium, F. mortiferum, F. necrogenes, and F. ulcerans from
the third clade. The classifications are based on 16S rRNA homology and are supported by
phylogenetic analysis of a group of conserved proteins (Hofstad, 1998; Gupta and Sethi, 2014).
1.1.2 Fusobacterium spp. and associated disease
F. necrophorum, the focus of this study, is known to cause oropharyngeal disease, such as
pharyngitis and tonsillitis. It also causes more serious infections such as peritonsillar abscess and in
rare cases a systemic infection known as Lemierre’s syndrome, which includes symptoms such as
septicaemia and metastatic abscesses. (Batty and Wren, 2005; Eaton and Swindells, 2014; Kuppalli
et al., 2012; Lyle et al., 2011). F. necrophorum causes infections in both humans and animals
(Langworth, 1977) and it is debated whether the organism is a commensal in the human upper
2respiratory tract (Riordan, 2007). It is known to have several virulence factors that are implicated
in disease states in humans and animals (section 1.8).
Fusobacterium nucleatum is a commensal of the human oral cavity and is implicated in various
diseases, including periodontal infections, gastrointestinal disorders and adverse pregnancy
outcomes. F. nucleatum is also a causative agent of Lemierre’s syndrome (Han, 2015), although less
commonly so than F. necrophorum (Ridgway et al., 2010). F. nucleatum has been shown to be
enriched in colorectal cancer (Castellarin et al., 2012). Rubinstein et al. (2013) reported an
association of the organism’s FadA adhesin/invasin, a key virulence factor, with inflammatory and
oncogenic responses. F. nucleatum has also been isolated from infected cat and dog bite wounds
(Abrahamian and Goldstein, 2011).
F. equinum has been isolated from horses in both healthy and diseased oral cavities, lower
respiratory tract infections, paraoral abscesses, necrotising pneumonia and pleurisy. It was
designated as a new species by Dorsch et al. (2001) after previously being classified as F.
necrophorum. Like F. necrophorum, F. equinum has been found to have a leukotoxin gene and
exhibit leukotoxic activity (Tadepalli et al., 2008; Zhou et al., 2009b).
F. russi and F. gonidiaformans have also been isolated from cat and dog bite wounds (Abrahamian
and Goldstein, 2011), as has F. canifelinum (Conrads et al., 2004). F. necrogenes and F. mortiferum
have been isolated from human faeces, while F. russii and F. varium have been isolated from both
human and animal faeces. F. periodonticum may be found in patients with advanced periodontal
disease and F. gonidiaformans is implicated in human infections involving the respiratory tract,
genitourinary tract and gastrointestinal tract.
1.1.3 Historical review of F. necrophorum
The early literature of the organism now referred to as F. necrophorum is predominantly published
in French and German languages. It has, however, been reviewed in English by Riordan (2007) who
described how the organism was first reported in a case of calf diphtheria in 1884 by Löffler (1884)
and named Bacillus necrophorus by Flügge (1886). It was first isolated and cultured by Bang (1890)
3from a cattle liver abscess and the term nekrosebazillus (necrobacillosis) was coined, meaning
septicaemic or necrotic infection from which the organism now referred to as F. necrophorum is
isolated. In 1891 the first known human infections with the organism were described by Schmorl
(1891), when the author and fellow researchers developed finger abscesses during work on rabbits
with necrobacillosis. The first description of the organism Bacillus funduliformis, now referred to as
F. necrophorum subsp. funduliformewas of that isolated from a female genital tract by Hallé (1898).
In 1900 this was followed by what is thought to be the first description of human systemic infection
with F. necrophorum, by Courmont and Cade (1900) although it was not until 1936 that Lemierre
provided a clear clinical description of postanginal septicaemia associated with F. necrophorum
(Lemierre, 1936). This condition is now commonly referred to as Lemierre’s syndrome, however
this was not until the late 1980s, and the terms postanginal septicaemia and necrobacillosis were
previously used until then (Riordan, 2007).
There have been many other names used to describe F. necrophorum, including Bacillus
funduliformis, Bacteroides funduliformis, Necrobacterium funduliforme and Sphaerophorus
necrophorus (Duerden, 1990). The term Fusobacteriumwas introduced by Knorr (1923) and by 1974
all species of Sphaerophorus had been transferred to Fusobacterium, leading to the name
Fusobacterium necrophorum being in use today (Hofstad, 1998).
1.1.4 Focus of introduction
F. necrophorum is the causative agent of approximately 10 % of sore throats, as well as the rare but
severe systemic infection known as Lemierre’s syndrome (Batty and Wren, 2005; Aliyu et al., 2004).
The organism is not consistently screened for in patient throat swabs and its genome and virulence
factors have not yet been extensively studied.
This introduction focusses on F. necrophorum infections originating in the oropharynx of humans
and also covers microbiology of the organism, along with the epidemiology, pathogenesis and
virulence factors.
41.2 Description and definition of F. necrophorum
1.2.1 F. necrophorum subspecies
F. necrophorum is divided into two subspecies: F. necrophorum subsp. necrophorum (Fnn) and F.
necrophorum subsp. funduliforme (Fnf). This division was proposed by Shinjo et al. (1991) based on
the previous biovar classification. Biovar A, now referred to as Fnn, is more often associated with
animal infections than human infections and is assumed to be more virulent due to a greater
production of a leukotoxin and haemagglutinin than biovar B. Biovar B, now referred to as Fnf, is
mostly associated with infections of humans and is less virulent (Smith et al., 1990). The two biovars
were divided based on haemagglutinating activity (see section 1.8.4). Using a glass slide method
and chicken erythrocytes, biovar A was positive for haemagglutination and biovar B was not. DNA
homology was also used to confirm the results with a membrane filter and measuring radioactivity.
Percentage homologies were then assigned to strains in pairs, with strains of the same biovar
having high levels of homology compared to strains of the other biovar (Shinjo et al., 1991).
Smith and Thornton (1997) examined the biotypes of a collection of human and animal isolates
using pathogenicity tests in mice. Fourteen strains, all of animal origin, were classified as biotype A,
while 10 animal strains and 18 human strains were classified as biotype B. They determined that
biotype A strains caused necrobacillosis in animals but not humans, whereas biotype B strains were
found in both humans and animals. The evidence appears to support the view that Fnn strains are
the predominant pathogen in animals and Fnf strains are predominant in humans.
1.2.2 Phenotypic and biochemical profile
F. necrophorummay be cultured on several different agars, such as Columbia blood agar, Soy agar
and Brain-Heart infusion agar, enriched with yeast extract, vitamin K and hemin, or Brucella agar
(Markey et al., 2013; Brazier et al., 1990). However it is the opinion of Batty and Wren (2005),
Brazier (2006) and Syed et al. (2007) that F. necrophorum is best cultured on fastidious anaerobe
agar (FAA), supplemented with 5 – 10 % defibrinated horse blood. This is due to F. necrophorum
being a fastidious organism, and FAA provides a ready-made nutritious medium for the organism
5to grow, with cysteine as a specific growth promoting agent. Colonial characteristics vary slightly
between the subspecies, with Fnf colonies typically cream in colour, opaque, smooth and
umbonate/raised. Fnn colonies are typically grey in colour, semi-opaque, mottled and umbonate
with an irregular edge. F. necrophorum colonies are usually 1 – 4 mm in diameter, with Fnn at the
larger end of the scale and Fnf at the lower end of the scale. F. necrophorum strains are usually
haemolytic and exhibit a butyric acid odour (Hall et al., 1997; Batty and Wren, 2005; Barrow and
Feltham, 2004).
F. necrophorum is a Gram negative, obligately anaerobic, pleomorphically rod shaped bacterium
which is non-motile and non-sporulating (Langworth, 1977; Batty and Wren, 2005). Cell
morphology ranges from a coccobacillus shape to long filaments, and is dependent on the strain,
the age of the culture and the media used (Langworth, 1977; Markey et al., 2013). Commercial kits
such as the API rapid ID 32A, the RapID-ANA II and API 20A strip tests can be used to identify F.
necrophorum, although as many of the tests on each strip are negative, excluding the indole and
alkaline phosphate tests, it is often better to use specific tests when F. necrophorum is suspected
(Batty et al., 2005; Riordan, 2007).
F. necrophorum is known to produce lipase, an enzyme involved in the breakdown of triglycerides,
which is exhibited as an opalescent sheen on the surface of cultures grown on egg yolk agar (Batty
et al., 2005; Markey et al., 2013). F. necrophorum also produces tryptophanase enzymes, which
produce indole as a metabolite from tryptophan. This is examined using a spot indole reagent which
turns a green colour if indole is present (Batty et al., 2005). Under long wave ultra-violet (UV) light
(365 nm), F. necrophorum colonies fluoresce a green-yellow colour, and where gas chromatography
facilities are available, propionic acid and butyric acid can be detected (Barrow and Feltham, 2004).
1.2.3 Species and subspecies identification using molecular techniques
In addition to using biochemical techniques to identify F. necrophorum strains, molecular
techniques have been developed that are faster and more sensitive than traditional culture
techniques. This is discussed in detail in chapter 3. Briefly, PCR primers specific to the 16S rRNA
6gene, the RNA polymerase (rpo) B gene and the gyrase (gyr) B gene of F. necrophorum have been
used to identify the species by Oikonomou et al. (2012), Aliyu et al. (2004) and Jensen et al. (2007),
respectively. In order to identify to the subspecies level, real-time PCR assays using subspecies-
specific TaqMan probes targeting the rpoB and gyrB genes have been designed and used by Aliyu
et al. (2004) and Jensen et al. (2007), respectively.
1.3 Is F. necrophorum a commensal or pathogen?
It is a matter of debate whether F. necrophorum is a component of the normal flora of the upper
respiratory tract in humans. In a review by Riordan (2007) it is discussed whether it can be
considered normal flora based on a meta-analysis of all available relevant publications. It was noted
that in some studies confirming the presence of F. necrophorum in healthy individuals, the primary
evidence was unclear, by often referring to the isolation of Fusobacteria with no mention of which
species. In other cases, such as the highly cited paper by Hallé (1898), it was concluded that F.
necrophorum (then Bacillus funduliformis) is a commensal, despite not being isolated from any of
the healthy subjects in the study (Riordan, 2007). Batty et al. (2005) commented that following their
own extensive search of the literature, there appeared to be no evidence that F. necrophorum is a
commensal in the human oral cavity.
Recent investigations into this issue have increasingly used molecular techniques. For example, as
part of a study discussed further in section 1.4.1, Aliyu et al. (2004) used real-time PCR to investigate
the presence of F. necrophorum in 100 healthy control throat swabs and found all were negative.
However Jensen et al. (2007) carried out a similar investigation (also discussed further in section
1.4.1) using real-time PCR and examined throat swabs from 92 healthy controls for the presence of
F. necrophorum. Fnf was found to be present in 21 %.
Jensen et al. (2007) and Aliyu et al. (2004) both used real-time PCR, although with different primers
and probes to target different genes. The differences between the F. necrophorum isolation rates
from the healthy control samples are quite striking. There is a possibility that the sampling methods
7varied, with one method sampling deeper into the tissue than the other. Or perhaps there were
problems with the primers such as non-specificity, or mismatches with the target gene. Jensen et
al. (2007) also tried to culture F. necrophorum from the swabs, however all of the healthy control
swabs were culture-negative. They attributed this to a poor standard of agar and to low numbers
of F. necrophorum present on healthy tonsils. It was also suggested that the low numbers of F.
necrophorum is likely to be due the organism being present predominantly deep in the tonsillar
crypts of healthy individuals, as opposed to on the surface, which is likely to occur with inflamed
and infected tonsils.
A large-scale study into the carriage of F. necrophorum in healthy individuals would be of great
value in understanding whether F. necrophorum is a commensal of the human upper respiratory
tract. If the organism is not a commensal, then it must be referred to as a pathogen. While F.
necrophorum is generally referred to as a commensal, sometimes without reference, this is not
always the case. Recently, Eaton and Swindells (2014) suggested that F. necrophorum should be
regarded as a true pathogen rather than a commensal and Yusuf et al. (2015) also describe the
organism as a primary pathogen and suggest that it is not a commensal in the oral flora, based on
their own interpretations of the literature.
It has been suggested that food and water contaminated with animal faeces are sources of F.
necrophorum infection in impoverished and malnourished children, particularly with poor oral
hygiene (Enwonwu et al., 1999). Perhaps close contact with animals such as livestock and pets could
be a source of infection in developed countries. This is discussed further in section 1.7.1.
F. necrophorum is considered to be a commensal of the gastrointestinal, respiratory and
genitourinary tracts of animals such as cattle (Narayanan et al., 1997; Tadepalli et al., 2008b).
Animal infections are briefly discussed in section 1.5, however are mostly beyond the scope of this
literature review.
81.4 F. necrophorum infectious disease
1.4.1 Pharyngitis and tonsillitis
Pharyngitis, also known as sore throat, and tonsillitis are the inflammation of the pharynx and
tonsils, respectively (Public Health England, 2015; Thibodeau and Patton, 1997). The pharynx is
divided into three sections: the nasopharynx, oropharynx and laryngopharynx (Figure 1). The
oropharynx, situated below the nasopharynx and above the laryngopharynx, is the region at the
back of the throat (Thibodeau and Patton, 1997) and is lined by stratified squamous epithelium
(Perry and Whyte, 1998). The palatine tonsils are situated either side of the back of the throat and
are comprised of mucosa-associated lymphoid tissue and contain crypts that greatly increase their
surface area (Barnes, 2000; Perry and Whyte, 1998). They sit within a capsule that provides blood
vessels and nerves (Galioto, 2008).
Figure 1: Sagittal view diagram of the location of the pharynx and tonsils. Source: (Merck Manuals Professional Edition,
2015).
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adenovirus, Epstein-Barr virus, and also common cold viruses such as rhinovirus and coronavirus
(Barnes, 2000; Bird et al., 2014). One of the most commonly implicated bacteria is Streptococcus
pyogenes, an aerotolerant anaerobe, also known as group A β-haemolytic streptococcus. Aerobic
bacteria isolated from cases of pharyngitis and tonsillitis include β-haemolytic streptococcus groups
C and G, and Corynebacterium diphtheriae (Batty and Wren, 2005; Public Health England, 2015).
Anaerobic bacteria are also implicated in throat infections. Increased numbers of anaerobes have
been found to be present in chronic throat infections and anaerobes have been isolated from the
cores of tonsils of children and adults with recurrent tonsillitis, in some cases with no aerobes
present. Pigmented Prevotella and Porphyromonas, Fusobacterium and Actinomyces spp. are the
anaerobic organisms that have been associated with tonsillitis and it has been suggested that they
play a role in acute inflammatory processes in the tonsils (Brook, 2005).
Symptoms of pharyngitis include a sore throat, redness, difficulty swallowing, fever, malaise and a
headache (Thibodeau and Patton, 1997; Public Health England, 2015). Symptoms of tonsillitis are
similar, and may also include swelling of the tonsils, swollen lymph nodes in the neck, and exudate
on the tonsils (Barnes, 2000). F. necrophorum is known to cause sore throats, persistent sore throat
syndrome (PSTS), recurrent and persistent pharyngitis and tonsillitis (Batty and Wren, 2005; Eaton
and Swindells, 2014). Incidence of F. necrophorum infections is discussed in section 1.6.1.
Batty and Wren (2005) investigated the presence of F. necrophorum in patient throat swabs using
culture techniques. Two hundred and forty eight samples with clinical diagnoses of sore throat,
tonsillitis and PSTS were tested; of those 24 (approximately 10 %) were positive for F. necrophorum.
F. necrophorum was noted to be the most frequently isolated pathogen from a clinical diagnosis of
PSTS. It was further noted that due to the lack of detail from the clinician, some cases may have
been categorised as sore throat when they should have been in the PSTS group. F. necrophorum
incidence in this cohort increased with age (section 1.6.2). It was suggested that this may be due to
patients acquiring an infection that persists, and therefore leads to the prevalence experiencing a
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cumulative effect. This study shows a strong link between F. necrophorum and PSTS, although no
control group of healthy throat swabs were included.
Aliyu et al. (2004) investigated F. necrophorum as the cause of a simple sore throat using real-time
PCR targeting the RNA polymerase B gene. One hundred throat swabs from a clinical diagnosis of
pharyngitis were analysed and compared to 100 healthy control throat swabs (previously
mentioned in section 1.3). Ten percent of the patient swabs were positive for F. necrophorum
subspecies funduliforme while all of the healthy controls were negative. The results are a strong
indication that F. necrophorum is implicated in some cases of pharyngitis. The 10 % incidence rate
of F. necrophorum matches that found by Batty and Wren (2005), as discussed in the previous
paragraph.
Jensen et al. (2007) examined throat swabs from 61 patients with non-streptococcal tonsillitis and
92 healthy controls (previously mentioned in section 1.3) for the presence of F. necrophorum. A
real-time PCR assay was developed using TaqMan probes in order to detect both subspecies of F.
necrophorum via the gyrase B gene. Forty eight percent of tonsillitis patients were positive for F.
necrophorum, compared to 21 % of healthy controls. They concluded that tonsillitis and particularly
recurrent tonsillitis may be caused by F. necrophorum present in large numbers. These prevalence
rates are much higher than those found by Batty and Wren (2005) and Aliyu et al. (2004). The
culture techniques are likely to be less sensitive than real-time PCR techniques. Culturing
techniques require careful sampling, storage, transport and culturing conditions to meet the
fastidious requirements of F. necrophorum. In contrast, PCR techniques do not require the organism
to be viable and can detect small amounts present. The potential reasons for the difference in
results between Jensen et al. (2007) and Aliyu et al. (2004) are discussed in section 1.3. It is unclear
whether these F. necrophorum infections of pharyngitis and tonsillitis are due to the organism




Peritonsillar abscess (PTA), also known as quinsy, is an acute infection that develops between the
palatine tonsil and its capsule. In addition to an abscess in the peritonsillar region, symptoms of
PTA may also include: sore throat, fever, malaise, uvula deviation, jaw muscle spasm, neck mass
and tenderness in the neck (Hsiao et al., 2012). It is thought that PTA may develop as a complication
of an existing infection within the tonsils (Jousimies-Somer et al., 1993), with an established
infection spreading from the tonsil through local tissue resulting in further tissue damage and
subsequent abscess formation (Powell et al., 2013). An alternative theory states that damaged
tissue in the peritonsillar region may be associated with abscess formation (Galioto, 2008; Powell
et al., 2013). Salivary glands, known as Weber glands, located in the supratonsillar space help to
keep the tonsils and surrounding area clean (Passy, 1994; Powell et al., 2013). The saliva excreted
from the glands washes the area and contains antimicrobial peptides which help to control the oral
flora (Ball et al., 2007). It has been hypothesised that damage to these glands, resulting in scarring,
inflammation and blockage, may lead to PTA (Passy, 1994). It has been suggested that the latter
theory may supersede the former (Galioto, 2008). Powell et al. (2013) states that PTA and acute
tonsillitis are distinct infections and describe how oral hygiene, smoking, antibiotic use and other
host factors may play a role in triggering pathogenesis. Focussing on controlling these host factors
may enable some degree of PTA prevention.
PTA are mostly polymicrobial with Prevotella, Porphyromonas, Fusobacterium and
Peptostreptococcus spp. the most predominant anaerobic organisms. Streptococcus pyogenes,
Staphylococcus aureus and Haemophilus influenzae are also predominant organisms within PTA.
Anaerobes are almost ubiquitous in these abscesses (Brook, 2005). F. necrophorum is known to be
a cause of tonsillar and peritonsillar abscesses (Batty and Wren, 2005).
Yusuf et al. (2015) carried out a 10 year epidemiology study by retrospectively reviewing patient
records and associated microbiological data from 2004 to 2014. They found that of 27 peritonsillar
abscesses, F. necrophorum was isolated as the major pathogen from 25 of them (92.6 %).
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Klug et al. (2009) also conducted a retrospective study, investigating all patients at a Danish hospital
with peritonsillar abscess from 2001 to 2006, totalling 847 patients. F. necrophorum was isolated
from 23 % of cultures, making it the most frequently detected bacteria, above group A Streptococci
at 17 %. Eighty one percent of the F. necrophorum cultures were pure. The isolation rate of 23 % is
much smaller than the rate of 92.6 % reported by Yusuf et al. (2015), however the higher isolation
rate came from a much smaller sample size.
Jousimies-Somer et al. (1993) investigated pus samples from 124 patients with peritonsillar
abscesses and isolated F. necrophorum from 38 % of samples. Those infected with F. necrophorum
had the highest rate of previous tonsillar or peritonsillar infections (52 %) and had the highest rate
of recurrent infections (57 %). Of 15 cases that isolated only anaerobic cultures, 14 contained F.
necrophorum, and three of these were pure cultures. This suggests that F. necrophorum is strongly
associated with peritonsillar abscesses.
Riordan (2007) noted that PTA was previously seen as a precursor for Lemierre’s syndrome
(Lemierre, 1936) however Riordan found PTA in only 7 % of Lemierre’s syndrome cases reviewed.
There are several routes of infection F. necrophorum may spread (discussed in section 1.7.4), and
it appears as if causing PTA is not a prerequisite for Lemierre’s syndrome, as previously suggested.
1.4.3 Lemierre’s syndrome
Lemierre’s syndrome (LS) is a severe and life threatening infection in humans that is characterised
by oropharyngeal infection, primarily in the palatine tonsils and pharynx (Chirinos et al., 2002),
thrombophlebitis of the internal jugular vein, metastatic abscesses and septicaemia. The metastatic
abscesses are typically located in the lungs and large joints, however abscesses may also occur in
the liver and spleen (Batty and Wren, 2005; Kuppalli et al., 2012; Lyle et al., 2011). A description of
the spread of LS is provided in section 1.7.4. F. necrophorum is the organism most commonly
isolated from cases of LS (Bennett and Eley, 1993; Golpe et al., 1999; Ridgway et al., 2010). Riordan
(2007) reported that in 222 LS cases, identified by searching French and English language literature
since 1970, an organism other than Fusobacteria was isolated in only 8 % of cases. The other species
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implicated include those of Bacteroides, Peptostreptococcus, Prevotella, Porphyromonas, Eikenella,
Enterococcus, Proteus and Streptococcus. LS typically affects children, adolescents and young adults
who were previously healthy (Lyle et al., 2011) and tends to occur in the winter months, during the
season of sore throats, common colds and flu (see section 1.6 for epidemiology).
1.4.4 Other head and neck infections
Of the anaerobic infections that originate in the head and neck, approximately half involve
Fusobacterium spp. (Brook, 2015). F. necrophorum infection is not required to begin in the pharynx
or tonsils in order for a diagnosis of LS. Infections may also originate in the ears, mastoids and teeth
(Hagelskjær et al., 1998). Hagelskjær et al. (1998) reported that in 49 cases of F. necrophorum
septicaemia, half were not related to the oropharynx, including eight originating in the
gastrointestinal tract, five in the genitourinary tract and seven from skin infections.
1.4.4.1 Otogenic infection
Otitis media is an infection of the middle ear. In a study by Yusuf et al. (2015), F. necrophorum was
found to be the major pathogen in 60 % of acute otitis cases. Mastoiditis is a suppurative infection
of the mastoid bone. The bone sits behind the ear and is comprised of air spaces that help drain the
middle ear. Mastoiditis can often follow otitis media (Yarden-Bilavsky et al., 2013). Riordan (2007)
reports that of the patients with F. necrophorum ear infections, 69 % of them also had mastoiditis.
1.4.4.2 Odontogenic infection
F. necrophorum does not typically cause dental infections, as it primarily infects the pharynx and
tonsils, rather than dental cavities (Brook, 2005; Eaton and Swindells, 2014), therefore LS
originating from a dental infection is rare (Riordan, 2007). However, there are cases such as that
reported by Ali et al. (2003) where a patient received dental work three weeks prior to the onset of
LS, with blood cultures positive for F. necrophorum.
Noma, also known as cancrum oris, is a form of gangrene affecting the face that causes facial
deformity, oral stenosis, trismus and death in 70 – 90 % of untreated cases (Falkler et al., 1999;
Enwonwu et al., 1999). F. necrophorum, thought to be acquired via animal faecal matter
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contamination, is known to be implicated in noma infections and is thought to be involved in tissue-
destruction that helps the lesion to spread. Noma infections typically only occur in children who are
immunocompromised, malnourished and have poor oral hygiene. It is particularly prevalent in sub-
Saharan Africa (Enwonwu et al., 1999).
1.4.4.3 Deep neck space infection
Deep neck infection, or sepsis in the neck, may include symptoms such as fever, swelling and pain
in the neck, sore throat, difficulty swallowing with pain associated, trismus and stridor (Lyle et al.,
2011). It commonly begins as odontogenic or oropharyngeal infection (Pinto et al., 2008) and from
there may spread throughout the fascial spaces of the neck (Lyle et al., 2011). F. necrophorum is
known to be capable of causing serious deep neck space infections, spreading through the fascial
spaces in the head, neck and around the lungs, potentially also causing abscesses in these regions
(Jousimies-Somer et al., 1993; Chow, 1992).
1.4.5 Bacteraemia
It is possible for patients to have F. necrophorum bacteraemia without necessarily having LS. For a
diagnosis of LS, thrombophlebitis of the internal jugular vein and metastatic abscesses would also
need to be present (Kuppalli et al., 2012; Batty and Wren, 2005). Centor et al. (2010) reports on
cases of bacteraemic tonsillitis and describe the symptoms as including fevers, vomiting, rigors and
sweating. It was noted that prompt admission to hospital and early antimicrobial treatment was
linked with a lack of metastasis. Improved diagnosis techniques, leading to faster administration of
appropriate antimicrobial treatment may therefore reduce the incidence of LS by limiting the
progression of the infection at the onset of bacteraemia, if not before.
1.4.6 Metastatic abscesses, joint infections and complications of LS
Metastatic abscesses are a symptom of LS and may be located in the lungs, large joints, liver and
spleen (Kuppalli et al., 2012; Batty and Wren, 2005). In a review by Riordan (2007), where 222 cases
of LS were studied (discussed previously in section 1.4.3), it was reported that pleuropulmonary
lesions, the most common metastatic complication, occurred in 92 % of cases, while empyema, the
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collection of pus and fluid particularly in the pleural cavity, occurred in 17 % of cases reviewed.
Septic emboli have been described as typical lesions present in LS, and are often part of the
inclusion criteria for diagnosis (Riordan, 2007; Lu et al., 2009). Mild disseminated intravascular
coagulation (DIC) with thrombocytopenia is another potential complication of LS, reportedly
developing in up to 23 % of cases (Hagelskjaer Kristensen and Prag, 2000). Riordan (2007) agrees
that thrombocytopenia is not uncommon, however states that DIC only occurred in 4 % of LS cases
reviewed. Other reported rates were septic shock developing in 7 % of cases and renal failure in 2
%. The prevalence of abscesses in the joints, liver and spleen were 9.5 %, 5 % and 3.6 % of LS cases,
respectively (Riordan, 2007).
1.5 F. necrophorum infections in animals
F. necrophorum is not only an infectious agent for humans, but is also the cause of necrobacillosis
in animals (Langworth, 1977). It is implicated in liver abscesses and footrot in cattle and sheep (Zhou
et al., 2009a). Nagaraja et al. (2005) describe these infections, stating that liver abscesses are the
most common F. necrophorum infection in cattle, and that infection tends to begin in the rumen
and spread via septic emboli to the liver. Footrot, also known as interdigital necrobacillosis, is a
necrotising infection of the soft tissues on the feet and surrounding skin which often leads to fever
and lameness in cattle and other hooved livestock. Damp ground and existing injury to the
interdigital skin region are predisposing factors. It is thought that the primary source of infection is
faecal secretion. F. necrophorum also causes calf diphtheria, also referred to as necrotic laryngitis,
and mastitis in cattle (Tan et al., 1996).
These infections have a large economic effect on the farming industry and also concern the welfare
of the animals. As a result of this, the majority of research carried out on F. necrophorum so far is
centred on the bacterium being predominantly an animal pathogen. Riordan (2007) describes the
bacterium as a more common and important pathogen in animals than in humans. However,Wright
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et al. (2012) describe this as a historical view, highlighting the increasing importance of the infection
in humans.
1.6 Epidemiology of F. necrophorum
1.6.1 Incidence
As discussed in section 1.4.1, Batty and Wren (2005) reported the incidence of F. necrophorum
among patients diagnosed with sore throat, tonsillitis and PSTS as 10 %. Aliyu et al. (2004) also
reported an incidence rate of 10 % among cases of pharyngitis compared to 0 % for healthy controls.
Jensen et al. (2007), however, reported an incidence rate of 48 % for tonsillitis swabs, compared to
21 % of healthy controls and Centor et al. (2015) found a F. necrophorum detection rate of 20.5 %
for patients compared to 9.4 % for asymptomatic controls using PCR methods. F. necrophorum is a
significant cause of sore throat, tonsillitis and PSTS and should therefore be routinely screened for
in laboratories receiving throat swabs (Batty and Wren, 2005).
The incidence of F. necrophorum in PTA appears to be higher, with Yusuf et al. (2015) reporting an
incidence rate of 92.6 %, as discussed in section 1.4.2. However, Jousimies-Somer et al. (1993)
reported an isolation rate of 38 % and Klug et al. (2009) reported an isolation rate of 23 %. The
mean annual incidence in Denmark of PTA was calculated as 41 cases per 100,000 population (Klug
et al., 2009).
Lemierre’s syndrome is rare, with a reported incidence of 0.9 cases per million inhabitants per year
in the southwest of England between 1994 and 1999 (Jones et al., 2001). Other reports give an
estimate of between 0.6 and 2.3 per million inhabitants per year based reviewing medical literature
(Syed et al., 2007). Hagelskjær Kristensen and Prag (2008) reported the incidence in Denmark as
3.6 cases per million inhabitants per year based on a study between 1998 and 2001. When broken
down by age group per year, the incidence was reported as 14.4 cases per million 15 – 24 year olds
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for the study duration. It was estimated by Centor (2009) that 1 in 400 F. necrophorum pharyngitis
cases will progress to LS.
Eaton and Swindells (2014) suggested that rural communities may experience lower incidences of
F. necrophorum infection, following their observation that the F. necrophorum isolation rate of 5.6
% from sore throat swabs during their study was lower than rates observed in London by Batty and
Wren (2005) (section 1.4.1). Karkos et al. (2009) reported that 10 % of acute sore throats and 21 %
of recurring sore throats were attributed to F. necrophorum.
1.6.2 Age distribution
Batty and Wren (2005) plotted, in 10 year increments, the patient age distribution from all throat
swabs containing F. necrophorum or group A streptococcus (GAS). They showed a steady increase
in F. necrophorum incidence with age up to 40 years, starting with an isolation rate of <4 % for the
0 – 10 years category, increasing to almost 18 % for the 31 – 40 years category. The GAS prevalence
remained fairly stable throughout, between 10 and 15 %.  For the 41 – 50 age group, the prevalence
of both fell to approximately 4 %. In the 10 year epidemiological study by Yusuf et al. (2015), the
median age of all F. necrophorum infections was 19. Broken down into groups, the median age for
acute tonsillitis was 30, peritonsillar abscess was 27 and acute otitis was 3 years of age.
LS typically affects previously healthy infants and adolescents (Lyle et al., 2011). Riordan (2007)
noted that among LS patients, 89 % were aged between 10 and 35 years and the median age was
19 years. Ridgway et al. (2010) describe that 70 % of LS cases are in the 16 – 25 year old group. This
is in agreement with Brazier et al. (2002) who noted the peak age range for F. necrophorum
bacteraemia is between 16 and 23 years old. They also describe those over 65 as having the next
highest incidence rate. Those over the age of 65 are more likely to have a weaker immune system
which could explain the peak in incidence for that age group. As for the peak age range between
16 and 23 years, this could be related to the similar peak age range for Epstein-Barr virus infections
(Brazier, 2006). There may be symbiotic relationship between the virus and bacterium, or it could
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be that simply close mouth-to-mouth contact between individuals in that age group leads to
increased transmission of the bacterium and therefore higher rates of infection.
1.6.3 Sex ratio
F. necrophorum infections tend to be more common in males than females, according to Brazier et
al. (2002), who showed that 68 % of F. necrophorum bacteraemia cases in England and Wales were
male. Hagelskjær et al. (1998) demonstrated that, in Denmark, two thirds of Lemierre’s syndrome
cases with tonsillitis as the primary focus were male. Riordan (2007) also discusses the male
predominance, although suggests no explanation. This does not always appear to be the case,
however, with a strong female predominance of 74 % in a Swedish study by Björk et al. (2015).
1.6.4 Seasonal and geographical distribution
A seasonal variation in the number of cases of F. necrophorum infections have been reported on a
number of occasions. Brazier et al. (2002) noted a peak in incidence in England and Wales from
January to March. Eaton and Swindells (2014) reported that during their UK study the peak in
incidence was between April and June. A slight seasonal variation was reported by Hagelskjær
Kristensen and Prag (2008) in Denmark, with peaks occurring during late winter and early autumn
months. Riordan (2007) states that reports of infections are mostly from Europe and North America,
suggesting ethnic group and geographical area play a role in the incidence. This could be due to
genetic differences between ethnic groups that affect the bacteria’s ability to cause an infection.
These may be similar factors to those pertaining to greater numbers of infections in males
compared to females. Alternatively, differing methods of detecting and reporting cases may be the
cause of this geographical variation in incidence.
1.6.5 Factors causing increase in incidence
Lemierre’s syndrome had become the forgotten disease (Hagelskjaer Kristensen and Prag, 2000)
following the introduction of penicillin treatment in the 1940s, however an increase in cases has
been reported in several publications more recently. Batty and Wren (2005) noted the increase in
isolation rate of F. necrophorum from patients in the accident and emergency department. This rise
19
is supported by Brazier (2006) who reported an increase in the number of F. necrophorum
bacteraemia referrals to the Anaerobe Reference Unit. Hagelskjær et al. (1998) also reported the
increase in the incidence of cases over time. A review of medical literature containing Lemierre’s
syndrome as the key word by Karkos et al. (2009) found an increase in the number of relevant
articles over time, from six between 1980 and 1990, 50 between 1991 and 2000, and 121 between
2001 and 2008. Several articles discuss the reasons for this alleged increase in incidence, suggesting
reasons such as a reduction in the number of tonsillectomies and a reduction in antibiotic
prescriptions for cases of sore throats (Kuppalli et al., 2012; Wright et al., 2012; Brook, 2015).
Additional suggestions were an increase in awareness of F. necrophorum infections and population
changes in areas that have seen an increase (Wright et al., 2012). An improvement in laboratory
techniques regarding methods for blood culture, isolation and identification of anaerobic
organisms, and the use of more sensitive detection methods, such as polymerase chain reaction
were also suggested as reasons for an increase in reported incidence (Brook, 2015). There is a
possibility that the importance of F. necrophorum as a pathogen has been greatly underestimated
for some time and the improvement of techniques and reporting has led to the perceived increase
in incidence. Alternatively, incidence could indeed be increasing. Surveillance of the organism
would be beneficial in order to track incidence and changes to the organism.
1.6.6 Mortality
Lemierre’s syndrome is associated with high morbidity and mortality, often due to delays in
diagnosis (Lyle et al., 2011). For patients who do not receive treatment for LS the mortality rate is
up to 90 % (Wright et al., 2012). However for those who do receive treatment (section 1.10) there
is usually a full recovery (Brazier et al., 2002). Karkos et al. (2009) reported a mortality rate of 5 %
among patients who had received treatment for LS, while Centor (2009) reviewed several case
series and reported a rate of 4.6 %. Hagelskjær Kristensen and Prag (2008) reported a mortality rate
of 9 % for LS, however the mortality rate for disseminated F. necrophorum infections was 26 %. The
median age for these two groups was 20 and 66, respectively. The variation in mortality rates
between these groups may be due to the group with disseminated infection containing
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predominantly elderly patients, who may have weakened immune systems, leading to a higher risk
of death from the organism.
1.7 F. necrophorum Pathogenesis
1.7.1 Source of infection
The source of F. necrophorum infection is unknown as it is unclear whether the organism is a
commensal or primary pathogen (section 1.3) (Riordan, 2007). If a commensal, then F. necrophorum
is present in the oropharynx but may potentially cause infection as a primary pathogen (Chirinos et
al., 2002), or opportunistically as a secondary invader (section 1.7.3). In either case the mucosal
tissue may previously be compromised due to other factors. If F. necrophorum is not a commensal
then the source of infection is less clear. Human-to-human transmission is thought to be possible,
following close contact between a carrier and susceptible individuals (Batty et al., 2005). Aside from
intimate contact such as kissing, sharing a toothbrush may also potentially transmit the organism
between individuals (Riordan, 2007). It is known that F. necrophorum is present in the
gastrointestinal tracts of animals, such as cattle (Narayanan et al., 1997), and therefore it may be
possible that infection may occur via the faecal-oral route due to contamination from animal faeces,
as previously mentioned in section 1.3.
1.7.2 Host factors
Certain host factors may enable F. necrophorum to invade more easily, such as the age and gender
of an individual, as discussed in section 1.6.2 and 1.6.3. The health of the oral mucosa is likely to be
important. If the mucosal barrier is compromised or damaged due to an existing or previous
infection, or trauma from an injury or surgery, then it will be easier for F. necrophorum to invade
and establish an infection (Brook, 2015; Syed et al., 2007; Riordan, 2007). Oral/dental hygiene is
important in order to maintain a healthy microflora and to prevent periodontal disease. The oral
microflora may be disrupted by the use of antibiotics and subsequently allow colonisation by a
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pathogen, such as F. necrophorum (Powell et al., 2013). Smoking has also been linked to an
increased risk of respiratory infections by damaging the normal oral microflora and mucosal barrier,
acting synergistically with bacterial toxins and compromising the inflammatory response and the
functioning of leukocytes (Bagaitkar et al., 2008). Variations in the immune systems and genetics
between individuals may affect the level of protection against F. necrophorum infection (Powell et
al., 2013).
1.7.3 Coinfection
Brook (2015) speculates that adhesion and invasion are possibly dependent on co-infection with
viruses such as Epstein-Barr. Eaton and Swindells (2014) also suggest that viral co-infection may be
a precursor for invasive F. necrophorum disease. This is supported by the overlap in peak ages of LS
and Epstein Barr virus (Brazier, 2006), as discussed in section 1.6.2, and the peak in cases during
the winter months coinciding with the common cold and influenza season, which could suggest
more individuals are immunocompromised and therefore prone to infection, or that F.
necrophorum is capable of coinfection with viruses present in the throat. Batty et al. (2005) suggest
that the bacteria is acquired simultaneously with infectious mononucleosis. There have also been
reports regarding coinfection and synergy between group A β-haemolytic streptococcus and other
aerobic and anaerobic bacteria involved in mixed tonsillitis infections (Brook and Gillmore, 1996).
1.7.4 Spread from tonsil to vein
F. necrophorum infections will most commonly cause only a primary infection of pharyngitis or
tonsillitis, however these infections may be persistent or recurrent (Batty and Wren, 2005). In rare
cases, F. necrophorum infection may progress to LS, which is thought to occur in a series of stages
(Figure 2) most commonly beginning in the tonsils and pharynx (Chirinos et al., 2002). Following
initial infection the organism may invade the lateral pharyngeal space, the peritonsillar vein and the
internal jugular vein (Ridgway et al., 2010; Chirinos et al., 2002). The organism may progress to
cause bacteraemia, septic emboli and subsequently metastatic complications. Complications may
be pertaining to cardiovascular, neurological, pulmonary, musculoskeletal, liver and renal systems
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(Ridgway et al., 2010). The exact pathogenic mechanisms of F. necrophorum attachment, invasion,
proliferation and host evasion, along with host inflammation and coagulation initiation mechanisms
have not yet been explained. Inflammation may cause disruption to local tissue that promotes
invasion (Wright et al., 2012) whilst damage to the mucocutaneous barrier may also allow for
Fusobacterial invasion (Brook, 2015).
Figure 2: Clinical progression of Lemierre’s syndrome following primary infection of the throat and/or tonsils with F.
necrophorum.
1.8 Virulence factors of F. necrophorum
The human body has evolved innate and adaptive host defence mechanisms to protect itself from
invading pathogens. Epithelial cells contributing to the oral mucosa provide a physical barrier, while
also producing and secreting inflammatory cytokines and antimicrobial peptides. Mucous provides
an extra barrier, assisting in the prevention of bacterial adherence and penetration into the tissue
and bloodstream. Mucous contains lysozyme, which digests peptidoglycan found in bacterial cell
walls, and lactoferrin, which prevents the growth of bacteria by sequestering iron (Wilson et al.,
2011). Immunoglobulins are also present and can identify and neutralise potentially pathogenic
material, while saliva is also thought to contribute to the defence process by containing receptors
to lipopolysaccharide present on the bacterium (Sugawara et al., 2002). There are also a variety of
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immune cells which defend against invading bacteria by phagocytosis. These include
polymorphonuclear cells (PMNs), monocytes, macrophages and dentritic cells and they ingest and
kill bacteria. They do this with the help of complement proteins and cytokines. Complement
proteins label bacteria for phagocytosis and also attract PMNs to the site of infection. Cytokines
also provide cell signalling to PMNs (Wilson et al., 2011). There are several putative virulence factors
which may be utilised by F. necrophorum to enable it to colonise more effectively and to avoid these
host defence mechanisms.
1.8.1 Leukotoxin
Many bacteria produce and secrete soluble proteins known as exotoxins that enter host cells and
alter the physiology to cause pathological effects (Barbieri, 2009). A type of toxin, referred to as a
leukotoxin is produced by F. necrophorum (Tadepalli et al., 2008a) and is toxic against leukocytes,
particularly PMNs (Narayanan et al., 2002a). It is believed to be the main virulence factor of this
species (Tan et al., 1994a). The killing of these PMNs prevents the invading bacteria from being
engulfed and therefore allows them the opportunity to establish an infection. The leukotoxin is
discussed further in chapter 5.
1.8.2 Endotoxin
Endotoxic lipopolysaccharide (LPS) is a bacterial membrane component that consists of a
polysaccharide chain, known as the O-antigen, and a toxic lipid segment, known as Lipid A, that is
released upon bacterial lysis (Caroff and Karibian, 2003). The lipid segment interacts with host
macrophages and neutrophils and promotes the uncontrolled secretion of proinflammatory
cytokines and nitric oxide resulting in endotoxic shock (Wilson et al., 2011). LPS is present in the
outer membrane of F. necrophorum and has been shown to be lethal to mice and rabbits (Tan et
al., 1996). It is thought to induce disseminated intravascular coagulation and be involved in abscess
formation by creating an anaerobic microenvironment (Nagaraja et al., 2005). According to Garcia
et al. (1998), Fnn and Fnf contain endotoxin lipid A in a 4:1 ratio, respectively, which may have some
relevance in relation to levels of virulence, considering that lipid A is toxic.
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1.8.3 Haemolysin
Haemolysins are a type of pore-forming toxin that damage the membrane of the host cell (Wilson
et al., 2011). They are cell-associated, extracellular proteins that lyse erythrocytes (Nagaraja et al.,
2005). F. necrophorum is known to produce a haemolysin that is thought to help the organism to
increase iron acquisition from the host, which stimulates bacterial growth. It has also been
suggested that it may also reduce the transportation of oxygen to the infection site, thus making
the environment more anaerobic (Tan et al., 1996; Nagaraja et al., 2005). When F. necrophorum is
grown on agar, β-haemolysis can usually be observed around the colonies (Batty and Wren, 2005).
1.8.4 Haemagglutinin
Haemagglutinin causes the clumping of red blood cells. It is produced by F. necrophorum and is
thought to be a cell wall associated protein (Nagaraja et al., 2005; Kanoe et al., 1997). Tan et al.
(1996) discuss the purification and characterisation of the F. necrophorum haemagglutinin by Nagai
et al. (1984) and describe it as filamentous and having a molecular weight of 19 kDa. PCR primers
specific for the haemagglutinin gene in Fnn have been used to subspeciate strains of F.
necrophorum (Kumar et al., 2013; Aliyu et al., 2004). It is unclear whether this method was chosen
due to an understanding that Fnf strains lack the gene or due to strict specificity of the primers.
However, a haemagglutination test using chicken red blood cells in vitro has been used to
subspeciate strains also, with only Fnn causing haemagglutination (Narongwanichgarn et al., 2001).
This is suggestive of Fnf strains either lacking the gene, or lacking sufficient haemagglutinin on the
cell surface to cause clumping. Haemagglutinin also mediates attachment to host cells (Nagaraja et
al., 2005) which is likely to assist the organism in establishing an infection.
1.8.5 Adhesins and invasins
Forming an attachment to the mucosal surface of the host is key to pathogenesis (Riordan, 2007).
As mentioned in section 1.8.4, the F. necrophorum haemagglutinin is thought to be one mechanism
that mediates F. necrophorum attachment to host cells (Nagaraja et al., 2005). In addition to this,
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it has been suggested that the organism possesses fimbriae, also known as pili, in order to aid
attachment (Riordan, 2007; Miyazato et al., 1978).
Brook and Walker (1986) used electronmicroscopy to show that F. necrophorum possesses a
mucopolysaccharide capsule. This protects the organism from harmful immune secretions and
helps it avoid detection by the host. Polysaccharide capsules prevent complement proteins from
binding to the bacteria and therefore help to avoid opsonisation and evade phagocytosis (Wilson
et al., 2011; Brook and Walker, 1986). Polysaccharide capsules may also be involved in adhesion
(Wilson et al., 2011).
F. nucleatum, F. periodonticum and F. simiae, all oral species, are known to express a conserved
adhesin known as FadA which binds to surface proteins of oral mucosa KB cells (Han et al., 2005).
It was not revealed whether F. necrophorum also expresses this adhesin and it would therefore be
of interest to search for this within F. necrophorum genome data and by PCR techniques.
It has been demonstrated that F. necrophorum is capable of adhering to ruminal cells by Takayama
et al. (2000), who suggest that collagen is responsible for mediating this attachment. It is also
thought that using collagenase may be a method that enables F. necrophorum to invade the host.
Rather than the organism expressing its own collagenase, a type of endopeptidase, it appears that
F. necrophorum and F. nucleatum are both capable of inducing Collagenase 3 mRNA production by
the host, via activation of multiple cell signalling systems (Uitto et al., 2005).
Proteolytic enzymes, or proteases, cause damage to host tissue and therefore promote invasion of
the host mucosa and spreading of the infection (Wilson et al., 2011). The presence of a F.
necrophorum protease is also discussed by Tan et al. (1996).
1.8.6 Platelet aggregation
The aggregation of platelets, leading to thrombophlebitis and disseminated intravascular
coagulation, is one of the main symptoms of Lemierre’s syndrome and is therefore of great
relevance (Tan et al., 1996; Riordan, 2007). Kanoe and Yamanaka (1989) investigated F.
necrophorum bovine platelet aggregation and demonstrated that it is mediated by haemagglutinin.
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When F. necrophorum cultures were pre-treated with haemagglutinin antiserum, platelet
aggregation was strongly inhibited in a dose-dependent manner up to 64 %. Forrester et al. (1985)
showed that 13 out of 16 biovar A strains could aggregate human platelets, whereas none of the
biovar B strains could. This demonstrates the greater virulence of biovar A and the need to further
understand how the less virulent strains maintain infection.
1.9 Diagnosis of F. necrophorum infections
1.9.1 Clinical diagnosis
Factors contributing to a diagnosis of LS are pharyngitis within the preceding 4 weeks,
thrombophlebitis of the jugular vein, evidence of metastatic lesions and isolation of F. necrophorum
or other bacteria from a typically sterile body site, such as the blood (Wright et al., 2012). A high
fever may often be the only indicator during the initial stage of LS (Kuppalli et al., 2012) as the
pharyngeal symptoms may have resolved by this stage (Wright et al., 2012). The diagnosis of LS is
most often determined through laboratory investigations rather than clinical observations due to
the rarity of the disease. This unfortunately leads to delays in diagnosis which allow for further
disease progression (Ridgway et al., 2010).
1.9.2 Radiology/imaging
Diagnostic imaging can be used in order to confirm the presence of thrombosis in the internal
jugular vein, emboli in the lungs and abscesses (Lyle et al., 2011; Chirinos et al., 2002; Kuppalli et
al., 2012). Ultrasonography is considered to be a cost effective, minimally invasive, readily available
method, therefore helping to provide a rapid diagnosis. However, it provides poor detection of
newly formed clots and in areas underneath the jaw or collarbone (Kuppalli et al., 2012; Syed et al.,
2007). Computed tomography (CT) is the best method for detecting thrombosis in the internal
jugular vein, according to Ridgway et al. (2010) and Kuppalli et al. (2012). It does involve the use of
X-rays, although it is more sensitive (Syed et al., 2007). Magnetic resonance imaging (MRI) is the
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most accurate and does not require exposure to X-rays, however it is very expensive and not widely
available and therefore has limited involvement in diagnosing LS (Syed et al., 2007; Kuppalli et al.,
2012).
1.9.3 Laboratory diagnosis
Throat swabs with subsequent laboratory analysis by culture and/or PCR are the methods to
determine the cause of bacterial pharyngitis, tonsillitis and PTA. In cases of persistent sore throat
or peritonsillar abscess, the current Public Health England guidelines are to test pus aspirate or
throat swabs for F. necrophorum (Public Health England, 2015). Batty and Wren (2005) suggest that
F. necrophorum should be routinely screened for, however it is unknown how widely this advice
has been adhered to.
As discussed in section 1.2.2, F. necrophorum is best cultured on fastidious anaerobe agar (FAA)
and grown under anaerobic conditions at 37 °C for 48 hours (Syed et al., 2007; Batty and Wren,
2005). The organism can then be purified if needed and identified using Gram staining and
biochemical tests such as indole production, lipase production and alkaline phosphatase testing, or
commercial API testing (Batty et al., 2005). PCR techniques can be used for rapid identification of
F. necrophorum, as discussed in section 1.2.3.
1.10 Treatment of F. necrophorum infections
1.10.1 Antibiotics
According to Centor et al. (2015), the United States do not have any guidelines for F. necrophorum
pharyngitis treatment, although they do support antibiotic prescriptions for GAS pharyngitis. In the
UK the National Institute for Health and Care excellence, also known as NICE, published guidelines
detailing three strategies for what it describes as self-limiting respiratory tract infections, including
acute cases of otitis media, sore throat, pharyngitis and tonsillitis. The strategies are no antibiotic
prescribing, delayed antibiotic prescribing and immediate prescribing (Tan et al., 2008). As
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discussed in section 1.6.5, a decrease in antibiotic prescribing for sore throats has been linked with
the reported increase of F. necrophorum infections (Brook, 2015). The NICE guidelines emphasise
the natural resolution time of each infection, with acute otitis media resolving in four days, and
acute sore throat, acute pharyngitis and acute tonsillitis usually resolving in one week (Tan et al.,
2008).
Brazier et al. (2002) reported antimicrobial susceptibility results of 100 F. necrophorum clinical
isolates and showed 2 % resistance to penicillin and 15 % resistance to erythromycin. In an
American study, 22.7 % of 22 F. necrophorum isolates were determined to be β-lactamase
producers, based on nitrocefin disk testing (Appelbaum et al., 1990), suggesting that penicillin was
not such an appropriate choice in that region unless in combination with a β-lactamase inhibitor.
Brazier et al. (2002) also reported that there was no resistance to metronidazole,
amoxicillin/clavulanate, cefoxitin, chloramphenicol, clindamycin or imipenem. However F.
necrophorum is resistant to gentamicin and quinolones, and tetracyclines are relatively ineffective
(Riordan, 2007).
Antimicrobial therapy for LS is usually prolonged (approximately 3 – 6 weeks) with high dosage due
to the inaccessible nature of septic emboli and abscesses (Ridgway et al., 2010) and also to prevent
local and systemic spread (Brook, 2015). Kuppalli et al. (2012) recommend a combination of 500
mg intravenous metronidazole every 8 hours and 2 g intravenous ceftriaxone every 24 hours for
adults. Brazier et al. (2002) recommend penicillin and metronidazole as appropriate treatments.
For antibiotic treatment of PTA it is recommended that both GAS and oral anaerobes should be
targeted (Galioto, 2008). A review by Wright et al. (2012) discusses the factors contributing to
metronidazole being the first choice antimicrobial, stating a lack of resistance and excellent
bioavailability and tissue penetration.
1.10.2 Surgery
In severe cases of F. necrophorum infection, in addition to antimicrobial treatment, patients may
require tonsillectomy (Björk et al., 2015) or abscess drainage (Riordan, 2007; Brook, 2015). Kuppalli
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et al. (2012) describe the drainage of pus and debridement of necrotic tissue as essential. In a
retrospective study on PTA patients in Denmark, 847 patients were included. Of these, 726 patients
had a tonsillectomy and 110 patients had pus aspirated. F. necrophorum was isolated from 191 of
these cases and GAS from 141 (Klug et al., 2009).
1.10.3 Anticoagulants
In cases of LS, anticoagulation therapy such as heparin may also be given to patients. It has been
controversial due to the argument that it is problematic if the patient requires surgery (Hagelskjær
Kristensen and Prag, 2008) and that clots generally resolve on their own. However, it has been
suggested that a faster resolution of septic emboli is clinically important and that anticoagulation
therapy should therefore be used where thrombosis occurs (Ridgway et al., 2010).
1.11 Genomics of F. necrophorum
At the beginning of this project, in September 2011, the only available Fusobacterium genome
sequence was that of F. nucleatum. The genome sequencing and metabolic analysis was completed
by Kapatral et al. (2002) and deposited in GenBank under accession number AE009951. The genome
features a single circular chromosome, containing 2.17 Mb, a GC content of 27 % and 2,067
predicted open reading frames. This annotated genome sequence was used to make predictions
regarding the F. necrophorum genome during this project, such as the expected size of the genome
and genes that it may contain. F. necrophorum and F. nucleatum occupy similar niches, with F.
nucleatum in the oral cavity (Han, 2015) and F. necrophorum in the oropharynx (Brazier et al., 2002),
therefore it seems plausible that they may share some virulence mechanisms.
Several months into the project, the first F. necrophorum genome became available on the GenBank
database. This has since been followed by the addition of a collection of F. necrophorum genomes
in 2014, leading to a total of eleven. The available genomes are strains isolated from bovine, deer
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and human origin and are approximately 2 Mb in size, as was expected based on the F. nucleatum
genome. This topic is discussed further in chapter 4.
1.12 Project aims
F. necrophorum appears to be a common cause of acute pharyngitis and tonsillitis and a rare cause
of more severe infections of the head and neck. Several virulence factors appear to be involved in
pathogenesis, however there is a limited understanding of them. The F. necrophorum genome is
also largely understudied.
This project intended to increase the understanding of F. necrophorum by using next generation
sequencing to analyse the genome and follow up laboratory analysis on virulence determinants of
interest. The project aims were as follows:
1. Collect clinical strains of F. necrophorum from human origin and a reference strain of
both F. necrophorum subspecies necrophorum and F. necrophorum subspecies
funduliforme. Grow and characterise strains using a combination of conventional
microbiological techniques and molecular techniques.
2. Use next generation sequencing technologies to de novo sequence the reference
strains of both subspecies Fnn and Fnf, along with a clinical strain known to have caused
Lemierre’s syndrome in a patient.
3. Assemble sequence data and annotate with gene products using F. nucleatum as a
reference. Use manual curation alongside automatic annotation in order to increase
the likelihood of novel and interesting characteristics of F. necrophorum being
discovered.
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4. Search databases for additional Fusobacterial sequences, particularly those related to
virulence, such as the leukotoxin. Perform sequence alignments to look for similarities
and conserved regions between strains.
5. Use PCR to determine the presence of putative virulence factors in the strain collection,
such as adhesins and proteases.
6. Carry out in vitro assays on virulence determinants of interest.
Upon completion of the genome annotation work, the virulence determinants chosen for in vitro
analysis were the leukotoxin, the organism’s primary virulence factor, and ecotin, a serine protease
inhibitor not previously described in F. necrophorum. The carriage and sequence of the leukotoxin
gene was investigated within the three sequenced strains and the larger collection of F.
necrophorum clinical strains. The cytotoxic effects on the HL-60 cell line and human white blood
cells were also investigated. Ecotin was investigated for inhibitory effects against human plasma






Bacterial strains used in this study were Fusobacterium necrophorum and chemically competent
Escherichia coli. F. necrophorum reference strains JCM 3718 and JCM 3724 from the Japan
Collection of Microorganisms, and clinical strain ARU 01, were provided by the Anaerobe Reference
Unit, Cardiff (Table 1). Strains JCM 3718 and JCM 3724, subspecies necrophorum and funduliforme,
respectively, are both of bovine liver abscess origin, and strain ARU 01 is known to have caused
Lemierre’s syndrome in a patient. A collection of 26 human clinical isolates, provided by Antonia
Batty, University College Hospital London (Table 2) were also used in this study. No identifying
patient data was provided with the strains. Chemically competent E. coli cells were Top10 and
BL21(DE3) strains (Table 3).
Table 1: Reference strains and clinical strain provided by the Anaerobe Reference Unit, Cardiff, UK.
Strain/isolate Subspecies
JCM 3718 Fusobacterium necrophorum subspecies necrophorum
JCM 3724 Fusobacterium necrophorum subspecies funduliforme
ARU 01 Fusobacterium necrophorum subspecies funduliforme




1, 5, 11, 21, 24, 30, 39, 40, 41, 42, 52, 59, 62, 70, 80, 82, 86,
87, 88, 89, 90, 91, 92, 93, 94, 95
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Table 3: Chemically competent strains used for cloning.
Strain Species Genotype Source
Top10 Escherichia coli F- mcrA Δ( mrr-hsdRMS-mcrBC)
Φ80lacZΔM15
Δ lacX74 recA1 araD139











A pET-16b plasmid was provided by Dr Anatoliy Markiv, University of Westminster, for use in section
2.14.
2.3 Cell line stocks
The HL-60 cell line (ATCC CCL-240) was purchased from Sigma, Gillingham. The cell line was derived
from peripheral blood leukocytes from a 36 year old Caucasian female with acute promyelocytic
leukaemia.
2.4 Reagents and solutions
Solutions were prepared using deionised water from a Purite Select deioniser. Sterilisation
conditions were by autoclaving at 121 °C for 15 minutes except where alternative conditions are
stated. Acetic acid, hydrochloric acid and Dimethyl sulfoxide (DMSO) were purchased from Sigma,
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Gillingham. Ethanol and isopropanol were purchased from VWR BDH PROLABO Chemicals,
Leicestershire.
Methods for preparing ethylenediaminetetraacetic acid (EDTA), 50X Tris base, acetic acid and EDTA
(TAE) buffer, 6X Gel electrophoresis loading dye, 6X Laemmli buffer, 10X Tris-Glycine buffer,
Bradford reagent and Phosphate buffered saline (PBS) are listed in Appendix 1.
2.5 Media and antibiotics
Methods for preparing LB agar and broth, fastidious anaerobe agar (FAA), fastidious anaerobe broth
(FAB), brain heart infusion (BHI) broth, complete cell culture medium, SOC media, 100 mg/ml
ampicillin and 100X penicillin-streptomycin solution are listed in Appendix 2.
2.6. Bacterial culture and storage
F. necrophorum strains were cultured on fastidious anaerobe agar (LabM, Lancashire)
supplemented with 5 % defibrinated horse blood (TCS Bioscience, Buckingham) and incubated in a
sealed chamber for 48 hours under anaerobic conditions at 37 °C using AnaeroGen sachets (Oxoid,
Basingstoke). F. necrophorum strains are usually 1 – 3 mm in diameter, cream-grey in colour with
an irregular or smooth edge, exhibiting beta-haemolysis and a butyric acid odour. For long term
storage, cultures were frozen at -80 °C in a solution of sterilised 15 % glycerol (Sigma, Gillingham).
2.7 Identification using biochemical tests
Tests were used to confirm the biochemical profiles of the strain collection matched that of F.
necrophorum. These tests consisted of Gram stains, oxidase and catalase tests and a test for indole
production using the Bactidrop Spot Indole test (Remel, Dartford). Expected results were Gram
negative pleomorphic rods, often with some long filaments present. Oxidase and catalase tests
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should be negative with a positive result for indole production. Methods for carrying out a Gram
stain, oxidase test, catalase test and indole production test are detailed in Appendix 3.
2.8 Nucleic acid analysis
2.8.1 DNA extraction
DNA was extracted using a Qiagen DNA mini kit. Several loopfuls of colonies from a 48 hour
anaerobic culture were suspended in 1 ml sterile deionised water (SDW) and a 200 µl sample was
aliquoted into a microfuge tube. 200 µl buffer ATL was added and the mixture vortexed, followed
by adding 20 µl 20 mg/ml proteinase K and vortexing again. The mixture was incubated at 56 °C for
10 minutes, vortexed every 2 minutes, and then briefly centrifuged in an Eppendorf 5415 D
benchtop centrifuge to remove drops from the inside of the lid. 200 µl buffer AL was then added
and pulse vortexed for 15 seconds, followed by incubating at 70 °C for 10 minutes and briefly
centrifuging again. 200 µl ethanol (96 – 100 %) was added to the sample, which was mixed again by
pulse vortexing for 15 seconds, and briefly centrifuged. The mixture was carefully applied to a spin
column in a 2 ml collection tube and centrifuged at 8000 rpm for 1 minute. The filtrate was
discarded. 500 µl buffer AW1 was added to the column before centrifuging at 8000 rpm for 1
minute and discarding the filtrate. 500 µl buffer AW2 was added to column. This was centrifuged
at 13,000 rpm for 3 minutes and the filtrate was discarded before an additional spin at 13,000 rpm
for 1 minute. The collection tube was discarded and the column placed in a new microfuge tube.
200 µl buffer AE was added and the sample was incubated at room temperature for 5 minutes. The
DNA was collected by centrifuging at 8000 rpm for 1 minute. The extracted DNA was stored in 1.5
ml tubes at -20 °C. Aliquots of the extracted DNA were diluted 1 in 20 and stored at -20 °C in 100 µl
aliquots for use in PCR.
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2.8.2 Polymerase chain reaction (PCR)
PCR master mixes were prepared using the components in Table 4. The components, excluding the
DNA template, were added to a single 1.5 ml microfuge tube in sufficient quantities for multiple
reactions, and then dispensed in 20 µl aliquots into 0.2 ml PCR tubes. DNA template (diluted 1 in
20 from stock) and a molecular grade water (Fisher Scientific, Loughborough) negative control were
added to the tubes, labelled with the corresponding sample name or number.
PCR was performed using a BioRad DNA Engine Peltier Thermal Cycler. Conditions were an initial
denaturation step of 95 °C for 5 minutes, then 35 cycles of denaturing at 95 °C for 30 seconds,
annealing at 55 °C for 30 seconds then extension at 72 °C for 1 minute. This was followed by a final
extension step of 72 °C for 5 minutes before holding at 8 °C.
Primer pairs used in PCR are listed in Table 20, Table 30, Table 42 and Appendices 10, 11 and 14.
Table 4: PCR components for each tube
Component Source Quantity
Taq PCR master mix kit Qiagen, Crawley 12.5 µl
Forward primer (10 µM) Synthesised by Eurofins MWG Operon 2.5 µl
Reverse primer (10 µM) Synthesised by Eurofins MWG Operon 2.5 µl
Molecular grade water Fisher Scientific, Loughborough 2.5 µl
DNA template 5 µl
2.8.3 Gel electrophoresis
Gel electrophoresis was used to visualise amplified PCR products. Dehydrated, molecular grade
agarose was obtained from Lonza, Rockland, USA. 0.8 % (w/v) or 1 % (w/v) solutions were prepared
in 1X TAE buffer. Solutions were boiled in a microwave until fully dissolved and then cooled to 50
°C – 60 °C. 10,000X GelRed nucleic acid gel stain (Biotum, Hayward, CA, USA) was added to the
cooled gel solution as a 1 in 10,000 dilution, which was then swirled and poured into a gel cast.
37
Plasmids were electrophoresed on 0.8 % (w/v) agarose gels with a GeneRuler 1 kb DNA ladder and
100 bp DNA ladder (Thermo Fisher Scientific, Hertfordshire), while PCR fragments were
electrophoresed on 1 % (w/v) agarose gels with a 100 bp ladder. DNA products were mixed with 6X
loading dye before loading into the agarose gel well. All gels were run with a negative control
sample. The electrophoresis running buffer was 1X TAE buffer. Gels were visualised using a UV
imaging system, UVIPRO (UVITEC, Cambridge). Plasmids and PCR fragment sizes were determined
by comparison to the DNA ladder standards run in parallel.
2.8.4 Real-time PCR using TaqMan probes
TaqMan probes were used in conjunction with gyrB primers in a RotorGene Q PCR machine in order
to subspeciate the F. necrophorum isolates. The gyrB primers (Table 20) and probes used were
taken from the paper by Jensen et al. (2007) and synthesised by Eurofins MWG Operon. The gyrB
primers were diluted to a working concentration of 4 µM and the probes were diluted to a working
concentration of 1 µM. See Table 5 for 5’ – 3’ probe sequences. The Fnn probe had a FAM
fluorophore (absorbance: 495 nm; emission 520 nm) and the Fnf probe had a JOE fluorophore
(absorbance: 520 nm; emission: 548 nm). Both probes used black hole quencher (BHQ) 1
(quenching range: 480 – 580 nm).
Master mixes were prepared using the components in Table 6. The components, excluding the DNA
template, were added to a single 1.5 ml microfuge tube in sufficient quantities for multiple
reactions, and then dispensed in 20 µl aliquots into 0.2 ml PCR tubes. DNA template (diluted 1 in
20 from stock) and a molecular grade water (Fisher Scientific, Loughborough) negative control were
added to the tubes, labelled with the corresponding sample name or number. The probes were
tested in separate reaction tubes.
Cycle conditions were an initial denaturation step of 95 °C for 5 minutes, then 40 cycles of 95 °C for
30 seconds followed by 60 °C for 60 seconds while acquiring on the green and yellow channels. The
subspecies necrophorum probe was detected on the green channel and the subspecies
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funduliforme was detected on the yellow channel. The RotorGene Q software was used to analyse
results.
Table 5: TaqMan probes used in conjunction with gyrB PCR primers to subspeciate F. necrophorum strains using real-time
PCR.
Probe 5’ – 3’ probe sequence
Subsp. necrophorum-specific gyrB probe FAM-TCTACTTTGGAGGTTGGAGAAACAAC-BHQ 1
Subsp. funduliforme-specific gyrB probe JOE-TCCGCTTTAGAGGCTGGAGAAACGAC-BHQ 1
Table 6: Reaction components for each real-time PCR tube
Component Source Quantity
RotorGene probe PCR kit Qiagen, Crawley 12.5 µl
Forward primer (4 µM) Synthesised by Eurofins MWG Operon 2.5 µl
Reverse primer (4 µM) Synthesised by Eurofins MWG Operon 2.5 µl
Fnn- or Fnf-specific probe (1 µM) Synthesised by Eurofins MWG Operon 2.5 µl
DNA template 5 µl
2.8.5 Gel extraction of nucleic acid product
The GenElute Gel extraction kit was used for purification of DNA fragments from agarose gels
according to the manufacturer’s instructions. See Appendix 4 for full details.
2.8.6 Quantification of DNA using Nanodrop
Concentrations of purified PCR fragments, plasmids, and other DNA samples were measured using
a Nanodrop2000 spectrophotometer (Thermo Scientific, Loughborough). The optical density of 1 µl
of sample DNA was measured at 260 nm and the concentration calculated by the Nanodrop2000
software.
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2.8.7 Sanger sequencing purified DNA fragment
Primers designed for closing gaps in the leukotoxin sequence data and those designed for
sequencing the full leukotoxin operon are detailed in Appendices 10 and 11, respectively. The PCR
products amplified using these primer pairs were sequenced using the Sanger method. Primer sets
used for detection of the lktA gene are detailed in Appendix 14. PCR products amplified using these
primer pairs were not sequenced, with the exception of the first 12 strains (1 – 59) for Ludlam_LT1.
A small selection of the Ludlam_LT1 amplicons were sequenced to determine variations within that
region, which were highlighted by non-amplification using lktA primers, targeting the same region.
A primer pair designed to amplify the ecotin gene (detailed in Table 42) was used to sequence
strains 1 – 59, JCM 3718, JCM 3724 and ARU 01. This was to enable analysis of the JCM 3718, JCM
3724 and ARU 01 sequence data and to design a F. necrophorum ecotin plasmid insert. The
remainder of the ecotin amplicons were sequenced to assess the level of conservation between the
strains. Products amplified using primer pairs gyrB (Table 20) and FadA (Table 30) were not
sequenced. The gyrB amplicons were not sequenced as verification of the strain identities as
TaqMan probes were also used for identification work. There was no amplification of product
within F. necrophorum strains using the FadA primers, so these primers were not used for
sequencing.
For Sanger sequencing, prepaid barcodes were used to send purified plasmids and PCR fragments
to GATC Biotech (Constance, Germany). 20 µl of purified PCR fragments (10 – 50 ng/µl) or purified
plasmid (30 – 100 ng/µl) were sent in 1.5 ml microfuge tubes and 20 µl of the forward and reverse
primers (10 pmol/µl), in separate 1.5 ml microfuge tubes, were sent via a London collection point.
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2.9 de novo genome sequencing, assembly and annotation
2.9.1 Next generation sequencing and assembly
Two F. necrophorum reference strains and a LS clinical isolate were commercially sequenced by
GATC Biotech (Konstanz, Germany) using Roche 454 GS-FLX+ next generation sequencing
technology. The raw sequence reads of the genomes were assembled into larger contigs semi-
automatically using Roche GS Assembler, also known as Newbler.
2.9.2 Genome annotation
The assembled contigs were uploaded into the xBASE pipeline (Chaudhuri et al., 2008) in FASTA
format for prediction of open reading frames and gene product annotations. The pipeline combines
several programs used for annotation purposes: Glimmer predicted the open reading frames,
tRNAScan-SE searched for tRNA genes, RNAmmer searched for ribosomal RNA genes, and BLASTp
searched translated coding sequences against the selected reference sequence (Fusobacterium
nucleatum in this case). The best result for each search was selected as the annotation product,
providing the criteria in Table 7 was satisfied:
Table 7: Criteria required for BLASTp assignment of product annotation by xBASE pipeline.
Minimum gene length: 90 base pairs
Maximum gene overlap: 50 base pairs
BLAST E-value cut-off: 1e-10
For BLASTp searches that yield no acceptable result, the product identity field was left blank.
2.9.3 File conversion script
xBASE output files are produced in GenBank format. To convert them to a user-friendly Microsoft
Excel file, a program was created using an OpenVMS operating system to extract the information
of interest. The GenBank file was the input and a comma-separated value file was the output. The
resulting Excel spreadsheet had data under the headings: assembly contig, base location,
orientation, product and protein sequence.
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2.9.4 BLASTp annotation
For manual annotation using a BLASTp search, the translated protein sequence was entered into
the query sequence field and then searched against the non-redundant protein sequence database
using the default settings. The Broad Institute prokaryotic annotation pipeline standard operating
procedure (2009) was used to define the acceptable parameters for BLAST annotation (Table 8).
For each query sequence the top BLAST result that satisfies the Broad Institute standard operating
procedure conditions was accepted as the gene naming product. Products labelled as hypothetical
protein were disregarded unless no other acceptable result was available. The results were added
to the Microsoft Excel file containing the xBASE annotation results.
Table 8: Acceptable parameters for BLAST annotation, as defined by the Broad Institute.
Blast Database: Non-redundant (bacteria)
Maximum E value: 10-10
Minimum identity: 30 %
Minimum query coverage: 30 %
2.9.5 Contig merging using Minimus2
Genomic data sets from the same strain were sent to Source Bioscience, Nottingham, to be merged
into a single set of contigs using the program Minimus2, in order to reduce the overall number of
contigs. This was carried out as a commercial package.
2.10 Web-based sequence tools and open source software
2.10.1 Primer3
Primer3 (Untergasser et al., 2012) is a PCR primer design and analysis tool that was used for all
primer design during this study. The DNA sequence to be targeted, and a region of flanking
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sequence were entered into the text box with regions to flank or avoid marked. PCR primers were
generated using default settings.
2.10.2 Clustal Omega
To compare multiple relatively short sequences of DNA or protein, Clustal Omega (Sievers et al.,
2011) was used (Clustal Omega, 2015). Sequence data for a single gene or operon were entered in
FASTA format into the input box from each of the different strains. The sequences were aligned
against one another with an asterisk below identical nucleotides or amino acids. Variation between
the strains is indicated by a lack of asterisk symbols.
2.10.3 ExPASy translate
To translate DNA sequence into protein sequence, the ExPASy translate tool was used (Expasy -
Translate Tool, 2015). DNA sequence was entered into the query text box and an output format
selected. The tool then translated the DNA sequence into the six reading frames.
2.10.4 Hydophobicity plots
To create a hydrophobicity plot of protein sequence data, ExPASy ProtScale was used (Expasy -
Protscale, 2015). Protein sequence was entered into the query text box and the Kyte and Doolittle
hydrophobicity plot option was selected. Potential transmembrane regions are found by peaks with
a score of 1.6 or greater when a recommended window size of 19 is used. The window size
represents the number of surrounding amino acids used at each amino acid position to generate
the average score that predicts hydrophobicity at that position.
2.10.5 Sequence alignments using WebACT
A web-based version of the Artemis Comparison Tool program (Abbott et al., 2005; Webact, 2015)
was used to generate comparison files of the leukotoxin operons of the three sequenced genomes.
Sequences were uploaded in FASTA format under the generate tab. The results from each query
were saved and viewed within the Artemis Comparison Tool program. Regions of similarity between
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sequences are shown by red blocks, reversed sections of similarity are shown by blue blocks and
white sections (or breaks) indicate unique regions.
2.10.6 Seaview and PhyML
Phylogenetic trees were constructed using programs Seaview and PhyML within a Linux operating
system. DNA sequences of interest were first loaded into Seaview, before selecting the view as
protein option. Once the DNA sequence had been translated, the align function was used. The
aligned sequence was then converted back into DNA sequence with optimised spacing between
nucleotides for a better alignment. To make the tree, the PhyML option was selected, with 100
bootstrap replicates set in options. The scale bar shown on the resulting tree represents the number
of inferred substitutions per site.
2.11 Cell line culture
All sterile work involving the HL-60 cell line was carried out in a Bioair Safeflow microbiological
safety cabinet. Methods for propagating from frozen, cell counting, serial passage and storage are
detailed in Appendix 5.
2.12 Donor blood collection and associated ethics approval
2.12.1 Ethics approval
Blood was taken from informed, consenting, healthy volunteers after obtaining ethics approval
from the University of Westminster. Application numbers were: 12_13_04 for blood collection for
use in the cytotoxicity assay with F. necrophorum leukotoxin and VRE1314-1070 for blood collection
for use in coagulation assays with F. necrophorum ecotin. For both assays, no participant
information is linked to the results. All samples were discarded by the end of the day and no cellular
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or DNA containing samples were retained. See Appendices 6 and 7 for associated participant
information sheets, consent form templates and ethics approval letters.
2.12.2 Venipuncture and blood collection
Samples of blood were collected from participants by venipuncture. This was carried out by an
experienced phlebotomist, and 20 ml of blood was collected from each donor in four 5 ml
vacutainers. EDTA vacutainers were used where white blood cells were to be separated by
histopaque method, and buffered sodium citrate vacutainers were used where platelet-poor
plasma was required.
2.12.3 Histopaque separation of blood components
White blood cells were prepared for cytotoxicity assays by Histopaque method. 3 ml of room
temperature Histopaque-1119 was added to a 15 ml conical centrifuge tube and 3 ml of room
temperature Histopaque-1077 was carefully layered on top. 6 ml of whole blood, diluted 1:1 with
1X PBS, was layered onto the upper gradient of the tube. The tube was centrifuged at 700 x g for
30 minutes at room temperature, resulting in two distinct opaque layers. The plasma was aspirated
to within 0.5 cm of the lower layer and discarded. Cells from this layer were transferred to a tube
labelled granulocytes. The cells were washed by the addition of 10 ml of 1X PBS to the tubes,
followed by centrifuging for 10 minutes at 300 x g. The supernatant was discarded. Wash steps
were repeated twice, with cells resuspended by gently drawing in and out of a Pasteur pipette. Cells
were then resuspended in complete RPMI 1640 culture medium (Life Technologies, Paisley). The
concentration of viable cells was determined by a 0.4 % trypan blue dye exclusion assay.
2.12.4 Collecting platelet-poor plasma by centrifugation
Platelet-poor plasma was prepared for clotting time assays by centrifugation method. Whole blood
was separated by centrifugation at 2000 x g for 15 minutes at room temperature and the plasma
layer was retained, taking care not to disturb the buffy coat layer. The plasma from one tube was




2.13.1 Collection of high molecular weight protein for cytotoxicity assay
JCM 3718, JCM 3724 and ARU 01 strains were grown on FAA media at 37 °C for 48 hours under
anaerobic conditions. They were subsequently cultured into BHI broth and incubated at 37 °C and
150 rpm until they reached an OD600 of 0.7 – 0.8. The cultures were centrifuged at 3000 x g for 30
minutes at 4 °C and the supernatant was sterile filtered using 0.2 µm filters (Millipore,
Hertfordshire) and 75X concentrated with 100 kDa molecular weight cut off filters (Millipore,
Hertfordshire) also centrifuged at 3000 x g and 4 °C for 30 minutes. The resulting high molecular
weight samples were aliquoted and stored at -20 °C for up to two weeks. Samples were not
defrosted more than once and were analysed for the presence of high molecular weight protein by
SDS PAGE.
2.13.2 Quantification of protein sample by Bradford assay
The concentrations of the high molecular weight protein fractions from section 2.13.1,
hypothesised to contain leukotoxin, were determined by Bradford assay (Bradford, 1976) in 96 well
clear flat-bottomed plates. A standard curve was constructed using 9, 11, 13, 15, 17 and 19 µg/ml
human serum albumin (HSA) in triplicate, in 200 µl final volumes containing 100 µl per well Bradford
reagent. Putative leukotoxin samples were diluted 1 in 50. Absorbance was measured on a
Versamax microplate reader at 595 nm, and the equation of the graph and R squared value were
recorded. Sample concentrations were adjusted for the dilution factor before reported.
2.13.3 Analysis of protein sample by SDS PAGE
Concentrated samples of high molecular weight protein (from section 2.13.1) were analysed using
a sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS PAGE) method introduced by
Laemmli (1970). Protogel buffers were purchased from Fisher (Loughborough) and Ammonium
persulfate (APS) and N,N,N′,N′-Tetramethylethylenediamine (TEMED) were purchased from Sigma
(Gillingham). 0.75 mm polyacrylamide gels were made using Mini Protean Tetra Cell apparatus
(BioRad, Hertfordshire, UK). 10 % polyacrylamide running gels were made by mixing the
46
components in Table 9 and poured between glass plates with a 4 % polyacrylamide stacking gel,
made by mixing the components in
Table 10, poured on top, as per the manufacturer’s instructions. The APS solution, made by adding
0.1 g to 1 ml deionised water, and TEMED were added quickly before pouring. 6X Laemmli reducing
buffer and non-reducing buffer were added to the samples separately, which were then boiled for
5 minutes before being loaded into the gel. Gels were run with either blue protein standard (broad
range) or colour protein standard (broad range) protein ladders, purchased from New England
Biolabs (Hitchin). Gels were run in a tank of 1X Tris-Glycine buffer (pH 8.3) at 110 V for 90 minutes.
Gels were stained with 0.5 % Coomassie blue dye for 1 hour, destained overnight in 7 % (v/v) acetic
acid and then viewed on a GS-800 scanner using the Quantity one program.
Table 9: Composition of 10 % running gel.
Component Volume
Protogel, containing 30 % (w/v) acrylamide/methylene bis-
acrylamide solution (37.5:1 ratio)
3.3 ml
Resolving buffer 2.6 ml
Deionised water 3.96 ml
Ammonium persulfate 10 % (w/v) 100 µl
TEMED 20 µl
Table 10: Composition of 4 % stacking gel.
Component Volume
Protogel, containing 30 % (w/v) acrylamide/methylene bis-
acrylamide solution (37.5:1 ratio)
1.3 ml
Stacking buffer 2.5 ml
Deionised water 6.1 ml
Ammonium persulfate 10 % (w/v) 50 µl
47
TEMED 10 µl
2.13.4 Cytotoxicity assay using HL-60 cell line
HL-60 cells were passaged as described in Appendix 5 in order to be used in a cytotoxicity assay,
with methods based on those of Tadepalli et al. (2008a). Following cell passage, cells were
resuspended in an appropriate volume to result in 1 x 106 viable cells/ml. 12 ml centrifuge tubes
were labelled with the sample treatments and 100 µl of cell suspension was added to each to result
in 1 x 105 viable cells per tube. Cell treatments included: 1X PBS as a negative control, ethanol as
positive control at a final concentration of 7.5 %, concentrated high molecular weight culture
supernatant collected from JCM 3718, JCM 3724 and ARU 01 at final concentrations 125 µg/ml, 150
µg/ml, and 175 µg/ml, concentrated high molecular weight culture supernatant collected from JCM
3718 and ARU 01 at a final concentration of 250 µg/ml, and filter flow through from the three
strains. Concentrated high molecular weight culture supernatant, filter flow through, PBS or
ethanol were added to each tube and the volume made up to 300 µl with 1X PBS. Treated cells
were incubated for 45 minutes at 37 °C in 5 % CO2. Cells were washed twice with 1X PBS and
centrifuging at 300 x g, with cells resuspended by gently drawing in and out of a Pasteur pipette.
Cells were then resuspended in 300 µl complete culture medium (Appendix 2.4) and stained with
10 µl propidium iodide (50 µg/ml) in the dark for 5 minutes before being processed on a flow
cytometer. Experiments were repeated over three separate days for triplicate data sets.
2.13.5 Cytotoxicity assay using human donor white blood cells
The cytotoxicity assay from section 2.13.4 using HL-60 cells was partially repeated using white blood
cells separated from human donor blood by Histopaque method (section 2.12.3). Following a trypan
blue dye exclusion assay, as described in Appendix 5.2, cells were adjusted to a concentration of 1
x 106 viable cells/ml by addition of RPMI 1640 culture medium (Life Technologies, Paisley). 12 ml
centrifuge tubes were labelled with the sample treatments and 100 µl of cell suspension was added
to each to result in 1 x 105 viable cells per tube. Cell treatments included: 1X PBS as a negative
control, ethanol as positive control at a final concentration of 7.5 %, and toxin collected from JCM
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3718, JCM 3724 and ARU 01 at a final concentration of 150 µg/ml. Treated cells were incubated for
45 minutes at 37 °C in 5 % CO2. Cells were washed twice with 1X PBS and centrifuging at 300 x g,
with cells resuspended by gently drawing in and out of a Pasteur pipette. Cells were then
resuspended in 300 µl RPMI 1640 culture medium and stained with 10 µl propidium iodide (50
µg/ml) in the dark for 5 minutes before being processed on a flow cytometer. Experiments were
repeated over three separate days for triplicate data sets.
2.13.6 Flow cytometric analysis
For each sample 10,000 cells were analysed on the Cyan ADP Flow Cytometer (DakoCytomation)
using the Summit V4.3 software. Unstained, untreated samples of cell lines and human white blood
cells were used to adjust the lasers and set gates for cell size and granularity before samples stained
with propidium iodide were measured for viability. The percentage viabilities for the negative
controls were set to match those of the trypan blue dye exclusion assay in order to obtain the most
accurate gate settings. Cells were therefore gated according to approximately 98 % viability.
2.14 Cloning
2.14.1 Preparation of competent cells using CaCl2 method
A few colonies from an overnight culture of Top10 or BL21(DE3) E. coli were inoculated into 10 ml
of LB broth in a sterile tube and incubated for 16 hours at 37 °C and 330 rpm. 50 ml of pre-warmed
LB broth in a conical flask was inoculated with 1 ml of the 16 hour culture and grown at 37 °C and
220 rpm until OD600 reached 0.3 – 0.4. The culture was transferred to a pre-chilled 50 ml tube and
chilled on ice for 20 minutes before being centrifuged at 3000 rpm for 5 minutes at 4 °C. The
supernatant was discarded and the cells gently resuspended on ice in 5 ml of filter sterilised 0.1 M
CaCl2 pre-chilled to 4 °C.  After 30 minutes on ice, the cells were centrifuged again at 3000 rpm for
5 minutes at 4 °C and the supernatant was discarded. The cells were gently resuspended in 2 ml
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pre-chilled, filter sterilised 0.1 M CaCl2 containing 15 % glycerol. Cells were left on ice for 30 minutes
before being aliquoted into pre-chilled 1.5 ml tubes and stored at -80 °C.
2.14.2 Plasmid design
A plasmid insert containing the F. necrophorum ecotin gene was designed to include an NcoI
restriction site, a deca-histidine tag, an enterokinase cleavage site, an NdeI restriction site, followed
by the ecotin gene sequence including the stop codon, and restriction site XhoI. It was ensured that
the ecotin gene start codon would be in frame. The plasmid was commercially synthesised by
GeneArt (Regensburg, Germany) and was supplied as 5 µg of lyophilised plasmid DNA. The DNA
sequence was verified as 100 % homologous to the design by Sanger sequencing.
2.14.3 Resuspending lyophilised plasmid DNA
Lyophilised plasmid DNA was pulse centrifuged to ensure all DNA collected at the bottom of the
tube. 50 µl of molecular grade water (Fisher Scientific, Loughborough) was added to 5 µg plasmid
DNA. This was mixed by gentle flicking of the tube and pulse centrifuged to incorporated all DNA
and incubated for 1 hour at room temperature. 1 µl of the resuspended DNA was transformed into
chemically competent E. coli cells (section 2.14.4) and the remainder stored in aliquots at -20 °C.
2.14.4 Transformation of plasmid into chemically competent Top10 cells using
heat shock method
The synthesised plasmid and the pET-16b plasmid provided by Dr Anatoliy Markiv, University of
Westminster, were both separately transformed into chemically competent Top10 E. coli cells in
order to amplify the plasmids. In each case, 30 µl Top10 cells were transferred to a 1.5 ml microfuge
tube on ice. 10 ng of plasmid was added to the cells which were incubated on ice for 30 minutes.
The cells were heat shocked at 42 °C for 40 seconds then placed back on ice for 2 minutes. 200 µl
SOC medium was added and the culture was placed in a shaking incubator for 45 minutes at 37 °C
at 330 rpm. 100 µl competent bacteria and plasmid were inoculated onto an LB agar plate with 100
µg/ml ampicillin and incubated overnight at 37 °C. One colony was selected and grown in 6 ml LB
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broth with 100 µg/ml ampicillin for 16 hours at 37 °C, shaking at 250 rpm. An aliquot was saved in
50 % glycerol and a plasmid miniprep kit from Life Technologies, Paisley (section 2.14.5) was used
to extract plasmid DNA, following the manufacturer’s instructions. Plasmid DNA was quantified
using a Nanodrop.
2.14.5 Plasmid extraction
Plasmid DNA was purified using a PureLink Quick plasmid miniprep kit, purchased from Invitrogen,
by Life Technologies (Paisley), and used as per the manufacturer’s instructions. 5 ml of an overnight
broth culture of E. coli cells transformed with plasmid was centrifuged at 12,000 x g and the
supernatant discarded. Cells were resuspended in 250 µl Resuspension buffer with RNase A and
mixed until homogenous. 250 µl Lysis buffer was added and mixed gently, then incubated at room
temperature for 5 minutes. 350 µl Precipitation buffer was added and mixed immediately by
inverting the tube until the mixture was homogenous. The sample was then centrifuged at 12,000
x g for 10 minutes. The supernatant was loaded into a spin column in a 2 ml wash tube and was
centrifuged for 12,000 x g for 1 minute and the flow through discarded. 700 µl Wash buffer with
ethanol was added to the column which was then centrifuged at 12,000 x g for 1 minute and the
flow through was discarded. The centrifugation step was repeated and the spin column placed in a
clean 1.5 ml recovery tube. 75 µl TE buffer, preheated to 65 – 70 °C, was added to the centre of the
column and incubated for 1 minute at room temperature. The column was centrifuged at 12,000 x
g for 2 minutes and the eluted, purified plasmid was stored in 25 µl aliquots at -20 °C.
2.14.6 Plasmid digestion
Purified plasmids from Top10 cells were digested using restriction enzymes to cleave the DNA at
the NcoI and XhoI cloning sites. Digestions were carried out simultaneously to provide the pET-16b
plasmid backbone and the ecotin gene insert. The reaction components listed in Table 11 were
added and the tubes were incubated at 37 °C for 30 minutes before being run in a 0.8 % agarose
gel. The resulting bands were excised with a scalpel and the DNA extracted using a DNA gel
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purification kit (Sigma, Gillingham) (section 2.8.5). The nucleic acid was then quantified using a
Nanodrop (section 2.8.6) for both the plasmid backbone and insert.
Table 11: Reaction components of plasmid digestion for both pET-16b plasmid and ecotin synthesised plasmid.
Reaction component Reaction volume
Plasmid (pET-16b and Ecotin, separately) 28 µl
Digestion buffer (Fermentas, Hertfordshire) 3.5 µl
Molecular grade water (Fisher Scientific, Loughborough) 0.5 µl
NcoI (Fermentas, Hertfordshire) 1.5 µl
XhoI (Fermentas, Hertfordshire) 1.5 µl
Total 35 µl
2.14.7 Plasmid ligation
The digested ecotin insert was ligated into the pET-16b plasmid backbone by adding the plasmid
components in a 1:3 molar ratio (1 part backbone – 3 parts insert). The reaction components from
Table 12 were added and the mixture was incubated at 4 °C overnight. The ligation mix was heat
inactivated at 70 °C for 10 minutes before 10 ng was transformed into Top10 cells using the method
described in section 2.14.4. One colony was selected and grown in 6 ml LB broth with 100 µg/ml
ampicillin for 16 hours at 37 °C, shaking at 250 rpm. An aliquot was then saved in glycerol and a
plasmid miniprep (section 2.14.5) was carried out to extract plasmid DNA. A second digest (section
2.14.6) was carried out on the purified plasmid and the resulting digested plasmid run on a 0.8 %
agarose gel (section 2.8.3) to check for the presence of the insert. This was indicated by two bands,
one being the plasmid backbone and the other being the insert.
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Table 12: Reaction components of plasmid ligation of pET-16b plasmid backbone and ecotin insert.
Reaction component Reaction volume
Ecotin insert 1.6 µl
pET-16b plasmid backbone 4 µl
10X ligation buffer (New England Biolabs, Hitchin) 1 µl
Molecular grade water (Fisher Scientific, Loughborough) 2.4 µl
T4 DNA ligase (New England Biolabs, Hitchin) 1 µl
Total 10 µl
2.14.8 Transformation of plasmid into chemically competent BL21(DE3) cells
using heat shock method
Purified pET-16b plasmid containing the ecotin insert was transformed into BL21(DE3) cells for
expression. 50 µl of chemically competent BL21(DE3) E. coli cells were transferred to a 1.5 ml
microfuge tube on ice. 10 ng of plasmid DNA was added to the cells and incubated on ice for 30
minutes. The cells were heat shocked by placing the tube into a 42 °C heat block for 10 seconds and
then placed on ice for 5 minutes. 950 µl SOC medium was added and the culture was incubated at
37 °C for 1 hour, shaking at 250 rpm. 100 µl was inoculated onto pre-warmed LB agar plates with
100 µg/ml ampicillin and incubated overnight at 37 °C. One colony was selected and grown in 6 ml
LB broth with 100 µg/ml ampicillin for 16 hours at 37 °C, shaking at 250 rpm. An aliquot was then
saved in 15 % glycerol and a plasmid miniprep (section 2.14.5) was carried out to extract plasmid
DNA, which was subsequently quantified using a Nanodrop (section 2.8.6). 500 ng of plasmid was
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sent for commercial Sanger sequencing (section 2.8.7) in order to verify the final plasmid contained
the correct sequence.
2.15 Histidine tag expression and purification
2.15.1 Expression of recombinant protein
BL21(DE3) expression strain, transformed with pET-16b/ecotin, was grown on LB agar containing
100 µg/ml ampicillin and incubated overnight at 37 °C. A BL21(DE3) expression strain containing no
plasmid was grown in parallel on media without ampicillin to be used as a negative control. The
following day, one colony from each culture was inoculated into 10 ml LB broth, containing 100
µg/ml ampicillin for the plasmid culture only, and incubated at 37 °C and 250 rpm for 16 hours. 5
ml of each starter culture was used to inoculate a 1 L conical flask containing 200 ml LB, with 100
µg/ml ampicillin for the plasmid-containing culture. The cultures were incubated at 37 °C and 250
rpm until the OD600 reached between 0.3 and 0.4. The flasks were placed on ice for 30 minutes then
protein production was induced with IPTG at 0.5 mM for 3 hours at 37 °C and 250 rpm. 1 ml samples
were taken from each culture at IPTG induction (0 hours) and 1, 2 and 3 hours post-induction for
analysis by Tricine method SDS PAGE (section 2.15.3). The flask cultures were pelleted in 50 ml
aliquots by centrifugation at 3000 x g and stored overnight at -20 °C.
2.15.2 Purification of histidine-tagged protein by immobilised metal ion
chromatography (IMAC) under native conditions
The histidine-tagged recombinant protein was purified by immobilised-metal affinity
chromatography (IMAC) using buffers listed in Table 13. Pellets were resuspended in 5 ml His-
Binding buffer with 1.5 µl rLysozyme solution added (Merck Millipore, Watford). Resuspended
cultures were mechanically lysed with 5 cycles of 10 seconds of sonicating followed by a 20 second
rest period. 20 µl of ‘Total’ fraction was collected for Tricine method SDS PAGE analysis (section
2.15.3) and stored as a 1:1 ratio in 6 M Urea. Lysate was centrifuged at 12,000 x g for 10 minutes at
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4 °C and the supernatant was collected. 20 µl of the ‘Soluble’ fraction was collected for SDS PAGE
analysis. IMAC was carried out using a nickel-nitrilotriacetic acid matrix. A 0.25 ml bed volume of
IMAC Sepharose 6 Fast Flow Resin (GE Healthcare, Amersham) was primed with 0.2 M NiSO4.6H2O
and equilibrated with His-Binding buffer. The lysate supernatant containing the His-tagged protein
was run through the column by gravity filtration. 20 µl of ‘Flow through’ was collected for SDS PAGE
analysis. The column was washed with 5 ml His-Wash buffer and 20 µl ‘Wash’ fractions were
collected for SDS PAGE analysis. After each wash step, a 2 µl aliquot was analysed on a
Nanodrop2000 using the A280 setting to quantify protein concentration. Wash steps were repeated
until the concentration had reduced to 0 mg/ml. His-tagged protein was eluted from the metal ion
matrix four times in 250 µl aliquots with His-Elution buffer. 40 µl of each ‘Elution’ fraction was
collected for SDS PAGE (section 2.15.3) and Bradford assay analysis (section 2.15.4). All purification
steps were carried out on ice with buffers at 4 °C and all protein aliquots were stored at -20 °C.
Table 13: Protein purification buffers used in IMAC under native conditions. Buffers were made up in water and filter
sterilised.
Buffer pH Composition
His-Binding buffer 8.0 50 mM HEPES, 500 mM NaCl, 5 mM Imidazole, 5% Glycerol
His-Wash buffer 8.0 50 mM HEPES, 500 mM NaCl, 30 mM Imidazole, 5% Glycerol
His-Elution buffer 8.0 50 mM HEPES, 500 mM NaCl, 250 mM Imidazole, 5% Glycerol
2.15.3 Analysis of protein expression and purification by Tricine SDS PAGE
Samples taken during protein expression and purification were analysed using the Tricine-SDS PAGE
method by Schagger and Jagow (1987) for separation of proteins in the range from 1 to 100 kDa.
Ammonium persulphate (APS) and N,N,N′,N′-Tetramethylethylenediamine (TEMED) were
purchased from Sigma (Gillingham). Buffers and 0.75 mm polyacrylamide gels were made as per
Table 14 and Mini Protean Tetra Cell apparatus was used (BioRad, Hertfordshire, UK). 15 %
polyacrylamide running gels were made and poured between the glass plates with a 5 %
polyacrylamide stacking gel poured on top. The APS solution, made by adding 0.1 g to 1 ml
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deionised water, and TEMED were added quickly before pouring the gels. 6X Laemmli reducing
buffer was added to the samples, which were then boiled for 5 minutes before being loaded into
the gel. Gels were run with either blue protein standard (broad range) or colour protein standard
(broad range) protein ladders, purchased from New England Biolabs (Hitchin). Gels were run with
1X cathode buffer between the glass plates and 1X anode buffer in the surrounding tank and at 110
V for 140minutes. Gels were stained with 0.5 % Coomassie blue dye for 1 hour, destained overnight
in 7 % (v/v) acetic acid and then viewed on a GS-800 scanner using the Quantity one program.
Table 14: Composition of gels and buffers used in Tricine SDS PAGE. All were prepared in deionised water.
Buffer/Gel pH Composition
Gel buffer 8.45 3 M Tris base, 0.3 % SDS
Running gel NT 15 % Acrylamide/bisacrylamide, 1 M gel buffer, 13.3 %
glycerol, 0.1 % APS, 2 µl/ml TEMED
Stacking gel NT 5 % Acrylamide/bisacrylamide, 0.75 M gel buffer, 0.1 % APS, 2
µl/ml TEMED
Anode buffer 8.9 0.2 M Tris base
Cathode buffer 8.25 0.1 M Tris base, 0.1 M Tricine, 0.1 % SDS
NT = Not tested
2.15.4 Bradford assay to obtain purified recombinant protein concentration
The concentration of purified His-tagged protein was determined by Bradford assay (Bradford,
1976) as described in section 2.13.2, with a standard curve constructed using human serum albumin
(HSA) concentrations of 0, 2, 4, 6, 8 and 10 µg/ml. Elution samples were first tested on a Nanodrop
using the default option within the A280 setting and results were used to approximate the
necessary dilution required to fit the concentration within the range of standards.
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2.16 Enzyme inhibition assays
Enzyme inhibition assays were conducted in 96 well flat-bottomed microtitre plate formats.
Changes in relative fluorescence units (RFU) were monitored on a Glomax Mulit+ E8032 for human
plasma kallikrein (HPK) assays and black microtitre plates were used. Excitation wavelength was set
at 405 nm and emission wavelength at 495 – 505 nm. Absorbance changes were monitored on a
Versamax microplate reader at 410 nm for human neutrophil elastase (HNE) assays and clear
microtitre plates were used.
Reaction buffers A and B were made according to Table 15 and were autoclaved, stored at 4 °C and
equilibrated to room temperature before use. Ecotin, the inhibitor, was stored in aliquots at -20 °C,
and was diluted to a working concentration of 500 nM in the corresponding enzyme buffer (A or B)
before use. Aliquots of enzymes, substrates and inhibitor were not defrosted more than once and
were used on the same day. For each set of enzyme assays, the standards were characterised on
day 1 and the inhibition was tested on day 2.
Table 15: Composition of buffers used for enzyme inhibition assays. Buffer A was used with human plasma kallikrein and
Buffer B was used with human neutrophil elastase.
Composition
Buffer A 50 mM Tris pH 7.5, 100 mM NaCl, 2 mM CaCl2, 0.005% Triton X-100
Buffer B 0.1 M Tris pH 7.5, 0.5 M NaCl
50 µg human plasma kallikrein was purchased from Merck Millipore (Watford) in liquid form in NaCl
and Tris-HCl buffer at a concentration of 6.28 µM. This was stored in 6 µl aliquots at -20 °C. A
working concentration of 0.1 µM was obtained by diluting in Buffer A. 5 mg fluorogenic HPK
substrate (H-D-Val-Leu-Arg-AFC.2HCl) was also obtained from Merck Millipore (Watford) and was
dissolved in DMSO at a concentration of 2 mM and stored in 405 µl aliquots at -20 °C. A working
concentration of 1 mM was obtained by diluting in Buffer A.
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50 µg of lyophilised human neutrophil elastase was purchased from Merck Millipore (Watford). This
was reconstituted in a buffer containing 50 mM sodium acetate pH 5.5 and 200 mM sodium chloride
to provide an enzyme stock concentration of 10 µM which was stored in 12 µl aliquots at -20 °C. A
working concentration of 0.1 µM was obtained by diluting in Buffer B. 50 mg chromogenic HNE
substrate (Methoxysuccinyl-Ala-Ala-Pro-Val-p-nitroanilide) was also obtained from Merck Millipore
(Watford) and was dissolved in DMSO at a concentration of 8 mM and stored in 500 µl aliquots at -
20 °C. A working concentration of 2 mM was obtained by diluting in Buffer B.
A range of substrate standards were tested to establish normal, uninhibited enzyme kinetics. HPK
was added to a microtitre plate in preparation for a final concentration of 10 nM in a final volume
of 100 µl. 1 mM HPK substrate was then added to produce final concentrations of 0.015, 0.03, 0.06,
0.125, 0.25 and 0.5 mM. All substrate concentrations were tested side by side in triplicate (see Table
16 for template), with the substrate added quickly using a multichannel pipette. The plate was pre-
blanked with Buffer A and fluorescence was monitored every minute for 30 minutes.
Table 16: Microtitre plate template for HPK substrate standards. [E] = enzyme concentration, [S] = substrate concentration
and [I] = inhibitor concentration. Final volume was 100 µl.
Location Contents
A1-A3 Buffer A
B1-B3 [E] = 10 nM, [S] = 0.015 mM, [I] = 0 nM
C1-C3 [E] = 10 nM, [S] = 0.03 mM, [I] = 0 nM
D1-D3 [E] = 10 nM, [S] = 0.06 mM, [I] = 0 nM
E1-E3 [E] = 10 nM, [S] = 0.125 mM, [I] = 0 nM
F1-F3 [E] = 10 nM, [S] = 0.25 mM, [I] = 0 nM
G1-G3 [E] = 10 nM, [S] = 0.5 mM, [I] = 0 nM
A calibration curve was produced for 7-Amino-4-(trifluoromethyl)coumarin (AFC), the fluorophore
cleaved from HPK substrate. Ten concentrations in 0.05 mM increments in the range of 0 – 0.5 mM
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were tested in triplicate and a graph of AFC concentration against mean relative fluorescent units
(RFU) was plotted and the equation of the line determined using linear regression as part of the
GraphPad Prism package.
To establish the rate of reaction for HPK at each substrate concentration, the changes in RFU were
recorded at 5 minutes. These values were converted into concentration of product using the
equation from the AFC calibration curve. The concentration values were adjusted to take into
account the volume of liquid (0.1 ml) in order to establish a quantity of product. The rate of reaction
was calculated by dividing this value by the number of minutes (5) in order to determine the rate
of reaction.
HNE standards were measured as follows: HNE was added to a microtitre plate in preparation for a
final concentration of 17 nM in a final volume of 200 µl. 2 mM HNE substrate was then added to
produce final concentrations of 0.015, 0.03, 0.06, 0.125, 0.25 and 0.5 mM. All substrate
concentrations were tested side by side in triplicate (see Table 17 for template), with the substrate
added quickly using a multichannel pipette. The plate was pre-blanked with Buffer B and
absorbance was monitored every minute for 30 minutes.
Table 17: Microtitre plate template for HNE substrate standards. [E] = enzyme concentration, [S] = substrate concentration
and [I] = inhibitor concentration. Final volume was 200 µl
Location Contents
A1-A3 Buffer B
B1-B3 [E] = 17 nM, [S] = 0.015 mM, [I] = 0 nM
C1-C3 [E] = 17 nM, [S] = 0.03 mM, [I] = 0 nM
D1-D3 [E] = 17 nM, [S] = 0.06 mM, [I] = 0 nM
E1-E3 [E] = 17 nM, [S] = 0.125 mM, [I] = 0 nM
F1-F3 [E] = 17 nM, [S] = 0.25 mM, [I] = 0 nM
G1-G3 [E] = 17 nM, [S] = 0.5 mM, [I] = 0 nM
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In order to calculate the rates of reaction from the data for Michaelis-Menten kinetics, the changes
in absorbance were recorded at 5 minutes for each substrate concentration. Beer-Lambert Law
(Equation 1) was used to establish the concentration of product from these values, where A =
absorbance, Ɛ = molar extinction coefficient and L = light path (cm). p-nitroanilide (pNA), the
chromophore product cleaved from HNE substrate, has a known molar extinction coefficient of
8800 M-1 cm-1, as published by Merck-Millipore. The light path was 0.7 cm.
Equation 1: Beer-Lambert Law equation. A = absorbance, Ɛ = molar extinction coefficient and L = light path (cm).
A = Ɛ C L
The concentration values were adjusted to take into account the volume of liquid (0.2 ml) in order
to establish a quantity of product. The rate of reaction was calculated by dividing this value by the
number of minutes (5) in order to determine the rate of reaction.
For each set of data, substrate concentration was plotted against rate of reaction and Michaelis-
Menten non-linear regression was applied as part of the GraphPad Prism package to calculate the
Vmax and Km values. Both HPK and HNE experiments were repeated using the templates from Table
16 and Table 17 with the enzyme excluded in order to test for autolysis of the substrate.
HPK inhibition was tested one substrate concentration per microtitre plate. In triplicate, each plate
contained a blank well of Buffer A and the full range of ecotin concentrations to be tested, using a
final volume of 100 µl. HPK was added into each well, excluding the blank, for a final concentration
of 10 nM. Ecotin was added at 0, 12.5, 25, 50 and 100 nM (See Table 18 for template). The plate
was incubated at room temperature for 1 hour to equilibrate. At 1 hour, a multichannel pipette was
used to quickly add HPK substrate to rows B – F, resulting in a final concentration of substrate that
was the same for all rows. Fluorescence was then monitored every minute for 30 minutes. Row F,
containing 0 nM ecotin, was compared to the substrate controls from the previous day to test for
reproducibility.
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Table 18: Microtitre plate template for range of ecotin concentrations against HPK and each substrate concentration. [E]
= enzyme concentration, [I] = inhibitor concentration, [S] = substrate concentration. Final volume was 100 µl.
Location Contents
A1-A3 Buffer A
B1-B3 [E] = 10 nM, [I] = 100 nM, [S] = v
C1-C3 [E] = 10 nM, [I] = 50 nM, [S] = v
D1-D3 [E] = 10 nM, [I] = 25 nM, [S] = v
E1-E3 [E] = 10 nM, [I] = 12.5 nM, [S] = v
F1-F3 [E] = 10 nM, [I] = 0 nM, [S] = v
v = variable from plate to plate
HNE inhibition was also tested one substrate concentration per microtitre plate. In triplicate, each
plate contained a blank well of Buffer B and the full range of ecotin concentrations to be tested,
using a final volume of 200 µl. HNE was added into each well, excluding the blank, for a final
concentration of 17 nM. Ecotin was added at 0, 12.5, 25, 50 and 100 nM (See Table 19 for template).
The plate was incubated at room temperature for 1 hour to equilibrate. At 1 hour, a multichannel
pipette was used to quickly add HNE substrate to rows B – F, resulting in a final concentration of
substrate that was the same for all rows. Absorbance was then monitored every minute for 30
minutes. Row F, containing 0 nM ecotin, was compared to the substrate controls from the previous
day to test for reproducibility.
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Table 19: Microtitre plate template for range of ecotin concentrations against HNE and each substrate concentration. [E]
= enzyme concentration, [I] = inhibitor concentration, [S] = substrate concentration. Final volume was 200 µl.
Location Contents
A1-A3 Buffer B
B1-B3 [E] = 17 nM, [I] = 100 nM, [S] = v
C1-C3 [E] = 17 nM, [I] = 50 nM, [S] = v
D1-D3 [E] = 17 nM, [I] = 25 nM, [S] = v
E1-E3 [E] = 17 nM, [I] = 12.5 nM, [S] = v
F1-F3 [E] = 17 nM, [I] = 0 nM, [S] = v
v = variable from plate to plate
For each concentration of ecotin, XY plots of time against RFU were plotted for HPK assays, and
time against absorbance for HNE assays. Plots were also made for the inhibitor concentration
against the ratio of inhibited to uninhibited rate of reaction for each substrate concentration.
Morrison Ki nonlinear regression was applied as part of the GraphPad Prism package in order to
establish the inhibition constants (Ki) for ecotin against each enzyme.
2.17 Clotting assays
Blood was taken from three different donors on separate days. The experiments with each blood
sample were completed within 6 hours of the sample being taken. Platelet-poor plasma was
prepared as described in section 2.12.4 and normal clotting times were established. A waterbath
was set to 37 °C and maintained with 0.5 °C. All tests were carried out in 12 x 75 mm glass test
tubes. Clotting was observed by visual assessment.
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2.17.1 Thrombin time (TT)
Bovine thrombin (Diagnostic Reagents, Thame) was purchased in a lyophilised preparation for use
in TT assays and was reconstituted in 1 ml of sterile deionised water and used within 2 hours.
Thrombin was diluted in barbitone buffered saline (TCS Biosciences, Buckingham) to a working
solution of 7.5 units/ml.
200 µl platelet-poor plasma was warmed to 37 °C in a waterbath. 50 µl His-Elution buffer (see Table
13) was added, to be used as the negative control, and the mixture was incubated for a further 2
minutes. 100 µl bovine thrombin was added and a stopwatch was used to record the clotting time.
2.17.2 Prothrombin time (PT)
Calcium rabbit brain thromboplastin (Diagnostic Reagents, Thame) was purchased in a lyophilised
preparation for use in PT assays and was reconstituted in 4 ml of sterile deionised water and used
within 2 hours.
100 µl platelet-poor plasma was warmed to 37 °C in a waterbath. 50 µl His-Elution buffer was
added, to be used as the negative control, and the mixture was incubated for a further 2 minutes.
200 µl warmed thromboplastin was added and a stopwatch was used to record the clotting time.
Tubes were gently tilted at regular intervals.
2.17.3 Activated partial thromboplastin time (APTT)
Kaolin platelet substitute mixture (Diagnostic Reagents, Thame) was purchased in a lyophilised
preparation for use in APTT assays and was reconstituted in 5 ml of sterile deionised water and
used within 4 hours.
200 µl kaolin platelet substitute mixture was warmed to 37 °C in a waterbath. 50 µl His-Elution
buffer was added, to be used as the negative control, and 100 µl platelet-poor plasma. The mixture
was incubated for 2 minutes. 100 µl of prewarmed 25 mM calcium chloride was added and a
stopwatch was used to record the clotting time. Tubes were gently tilted at regular intervals.
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2.17.4 Effect of ecotin on TT, PT and APTT assays
Once the clotting time of the negative controls (0 µM ecotin) had been recorded for TT, PT and
APTT assays, a range of ecotin concentrations were tested. The ecotin concentrations tested were
0, 0.25, 0.5, 0.75, 1 and 2 µM for TT and PT tests and 0, 0.06, 0.125, 0.25, 0.5, 0.75, 1 and 2 µM for
APTT tests. Following inhibition tests, uninhibited clotting was repeated to confirm that the
prolongation of clotting was not due to time bias. All experiments were run in duplicate and mean
clotting times were plotted as ecotin concentration against fold prolongation.
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Chapter 3:
F. necrophorum strain collection and
identification
3.1 Introduction and aims
Strain type collections include those of the Japan Collection of Microorganisms (JCM) (Microbe
Division (Jcm)(Riken Brc), 2015), the American Type Culture Collection (ATCC) (Atcc: The Global
Bioresource Center, 2015) and the National Collection of Type Cultures (NCTC) (Culture Collections,
2015). These collections represent bacterial strains, cell lines, viruses, fungi and DNA material that
are preserved and characterised, and can be used as standards and controls during experiments,
such as antimicrobial testing, or biochemical tests.
F. necrophorum can be identified biochemically, by molecular techniques, or a combination of the
two; see section 1.2.2 for biochemical profile. Narongwanichgarn et al. (2001) used the API 20A test
for identification of anaerobes to confirm strains as F. necrophorum, based on the key test of indole
production. A haemagglutination test was used to subspeciate them, with strains causing
haemagglutination of washed chicken red blood cells classed as subspecies necrophorum, and those
not causing haemagglutination were classed as subspecies funduliforme. All 19 strains
demonstrated β-haemolysis on agar plates. They trialled the use of Random Amplified Polymorphic
DNA PCR (RAPD PCR) as a new test for subspeciation and found one primer (W1L-2) to be effective,
causing amplification in those identified as Fnn and no amplification in those identified as Fnf. This
work was followed up by using two new primer pairs in a one-step duplex PCR reaction. One of the
primer pairs amplified a 250 bp product from both subspecies, while the other a 900 bp from Fnn
only. These fragments were identified by sequence data as the rpoB and haemagglutinin-related
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protein genes, respectively (Narongwanichgarn et al., 2003), suggesting that these genes are
appropriate targets for molecular subspeciation assays.
Jensen et al. (2007) developed an assay to detect the subspecies of F. necrophorum using real-time
PCR. Colonies on agar plates were initially identified based on colony morphology, odour, green
fluorescence when irradiated with UV light, Gram stain, antimicrobial susceptibility testing and β-
haemolysis on blood agar plates to be confirmed as F. necrophorum. PCR primers were then used
to target the gyraseB (gyrB) gene of both subspecies, amplifying a region of 306 bp. Subspecies-
specific TaqMan probes were designed to bind within the amplified region. The PCR results were
followed up by using species-specific RNA polymerase β-subunit (rpoB) PCR primers and a single
probe specific to F. necrophorum. Both sets of primers amplified product in 100 % of F.
necrophorum strains. All isolates were assigned the correct subspecies by the gyrB probes, based
on previous records of the strains.
Aliyu et al. (2004) also used real-time PCR targeting the rpoB gene. Two TaqMan probes were used
that were both specific to F. necrophorum, but did not subspeciate the strains. Strains were
subspeciated using PCR primers targeting the haemagglutinin-related protein gene in a SYBR-green
assay. Strains showing amplification in the SYBR-green assay were identified as Fnn, and those that
did not show amplification were identified as Fnf.
Other studies have used 16S rRNA gene sequences to identify (Oikonomou et al., 2012) or diagnose
infection with (Sanmillán et al., 2013) F. necrophorum. Farooq et al. (2015) used PCR primers
specific to the leukotoxinA (lktA) gene alone to identify F. necrophorum strains, suggesting
confidence that this gene is universal among F. necrophorum strains. Antiabong et al. (2013) used
PCR primers targeting the rpoB and haemagglutinin-related protein genes in order to identify and
subspeciate strains. 16S rRNA and lktA primers were also tested.
A collection of F. necrophorum strains was required to carry out experimental work for this project.
Two laboratories were approached and strains were donated for use in this study. Type strains of
F. necrophorum subspecies necrophorum and F. necrophorum subspecies funduliforme and a
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collection of clinical isolates were acquired. All isolates for use in this project were identified to
species and subspecies levels, using a mixture of biochemical and molecular techniques, and type
strains as positive controls. All of the strains received had been identified as F. necrophorum prior
to arrival at the University of Westminster. It was therefore hypothesised that all strains would be
identified as F. necrophorum during identification tests for this project. It was also hypothesised
that all of the clinical strains would be identified as subspecies funduliforme, as human infections
are most often this subspecies (Smith et al., 1990; Riordan, 2007).
3.2 Results
3.2.1 Fusobacterium necrophorum strain collection
F. necrophorum strains JCM 3718 and JCM 3724 were kindly donated by the Anaerobe Reference
Unit (ARU), Cardiff, for use in this study. The strains are from the Japan Collection of
Microorganisms, although also feature in the American Type Culture Collection, as strains ATCC
25286 and ATCC 51357 for JCM 3718 and JCM 3724, respectively. JCM 3718 has been identified as
being subspecies necrophorum and JCM 3724 as subspecies funduliforme. Both strains were
isolated from bovine liver abscesses and added to the JCM in 1985. The two subspecies were
proposed and named by Shinjo et al. (1991) based on haemagglutination tests and DNA homology
(section 1.2.1) and the type strains JCM 3718 and JCM 3724 were selected.
The ARU also provided a clinical strain, isolated in 2002 from a blood sample of a patient with
Lemierre’s syndrome. For this study the isolate was named ARU 01. A collection of F. necrophorum
human clinical isolates were also provided by Antonia Batty, University College Hospital London.
Twenty six of these were used for this study.
3.2.2 Identification of strains using biochemical tests
Biochemical profiles of the human clinical isolates were characterised to ensure they matched that
of F. necrophorum (methods section 2.7). Twenty six strains were subcultured and confirmed as
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Gram negative rods, with negative results for oxidase and catalase tests and a positive result for
indole production. All strains had a typical cream-grey appearance and butyric acid odour
characteristic of F. necrophorum, with the exception of strain number 88 which had a white
appearance on the agar plate, which was noted as atypical.
The three strains provided by the ARU were also tested for biochemical profiles. JCM 3718, JCM
3724 and ARU 01 all matched the expected profile and appearance.
3.2.3 Identification of strains using F. necrophorum-specific gyraseB PCR
primers
The 26 strains from the clinical collection and the three strains from the ARU were tested with F.
necrophorum-specific gyrB PCR primers (Jensen et al., 2007) (Table 20) to confirm the identity of
the strains as F. necrophorum (methods section 2.8.2 and 2.8.3). Twenty five out of the 26 strains
from the clinical collection produced amplified products of the expected size (306 bp). Strain
number 88, which was previously noted as having an atypical appearance had no amplification of
product. The strain was therefore identified as not being F. necrophorum and was excluded from
the collection. JCM 3718, JCM 3724 and ARU 01 all had amplified products of the expected size. See
Figure 3 for a gel electrophoresis image of amplified gyrB products.
Table 20: PCR primers used to amplify F. necrophorum gyrB genes.




1 2 3 4 5 6 7 8
Figure 3: Analysis of PCR products from F. necrophorum-specific gyrB primers on a 1% agarose gel. Lane 1: 100bp ladder;
lanes 2 – 7: strains 1, 5, 11, 21, 24, 30, respectively; lane 8: negative control (molecular grade water).
3.2.4 Subspeciation using TaqMan probes
The strains were subspeciated using Fnn and Fnf-specific TaqMan probes (Jensen et al., 2007) with
the F. necrophorum specific gyrB primers; with the probes tested in separate PCR tubes (see
methods 2.8.4). Fluorescence from Fnf-specific probes was measured on the yellow channel of the
RotorGene Q PCR machine, while fluorescence from Fnn-specific probes was measured on the
green channel. Samples showing an increase in fluorescence sufficient to exceed the threshold were
considered as having a positive result for the associated probe. Thresholds were set in the early
logarithmic phase of the amplification curves.
JCM 3718, JCM 3724 and ARU 01 were first tested along with five of the clinical strains in order to
validate the probes. Figure 4 (and sample key in Table 21) displays the result of these strains tested
with the subspecies funduliforme probe. JCM 3724 and ARU 01 had a positive result with the Fnf
probe while JCM 3718 and the negative control showed no increase in fluorescence. The five clinical
strains from the collection were also expected to be subspecies funduliforme, due to their human
origin, and all showed a positive result with the Fnf probe.
300 bp
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Figure 4: Fluorescence from Fnf-specific TaqMan probes measured on the yellow channel of a RotorGene Q PCR machine.
See Table 21 for sample key.
Table 21: Sample key for Figure 4. All tubes contained Fnf probe.










The same strains were tested with the subspecies necrophorum probe (Figure 5 and Table 22),
which measured a positive result for JCM 3718 only.
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Figure 5: Fluorescence from Fnn-specific TaqMan probes measured on the green channel of a RotorGene Q PCR machine.
See Table 22 for sample key.
Table 22: Sample key for Figure 5. All tubes contained Fnn probe.










The probes had the expected results for the reference strains, resulting in a confirmed subspecies
of funduliforme for JCM 3724 and necrophorum for JCM 3718. For the remaining samples sets, the
number of cycles was reduced from 55 to 40 and JCM 3724 was used as a positive control. Figure 6
and associated sample key Table 23, along with Figure 7 and Table 24 show the remainder of the
clinical strain collection testing positive for subspecies funduliforme.
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Figure 6: Fluorescence from Fnf-specific TaqMan probes measured on the yellow channel. See Table 23 for sample key.
Table 23: Sample key for Figure 6. All tubes contained Fnf probe.











Figure 7: Fluorescence from Fnf-specific TaqMan probes measured on the yellow channel. See Table 24 for sample key.
Table 24: Sample key for Figure 7. All tubes contained Fnf probe.


















It had been hypothesised that all strains would identify as F. necrophorum during identification tests
for this project, due to prior identification of the strains. The isolates received from Antonia Batty,
University College Hospital London, had previously been confirmed as F. necrophorum as part of
previously published work (Batty et al., 2005; Batty and Wren, 2005). The strains received from the
ARU consisted of two type strains that had been well characterised and identified to the subspecies
level and a clinical isolate that had previously been identified as subspecies funduliforme. The
biochemical tests that were chosen for identification purposes were therefore not exhaustive. The
most important tests were determined to be a Gram stain and the indole test (Barrow and Feltham,
2004).
The gyrB TaqMan probe method developed by Jensen et al. (2007) was chosen as the method of
subspeciation due to its simplicity. The haemagglutinin PCR primer method was avoided as the
presence of the haemagglutinin gene in F. necrophorum subspecies has not been thoroughly
studied in a large sample set. In addition, the type strains ATCC 25286 and ATCC 51357, which are
the same strains as JCM 3718 and JCM 3724, respectively, had been tested with the gyrB primers
and TaqMan probes as part of the Jensen et al. (2007) publication, and therefore served as both
positive and negative controls for their corresponding/opposing probes.
The strains were first tested with the gyrB primers under standard PCR conditions and viewed on a
gel to confirm the presence of one band of the expected size before the real-time PCR method was
used. In future, it would be enough to test strains using the real-time PCR alone, as detection by
the probes is dependent on amplification of the gyrB product.
Strain number 88 was determined not to be F. necrophorum based on a lack of amplification by the
gyrB primers. This therefore demonstrated the hypothesis that all strains would prove to be F.
necrophorum was invalid. Had the molecular techniques not have been used, additional
biochemical tests would have been required to ensure an accurate identification. It was, however,
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noted that the appearance and smell of strain 88 were not as expected, and more emphasis would
have been placed on this, if not for the gyrB PCR and TaqMan probe work.
It had also been hypothesised that all clinical strains would be identified as Fnf. Upon completion
of this section of the work, there were 28 F. necrophorum strains available for use in this study. 25
were Fnf strains from the UCLH collection, one Fnf clinical strain from the ARU collection, known to
have caused Lemierre’s syndrome in a patient, and one type strain of each subspecies. Of the
clinical strains that were identified as F. necrophorum, 100 % were identified as Fnf, which is in
agreement with the hypothesis.
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Chapter 4:
Genomics of F. necrophorum
4.1 Introduction and aims
DNA sequencing has progressed a great deal since Sanger et al. (1977a) sequenced the first DNA
genome, that of bacteriophage φX174, using the ‘plus and minus’ method. This method was soon
developed into what is now commonly referred to as the Sanger sequencing method (Sanger et al.,
1977b). In 1995 the first bacterial genome, that of Haemophilus influenzae, was sequenced in full
using a whole-genome, random sequencing method (Fleischmann et al., 1995). Large sequencing
projects have contributed a great deal to the advancement of DNA sequencing techniques and
subsequent data analysis, particularly The Human Genome Project, which was launched in 1990.
The initial draft and analysis of the genome was published in 2001, by which time the cost of
sequencing had dropped 100-fold (Lander et al., 2001), making DNA sequencing a far more
accessible tool for researchers. More recently, large numbers of bacterial genomes have been
sequenced as part of projects such as the Human Microbiome Project (HMP) and the Genomic
Encyclopedia of Bacteria and Archaea. The HMP began in 2008 with the aim of sequencing microbial
samples obtained from multiple body sites of healthy volunteers in order to study the correlation
between human health and the microbiome. A metagenomic sequencing approach was used and
in excess of 12,000 DNA samples were sequenced (Aagaard et al., 2013). As there had been some
debate over whether F. necrophorum is a commensal or strictly a pathogen, as reviewed by Riordan
(2007) and discussed in section 1.3, it was unclear whether F. necrophorum genomes would be
sequenced as part of the project. Also, if they were to be sequenced, there was uncertainty
regarding the reliability of metagenomic data due to the nature of sequencing from mixed DNA
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samples. A reliable genome sequence of an F. necrophorum type strain was required if the organism
and its pathogenic mechanisms were to be better understood.
Bacterial genomes are comprised of double-stranded DNA as single circular chromosomes. They
tend to have a high density of genes, with about 90 % of the DNA present encoding proteins.
Plasmids may also be present as extrachromosomal DNA (Madigan and Martinko, 2006).
There are a variety of techniques used for bacterial genome sequencing, assembly and annotation,
which change as new technologies become available. Next generation sequencing, also known as
high-throughput sequencing, includes technologies such as Roche 454, Illumina, Ion Torrent and
Pacific Biosciences (summarised in Table 25). The choice of technology is dependent on the project
type and available funding. At the time the current project was planned, 454 sequencing was the
primary choice for de novo sequencing projects, i.e. where there is no similar genome available to
be used as a reference sequence.
454 sequencing uses pyrosequencing, which involves pyrophosphate being released each time a
nucleotide is incorporated by DNA polymerase which subsequently leads to the production of light
by the enzyme luciferase. The amount of light produced is proportional to the number of
nucleotides incorporated. 454 sequencing produces longer sequence reads than Illumina, allowing
for easier assembly, however the data is susceptible to errors in homopolymer regions due to the
nature of simultaneously adding multiple nucleotides (Mardis, 2008).
Illumina technologies tend to be more cost effective than 454 sequencing and use a method
resembling traditional Sanger sequencing (Hodkinson and Grice, 2015). At each base position,
reversible terminators with removable fluorophores are incorporated and identified, then the
fluorophore removed ready for the next base incorporation (Bentley et al., 2008). Sequencing with
Illumina technologies such as HiSeq or MiSeq are often used where a reference genome is already
available, or to resequence a genome in order to correct errors, and improve coverage and
assembly by providing additional sequence data. PCR and Sanger sequencing, which are not
appropriate for acquiring high throughput data, may then be used to complete the genomes and
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bridge gaps in the sequence. Due to financial constraints, resequencing and gap closing steps are
often excluded. Errors in Illumina sequencing tend to be substitution errors rather than frame shift
errors as nucleotides are added one by one (Hodkinson and Grice, 2015). Frame shift errors affect
annotation to a much greater extent than substitution errors, as with a substitution a protein can
still be annotated in full, whereas with a frameshift the remaining protein sequence will be read
incorrectly or may be abruptly terminated.
Ion Torrent machines, which were not widely available at the time the current project was in the
planning stages, were designed to be inexpensive and more accessible to research laboratories.
Here, the technology monitors pH as nucleotides are added during the sequencing reaction,
detecting H+ ions that are released as a by-product. As with 454 technology, Ion Torrent sequence
data is also susceptible to errors in homopolymer regions.
A different type of technology is used by Pacific Biosciences, whose machines utilise a
nanotechnology chip with DNA polymerases attached to detectors. Nucleotides with
phospholinked dye-labels are incorporated and imaged in real time during the synthesis of DNA
strands. The technology has a high base call error rate, however each DNA fragment is sequenced
multiple times which corrects most errors and leads to a high level of accuracy (Mardis, 2013;
Hodkinson and Grice, 2015).
78
Table 25: Summary of sequencing technologies and associated advantages and disadvantages of each.
Platform Chemistry Highest average
read length
Advantages Disadvantages
Roche 454 Pyrosequencing 700 bp Longer read lengths









300 bp Cost effective
Errors are usually
substitution errors














8,500 bp Very long read lengths
High level of accuracy
Expensive
Sequence data is created in multiple formats; FASTA format is a simple text-based format in which
DNA or protein sequence is displayed using single letter nucleotide or amino acid code. Each
sequence begins with a greater than symbol (>) and an identifying sequence header, containing the
name of the sequence and/or a description. FASTQ format contains FASTA format along with
corresponding data quality scores and is also a text based format. 454 sequence data uses Qual
format instead of FASTQ. The difference being that in Qual files the FASTA data is not present, as it
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is with FASTQ files, but quality scores are in the same order as the corresponding sequence file
containing FASTA format data.
Once genomes have been sequenced the raw output data must be assembled by looking for
overlapping sequence regions. Contiguous sequence data, known as contigs, are formed in order
to create a putative reconstruction of the genome that is as complete as possible. Two common
methods used in assemblers are Overlap Layout Consensus methods, which rely on overlap graphs,
and de Bruijn Graph Methods, which use K-mer graphs. K-mers are sequences of base calls of length
K, which can be any positive integer. Sequence reads that share K-mers in overlapping regions are
connected into a graph which generates connected sequences (Miller et al., 2010). Many sequence
assembly algorithms are based on de Bruijn graphs, such as Velvet (Zerbino and Birney, 2008),
ABYSS (Simpson et al., 2009) and AllPaths (Butler et al., 2008). K-mers are ideal for reads with short
lengths and high coverage. They are less computationally expensive as redundant data is
compressed (Miller et al., 2010). Overlap Layout Consensus (OLC) methods are used for de novo
assemblies and have three steps. Firstly overlaps are found by comparing every sequence against
every other sequence, known as an all-against-all alignment, in the forward and reverse
orientations. This is a very computationally expensive step and creates a graph of overlaps which
are subsequently simplified during the layout step into contigs. The consensus stage uses the
multiple sequence alignments to exclude sequencing errors. Higher sequencing coverage results in
better error correction (Li et al., 2012). Newbler (Margulies et al., 2005) is a genome sequence
assembler designed by 454 specifically for 454 data and uses the OLC method (Miller et al., 2010).
Statistics of interest for genome sequence data are the coverage, number of contigs, and contig
sizes, including N50 and N90 sizes. Coverage is determined by the total length of all sequenced
bases in a genome divided by the total number of expected bases. It equates to the average number
of reads that each base position is present on. The number of contigs indicates how close to
completion the genome is. The N50 and N90 values are the sequence lengths at which 50 % and 90
% of the total assembly residues are contained within contigs of this size or larger.
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Once a genome is assembled into contigs the next aim is to annotate the genes it contains. Open
reading frames are defined by coding sequence with an initiation codon and stop codon in the same
frame, and exceed a pre-defined base pair length. The number of genes are recorded along with
their function. Non-protein encoding genes such as tRNAs and rRNAs are often also annotated.
Automated web-based tools such as xBASE (Chaudhuri et al., 2008), BASys (Van Domselaar et al.,
2005) and RAST (Aziz et al., 2008) can be used for gene prediction and annotation. As part of the
genome annotation process, virulence genes are often characterised based on sequence homology
to those that have been previously characterised by laboratory analysis.
The Basic Local Alignment Search Tool (BLAST) (Blast: Basic Local Alignment Search Tool, 2015) can
be used as part of automatic or manual annotation. BLAST finds regions of similarity between
sequences by comparing nucleotide or protein input sequences to sequences in a database, and
calculates the statistical significance of the matches. Expect (E) values are reported and correspond
to the likelihood of the match occurring by chance. The lower the E value, the more significant the
match is. BLAST can be used to identify conserved domains and members of gene families as well
as providing clues to functionality and evolutionary history relationships between sequences
(Altschul et al., 1997). BLAST has several different programs, including BLASTn for searching a
nucleotide database with a nucleotide input sequence and BLASTp for searching a protein database
with a protein input sequence. Pfam (Pfam, 2015) is a protein database used for identifying protein
families, domains and inferring protein function (Finn et al., 2014), complementing BLAST query
search results well. Most commonly, an automated, often web-based, tool is used for annotating
genome data. The results may subsequently be manually curated. The annotation results are based
on in silico predictions and are therefore hypothetical protein annotations, unless they have also
been experimentally shown.
Different strains of the same species can show variation in the genes they contain and within the
sequences of their genes, affecting metabolic pathways, virulence mechanisms, antimicrobial
resistance mechanisms and genes that help the bacteria adapt to their environment. Bioinformatic
tools can be used to compare genomes in order to identify these differences (Sangal et al., 2014).
81
Programs such as Artemis Comparison Tool (Carver et al., 2005), Mauve (Darling et al., 2004) and
CGView (Stothard and Wishart, 2005) are all available as open source software for comparative
work.
When this project started, in September 2011, there was no available genome sequence for F.
necrophorum. Genomic data was becoming increasingly important and providing new methods for
analysing organisms and the genes that they contain. The aim of this chapter was to provide the
first genome sequence for both subspecies of F. necrophorum, complete with annotation. This was
to identify genes in F. necrophorum that were previously unknown. It was also to increase the
sequence data available for individual genes within F. necrophorum that have already been
sequenced and studied, while also providing additional information such as the surrounding genes
and operons. Type strains JCM 3718 and JCM 3724, alongside ARU 01, a clinical strain of human
origin associated with Lemierre’s syndrome (section 3.2.1) were sequenced. It was hypothesised
that the genomes would be approximately 2.2 Mb, based on the sequenced genome of F.
nucleatum (Kapatral et al., 2002); the most closely related organism with a completed genome. It
was also hypothesised that once annotated the genome data would contain virulence genes such
as the leukotoxin, which had previously been described in F. necrophorum, and additional virulence
genes that had not previously been described in F. necrophorum. An additional aim of the chapter
was to investigate whether differences in virulence between the two subspecies could be explained
by genomic differences, testing the hypothesis that there was a simple explanation for the
difference in virulence between Fnn and Fnf.
The best available method was used for de novo sequencing and assembly, which at the time was
454 sequencing and Newbler assembly. The genomes were annotated using the xBASE pipeline
(Chaudhuri et al., 2008) and BLASTp, and were subsequently mined in order to search for genes
reported to be associated with virulence in other organisms, with the intention of further
characterising some of these. Once the genomes had been sequenced, the first F. necrophorum
genome became available online and was subsequently followed by additional genomes. The initial
genome sequencing and analysis was carried out in 2012. In 2015, an update on the genomic data
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available was incorporated to compare the data from other projects to the data generated as part
of this project.
4.2 Results
4.2.1 Genome sequencing and assembly
JCM 3718, JCM 3724 and ARU 01 were commercially sequenced by GATC Biotech (Konstanz,
Germany) using Roche 454 GS-FLX+ next generation sequencing. The raw sequence reads, which
had mean sizes of 301, 299 and 296 nucleotides for JCM 3718, JCM 3724 and ARU 01 respectively,
were assembled into larger contigs using Roche GS Assembler, also known as Newbler. Table 26
summarises the resulting data. Genome coverage was calculated using Equation 2 and an initial
estimate of 2.17 Mb for the expected number of base pairs in each genome, based on the genome
size of F. nucleatum (Kapatral et al., 2002). Sequence information that later became available (first
sequence shown in Table 28) led to this figure being revised to 1.96 Mb, which lead to the value
1,960,000 being used in the calculations in Table 26.
Equation 2: Equation to calculate the coverage of a genome sequence.
Coverage = (Number of raw reads x mean size of raw reads)
Expected number of base pairs in genome
Files containing the raw sequence reads, the associated quality (Qual) files and the FASTA format
assembly contigs are located in Appendix files A – I.
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Table 26: Summary of sequencing data from the three genomes.
JCM 3718 (Fnn) JCM 3724 (Fnf) ARU 01 (Fnf)
Number of raw reads 85,434 64,685 90,274
Mean size of raw reads 301 299 296




Average contig size 2,835 3,097 4,715
Largest contig 28,070 40,328 41,389
Total number of bases
in contigs
2,301,868 1,947,814 2,055,836
4.2.2 Contig annotation using xBASE and BLAST
The assembled contigs were uploaded into the xBASE pipeline (Chaudhuri et al., 2008) in FASTA
format for prediction of open reading frames and gene product annotations, using F. nucleatum as
a reference (methods section 2.9.2). Table 27 summarises the xBASE annotation data. Files
containing the xBASE annotation data in Genbank format are located in Appendix files J – L.
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Table 27: Summary of xBASE annotation showing the number of predicted open reading frames (ORFs) for each genome,
and the proportion that were assigned a gene product. Those unlabelled or labelled as hypothetical were later annotated
using BLAST.
JCM 3718 (Fnn) JCM 3724 (Fnf) ARU 01 (Fnf)









797 (40 %) 642 (37 %) 751 (39 %)
xBASE output files are produced in GenBank format. To convert them to a user-friendly comma-
separated value file to be used with Microsoft Excel, a program was created using an OpenVMS
operating system to extract the information of interest (Program code in Appendix M). The
GenBank file was the input and a comma-separated value file was the output. The resulting Excel
spreadsheet had data under the headings: assembly contig, base location, orientation, product and
protein sequence.
The predicted open reading frames that were unlabelled or had been labelled as hypothetical were
then manually annotated using BLASTp searches using the methods described in section 2.9.4. The
results were added to the Microsoft Excel file containing the xBASE annotation results (Appendix
files N – P). See section 4.2.6 for genes of interest.
4.2.3 Comparison of additional F. necrophorum draft genomes
Following the genome sequencing from section 4.2.1 of this project, the F. necrophorum subsp.
funduliforme ATCC 51357 genome sequence was made available online as part of the Human
Microbiome Project (HMP). This strain from the American Type Culture Collection is also known as
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JCM 3724, from the Japan Collection of Microorganisms and hence should be identical to the DNA
sequenced as part of the current project. This resulted in two sets of available genome data for this
strain.
The genome sequence for strain Fnf 1_1_36S was the first F. necrophorum genome available online,
labelled as the reference genome for the Human Microbiome Project. This genome sequence was
later labelled as misassembled and was therefore excluded from the following comparisons.
Additional draft F. necrophorum genomes have also been recently sequenced and made available
on the NCBI online database (National Center for Biotechnology Information, 2015) and are listed
in Table 28. One of these, F. necrophorum subspecies funduliforme strain B35, has been published
(Calcutt et al., 2014). See section 4.2.6 for genes of interest that were found.
The strains that have been sequenced are mostly of animal origin therefore there is still a need for
genome sequences of F. necrophorum isolated from humans, particularly those associated with
disease.
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Table 28: F. necrophorum genomes downloaded from the NCBI database.








D12 Human GCA_000158295.2 454 Newbler 15x 1.96 17 1942 27/07/2011
ATCC 51357f Bovine liver abscess GCA_000262225.1 Illumina Newbler 23.27x 2.11 45 2026 10/05/2012
Fnf 1007f Human GCA_000292975.1 Illumina Newbler 30x 2.17 87 2145 27/08/2012
B35f Bovine liver abscess GCA_000600355.1 454 Newbler 59x 2.09 40 1978 26/03/2014
HUN048 Rumen microbiome GCA_000622045.1 Illumina HiSeq Allpaths Unknown 2.03 17 1945 08/04/2014
BL Bovine liver GCA_000691645.1 Illumina MiSeq Velvet 22.26x 2.46 235 2309 15/05/2014
DAB Deer jaw abscess GCA_000691705.1 Illumina MiSeq Velvet 17.92x 2.52 254 2347 15/05/2014
BFTR-1 Bovine footrot GCA_000691685.1 Illumina MiSeq Velvet 15.77x 2.53 304 2412 15/05/2014
BFTR-2 Bovine footrot GCA_000691725.1 Illumina MiSeq Velvet 11.96x 2.61 389 2599 15/05/2014
DJ-1 Deer Jaw GCA_000691665.1 Illumina MiSeq Velvet 11.47x 2.46 370 2393 15/05/2014
DJ-2 Deer Jaw GCA_000691745.1 Illumina MiSeq Velvet 25.98x 2.52 226 2382 15/05/2014
f = subspecies funduliforme
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The average sizes of the contigs in Table 28 were calculated by dividing the genome size by the
number of contigs. These values were then plotted against the number of genes present in each
genome (Figure 8). Gene numbers were retrieved by Batch Entrez (Batch Entrez, 2015). Nonlinear
regression was applied using GraphPad Prism and a strong trend, with an R squared value of 0.94,
seemed to show that smaller average contig sizes are linked with higher numbers of genes. Smaller
average contig sizes are a result of higher contig numbers and/or poor assembly. The graph does
not take into consideration the varying overall sizes of the genomes but still has a strong pattern,
suggesting that all F. necrophorum genomes may have very similar numbers of genes present and
be approximately the same size. The graph was estimated to plateau at 1,950 genes. The majority
of the variation in total gene numbers may be due to the assembly and annotation. Gaps in the
genome may cause a gene to be split over two contigs, being counted as two genes instead of one.
The more gaps in a sequence there are, the more false genes that will be counted.














Figure 8: XY plot of average contig size against the number of overall genes annotated in the genomes listed in Table 28.
The majority of F. necrophorum genomes available in Table 28 have not been subspeciated. Isolates
ATCC 51357, Fnf 1007 and B35 have been previously identified as subspecies funduliforme. As the
strains were not available for laboratory based work, in silico analysis of the genome data was the
only option for subspeciating the strains. The DNA sequences of the gyrase B PCR primers and
TaqMan probes used in section 3.2.4 and the gyrB sequences from each of the genomes were
downloaded from the European Nucleotide Archive website (European Nucleotide Archive, 2015).
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The sequences were trimmed to exclude sequence upstream of the forward primer and
downstream of the reverse primer and a phylogenetic tree was made using Seaview and PhyML
(methods section 2.10.6). Figure 9 shows two distinct groups of strains. The bottom group contains
strains of bovine and deer origin and they appear to have identical sequences in this region. JCM
3718 is known to be subspecies necrophorum. The top group contains strains that were previously
known to be subspecies funduliforme, with the exception of D12 and HUN048 which were not
subspeciated. They are noted as being from human origin, so subspecies funduliforme seems likely,
suggesting that those in the top group are Fnf, while those in the bottom group are Fnn.
Figure 9: Phylogenetic tree of gyrB sequences to subspeciate strains, constructed using Seaview and PhyML. The scale
represents the average number of base changes per position for the length shown. Longer branch lengths therefore
represent a greater number of base changes.
In addition to the phylogenetic tree in Figure 9, a Clustal alignment was made of the top group
sequences against the subspecies funduliforme TaqMan probe sequence, and the bottom group
sequences against the subspecies necrophorum TaqMan probe (Appendix 8). In both cases, the
sequences were all 100 % congruent with the expected matching probe.
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4.2.4 Contig merging JCM 3724 data for assembly improvement
As there were two available genome data sets for strain JCM 3724/ATCC 51357, the genome
assembly was improved by merging the two sets of data in order to bridge gaps between the
contigs. The sequence data for ATCC 51357 was produced by Illumina sequencing and had been
assembled using Newbler. The 45 assembled contigs were downloaded from the European
Nucleotide Archive (Data contained in Appendix Q).
The Illumina set of contigs from the HMP and the 454 set of contigs from this project were sent to
Source Bioscience to be merged into one set of contigs using the program Minimus2, in order to
reduce the number of contigs (Resulting FASTA file in Appendix R).
Statistical analysis of the FASTA contigs from the Illumina contigs, 454 contigs and the Minimus2
merged data was carried out using the program Stats, within a Linux operating system. The
minimum, maximum and average lengths of the contigs were calculated, along with the N50, N80
and N90 values, the number of ‘N’s within each set of contigs, the number of contigs and the total
residues for each set of data (Table 29). The N50 is the length at which 50 % of the total assembly
residues are contained within contigs of this size or larger. The N80 and N90 correspond to 80 %
and 90 %, respectively.
The Minimus2 data had a larger average contig size and smaller number of contigs. It also had a
larger number of total residues, leaving fewer bases to be sequenced if the gaps are to be filled in
future work. The Minimus2 data is a substantial improvement on the 454 sequence data of JCM
3724. This is reflected in the marked increase in the N50, N80 and N90 statistics in Table 29.
90
Table 29: Genome assembly statistics using the program Stats.





Minimum 112 530 116
Maximum 40,328 183,913 305,638
Average 3,096.68 46,906.71 60,714.86
N50 5,720 85,366 95,412
N80 2,294 53,256 66,012
N90 1,308 38,220 41,642
‘N’ count 9 0 0
Number of contigs 629 45 35
Total residues 1,947,814 2,110,802 2,125,020
4.2.5 BASys statistics
In addition to the statistics calculated using the Stats program in Table 29, the BASys annotation
pipeline was used to compare the gene lengths of the JCM 3724 genome before and after it was
merged with the sequence data available under the strain name ATCC 51357. Figure 10 shows the
changes that occurred to the predicted genes as a result of having a more complete assembly. The
JCM 3724 sequence data was 1,947,814 bases in length and was predicted to include 2,521 genes.
After the data was merged with the additional sequence data available as ATCC 51357, the number
of bases increased to 2,125,020 and the number of genes predicted by BASys reduced to 2,368. This
supports the suggestion that a higher number of contigs increases the number of false gene
predictions. It appears that the additional gaps in the contigs cause more genes predicted of
between 100 bp and 200 bp. The reduced number of contigs causes a more even spread of gene
sizes. Graphs for strains JCM 3718 and ARU 01 are shown in Appendix 9. They show that JCM 3718,
with 812 contigs, and ARU 01, which has 436 contigs also have a large proportion of small genes
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that are likely to be overestimated. The predicted number of genes is higher than the number
predicted by xBASE, however as xBASE is no longer operational, the merged data cannot be















































































































































Figure 10: Gene lengths predicted by BASys in A) JCM 3724 genome data, and B) genome data sets merged using
Minimus2.
4.2.6 Putative virulence genes
The annotation data from section 4.2.2 was mined for genes hypothesised to be related to virulence
of the organism, based on characterisation within other organisms. The results were compared to
those found in strain B35 (Calcutt et al., 2014) and also to the annotation data present on the BioCyc
database (Biocyc, 2015) for strains ATCC 51357 and D12. Calcutt et al. (2014) discussed finding
unique genes linked to lipopolysaccharide biosynthesis, an adhesin-filamentous haemagglutinin
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and four CRISPR loci. A selection of the virulence genes found in the genome data of JCM 3718, JCM
3724 and ARU 01 are discussed below.
4.2.6.1 Leukotoxin
The annotation for B35 on the ENA database (European Nucleotide Archive, 2015) includes the
leukotoxin, which is thought to be the primary virulence factor of the organism (Tan et al., 1994a).
The leukotoxin operon, containing a total of three genes, was found in the genome annotations of
JCM 3718, JCM 3724 and ARU 01 (annotation data in Appendix files N – P). Strains D12 and ATCC
51357 are annotated on the BioCyc database as containing the leukotoxin operon. While this is
clearly annotated and named for strain D12, the ATCC 51357 strain includes it as a hypothetical
protein and does not feature the label leukotoxin. The leukotoxin is investigated in further detail in
chapter 5.
4.2.6.2 Ecotin
Strains JCM 3718, JCM 3724 and ARU 01 were all found to contain a serine protease inhibitor,
known as ecotin. This was found by manual BLASTp search and not by the xBASE automatic
annotation pipeline. Strains ATCC 51357 and D12 include ecotin in their annotation data, and
searching the ENA database for ecotin within F. necrophorum shows that it is also present in strains
Fnf1007, B35, BFTR-1, BFTR-2, DAB, BL, DJ-1 and DJ-2. This protein from F. necrophorum has not
previously been characterised in laboratory experiments and is investigated in chapter 6.
4.2.6.3 FadA adhesin
As discussed in section 1.8.5, the FadA adhesin is a known virulence determinant in F. nucleatum
and other oral Fusobacterium spp., F. periodonticum and F. simiae. The xBASE and BLASTp genome
annotation data (section 4.2.2) was mined for the FadA gene and no copies of the gene were initially
found. In order to further test for the presence of the gene within F. necrophorum genomes, PCR
primers were used, designed to amplify a product of 359 bp based on the F. nucleatum FadA gene
(Han et al., 2005) (Table 30). Late in the project, when additional genomes had become available
online, the BLAST searches were repeated for the FadA adhesin, and copies of the gene were found
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in strains DJ-1, DJ-2, BFTR-1, BFTR-2, BL, DAB and JCM 3718. There was not sufficient time or
resource left to investigate this further as part of this project, but this would be studied as part of
future work.
As part of the strain identification work in chapter 3, strain number 88 was excluded from the F.
necrophorum clinical collection due to its atypical morphology and non-amplification of the F.
necrophorum gyraseB gene. The biochemical profile and morphology (section 3.2.2) indicate a
possibility that it could be a F. nucleatum strain. The strain was therefore determined to have
potential for amplification of FadA and providing an indication of how a positive control may appear
for this gene. Strains JCM 3718, JCM 3724, ARU 01 and all 25 of the clinical F. necrophorum isolates
were tested and resulted in non-amplification of FadA. See Figure 11 for example gel. Due to non-
amplification of the gene product among the F. necrophorum strains, the identification of strain 88
was not confirmed and the FadA gene was deemed unlikely to be present within any of the strains
in the collection that were identified as F. necrophorum.
Table 30: PCR primers used to amplify FadA gene.
Primer Oligonucleotide sequence (5’ → 3’)
FadA_F TTAGCTGTTTCTGCTTCAGC
FadA_R TTACCAGCTCTTAAAGCTTG
1 2 3 4 5 6 7 8
Figure 11: Analysis of PCR products from FadA primers on a 1% agarose gel. Lane 1: 100bp ladder; lanes 2 – 4: strains JCM
3718, JCM 3724, ARU 01, respectively; lane 5: blank; lane 6: negative control (molecular grade water); lane 7: previously
excluded strain 88; lane 8: blank.
400 bp
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4.2.6.4 Type V secretion systems
There are three subtypes of type V secretion systems: Type Va are autotransporters, type Vb are
two-partner secretion (TPS) systems, and type Vc are trimeric autotransporter adhesins. TPS
systems are comprised of a secreted TpsA protein and a TpsB transporter protein. The TpsA protein
is an exoprotein that also includes a signal peptide and a TPS domain that makes it specific to the
TpsB protein. The TpsB protein is a β-barrel transporter and also contains a signal peptide and a
polypeptide transport-associated domain (POTRA) (Figure 12). Each TpsB protein is specific for the
TpsA protein that it secretes (Hodak and Jacob-Dubuisson, 2007).
Figure 12: Protein organisation of TPS secretion system.
TPS systems are often used for secreting large virulence proteins, such as adhesins. Examples
include the filamentous haemagglutinin (FHA) of Bordetella pertussis and haemolysin of Serratia
marcescens. They contain conserved motifs with amino acid sequences NPNL and NPNGI within the
TPS domain, although some TPS systems may contain slight variations (Jacob‐Dubuisson et al.,
2001).
The BLASTp annotation data of strains JCM 3718 and JCM 3724 was found to contain TPS secretion
domains, with motifs NPNL and NENGI, 35 residues apart within a haemolysin protein. Figure 13
shows a section of a protein sequence Clustal alignment of B. pertussis FHA and haemolysins from
JCM 3718 and JCM 3724 (xBASE protein annotation numbers 1,601 and 1,234, respectively). ARU
01 contained a haemolysin gene with NDNGI 39 bases upstream of NKNL. The TPS motifs were not
found in any other proteins.
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fhaB         NP-GVVFNNGLTDGVSRIGGALTKNPNLTRQASAILAEVTDTSPSRLAGTLEVYGKGADL 172
JCM3718      DKNNVIFNNSQKNGTSVTGGEVSANPNLTNSASVILNEIQGNSASELNGGLEVFGKRADL 118
JCM3724      DKNNVIFNNSQKNGTSVTGGEVSANPNLTNSASVILNEIQGNSASELNGGLEVFGKRADL 151
:   *:***. .:*.*  ** :: *****..**.** *:  .* *.* * ***:** ***
fhaB         IIANPNGISVNGLSTLNASNLTLTTGRPSVNGGRIGLDVQQGTVTIE--RGGVNATGLGY 230
JCM3718      VIANENGINVNGARFINTSALTLSTGKVSVDNKKISFNTATNNAKIAVKEKG-IETDSDY 177
JCM3724      VIANENGINVNGARFINTSALTLSTGKVSVDNKKISFNTATNNAKIAVKETG-MKTDSDY 210
:*** ***.***   :*:* ***:**: **:  :*.::.   ...*   . *   *   *
Figure 13: Clustal Omega protein alignment of B. pertussis FHA, a well characterised TPS system, and haemolysins from
JCM 3718 and JCM 3724. The alignment is trimmed to focus on the TPS domain motifs, highlighted in yellow.
Autotransporters differ from the TPS system in that the gene is coded in a single coding sequence.
There is one signal peptide, followed by the sequence for both the secreted protein and the
transporter (Figure 14). The secreted protein, also known as the passenger domain, is passed
through the outer membrane by the transporter, also known as the translocation domain. The two
regions remain connected by a linker region (Hodak and Jacob-Dubuisson, 2007). Type Va and Vc
secretion systems are both autotransporters, however trimeric autotransporter adhesins are
formed by three monomers that each include head, stalk and anchor regions (Linke et al., 2006).
Figure 14: Protein organisation of autotransporter secretion system.
The BLASTp annotation data of strains JCM 3718, JCM 3724 and ARU 01 was found to include head,
stalk and anchor regions of a trimeric autotransporter adhesin (TAA) similar to the YadA adhesin in
Yersinia spp. YadA-like adhesins have been found in other organisms, such asMoraxella catarrhalis,
and have been linked with autoagglutination and binding to host cells (Hoiczyk et al., 2000).
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4.2.6.5 CRISPR-associated genes
As mentioned in the B35 strain publication by Calcutt et al. (2014), F. necrophorum contains CRISPR-
associated genes. These were also found within strains JCM 3718, JCM 3724 and ARU 01. The
CRISPR-associated genes annotated by the manual BLASTp search are listed in Table 31.
Table 31: CRISPR-associated genes






When the ATCC 51357 database was searched on BioCyc, the operon in Figure 15 was detailed.
CRISPR-associated genes have recently been shown to be effective tools for genome editing (Liu
and Fan, 2014; Pennisi, 2013) and therefore they have been noted here as being present within the
genomes, however they are not investigated further as part of this project.
Figure 15: CRISPR-associated (cas) genes present in ATCC 51357 database on BioCyc.
4.2.6.6 Additional putative virulence genes
The JCM 3718, JCM 3724 and ARU 01 genomes were also found to contain genes associated with
phage, hemin receptors and iron acquisition, a filamentous haemagglutinin and other genes of
interest listed in Table 32. These are annotated in Appendix files N – P but were not selected for
further investigation within this project.
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4.2.6.7 Prevalence of virulence genes within Fusobacterium spp. and other organisms and
rationale for further work
Of the gene products covered within this chapter and in Table 32 below, many of these are
prevalent within other organisms, while others are more specific to certain Fusobacterium spp.
The leukotoxin gene, lktA, has been found in F. necrophorum spp. (Tan et al., 1994a) and F. equinum
(Tadepalli et al., 2008), but no other Fusobacterium spp. (Oelke et al., 2005). Other leukotoxins have
also been found in Staphylococcus aureus (Yoong and Torres, 2013), Mannheimia haemolytica
(Highlander et al., 1989) and Actinobacillus actinomycetemcomitans (Karakelian et al., 1998),
although there is very little similarity between the lktA gene and any other leukotoxins when
compared by DNA or protein sequence alignments. This suggests that the lktA gene is unique to F.
necrophorum and F. equinum.
The presence of ecotin has been shown in Escherichia coli (Chung et al., 1983) and other Gram
negative bacteria, including Pseudomonas aeruginosa and Yersinia Pestis, (Gillmor et al., 2000).
Searching online databases such as NCBI reveals additional ecotin sequence data for Gram negative
bacteria. Prior to this project, ecotin had not been described in Fusobacterium spp. There are now
sequences available on the NCBI database for F. necrophorum, F. equinum and F. gonidiaformans.
No sequence data was found for ecotin in F. nucleatum despite a completed genome being
available.
The FadA adhesin is unique to oral Fusobacteria spp., and was found to be absent from non-oral
species, although F. necrophorum was not tested (Han et al., 2005). Upon initial searches of the
genomes of JCM 3718, JCM 3724 and ARU 01 during this project, no copies of the FadA gene were
found. When tested with F. nucleatum FadA-specific PCR primers all F. necrophorum strains had no
amplification of product. However, very late into the project, the FadA gene was located in several
Fnn genomes using BLAST programmes. These strains, identified as presumptive Fnn in section
4.2.3, were JCM 3718, DJ1, DJ2, DAB, BL, BFTR-1 and BFTR-2.
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Type V secretion systems are only present in Gram negative bacteria, due to the presence of the
outer membrane in these organisms but not Gram positive bacteria (Leo et al., 2012). These
secretion systems are often associated with virulence factors that can be either maintained on the
surface of the cell or secreted into the cell’s surroundings (Leo et al., 2012; Desvaux et al., 2005).
Secretion systems Va, Vb and Vc have been found in F. nucleatum using bioinformatics techniques
(Desvaux et al., 2005) and it was therefore expected that F. necrophorum would contain some of
these, to support the organism’s need to adhere to host surfaces in order to be pathogenic. Type V
secretion genes found are briefly covered in section 4.2.6.4.
CRISPR-associated genes are found in many bacterial species (Kirchner and Schneider, 2015). The
CRISPR-Cas system is considered to be a prokaryotic immune system, protecting the organism from
foreign invading genetic elements (Rath et al., 2015). A search of Fusobacterium CRISPR genes on
the BioCyc website returns sequences for F. necrophorum, F. nucleatum, F. gonidiaformans, F.
mortiferum, F. periodonticum, F. russii, F. ulcerans and F. varium.
Overall, the leukotoxin and ecotin sections of work were chosen as they were considered to be
achievable within the restricted budget and timeframe, the facilities and tools were available for
the experiments required, and there was potential for novel findings. The leukotoxin has been
described as the organism’s primary virulence factor (Tan et al., 1994a) and was therefore
considered important to investigate. Ecotin was a protein that had not previously been described
in F. necrophorum and therefore had potential for novel findings.
The FadA gene was discovered in the Fnn strains too late in the project to proceed with
experimental work, however it would be interesting to investigate as part of future work. Assays to
investigate the haemagglutinin and haemolysin as part of a study into type V secretion systems
were considered in depth, however it was concluded that the facilities required for the assays were
not available, therefore work on these proteins was not taken any further. CRISPR genes became
very topical in scientific literature during the course of this project, however it would have been
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unlikely to achieve any novel findings that were specifically linked with F. necrophorum
pathogenesis, as opposed to CRISPR processes in general, therefore these genes were not studied
as part of this project. Phage-associated proteins and hemin receptor and transport system proteins
were considered of interest, but it was concluded that these proteins were not the most likely to
yield novel results and they were not investigated further.
Virulence-associated protein E and virulence factor mviN are both claimed to be virulence related,
however there was not enough information available on these proteins to make an assessment of
the likelihood of producing any novel work. Drug resistance proteins are important in terms of
virulence and infections in vivo, however were not intended as the focus of this project, so were
not investigated further. The lipid A biosynthesis protein from Table 32 was of interest due to lipid
A being a component of endotoxic lipopolysaccharide (Caroff and Karibian, 2003). The capsular
polysaccharide biosynthesis protein was also of interest due to F. necrophorum possessing a
mucopolysaccharide capsule (Brook and Walker, 1986). Investigating either of these two proteins
was not considered likely to produce novel information. Neutrophil-activating protein A could play
a role in virulence of F. necrophorum. Helicobacter pylori is known to produce its own neutrophil-
activating protein which acts as a virulence factor, stimulating immune responses (Amedei et al.,
2006). Investigating this in F. necrophorum could potentially yield some important novel findings,
however this gene was not located until late into the project and the facilities to investigate this
were also not available.
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Table 32: Summary table of annotated genes of interest
Gene product JCM 3718
Gene present in:
JCM 3724 ARU 01
leukotoxin operon ✓ ✓ ✓
haemolysin ✓ ✓ ✓
haemagglutinin ✓ ✓ ✓
FadA ✓ NF NF
YadA-like adhesin ✓ ✓ ✓
ecotin ✓ ✓ ✓
CRISPR/CRISPR-associated proteins ✓ ✓ ✓
haemin receptor and binding/transport systems ✓ ✓ ✓
Phage proteins ✓ ✓ ✓
5-nitroimidazole antibiotic resistance protein ✓ ✓ ✓
acriflavin resistance proteins ✓ ✓ ✓
multi-drug resistance proteins ✓ ✓ ✓
Na+ driven multidrug efflux pump ✓ ✓ ✓
penicillin-binding protein ✓ ✓ ✓
florfenicol resistance ✓ ✓ ✓
virulence factor mviN ✓ ✓ ✓
virulence-associated protein E ✓ ✓ NF
capsular polysaccharide biosynthesis protein ✓ NF ✓
Lipid A biosynthesis protein NF ✓ ✓
neutrophil-activating protein A ✓ ✓ ✓
NF = Not found
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4.3 Discussion
At the time of sequencing, in early 2012, the use of 454 sequencing and Newbler assembly was an
appropriate choice for de novo genome sequencing. The Pacific Biosciences technology was too
expensive and Ion Torrent was not widely available at the time. 454 was more suitable than Illumina
for de novo sequencing due to producing longer mean read lengths.
Genome sequencing has dramatically increased in popularity, with lower costs making the
technology more accessible to researchers. The increasing number of F. necrophorum genomes,
listed in Table 28, demonstrates this with only one submitted to the NCBI in 2011, increasing to
eight in 2014. Table 28 also shows how the choice of sequencing technology switched from 454 to
Illumina. This could be due to the fact that there was no longer the need to carry out a de novo
assembly once an initial F. necrophorum sequence was available and also that the Illumina
sequencing technology was improving, producing longer reads and better value for money. There
does not appear to be an overall improvement in levels of coverage of the genomes between 2011
and 2014. Rather than being representative of sequencing technology it is likely to be due to project
planning and the coverage deemed necessary for each genome, considering that additional
coverage comes at additional cost.
A more appropriate choice for F. necrophorum de novo sequencing would now be Pacific
Biosciences technology, due to the long read lengths, high level of accuracy and lower costs than in
2012. Although considering the number of genomes already available, de novo sequencing is no
longer required, and Illumina sequencing now is the most cost effective method to acquire F.
necrophorum genome sequence data. 454 will not be an option for much longer, as according to
Hodkinson and Grice (2015), Roche are no longer supporting the 454 sequencing platforms after
2016. GATC Biotech have already stopped commercially using the technology.
The switch from 454 to other sequencing platforms also signals the potential switch away from
Newbler assembly, which as mentioned in section 4.1 is specifically designed for 454 data (Miller et
al., 2010). Velvet is becoming much more popular and more recent versions are allowing for larger
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K-mers, which is beneficial as regions of sequence repeats are subsequently more likely to be
spanned (Chikhi and Medvedev, 2014). In addition to this, the web-based annotation pipeline
xBASE, which was used for this project is no longer available for use. The field of genomics has
advanced a great deal over recent years and as new technologies and analytical software become
available, older ones become redundant.
At the start of this project there was no available genome sequence data for F. necrophorum. With
much unknown about the pathogenesis of the organism during infection, and the greater emphasis
recently on the use of genomic data, it was clear that the bacterium needed to be sequenced.
Despite the addition of eleven genomes to the NCBI database, there remains only one published
article on the F. necrophorum genome. The article, published by Calcutt et al. (2014) covers a brief
description of a draft genome. There is still clearly a great deal of the genome left to be investigated.
The genome data provided by the work in this chapter represents the most complete assembly for
strain JCM 3724/ATCC 51357 by combining the 454 and Illumina sequencing data. This strain is
important as it is the type strain for F. necrophorum subsp. funduliforme (Shinjo et al., 1991). The
genome data also provides the first genome sequence for strain JCM 3718, also known as ATCC
25286, which is the type strain for F. necrophorum subsp. necrophorum (Shinjo et al., 1991). These
type strains are used as references during various types of characterisation experiments and
provide a method of external quality control. For example, during the TaqMan PCR work by Jensen
et al. (2007) that was used in section 3.2.4. The third genome sequenced as part of this project is
the first to be recognised as originating from human disease. This is important as there may be
virulence genes present in strains that are capable of causing LS that could be lacking from other F.
necrophorum strains. Therefore, if the genome is to be studied for virulence factors associated with
disease, then isolates should be used from disease sources.
While there is still no complete genome for F. necrophorum, the data provided in this chapter, along
with the genomes available on the NCBI database (listed in Table 28), provide a great deal of
information that was lacking at the start of this project, and also opportunity to further study the
organism. By mapping the different sets of genome contigs against one another there is also enough
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data to predict the order of some of the contigs in data sets with small contig numbers and begin
the process of gap closing by PCR and Sanger sequencing.
The coverage of the three sequenced genomes ranged between 9.87X and 13.63X (Table 26). The
level of coverage expected was 13X – 24X, as predicted by the GATC Biotech sequencing specialist.
Factors that may cause a decrease in coverage include biases in the sample preparation or the
sequencing (Sims et al., 2014). As mentioned in section 4.2.1, the coverage is determined using the
values for the number of raw reads, the mean size of the raw reads, and the expected number of
base pairs in the genome. The low level of coverage with the GATC Biotech data appears to be due
to the read lengths, detailed in Table 26. The 454 data was expected to produce read lengths with
a mean of 700 bp, however it produced mean read lengths of approximately 300 bp. This is more
closely aligned with the mean read length of Illumina technology. It seems that the short read
length is the likely cause of the coverage being lower than expected, although no explanation was
provided by GATC Biotech. As a consequence of this, the number of contigs for each genome was
quite large, which is a problem if trying to complete the genome by gap closing, but does not greatly
hinder the study of the genes contained within the genome.
The total number of bases in each of the three sequenced genomes ranges from 1.95 Mb – 2.3 Mb.
Once the JCM 3724 454 data was merged with the Illumina data, the total number of bases in the
assembly increased from 1.95 Mb to 2.13 Mb, causing the new size range for the three genomes to
be 2.06 Mb – 2.3 Mb. This closely matches the hypothesis in section 4.1, which stated that the
sequenced F. necrophorum genomes were expected to be approximately 2.2 Mb, due to the size of
the F. nucleatum genome sequenced by Kapatral et al. (2002). The genome sequence of strain B35,
published in 2014, was reported to be 2.09 Mb (Calcutt et al., 2014), and it is also within the range
of genome sizes listed in Table 28: 1.96 Mb – 2.61 Mb. When the genome sizes from Table 28 are
separated according to assembly software, the size range for Newbler is 1.96 – 2.17 Mb, whereas
the size range for Velvet assemblies is 2.46 Mb – 2.61 Mb, suggesting the choice of assembly
software has a large effect on the total number of bases. When the phylogenetic tree (Figure 9)
used to subspeciate the strains is taken into account, it can be seen that the genomes assembled
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with Newbler are all Fnf, while the Velvet assembled genomes are all Fnn, so perhaps the Fnn
genome is larger than that of Fnf. Such large differences seem unlikely, however, and differences
in assembly methods are the most probable cause.
The annotation of F. nucleatum by Kapatral et al. (2002) using the ERGO bioinformatics suite
resulted in 67 % of ORFs assigned a function. Using xBASE, with F. nucleatum as a reference,
between 60 – 63 % of the ORFs in the F. necrophorum genomes were annotated (Table 27). Both
organisms are likely to contain some genes that are absent in the other, such as the leukotoxin in
F. necrophorum but not F. nucleatum, therefore the 60 – 63 % ORF annotation rate was within the
expected range. The remaining ORFs were analysed using BLASTp to annotate as much of the
genomes as possible and provide some manual curation. The graph in Figure 8 and associated non-
linear regression suggest that the number of genes in the F. necrophorum genome is approximately
1,950. This is similar in number to 2,067 genes present in F. nucleatum (Kapatral et al., 2002). If the
Fnn genome was in fact larger than that of Fnf, then the data points would perhaps have an R
squared value far lower than 0.94.
While GenBank is a commonly used file format and is compatible with some viewer programs, such
as Artemis, it is not easy to read by eye. The script written for conversion to excel file format
provides a table that is simple to read, and also allows easy extraction of the protein sequence.
The additional genomes that have been sequenced and are available on the NCBI database have
been assembled and include some annotation data, however no analysis of this has been published,
with exception of strain Fnf B35 which has brief details published (described in section 4.2.6). The
subspecies of the majority of these F. necrophorum strains was unknown. The use of a phylogenetic
tree to subspeciate these genomes allows for a better understanding of the data provided and
allows for comparisons to be made between the subspecies. It also supports the general
understanding that animal infections are caused by Fnn and that Fnf can be found in both animals
and humans. The phylogenetic tree (Figure 9) and the alternative method of using Clustal
alignments with the sequence of the gyrB TaqMan probes (4.2.3 and Appendix 8) were both an
effective use of bioinformatic tools where no laboratory option was available. The tree provides
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some additional information in that the gyrase B sequences of Fnn are very well conserved whereas
there is a small amount of variation between the Fnf isolates. Given that these strains infect a wider
range of hosts, that is perhaps not so surprising.
The genomes for strains JCM 3718, JCM 3724 and ARU 01 were mined for genes previously reported
to be associated with virulence in other organisms. The hypothesis in section 4.1 stated that the
genome annotation data would contain the leukotoxin and additional virulence genes that had not
previously been described in F. necrophorum. The leukotoxin, which has been described as the
organisms primary virulence factor (Tan et al., 1994a), was found in all three genomes. Ecotin, a
serine protease inhibitor which had not previously been described in F. necrophorum was also
found in all three. E. coli ecotin has been associated with increased clotting times in human blood
(Ulmer et al., 1995) and this protein was therefore determined to be of interest. The FadA adhesin
gene, known to be present in F. nucleatum (Han et al., 2005), was briefly investigated in F.
necrophorum genomes and found in JCM 3718, as well as other Fnn genomes. Chapters 5 and 6
discuss the leukotoxin and ecotin in further detail.
Motifs were found within a haemolysin gene in strains JCM 3718 and JCM 3724 (Figure 13), which
suggest the protein is secreted via a two-partner secretion system. This has not previously been
described in F. necrophorum. The motifs within strain ARU 01 are less well conserved and also in
the reverse order, however, not all TPS proteins need both motifs (Jacob‐Dubuisson et al., 2001),
so secretion may be unaffected if this system is indeed used. A YadA-like adhesin that acts as an
autotransporter was also found within the annotation data. This, like the TPS system, is another
type V secretion system. The head, stalk and anchor regions were all located.
With so little information published on the F. necrophorum genome, the information in this chapter
represents the first description of several F. necrophorum virulence factors.
It had been hypothesised that there was a simple explanation for the difference in virulence
between Fnn and Fnf, such as genomic differences between the strains. After studying and
comparing the annotated genomes it was concluded that the differences in virulence cannot be
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explained by gross differences in the genomes and that variations in virulence between strains is
much more complex. Host and environmental factors are likely to play a role as well as subtle gene
differences which could make virulence proteins more or less effective.
107
Chapter 5:
Analysis of F. necrophorum leukotoxin
sequence, prevalence and activity
5.1 Introduction and aims
Many bacteria are known to produce toxins, which may be either toxic proteins released
extracellularly (exotoxins) or toxic lipopolysaccharides maintained as part of the outer layer of the
cell envelope (endotoxins) (Madigan and Martinko, 2006). Bacterial toxins cause damage to human
and animal target cells in a variety of ways, such as by forming pores in membranes, inhibiting
protein synthesis, activating secondary messenger pathways, activating the immune system and by
protease action (Schmitt et al., 1999). Examples of bacterial toxins include the leukotoxins of
Staphylococcus aureus (Yoong and Torres, 2013),Mannheimia haemolytica (Highlander et al., 1989)
and Actinobacillus actinomycetemcomitans (Karakelian et al., 1998). Leukotoxins are a type of
exotoxin that are toxic to leukocytes, particularly polymorphonuclear cells (PMNs) (Narayanan et
al., 2002a). F. necrophorum subspecies necrophorum (Fnn) and F. necrophorum subspecies
funduliforme (Fnf) are both known to produce a leukotoxin (lktA) that is a water soluble, heat-labile,
protein exotoxin with an affinity for ruminant and human leukocytes (Tan et al., 1994a; Tadepalli
et al., 2008a).
During F. necrophorum infection, the leukotoxin appears to be the primary virulence factor (Tan et
al., 1994a), with a correlation between the amount of toxin produced by strains and their ability to
cause abscesses in laboratory animals demonstrated by Emery et al. (1986). The toxin is known to
target blood cells. When tested, PMNs from cattle and sheep were the most susceptible to the
leukotoxic supernatant, whereas pig and rabbit PMNs were unaffected (Tan et al., 1994a).
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The leukotoxin, which can be found in the culture supernatant of the two subspecies of F.
necrophorum (Tan et al., 1994a), has been described as larger than other bacterial leukotoxins, with
a molecular mass of 336 kDa (Narayanan et al., 2001b). The leukotoxin ofMannheimia haemolytica
is 105 kDa (Chang et al., 1987), Actinobacillus actinomycetemcomitans is 114 kDa (Kachlany et al.,
2002), and Staphylococcus aureus is 37 kDa (Marshall et al., 2000). The F. necrophorum leukotoxin
has also been described as potentially novel, due to its lack of sequence similarity to other known
bacterial leukotoxins (Narayanan et al., 2001b). More recently, BLASTp searches of lktA protein
sequences have revealed homology of approximately 25 – 30 % to adhesin and haemagglutinin
proteins. Oelke et al. (2005) investigated the presence of the leukotoxin in Fusobacterium spp. using
Southern blotting and Western blotting for leukotoxin DNA and protein, respectively. They reported
a positive finding for F. necrophorum and negative findings for F. nucleatum, F. gonidiaformans, F.
mortiferum, F. necrogenes, F. simiae, F. ulcerans and F. varium. The leukotoxin has also been found
in F. equinum, an organism closely related to F. necrophorum that causes equine necrotic infections.
The lktA protein was shown to be secreted, but lktB and lktC, the remaining proteins coded for by
the leukotoxin operon in F. necrophorum were not found (Tadepalli et al., 2008). This finding was
supported by Zhou et al. (2009b) who confirmed the presence of the F. equinum leukotoxin but
reported difficulties in identifying the DNA sequence data, resulting in only a short fragment of the
lktA gene being sequenced. It would be of great interest to compare the leukotoxins of F.
necrophorum and F. equinum, however due to the lack of available F. equinum sequence data and
lack of access to F. equinum strains, the F. equinum leukotoxin was not studied as part of this
project.
The mode of action of the F. necrophorum leukotoxin is unknown. A limited amount of research has
been carried out on the leukotoxin, predominantly by a research group based in Kansas State
University, Kansas, USA. The purification of the leukotoxin and determining the DNA sequence of
the lktA gene have been particularly valuable contributions, enabling in depth analysis of purified
leukotoxin, cloning experiments, molecular detection work and bioinformatic analysis.
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In order to be able to carry out affinity purification of F. necrophorum leukotoxin, Tan et al. (1994b)
produced monoclonal antibodies (mAbs) of the IgG class by injecting mice with semipurified
leukotoxin. Antibodies were harvested, purified by affinity chromatography and labelled with
biotin. The group showed that two of the mAbs partially neutralised the activity of the leukotoxin,
but only when they used polyclonal serum could they completely neutralise the leukotoxin activity.
This may suggest that the epitopes of the mAbs may be inaccessible when the leukotoxin is
interacting with target cells, or in a region that does not largely affect toxin activity. The mAbs
remain useful for affinity purification purposes.
Narayanan et al. (2001b) produced a library of bovine strain F. necrophorum subsp. necrophorum
A25 genomic DNA fragments between 10 and 12 kb in length into Lambda Zap Express vectors for
cloning and expression. Anti-leukotoxin polyclonal serum was used to determine which of the
clones contained the leukotoxin. The recombinant DNA from the leukotoxin clone was sequenced
and inverse PCR was used to extend the sequence to encompass the entire leukotoxin gene. The
open reading frame was shown to be 9,726 bp, encoding for a protein of 3,241 amino acids and a
molecular weight of 335,956 Da. The secreted protein was described as having substantial
hydrophobicity, with 14 potentially membrane spanning regions, which could be very important in
determining a potential mode of action. Pore-forming toxins insert transmembrane pores in the
target cell to disrupt ions across the plasma membrane (Schmitt et al., 1999). If the F. necrophorum
leukotoxin is a pore-forming toxin it would require hydrophobic regions to create the pores.
E. coli host cells containing the first 3.5 kb of the cloned lktA gene lysed upon IPTG induction of the
protein. This may have been due to the tertiary folding pattern of the truncated leukotoxin leaving
an active region more exposed. Narayanan et al. (2001b) therefore constructed five smaller
truncated polypeptides of the lktA gene (P1 – P5), which were purified and analysed by Western
blotting for reactivity against polyclonal and monoclonal antibodies raised against native leukotoxin
(Figure 16). The polyclonal serum reacted strongly with peptides one, two and five, which equated
to bases 1 – 1,107, 919 – 3,696 and 7,405 – 9,723 of the lktA gene and weakly against peptides
three and four (bases 3,553 – 5,691 and 5,626 – 7,509, respectively). The monoclonal antibody
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reacted against the first peptide only. Antisera raised against peptides one and three were shown
to have neutralising activity against the native leukotoxin, as determined by a microculture
tetrazolium assay. Antibodies raised against peptides two, four and five did not have neutralising
activity, suggesting they may be concealed by the folding pattern of the native leukotoxin. This
analysis of truncated polypeptides provides some insight into which regions are immunogenic and
potentially active toxin regions and may be of use during future sequence analysis. P1 reacted with
monoclonal antibodies and strongly with polyclonal serum. Antisera raised against this truncated
polypeptide had neutralising activity against native leukotoxin, suggesting that the P1 region of the
lktA gene may be important to the structure and function of the leukotoxin. The 3.5 kb truncated
peptide (which had the approximate length of truncated peptides 1 and 2 combined) was toxic to
E. coli host cells, however full length recombinant leukotoxin was not. The toxicity of the 3.5 kb
truncated peptide to E. coli cells further supports the suggestion that the active region may be
within region P1 and/or P2. P2 also reacted strongly with polyclonal serum.  The full length
recombinant protein was found to be extremely unstable, with many breakdown products visible
on Western blots. This was also observed with native purified leukotoxin. This will be a factor for
consideration during future leukotoxin assays. Recombinant full length leukotoxin was toxic to
bovine neutrophils (Narayanan et al., 2001b).
Figure 16: Diagram of five truncated polypeptides of the cloned leukotoxin gene and their respective reactivity with
polyclonal serum and monoclonal antibodies. The lktA box represents the 9,726 bp leukotoxin gene and boxes P1 – P5
represent the truncated polypeptides. Labels P**, P, mAb and N represent a strong reaction with polyclonal serum, a weak
reaction with polyclonal serum, a reaction with monoclonal antibodies and neutralising activity of native toxin by antisera
raised against this truncated polypeptide, respectively.
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In order to investigate the mechanism of toxicity induced by the leukotoxin, Narayanan et al.
(2002b) exposed bovine peripheral leukocytes suspended in RPMI medium to various
concentrations of immunoaffinity purified leukotoxin. After 45 minutes at 37 °C in an atmosphere
of 5 % CO2, the cells were washed and resuspended in Hank’s balanced salt solution and stained
with propidium iodide to evaluate cell viability. Flow cytometry and scanning and transmission
electron microscopy were used to analyse the cells post treatment. The flow cytometry data
showed that upon leukotoxin treatment the mononuclear cells had a dose-dependent decrease in
cell size and an increase in granularity, which are both characteristics of apoptosis. The PMNs had
decreased in size but had no significant increase in granularity. The reduction in cell size was
suggestive of apoptosis being the mechanism of leukotoxic action, as opposed to necrosis. Numbers
of cells decreased significantly at very high concentrations of toxin (>1,250 U/ml) which was
suggestive of complete cell lysis. The amount of leukotoxin present in the host during infections is
unknown. F. necrophorum is known to cause necrotic infections (Riordan, 2007; Hagelskjaer
Kristensen and Prag, 2000), which suggests that the organism utilises toxic mechanisms potent
enough to cause tissue necrosis to occur.
PMNs viewed with scanning electron microscopy appeared to clump, decrease in size and show
lesions resembling pores after treatment with leukotoxin. At very high concentrations they showed
large craters and were agglutinated. Indicators of apoptosis were plasma membrane blebbing and
apoptotic bodies. Transmission electron microscopy of treated PMNs showed signs of apoptosis,
including nuclear collapse, condensed chromatin, condensed cytoplasmic organelles, and a
decrease in the cytoplasmic layer. The PMNs also showed signs of activation, such as translocation
of granules to the cytoplasm periphery. The study concluded that at low concentrations of
leukotoxin, apoptosis and activation were induced and at higher concentrations necrosis occurred.
For PMNs, 0.02 – 0.2 U/ml leukotoxin induced apoptosis, 20 U/ml enhanced activation, and >200
U/ml induced necrosis. For monocytes, 2 – 20 U/ml induced apoptosis and >600 U/ml induced
necrosis. They speculated that while membrane damage did occur to PMNs, pore formation was an
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unlikely cause as the cells would have increased rather than decreased in size due to the
uncontrolled entry of water into the cell (Narayanan et al., 2002b).
Tadepalli et al. (2008a) tested for the leukotoxin gene and leukotoxic activity in four strains of F.
necrophorum subsp. funduliforme of human origin. Analysis by PCR confirmed that all four strains
contained the lktA gene and promoter, and using Western blotting the secretion of leukotoxin was
confirmed. Human peripheral PMNs were treated with culture supernatants for 45 minutes at 37
°C and 5 % CO2. Cells were washed twice and resuspended in 0.01 M PBS and stained with
propidium iodide. Samples were processed on a flow cytometer to test for viability. All of the
culture supernatants from the human strains exhibited toxicity to human PMNs. Bovine PMNs were
not tested. The data showed strain to strain variation in the level of cytotoxicity. When culture
supernatants were pretreated with proteases, leukotoxic activity decreased. It was therefore
suggested that the strain variation in levels of cytotoxicity may be partly related to the levels of
proteolytic enzymes secreted by the strains, cleaving the leukotoxin.
Secreted toxins from Fnn and Fnf had the same banding pattern on a Western blot (Tadepalli et al.,
2008b). This may represent consistency with the breakdown of products, or it may be specific
proteolytic products. It was suggested by Tadepalli et al. (2008b) that these products are
breakdown products, as the leukotoxin is known to be unstable (Tan et al., 1994a; Narayanan et al.,
2001b), and that the differences in toxicity are therefore due to differing quantities of expression
rather than differing stabilities. Recurring intense bands for F. necrophorum subsp. necrophorum
were at ~250, 150, 130 and 110 kDa, amongst other less intense bands. F. necrophorum subsp.
funduliforme produced less intense bands overall, although this may have been due to the
polyclonal serum being raised against leukotoxin from a Fnn strain (Tadepalli et al., 2008a). These
banding patterns will provide a useful comparison for any protein analysis carried out as part of this
project.
F. necrophorum leukotoxin has been shown to be very sensitive to changes in temperature and pH.
Leukotoxic activity of culture supernatant was retained at 4 °C and 25 °C for up to 4 hours, however
incubating at 56 °C or boiling for 5 minutes removed leukotoxic activity. At 37 °C leukotoxic activity
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was decreased by 19 %. As this is a physiological temperature it has implications during infections.
However, during infections leukotoxin may be continuously produced and therefore degraded toxin
would be replaced. Maximal leukotoxic activity occurred between pH 6.6 and 7.8. At pH <6 the
leukotoxin was inactivated (Tan et al., 1994a). It is therefore of great importance to carefully store
and handle the leukotoxin.
The Fnn leukotoxin gene is considered to be part of an operon of three genes (Narayanan et al.,
2001b). The leukotoxin operon of F. necrophorum subsp. funduliforme strain B35 was sequenced in
full to include the lktB, lktA and lktC genes, concluding that both F. necrophorum subspecies
contained these genes. When the genes were compared, strains A25 (Fnn) and B35 (Fnf) had
similarities of 88% for lktB, 90% for lktA and 96% for lktC. The sequence lengths for Fnf B35 were
1,650 bp for lktB, 9,732 bp for lktA and 438 for lktC, as represented in Figure 17 (Tadepalli et al.,
2008b).
Figure 17: Representation of the leukotoxin operon of F. necrophorum subsp. funduliforme strain B35, showing genes lktB,
lktA and lktC along with corresponding gene lengths.
It was found that lktB contained a POTRA_2 polypeptide transport associated domain which is
highly suggestive of this protein being involved in the secretion of the lktA protein. Most of the
differences between the two lktA genes were noted to be in the N-terminal and middle section of
the gene. The lktC gene was described as highly conserved but the function was not hypothesised
(Tadepalli et al., 2008b).
When the titre of leukotoxin in the culture supernatant of both Fnn and Fnf strains was tested, the
amount of leukotoxin present in the Fnn supernatant was 15-fold higher than the Fnf supernatant
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(Tan et al., 1994a). Tadepalli et al. (2008b) used qPCR to measure the relative expressions of lktA
and found that for both subspecies the mid-log phase expressed the highest concentration of
leukotoxin messenger RNA. When the two subspecies were compared they found that subspecies
necrophorum had a 21.1 fold higher transcript level of lktA during the mid-log phase peak. It was
concluded that the necrophorum subspecies is more virulent than the funduliforme subspecies, due
to the likelihood that a higher transcript level of lktA would result in a higher level of leukotoxin
secretion, and therefore cause a greater amount of cell death to leukocytes during infections. A
comparison of the promoter regions of the two subspecies showed variations between the
sequences, despite appearing to be conserved within each subspecies. The differing sequences for
each subspecies may therefore provide a target for subspeciating strains. When assayed using E.
coli cells, the Fnn promoter activity was approximately four-fold higher than that of the Fnf (Zhang
et al., 2006). This appears to support the hypothesis that Fnn strains produce more leukotoxin
mRNA, and subsequently more leukotoxin protein, and are therefore more virulent.
In order to determine the prevalence of the lktA gene, a collection of F. necrophorum isolates from
humans (43) and animals (57 – including mostly cows and sheep) were tested with a panel of
custom designed leukotoxin primers. Two lktA gene sequences with 99.75% similarity were used to
design three sets of primers targeting different regions of the gene. Each strain was tested against
all three primer pairs and it was concluded that the lktA gene was present in 47 out of 100 strains
studied. The lktA gene was found to be more prevalent in bovine strains and subspecies
necrophorum strains than those of human origin, or subspecies funduliforme (Ludlam et al., 2009a).
This was later disputed by Bennett et al. (2010) who observed the dangers of declaring a gene to
be absent based on non-amplification of a PCR product. They also highlighted how the two
sequences used to design the primers were both of bovine origin and were identical. Several
publications by one research group have since reported variations among lktA genes (Zhou et al.,
2009a; Zhou et al., 2010; Zhou et al., 2011b; Zhou et al., 2011a). In order to more reliably test for
the presence of the leukotoxin gene within a collection of isolates, PCR primers should be designed
using a range of dissimilar sequences to take a greater level of variation into account.
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F. necrophorum type strains JCM 3718 and JCM 3724 have been used by other research groups as
control strains in F. necrophorum leukotoxin experiments. As previously mentioned in Chapter 4,
prior to the start of this project the genomes of these strains had not been sequenced. This project
provided the opportunity to sequence the genomes of these two strains, with the addition of a third
strain of human clinical origin. This was to provide high quality sequence data of the leukotoxin
operon and to carry out in vitro tests for cytotoxic activity analysis alongside this, looking at activity
in human derived cells. The F. necrophorum leukotoxin has been studied previously, but there is
still a great deal to be understood regarding its mode of action and the level of cytotoxic activity of
the two subspecies. High quality sequence data can greatly contribute to the understanding of the
leukotoxin operon, therefore the leukotoxin was considered worth investigating.
For this chapter, the sequence of the F. necrophorum leukotoxin operon was investigated within
the two type strains JCM 3718 (Fnn) and JCM 3724 (Fnf) and the human clinical strain ARU 01. The
majority of the work carried out on the leukotoxin previously has been by two research groups
which investigate from a veterinary perspective, whereas human clinical isolates were also
investigated here. The prevalence of the leukotoxin operon within a clinical collection of human
isolates was also studied, using PCR primers from other studies, as well as custom primers, in order
to critique the previously published primers. It was hypothesised that the leukotoxin would be
found to be universal within the F. necrophorum strain collection, with the three sequenced
genomes containing the leukotoxin operon in full. It was also predicted that when the sequences
were aligned, those of the same subspecies would demonstrate greater similarity to each other
than those of different subspecies, and that variations in activity could be explained by variations
in the sequences. To confirm cytotoxic activity of the sequenced strains, concentrated culture
supernatants were tested against the HL-60 human promyelocytic leukaemia cell line and human
donor white blood cells. It was hypothesised that the concentrated, high molecular weight fraction
of culture supernatant would demonstrate a cytotoxic effect in a dose-dependent manner. The
antibodies described above have not been made commercially available and therefore were
unavailable for use in this project.
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5.2 Results
5.2.1 Locating the leukotoxin operons within the genome sequence data of
JCM 3718, JCM 3724 and ARU 01.
The Fnf strain 1_1_36S draft genome (previously introduced in section 4.2.3; Genbank accession
numbers ADLZ01000001-ADLZ01000040) was searched for the leukotoxin operon. Each of the 40
contigs was entered in FASTA format into a nucleotide BLAST search on the NCBI website (Blast:
Basic Local Alignment Search Tool, 2015). Search settings were as follows: Database: Nucleotide
collection (nr/nt). Organism: Fusobacterium necrophorum. One copy of the leukotoxin operon was
found on accession number ADLZ01000005 from base pair 80957 to 93479.
As part of the commercial sequencing package, the raw reads from JCM 3718, JCM 3724 and ARU
01 were mapped to accession numbers ADLZ01000001-ADLZ01000040 using GS Reference Mapper.
For reads that mapped within bases 80957 to 93479 on accession number ADLZ01000005, the
corresponding assembly contigs were recorded in Table 33.

















Contigs were reverse complemented using a sequence editor (Fr33.Net, 2015) in the case of raw
reads mapping to the complement strand. Each set of leukotoxin operon containing contigs were
then concatenated into one FASTA file and aligned against bases 80957 to 93479 of accession
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number ADLZ01000005 using Clustal Omega. The sequences were trimmed to exclude any bases
outside of the region aligning to the ADLZ01000005 leukotoxin sequence. The locations of these
operons were confirmed by the genomic annotation in chapter 4.
5.2.2 Sanger sequencing the leukotoxin operon in JCM 3718, JCM 3724 and
ARU 01 to close gaps and confirm next generation sequencing data
All three of the leukotoxin operon sequences contained gaps in the next generation sequence data
where the leukotoxin sequence had spanned multiple contigs. This was resolved by designing PCR
primers to amplify these regions and using Sanger sequencing to obtain the missing bases. The
primers were designed using the methods in section 2.10.1 and primer sequences were recorded
in Appendix 10. Sanger sequencing was as described in methods section 2.8.7. The resulting
sequence data was inserted into the appropriate gaps and a Clustal Omega alignment was carried
out between the ADLZ01000005 leukotoxin sequence and the JCM 3718, JCM 3724 and ARU 01
leukotoxin sequences. This ensured the full leukotoxin operon was present in the new sequence
data. As discussed in section 4.2.3, assembly contig accession numbers ADLZ01000001-
ADLZ01000040 weremisassembled. The results of the leukotoxin work were not adversely affected
by this due to the leukotoxin sequences being confirmed by Sanger sequencing and aligned to other
the leukotoxin genes from other F. necrophorum strains.
Next generation pyrosequencing is prone to errors in homopolymer regions (Hodkinson and Grice,
2015) which can lead to frame shift errors. In order to be confident about the leukotoxin operon
sequence data a series of PCR primers were designed to Sanger sequence each of the three
operons. A total of 37 PCR primers were designed (see Appendix 11 for primer sequences) with an
average of 17 primer pairs being used for each strain. PCR, gel electrophoresis, gel extraction, and
Sanger sequencing were carried out as described in section 2.8.7. Resulting Sanger sequence data,
sequenced in both the forward and reverse orientations, were assembled using Clustal Omega. The
next generation sequence data (sequence locations detailed in Table 33) and Sanger sequence data
for the leukotoxin operon from each strain was aligned again using Clustal Omega to compare the
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data sets. In each discrepancy between the two sets of data, the Sanger sequence data was taken
as accurate. All three strains contained frame shift errors in the pyrosequencing data that were
corrected by the Sanger sequencing data. The final Sanger sequence data for the three strains can
be found as an alignment in Appendix 12.
5.2.3 Bioinformatic analysis of leukotoxin sequence
The leukotoxin operon sequences were translated into protein sequence using ExPASy Translate
(methods section 2.10.3). For each operon sequence, the genes for lktB and lktA were present in
full within the Sanger sequence data. There were, however, difficulties with designing primers for
the lktC sequence due to the DNA sequence following the lktC gene being unknown at the time.
The lktC sequence data is therefore taken from the next generation sequence data.
5.2.3.1 lktB
Figure 18 shows a Clustal Omega alignment of the three lktB protein sequences. The two Fnf lktB
sequences are both 447 amino acids long and show a 99.8 % similarity. The only difference is at
position 174, with a leucine present in the JCM 3724 strain and a valine present in the ARU 01 strain.
Both amino acids are non-polar and hydrophobic. The JCM 3718 lktB is 336 amino acids long.
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3718_lktB ------------------------------------------------------------ 0
3724_lktB       MERIWESYIEKEITITELYTIVQKINELYQEKGYLVCRAVLPAQKIQNGIVNILLIEGKT 60
ARU01_lktB      MERIWESYIEKEITITELYTIVQKINELYQEKGYLVCRAVLPAQKIQNGIVNILLIEGKT 60
3718_lktB ---------------------------------------------------MASGKVPGT 9
3724_lktB       GDITIQGNHSTREKYIKERIPLEKGKISNFKELDRSLTRFNLTNDSPIQVNMTSGKVLGT 120
ARU01_lktB      GDITIQGNHSTREKYIKERIPLEKGKISNFKELDRSLTRFNLTNDSPIQVNMTSGKVLGT 120
*:**** **
3718_lktB       TDYFVQIYEPKRQQFFVFADNLGQKNTGELRWGLNYINNSVTGNRDQLSLTSLVTEGTAS 69
3724_lktB       TDYFLQIYEPKRQQFFTFADNLGQKNTGELRWGISYINNSVTGNRDQLSLTSLLTEGTAS 180
ARU01_lktB      TDYFLQIYEPKRQQFFTFADNLGQKNTGELRWGISYINNSVTGNRDQLSLTSLVTEGTAS 180
****:***********.****************:.******************:******
3718_lktB LSSFYTFPVSKKGTKISLQHSVGKLKHIQGALKHKITGNSYSYGVGIVHPILVHEKNKVE 129
3724_lktB       LSSIYTFPVSKKGTKVSLQHSLGKLKHIQGALKHKITGNSYSYGIGIVHPVLVDEKNKIE 240
ARU01_lktB      LSSIYTFPVSKKGTKVSLQHSLGKLKHIQGALKHKITGNSYSYGIGIVHPVLVDEKNKIE 240
***:***********:*****:**********************:*****:**.****:*
3718_lktB       LSLDWVKQRTVTDLLKLKWVNNRLSKYTAGIGISHYEEDSVFYTKQNITKGKFIPISGDA 189
3724_lktB       LSLDWGRQRTVTDLLKLNWVNNRLSKYTAGIGISHYEEDSIFYTKQNITKGKFIPISGDE 300
ARU01_lktB      LSLDWGRQRTVTDLLKLNWVNNRLSKYTAGIGISHYEEDSIFYTKQNITKGKFIPISGDE 300
***** :**********:**********************:******************
3718_lktB       RNYTKYDMFLIYQKNLKYNTLVTLKMAGQYSLSKKLPSVEQIYAGGAYNVRGYPENFMGA 249
3724_lktB       KKYTKYDMFLMYQKNLKYHTLATLRMTGQYSLSKKLPSVEQIYAGGAYNVRGYPESFMGA 360
ARU01_lktB      KKYTKYDMFLMYQKNLKYHTLATLRMTGQYSLSKKLPSVEQIYAGGAYNVRGYPESFMGA 360
::********:*******.**.**:*:****************************.****
3718_lktB       EHGVFFNAELSKLVENKGEFFVFLDGASLHGESAWQENRIFSSGFGYKIRFLEKNNIAVS 309
3724_lktB       EHGIFFNIELSKLVENKGEFFVFLDGASLHGESAWQENRIFSSGFGYRLRFLEKNNIAVS 420
ARU01_lktB      EHGIFFNIELSKLVENKGEFFVFLDGASLHGESAWQENRIFSSGFGYRLRFLEKNNIAVS 420
***:*** ***************************************::***********
3718_lktB MAFPWKKKINSISVDSNRIYITINHEF 336
3724_lktB       MAFPWKKTINSISVDSNRIYITINHEF 447
ARU01_lktB      MAFPWKKTINSISVDSNRIYITINHEF 447
*******.*******************
Figure 18: Clustal Omega alignment of the three lktB protein sequences from JCM 3718, JCM 3724 and ARU 01.
When entered into a protein BLAST search all three sequences resulted in a match of Fusobacterium
necrophorum lktB with E values of 0. Table 34 lists the conserved domain hits found by the BLASTp
search.
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Found towards the N-terminus of ShlB family proteins and
important in the secretion and activation of the haemolysin ShlA.





Found primarily in bacterial surface antigens, usually as variable
number repeats at the N-terminus.
6.36e-14
Surface antigen This domain is found in outer membrane proteins from











Members of this protein family are for assembling proteins into the
outer membrane of Gram-negative bacteria. They typically have five
tandem copies of a surface antigen variable number repeat,
followed by an outer membrane beta-barrel domain.
6.02e-06
The lktB sequences were also entered into a Pfam search to look for conserved domains (Table 35).
Table 35: Conserved domains found within the lktB protein by a Pfam search.
Family Description E value
POTRA_2 POTRA domain, ShlB-type 8.3e-13
Bac_surface_Ag Surface antigen 0.0002
The conserved domains found within the lktB proteins are suggestive of the protein having a role
in secretion. The POTRA domain was found during both BLASTp and Pfam searches and is associated
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with secretion. Several other domains are linked to the outer membrane of the bacteria and
secretion.
5.2.3.2 lktA
A Clustal Omega alignment of the lktA protein sequences of JCM 3718, JCM 3724 and ARU 01 was
made to compare the three sequences (Appendix 13). JCM 3724 was demonstrated to be 88.7 %
similar to JCM 3718 and 75.3 % similar to ARU 01, while ARU 01 and JCM 3718 were 75.9 % similar
to one another. A Clustal Omega alignment was also made using the DNA sequence for the lktA
region. The resulting similarities were 90.0 % for JCM 3724 and JCM 3718, 78.5 % for JCM 3724 and
ARU 01, and 79.1 % for JCM 3718 and ARU 01. This protein appears to be less conserved than the
lktB protein. This could be due to sections of the lktA protein not being particularly important to
the function of the leukotoxin and therefore not needing to be so well conserved. The lktB protein
is considerably smaller and therefore is less likely to have regions that are of low importance.
Due to the large size of the protein, at approximately 3,200 amino acids, the sequence alignment is
displayed here graphically using Artemis Comparison Tool (ACT) (Figure 19). The DNA sequences of
the three lktA genes were submitted for comparison via the WebACT tool (methods section 2.10.5).
The grey bars represent the three lktA sequences and the red bars represent areas of similarity.
White spaces, or breaks, represent unique regions. The five truncated peptide regions from Figure
16 are overlaid onto this diagram. This enables the reactivity of these regions, based on
experimental studies by Narayanan et al. (2001b), to be compared to how conserved the sequences
of these regions are between the strains used in this project. P5 is the only truncated peptide region
conserved between all three strains. Peptide regions P1 and P2, which both had a strong reaction
with polyclonal serum in leukotoxin experimental studies by Narayanan et al. (2001b), show some
sequence variation is present. P3 which was associated with neutralising activity shows a great deal
of variation between the three strains.
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Figure 19: Artemis Comparison Tool alignment of the lktA genes from JCM 3718, JCM 3724 and ARU 01. Grey bars
represent the three lktA sequences, red bars represent areas of similarity and white spaces represent unique regions. The
five truncated peptides from Figure 16 are overlaid onto this diagram. In Figure 16, region P1 was associated with a strong
reaction with polyclonal serum, a reaction with monoclonal antibodies and to neutralising activity of native toxin by
antisera raised against truncated P1 peptide. Region P2 was associated with a strong reaction with polyclonal serum only.
P3 was associated with neutralising activity of native toxin by antisera raised against truncated P3 peptide and P5 was
associated with a strong reaction with polyclonal serum.
A phylogenetic tree was created in order to investigate the relationship between isolate source,
DNA sequence and subspecies (Figure 20). DNA sequences of F. necrophorum lktA genes were taken
from the NCBI website (National Center for Biotechnology Information, 2015) using the nucleotide
database, and included with the Sanger sequence data of strains JCM 3718, JCM 3724 and ARU 01.
The strains from which the DNA sequences were collated from are detailed in Table 36. The
resulting tree shows no tight clustering between Fnn and Fnf strains. The top five strains are all Fnf;
the top two are human strains, grouped with a rumen microbiome strain. Strains JCM 3724 and B35
are both of bovine liver abscess origin, and group more closely with the animal Fnn strains, although





Table 36: Isolates used for collection of lktA gene sequence data.
Isolate name Source Subspecies (if known)
ARU 01 Human funduliforme
D12 Human funduliforme*
HUN 048 Rumen microbiome funduliforme*
JCM 3724 Bovine liver abscess funduliforme
B35 Bovine liver abscess funduliforme
JCM 3718 Bovine liver abscess necrophorum
H05 Bovine footrot
BFTR1 Bovine footrot necrophorum*
DJ-2 Deer jaw necrophorum*
DAB Deer jaw abscess necrophorum*
A25 Bovine liver abscess necrophorum
BFTR-2 Bovine footrot necrophorum*
* = subspeciation result of phylogenetic analysis in section 4.2.3 (Figure 9).
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Figure 20: Phylogenetic tree of lktA genes of sequenced strains of F. necrophorum. Alignments were made in Seaview and
maximum likelihood trees were made using PhyML. The scale represents the average number of base changes per position
for the length shown. Longer branch lengths therefore represent a greater number of base changes.
Kyte and Doolittle hydrophobicity plots were made for the three lktA proteins in order to further
characterise them. Large sections of hydrophobicity could indicate that the protein is membrane
spanning, which is a requirement for pore-forming toxins. Due to the high level of similarity
between the plots, only one is shown, characterising the hydrophobicity of the JCM 3718 lktA
protein sequence (Figure 21). Potential transmembrane regions are found by peaks with a score of
1.6 or greater when a recommended window size of 19 is used. The window size represents the
number of surrounding amino acids used at each amino acid position to generate the average score
that predicts hydrophobicity. Figure 21 shows only two peaks reaching a score of 1.6, which
disputes the suggestion of the protein being membrane spanning.
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Figure 21: Kyte and Doolittle hydrophobicity plot of the JCM 3718 lktA gene. An amino acid window size of 19 was used.
The first 60 amino acids from the lktA protein from each of the three strains were entered into
SignalP (Petersen et al., 2011) for prediction of signal peptides. JCM 3724 and ARU 01 had identical
sequences in this region. Figure 22 shows the output of the two Fnf sequences and the resulting
prediction of a signal peptide and a cleavage site between positions 36 and 37. JCM 3718 had some
sequence variation (as shown in the Clustal Omega alignment in Appendix 13), however the
prediction was the same, with a signal peptide and a cleavage site between positions 36 and 37. A
signal peptide at the N-terminus of the protein is highly indicative that the protein will be targeted
to the secretory pathway of the bacterium. The F. necrophorum leukotoxin is found in the culture
supernatant, but the method of secretion is not yet known.
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Figure 22: SignalP prediction of a signal peptide and a cleavage site at the start of the lktA protein sequence. C scores are
high at the position immediately after the cleavage site, S scores distinguish between regions within the signal peptide
and regions within the mature protein, and Y scores are a combination of the C score average and S score slopes. A D score
is then used to make a weighted average of the mean S scores and the maximum Y scores which then determines whether
a signal peptide is present.
When entered into a protein BLAST search, no conserved domain hits were found for the three lktA
proteins. All three sequences did, however, match Fusobacterium necrophorum leukotoxin with E
values of 0. As previously mentioned in section 5.1, recent BLASTp searches of these sequences
have revealed homology of approximately 25 – 30 % to adhesin and haemagglutinin proteins. The
lktA protein sequences were entered into a Pfam search to look for conserved domains. When the
whole protein was entered no matches were found. However, when the protein was broken into
smaller sequences and entered as individual searches, both of the Fnf strains had a
haemagglutination activity domain with the first 180 bases, of 3,229 – 3,243 bases, with E values of
4e-06 for ARU 01 and 3.2e-06 for JCM 3724. This was not found for JCM 3718.
5.2.3.3 lktC
Figure 23 shows a Clustal Omega alignment of the three lktC protein sequences, which appear
highly conserved. The JCM 3718 sequence contained a stop codon at the end, but for the two Fnf
sequences, the remaining part of the sequence was unavailable.
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When entered into a BLASTp search, the top hits for the three sequences resulted in a match of
Fusobacterium necrophorum histidine kinase, E value 2e-99, for JCM 3718, Fusobacterium
necrophorum histidine kinase, E value 3e-94 for JCM 3724 and sensory transduction regulator, E
value 4e-96 for ARU 01.
A Pfam search of the three protein sequences resulted in a putative bacterial sensory transduction
regulator domain, with E values of 7.6e-07, 1.9e-07 and 2.7e-07 for JCM 3718, JCM 3724 and ARU
01, respectively.
3718_lktC       MNLRESKFSEFLKNSNITCFEREEVKDELETVVYRSFMEVEGQNLPMVIVMDNSIYTNIR 60
3724_lktC       MNLRESKFSEFLKNSNITCFEREEVKDELETVVYRSFMEVEGQNLPMVIVMDNSIYTNIR 60
ARU01_lktC      MNLRESKFNDFLKNSNITCFEREEVKDELETVVYRSFMEVEGQNLPMVIVLDNSIYTNIR 60
********.:****************************************:*********
3718_lktC       VQIAPKVIKDTNKEAVLSYINELNREYKVFKYYVTEDADVCLDSCVTSIAEEFNPEMVYT 120
3724_lktC       VQIAPKVIKDSNREAVLSYINELNREYKVFKYYVTEDADICLDSCITSIAEEFNPEMVYT 120
ARU01_lktC      VQIASKVIKDSNKEAVLSYINELNREYKVFKYYVTEDADVCLDSCVTSIAEEFNPEMVYT 120
**** *****:*:**************************:*****:**************
3718_lktC       ILNVILEHITKHYSTFMKKIWSEEK 145
3724_lktC       ILNVILEHITEHYSTFMKKI----- 140
ARU01_lktC      ILNVILEHITEHYSTFMKKIW---- 141
**********:*********
Figure 23: Clustal Omega alignment of the three lktC protein sequences from JCM 3718, JCM 3724 and ARU 01.
5.2.4 Testing the clinical strain collection with a range of leukotoxin-specific
primers
A selection of published and custom designed leukotoxin primers were tested on the collection of
25 clinical strains, alongside strains JCM 3718, JCM 3724 and ARU 01, in order to test the prevalence
of the gene. Ludlam_LT1 and Ludlam_LT2 primer pairs were designed by Ludlam et al. (2009a),
primer pair lktA was designed by Tadepalli et al. (2008b) and lkt1 and lkt2 primer pairs were
designed as part of this project. See Appendix 14 for primer sequences. All primers targeted the
lktA gene and all results were recorded in duplicate over separate days.
The locations targeted by the primers are displayed in Table 37. Locations relate to JCM 3724 lktA
gene. A summary of results is displayed in Table 38, with full results found in Appendix 15.
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Table 37: Locations targeted by lktA primers. Base positions relate to the JCM 3724 lktA gene.
Primer set 5’ start 3’ end Product size (bp)
Ludlam_LT1 2297 2668 372
lktA 2394 2589 196
Ludlam_LT2 6343 6540 198
lkt2 8181 8575 395
lkt1 8688 8854 167
Table 38: Summary of leukotoxin PCR results.
Primer set
lktA Ludlam_LT1 Ludlam_LT2 lkt1 lkt2
Number of isolates with a
positive PCR result
12/28 28/28 25/28 28/28 28/28
Percentage of isolates with a
positive PCR result
43 100 89 100 100
As shown in Table 37, the full length of the lktA product is within the forward and reverse primer
of Ludlam_LT1 (see Appendix 14 for primer sequences). There was amplification of the Ludlam_LT1
product in 100 % of strains tested, compared to 43 % using primer pair lktA.
An example gel image of each of the five PCR primer sets is shown in Figure 24, showing the first
six strains of the collection. Interestingly, the gel image of Ludlam_LT2 shows two different sized
bands present. Two of the bands are of the expected size of 200 bp, and three bands in separate
lanes are approximately 30 bp larger. Due to a positive result being recorded with the Ludlam_LT1
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Figure 24: PCR products from the primer sets in Table 37 and Appendix 14. For each gel the lanes are as follows: 1) 100 bp
marker; 2) F. necrophorum 1, 3) F. necrophorum 5; 4) F. necrophorum 11; 5) F. necrophorum 21; 6) F. necrophorum 24; 7)
F. necrophorum 30; 8) Negative control (molecular grade water).
The first 12 strains tested with the Ludlam_LT1 primer set were sequenced by Sanger method in
order to determine why there was no amplification for eight out of the first 12 strains tested with
the lktA primers. The sequences were aligned using Clustal Omega (Appendix 16) and a
phylogenetic tree was made (Figure 25). The lktA primer positions were highlighted on the Clustal
alignment. All strains had a perfect match to the reverse primer, however only four strains matched




phylogenetic tree shows two very distinct clusters that group into those that had amplification with
lktA primers and those that did not.
Figure 25: Phylogenetic tree of Ludlam_LT1 Sanger sequences. Produced using PhyML. The scale represents the average
number of base changes per position for the length shown. Longer branch lengths therefore represent a greater number
of base changes.
5.2.5 Collection of filtered culture supernatant of F. necrophorum strains
Aliquots of culture supernatant, hypothesised to contain a secreted leukotoxin, were collected from
strains JCM 3718, JCM 3724 and ARU 01 to be used to check for cytotoxic activity against human
white blood cells. Broth cultures were centrifuged and the supernatant was sterile filtered and then
concentrated approximately 75X using 100 kDa molecular weight cut off filters (Millipore,
Hertfordshire) (methods section 2.13.1). The aliquots of concentrated high molecular weight
protein were frozen at -20 °C for up to a week and were defrosted one time only.
Bradford assays were used to determine the protein concentration of the high molecular weight
fractions (methods section 2.13.2). A calibration curve was defined and samples were diluted 1 in
50 to measure within the range, using a Nanodrop as an initial indicator. Concentrations were then
adjusted to account for the dilution factor and results were recorded in Table 39.
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The equation of the calibration curve was y=0.043+0.0183x with an R squared value of 0.992.
Samples were analysed using sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS
PAGE) under both reducing and non-reducing conditions (Figure 26 and Figure 27) (methods section
2.13.3). Samples were diluted 1:1 with loading buffer from neat concentrations.
Figure 26 shows the banding patterns of the high molecular weight fraction when boiled in reducing
Laemmli buffer. The samples in Figure 27 were boiled in non-reducing buffer and do not show the
same pattern. Some protein can be seen in the area of the well and has not migrated through the
gel, possibly due to its large size. This protein is likely to be high molecular weight (>245 kDa) and
is therefore expected to be the leukotoxin. There are very few additional bands so this indicates
that the concentrated culture supernatant is not heavily contaminated with other proteins.
Without using a monoclonal antibody for affinity purification, a low level of contamination is
possible. The very high molecular weight protein in Figure 27 is missing from Figure 26 which
increases the confidence that the bands present in Figure 26 are breakdown products of the
leukotoxin. This is in agreement with the understanding that the leukotoxin protein is unstable (Tan
et al., 1994a; Tadepalli et al., 2008a). No bands were present in the flow through lanes. This may
be due to proteins running off the end of the gel, or because this fraction was not concentrated,
unlike the leukotoxin-containing fraction, and therefore would have been a very dilute solution.
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Figure 26: Leukotoxin samples boiled for 5 minutes in reducing buffer. Lane 1: NEB 245 kDa marker; 2: JCM 3718 putative
toxin; 3: JCM 3718 filter flow through; 4: JCM 3724 putative toxin; 5: JCM 3724 filter flow through; 6: ARU 01 putative
toxin; 7: ARU 01 filter flow through.
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Figure 27: Leukotoxin samples boiled for 5 minutes in non-reducing buffer. Lane 1: NEB 245 kDa marker; 2: JCM 3718
putative toxin; 3: JCM 3718 filter flow through; 4: JCM 3724 putative toxin; 5: JCM 3724 filter flow through; 6: ARU 01
putative toxin; 7: ARU 01 filter flow through.
5.2.6 Assay to show cytotoxicity of filtered culture supernatant of F.
necrophorum strains against HL-60 cells
Human promyelocytic leukaemia (HL-60, ATCC CCL-240) cells were used to represent human white
blood cells for a cytotoxicity assay. HL-60 cells were treated with putative leukotoxin from strains







concentrations were set at 125 µg/ml, 150 µg/ml and 175 µg/ml for JCM 3718, JCM 3724 and ARU
01, and 250 µg/ml as an additional concentration for JCM 3718 and ARU 01. JCM 3724 was excluded
from the additional concentration due to limitations with concentrating the culture supernatant.
1X PBS was used as the negative control. After preliminary tests, 7.5 % ethanol was chosen as the
positive control for cell death. Following treatment with the culture supernatant, cells were stained
with propidium iodide (PI) and analysed on a flow cytometer (methods section 2.13.6) to assess the
percentage viabilities of the cells. Uptake of PI is indicative of cell death. Results were recorded in
triplicate over separate days, with 10,000 cells analysed per sample.
The concentrations for the cytotoxicity assay were chosen following a pilot study, where
concentrations below 75 µg/ml appeared to have little effect. 125 µg/ml was chosen as the lowest
concentration that had a notable effect on the cell viability. The top concentration was chosen to
be 175 µg/ml for JCM 3724 due to limitations with the initial concentration of toxin obtained,
although it was possible to use a higher concentration of 250 µg/ml for JCM 3718 and ARU 01. It
was noted that once the viability of the cells fell below approximately 50 %, the structure of the
cells were affected and the flow cytometer plots appeared to show severely disrupted cells. This
resulted in dead cells not falling within the gated region and therefore being excluded from the
results, which would skew the data. Care was taken to choose concentrations that were not high
enough to cause this to happen.
Figure 28 demonstrates the creation of the HL-60 protocol within the Summit 4.3 program. Part A
includes a gate created to exclude any cells that were not typical of the majority of cells. Each cell
is represented as a red dot and is plotted according to forward scatter versus side scatter. Forward
scatter is representative of cell size and side scatter relates to the granularity of the cell. This is
independent of any staining. Part B excludes any cells external to the R1 gate in Part A. It plots the
granularity of the cell against PI fluorescence, i.e. viability. A trypan blue exclusion assay
predetermined the percentage viability of the healthy cells to typically be between 98 and 99% of
cells present, and the threshold was therefore set on the plot to match this. The plot shows 98.13%
cell viability (or 1.87% cell death) for this negative control sample. For the remainder of the samples
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the gate and threshold remain the same, and cell death was determined as the number of cells
recorded above the threshold, in the R4 region. Part C is a histogram of the PI data from plot B. The
gated region is set at the same PE log value, measuring PI fluorescence, as in part B and therefore
records cell death in the same way. Histograms can be overlaid to see the relationship between
different sample treatments (see Figure 29).
Figure 28: Gating of negative control HL-60 cells stained with propidium iodide (PI). (A) Plot of forward scatter versus side
scatter. R1 gate denotes region that majority of cells presumed to be healthy fall within and contains 10,000 cell counts.
(B) Plot of side scatter versus the log of PI fluorescence, containing 10,000 cell counts. Only cells from within R1 on plot A
are analysed further on plot B. R6 contains cells presumed to be viable and those that fall into R4 are classed as not viable
due to increased PI uptake. (C) PI fluorescence data from plot B displayed as a histogram.
Data represented as an overlay graph (Figure 29) is useful for analysing the relationship between
putative leukotoxin concentration and cell viability, however it lacks clarity when displaying data in
triplicate as the graph becomes crowded. Also the data cannot be normalised to the negative




to the negative control. The mean of the three sets is displayed, with standard error bars included
(Figure 30, Figure 31 and Figure 32).
Figure 29: Overlay of a set of data from strain JCM 3724 showing dose-dependent cell death. PI fluorescence data is plotted
against cell counts, as in Figure 28C. Red: Negative control; Green: 125 µg/ml putative leukotoxin; Blue: 150 µg/ml putative
leukotoxin; Yellow: 175 µg/ml putative leukotoxin. Each is comprised of 10,000 cells. Cells within region R2 are considered
not viable. See Table 40 for percentages.
Table 40: Percentage viability and percentage death data from samples shown in the overlay graph (Figure 29).
Symbol Treatment group Percentage viability Percentage death
Negative control 98.13 1.87
125 µg/ml 78.11 21.89
150 µg/ml 64.88 35.12
175 µg/ml 54.70 45.30
Figure 30, Figure 31 and Figure 32 show a clear dose-dependent cytotoxic response of the high
molecular weight fraction against the HL-60 cells. The higher the concentration of the putative
toxin, the lower the percentage viability of the cells. See Appendix 17 for full results. The negative























































Figure 30: Percentage viabilities of HL-60 cells following treatment with putative toxin from JCM 3718 at a range of
concentrations. All values are the mean of triplicate readings and are normalised to the negative control. * = P <0.05 using


















































Figure 31: Percentage viabilities of HL-60 cells following treatment with putative toxin from JCM 3724 at a range of
concentrations. All values are the mean of triplicate readings and are normalised to the negative control. * = P <0.05 using






















































Figure 32: Percentage viabilities of HL-60 cells following treatment with putative toxin from ARU 01 at a range of
concentrations. All values are the mean of triplicate readings and are normalised to the negative control. * = P <0.05 using
Fisher’s LSD test; ** = P<0.01.
5.2.7 Statistical analysis
A one way ANOVA carried out on the cell viability data from Figure 30, Figure 31 and Figure 32
resulted in a P value of <0.01 for each set of data, concluding that there is a significance between
the treatment groups.
Fisher’s Least Significant Difference (LSD) test was performed on the data to test for statistical
significance between the treatment groups. The statistical analysis labels in Figure 30, Figure 31
and Figure 32 show a P value of <0.01 between the negative control and the lowest protein
concentration of 125 µg/ml for each of the three sets of data. The level of statistical significance
between the remainder of the concentrations varies between strains, with JCM 3724 having the
strongest significance and ARU 01 having the weakest significance in the range of 125 µg/ml and
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175 µg/ml. In each of the three sets of data the P value was <0.01 for the comparison of the negative
control to the positive control, and for the positive control to the filter flow through. See Appendix
18 for full statistical analysis.
5.2.8 Cytotoxicity assay with human white blood cells
In order to confirm the suitability of HL-60 cells as a substitute for human white blood cells, the
experiment was repeated using human white blood cells and a single concentration of 150 µg/ml
leukotoxin, to match the middle of the three initial concentrations tested. The results were
recorded in triplicate on three separate days, with 10,000 cells analysed per sample. Figure 33
shows the percentage viability of each treatment group, with HL-60 data in parallel with the donor
blood data. See Appendix 19 for full results. Fisher’s LSD test was performed on the data as before
to test for statistical significance between each set of HL-60 data and that from the corresponding
WBC data. In each case, despite the appearance of the HL-60 cells having a slightly lower percentage

































































Figure 33: HL-60 results compared to those using human donor blood at a single concentration of 150 µg/ml. All values
are the mean of triplicate readings and are normalised to the negative control.
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5.3 Discussion
One copy of the leukotoxin operon was found in each of the three sequenced strains, which was as
hypothesised, based on the prevalence of the gene according to the F. necrophorum literature and
based on reports that it was the primary virulence factor of the bacterium (Tan et al., 1994a). The
size of the leukotoxin operon is in excess of 11,000 bp, and the average genome assembly contig
size for JCM 3718, JCM 3724 and ARU 01 were all <5,000bp (chapter 4.2.1; Table 26), therefore it
was likely that there would be gaps within the sequences. The majority of these could be bridged
using PCR and Sanger sequencing, however, where the C terminus of the lktC gene was missing it
was more difficult to design matching primers due to the neighbouring sequence not having been
characterised previously in the literature at the time. More recently, F. necrophorum genomes have
been deposited in online databases such as NCBI and BioCyc that now mean that this region of
sequence could be located in other genomes and primers designed based on those sequences.
When the leukotoxin genes were translated into protein sequences it was noted that they began
similarly and then lacked similarity later in the sequence. It was suspected that this was due to
errors in the sequencing leading to frameshifts, most likely in homopolymer regions due to the use
of pyrosequencing. It was therefore decided to use Sanger sequencing to confirm the sequence and
remove the errors. Primers designed based on the JCM 3724 sequence were first tested against the
three strains. Only four of the 17 primer sets resulted in amplification of product for ARU 01 and
nine of the primer sets for JCM 3718, which indicates the level of variation between the three
sequences. Once the sequences of the amplified products were assembled and aligned to the
original sequence the presence of errors was confirmed and the new Sanger sequence data was
used in its place. When these sequences were translated into protein sequence and aligned, some
similarity was evident throughout the sequence, suggesting the frameshift errors had been
removed. This illustrates that the Sanger sequence data was more reliable.
The Clustal Omega alignment of the lktB protein sequence (Figure 18) shows that it is highly
conserved for the two Fnf strains, but has a different start codon location for the Fnn strain. Where
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JCM 3724 and ARU 01 have the start codon (ATG), JCM 3718 has ATC instead, which codes for
isoleucine rather than methionine. The result of this is that the JCM 3718 lktB protein sequence
starts 112 amino acids later at the next methionine. The next generation sequence data and the
Sanger sequence data of both the forward and reverse strand of the associated PCR product were
all congruent for this section of the sequence, so it is highly unlikely to be a sequencing error. All
three lktB sequences still matched F. necrophorum lktB in a BLASTp search. It had been
hypothesised that sequences from the same subspecies would demonstrate greater similarity to
each other than those of the other subspecies. This was therefore shown to be the case for lktB
sequences in these strains with the two Fnf protein sequences almost identical and the Fnn
sequence only three quarters of the length of the Fnf strains.
The Pfam search for conserved domains (Table 34) within the three lktB sequences used sequences
both whole and also in smaller segments. The POTRA domain was found at the N terminus of the
lktB sequence for JCM 3724 and ARU 01, and was missing from JCM 3718 due to the start codon
appearing later in the sequence for that strain. It is this domain that has led to the speculation that
the lktB protein is responsible for assisting the active toxin to be secreted (Tadepalli et al., 2008b).
Other related domains found towards the C terminus of the lktB sequence by BLASTp were those
of a haemolysin activation/secretion protein and outer membrane protein assembly complex. A
possible implication of the POTRA domain being absent in JCM 3718 could be the inability for lktA
to be secreted, however the results of the cytotoxicity assay suggest this is not the case. Other
possibilities include multiple secretion domains being present so that back up secretion systems
are in place, or that the POTRA domain is redundant or only partial. For the Fnf strains, the first 20
of 76 amino acids are missing from the POTRA hidden Markov model alignment so it may be that
the domain is not functional. The signal peptide found in the Fnf strains (Figure 22) and Fnn strain
support the knowledge that this is a secreted protein (Tadepalli et al., 2008b), although the
mechanism of secretion remains unknown.
The lktA protein sequences aligned using Clustal Omega (Appendix 13) had a higher percentage
similarity for the two bovine strains, JCM 3718 (Fnn) and JCM 3724 (Fnf), than for the two Fnf
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strains, JCM 3724 and ARU 01. The ACT alignment (Figure 19) supports this and shows a greater
level of similarity between JCM 3718 and JCM 3724 than between JCM 3724 and ARU 01. The first
500 bp appear to be more similar between the Fnf strains, with a similarity of 98 %. For the
remainder of the alignment the JCM strains appear more similar, with similarities of 94 % between
1,000 bp and 4,000 bp, and 97 % between 6,100 bp and 9,700 bp. In comparison, the majority of
regions of similarity between the two Fnf strains are between 80 % and 90 % similar. It had been
hypothesised that the two Fnf strains would exhibit more similarity with each other than with the
Fnn strain, but this has been shown not to be the case for these three lktA sequences. The reason
for the unexpected result could be related to the source of the isolates. Both JCM 3718 and JCM
3724 were isolated from bovine liver abscesses, whereas ARU 01 was isolated from a blood sample
of a human Lemierre’s syndrome patient. The date of isolation may also be important. The JCM
reference strains were isolated prior to 1985 (Shinjo et al., 1991), whereas ARU 01 was isolated in
2002. The differences seen between the Fnf strains may be an indication of the evolution of the
sequence over the years. As discussed below, when lktA genes from a number of additional
genomes were investigated using phylogenetic analysis, Fnf strains were in distinct clusters from
Fnn strains, which appears to support the hypothesis that strains of the same subspecies would
demonstrate greater levels of similarity.
The implication from the work by Narayanan et al. (2001b) is that the active toxin region is within
the first 3.5 kb of the lktA gene, as discussed in section 5.1. The ACT alignment displays the region
as not highly conserved between the two Fnf strains, however it is well conserved between the two
bovine strains, with similarities of 94 %.
The phylogenetic tree in Figure 20 was created using the data generated from the current project
and that now available in databases in order to investigate the relationship between the isolate
source, DNA sequence and subspecies, where known. The top cluster contains the two human Fnf
isolates: ARU 01 and D12. HUN048, the third isolate, is also Fnf and presumably a commensal, as
this was isolated from a rumen microbiome with no associated disease. These three isolates are
tightly clustered as a result of having highly similar lktA sequences. The second cluster from the top
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contains two Fnf strains, JCM 3724 and B35, both isolated from bovine liver abscesses. These first
five isolates are all subspecies funduliforme, but the bovine liver abscess Fnf strains are clearly
distinct from the remaining Fnf strains. The remaining clusters of isolates contain subspecies
necrophorum strains and strain H05 that has an unknown subspecies identity due to a lack of
sequence data for the gyraseB gene. Isolates DAB and DJ-2 are very tightly clustered and are both
from deer jaw abscesses. The remaining isolates are bovine liver abscess or bovine footrot. There
appears to be no separation of liver abscess or footrot source within the clusters, with a footrot
isolate being clustered with a liver abscess isolate two separate times. The animal species from
which the isolate is sourced appears to have a strong effect on the sequence, with bovine and deer
strains distinctly separated from human strains, with the possible exception of the ruminant strain.
It appears that both the subspecies and source of the isolate have a strong effect on sequence
clustering.
According to Narayanan et al. (2001b), there are 14 regions within the lktA protein that have the
potential to be membrane spanning. The Kyte and Doolittle hydrophobicity plot in Figure 21
disputes this and found only two potential membrane spanning regions for each of the three
strains. Figure 21 was produced using the ExPASy ProtScale tool (Expasy - Protscale, 2015), whereas
Narayanan et al. (2001b) used TMpred (Tmpred, 2015). When the JCM 3718, JCM 3724 and ARU 01
lktA protein sequences were entered into the TMpred online tool, it found 14, 19 and 15 potential
transmembrane helices for the three strains, respectively. The peaks are very thin and are not
sustained over many base pairs, and therefore these predictions seem less likely to be accurate.
The lktC protein is highly conserved between the strains, which suggests that it may play an
important role. As all three sequences were so highly conserved, these results do not support the
hypothesis from section 5.1, which predicted greater levels of similarity between strains of the
same subspecies. Hypotheses regarding the function appear to be lacking from the literature,
however, the lktC protein from strain F. necrophorum D12 is annotated on the NCBI website as a
sensory transduction regulator (accession number: NZ_GL988012.1). This same protein from the
same strain is annotated on the BioCyc genome database (Biocyc, 2015) as leukotoxin-activating
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lysine-acyltransferase. The BLASTp and Pfam searches for protein product matches and conserved
domains from section 5.2.3.3 resulted in hits to a histidine kinase and sensory transduction
regulator. Histidine kinases are enzymes involved in signal-transduction and are very widespread in
bacteria (Wolanin et al., 2002). This could suggest that lktC is somehow involved in regulating
leukotoxin production. Alternatively, the annotation of leukotoxin-activating lysine-acyltransferase
may be more accurate. There are examples in the literature of lysine-acyltransferases activating
other toxins, such as a haemolysin in Escherichia coli (Langston et al., 2004) and a haemolysin in
Bordetella pertussis (Basar et al., 2001).
A range of PCR primers were needed to test for the prevalence of the leukotoxin within the strain
collection; this has been disputed in the literature (Ludlam et al., 2009a; Bennett et al., 2010). It
was determined that by using a range of published PCR primers and designing custom sets that an
analysis of the PCR primers in the literature could be performed. The three sets of primers designed
and tested by Ludlam et al. (2009a) were initially tested, all renamed to add a prefix of Ludlam,
although primer set Ludlam_LT3 was later discarded due to non-specific binding. The DNA
sequences used to design the PCR primers from this publication were strains F. necrophorum A25
(Oelke et al., 2005) and H05 (Sun et al., 2009), from bovine liver abscess and bovine footrot,
respectively. All of the strains tested with primer set Ludlam_LT1 in this project produced
amplicons, so it is difficult to speculate on the reasons for an overall amplification rate of 47 % in
the strains tested by Ludlam et al. (2009a) after the use of three sets of PCR primers. When their
results were separated by subspecies, only 33 % of Fnf strains had amplification with at least one
of the primer sets. Of the strains tested in this project, all were subspecies funduliforme, with the
exception of JCM 3718, and all had amplified product with Ludlam_LT1. There was a high rate of
amplification with primer set Ludlam_LT2, at 89 %, although there were two different band sizes
present. The expected band size was 198 bp. For the gel image in Figure 24C, two bands can be
seen at the expected size and three bands can be seen that are slightly larger than expected at just
above 200 bp. All bands were recorded as a positive result and this was not investigated further
due to the positive result with Ludlam_LT1 for the strains. The lktA primers were found to be quite
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ineffective for the strain collection used in this project, with an amplification rate of 43 %. The
Sanger sequences of the first 12 Ludlam_LT1 products showed two very distinct groups. On closer
analysis it was apparent that the sequences of strains 1, 21, 39 and 40 were identical to each other,
as were the sequences of strains 5, 11, 24, 30, 41, 42, 52 and 59. There is a possibility that the same
strain has infected multiple patients who contributed to the strain collection, or that these strains
are simply closely related, possibly due to being isolated from the same geographic region. The
amplicon sequences were only 291 bp long, which is not large enough to make any conclusions
regarding strain similarity. The lkt1 and lkt2 PCR primer sets were designed based on a region that
was believed to be highly conserved, based on the ACT alignment in Figure 19. They appeared to
be very effective with 100 % amplification for each primer set for the strain collection tested. The
hypothesis that the leukotoxin would be universal within the F. necrophorum strain collection is
supported here, with three of the leukotoxin primer sets having an amplification rate of 100 %. For
future testing, primer sets Ludlam_LT1, lkt1 and lkt2 would be considered. However, the Clustal
Omega results in Figure 18 show that the lktB protein is more highly conserved. This may make it
likely that the lktB gene sequence would be a better target for leukotoxin detection using PCR
primers. The Clustal alignment in Appendix 12 shows the beginning of the leukotoxin operon,
containing the lktB gene, as more conserved than the region containing the lktA gene, suggesting
that this would be a good target for PCR primers.
F. necrophorum leukotoxin is known for being highly unstable (Tan et al., 1994a; Tadepalli et al.,
2008a), therefore great care was taken during the steps to collect the leukotoxin fraction of the
culture supernatants. The products analysed by SDS PAGE under denaturing conditions (Figure 26)
showed a variety of bands that are likely to be breakdown products. Tadepalli et al. (2008a; 2008b)
showed this with both subspecies of F. necrophorum. The three leukotoxin fractions, which were
approximately 75X concentrated from the culture supernatant, were not diluted prior to mixing
with the loading buffer and the intensity of the bands on the gel appear to correspond with the
varying concentrations as measured by Bradford assay, with JCM 3724 having the faintest bands.
The image in Figure 27 is the SDS PAGE under non-reducing conditions. It shows a band at
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approximately 46 kDa, and one larger than 245 kDa for each of the three strains, as well as a few
other very faint bands. There also appears to be some high molecular weight protein that failed to
migrate into the gel and has remained at the gel interface. This has also been seen by Tan et al.
(1994a; 1994b) in 7.5 % and 10 % SDS PAGE gels when imaging leukotoxin fractions. 10 % gels were
used here.
For the cytotoxicity assay (section 5.2.6), HL-60 cells were used in place of human donor blood for
the majority of the study in order to minimise the number of times blood samples would need to
be taken. This cell line has been used in previous research to test the toxicity of Actinobacillus
actinomycetemcomitans leukotoxin (Karakelian et al., 1998; Lear et al., 2000), which suggests that
this cell line is an appropriate model to use in place of healthy human blood cells. Apoptotic effects
on HL-60 cells have also been studied upon addition of cytotoxic cancer treatments (Willimott et
al., 2007). The inclusion of human donor blood later in the experiment helped to validate the HL-
60 cell line results and demonstrate that they were an appropriate choice. HL-60 cells can be
induced to differentiate into mature granulocyte types (Birnie, 1988). While this would potentially
have given a more suitable model, this takes six days to occur, by which point the cells are less
viable and give a more scattered plot on the flow cytometer. It was therefore decided to use the
cells at two days after passage, as they were healthy and had not differentiated, giving a more
uniform and healthy sample of cells.
It had been hypothesised that the concentrated, high molecular weight fraction of culture
supernatant would demonstrate a cytotoxic effect in a dose-dependent manner. A dose-dependent
cytotoxic response against HL-60 cells can be clearly seen in Figure 30, Figure 31 and Figure 32,
which supports the hypothesis. For each of the three strains, they show high statistical significance
between the negative control and the 125 µg/ml treatment group, and while not necessarily
statistically significant between each step, as is the case with ARU 01, they do show further
significance with higher treatment concentrations. The graphs also consistently show high
statistical significance between the negative control and the positive control, as well as between
the positive control and the filter flow through, which serves as a second negative control. There
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was no statistical significance between the negative control and the filter flow through,
demonstrating that this fraction was not toxic to the HL-60 cells.
Fisher’s least significant difference test was chosen because the analysis was not an all against all
comparison, so there was no correction for multiple comparisons as there would have been with a
Bonferroni test. Specific comparisons were chosen in advance of the statistical test being carried
out. While Fisher’s LSD test is less vigorous, it does allow a better comparison between the three
data sets as there is more variation with the statistical significance results. The test was chosen to
for a better comparison between the strains rather than to test whether the cytotoxicity was
significant or not. With the P values <0.01 for each of the 125 µg/ml treatment groups the cytotoxic
effect was clear.
The expectation of the cytotoxicity results was that JCM 3724 would have the weakest cytotoxic
effect, due to the funduliforme subspecies being known for being less virulent (Tadepalli et al.,
2008b); JCM 3718 and ARU 01 were expected to have a stronger cytotoxic effect, as JCM 3718 is a
Fnn strain, and ARU 01 exhibited high virulence in a patient. The lower virulence of Fnf, however,
is due to a lower expression of the toxin. For this assay the concentrations were standardised across
the three strains and therefore the effect of the differing expression was negated. For the three
sets of data it appears that a higher concentration of leukotoxin in the culture supernatant did not
necessarily correlate with a highly virulent protein. The bovine strains were more toxic than the
human strain, although the human strain had a higher concentration in the Bradford assay than
JCM 3724. Strains that cause Lemierre’s syndrome may therefore have more efficient leukotoxin
promoters; investigating this as part of future work would be of interest. In order to confirm that
the high molecular weight fractions were not contaminated with other non-toxic high molecular
weight proteins that affected the protein concentrations measured by Bradford assay, anti-
leukotoxin antibodies would be needed for affinity purification. As discussed previously in the aims
of this chapter (section 5.1) these antibodies are not commercially available. It had been
hypothesised that variations in activity could be explained by variations in the leukotoxin
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sequences. From examination of the DNA and protein sequence data alongside the cytotoxicity
results, it appears that there is no obvious link between these data sets.
The results of the cytotoxicity assay in section 5.2.8 using human donor blood confirm the results
of the HL-60 experiments. The Fisher’s LSD test was used again for consistency and specific
comparisons were selected in advance of the test. In each case the corresponding pair of HL-60 and
human donor blood data had no statistical significance between them, supporting the suggestion
that HL-60 cells are a good model to use in place of human donor blood cells.
When the data from the cytotoxicity assay was compared to results from related publications there
was a consensus that the leukotoxin is unstable (Tan et al., 1994a), shows many breakdown
products with SDS PAGE analysis under denaturing conditions (Tadepalli et al., 2008a), and that
some product fails to migrate into the gel (Tan et al., 1994a; Tan et al., 1994b). The Fnn strain was
expected to produce a higher concentration of leukotoxin than the Fnf strains, due to the findings
by Zhang et al. (2006) that showed the Fnn promoter activity was four-fold higher. The Bradford
assay results in Table 39 show the Fnn strain had the highest concentration. The promoter region
of the leukotoxin operon was not present in the sequence data and therefore these could not be
compared, but it is likely that the Fnf promoters were weaker, due to lower concentrations of
protein product in the high molecular weight fractions. Both the human and bovine strains were
cytotoxic to human white blood cells, as expected based on the findings of Tadepalli et al. (2008a;
2008b). Similarly the statement applies that strains of both subspecies were cytotoxic. The three
strains contained the full leukotoxin operon (lktB, lktA and lktC) within the genomes and a signal
peptide at the beginning of the lktA protein. The two bovine strains, JCM 3718 and JCM 3724 had
the most cytotoxic effect, compared to ARU 01, which had the highest cell viabilities following
leukotoxin treatment for both HL-60 and human donor blood data (Figures 30 – 33) and therefore
the least statistical significance. It was thought that this strain may be highly virulent as it was
isolated from a patient with Lemierre’s syndrome, however this was not the case and the bovine
strains were more cytotoxic when concentrations were standardised. Virulence is likely to be
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multifactorial, therefore additional factors such as coinfection with another bacteria or virus, or
health of the host may determine F. necrophorum progression to Lemierre’s syndrome.
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Chapter 6:
Ecotin: a serine protease inhibitor
6.1 Introduction
Serine proteases are a widespread class of proteolytic enzymes, of which chymotrypsin/trypsin-like
proteases are the most abundant type. They have functions involved with the immune response,
blood coagulation, fibrinolysis, digestion and reproduction. Serine proteases are characterised by a
nucleophilic serine residue at the active site of the enzyme (Hedstrom, 2002). Serine protease
inhibitors (serpins), which have a critical role of regulating proteolytic activity, such as in clotting,
thrombolytic and inflammatory pathways, are also widespread (Silverman et al., 2010).
Neutrophils are abundant in normal, healthy adults, accounting for more than half of circulating
white blood cells. They are the body’s core defence against purulent, inflammatory bacterial
infections (Bain et al., 2012). They are classified as granulocytes due to their granule content within
the cytoplasm and it is these granules that contain serine proteases: neutrophil elastase, proteinase
3 and cathepsin G, which are involved in the destruction of pathogens. The proteases digest
microorganisms that have been engulfed into phagosomes and are also released at inflammatory
sites in order to degrade microorganisms extracellular to the neutrophils (Korkmaz et al., 2010).
Human neutrophil elastase (HNE) is a 30 kDa trypsin-like serine protease that is able to degrade a
variety of proteins in addition to elastin, including bacterial virulence proteins (Thusberg and
Vihinen, 2006) such as outer membrane protein A (Belaaouaj et al., 2000).
Human plasma kallikrein is involved in blood clotting as part of the contact activation system,
otherwise known as the intrinsic pathway. Formed by the activation of prekallikrein, it is involved
in the cleavage of high molecular weight kininogen and Factor XII, which also contribute to
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coagulation. Kallikrein and Factor XIIa additionally attract neutrophils by chemotaxis (Bain et al.,
2012). Kallikrein consists of a heavy chain (52 kDa) and two light chains (33 – 36 kDa), linked by
disulphide bonds (Colman et al., 1985).
Ecotin is a serine protease inhibitor that forms dimers with a molecular weight of 32 kDa (Gaboriaud
et al., 2013). It was first isolated from the periplasm of Escherichia coli and was found to be a strong
inhibitor of pancreatic chymotrypsin and elastase, rat mast cell chymase, and a less effective
inhibitor of human plasma urokinase; it did not inhibit kallikrein, plasmin or thrombin. Ecotin was
tested against all of the known E. coli proteases and was found to inhibit none of them, suggesting
that ecotin plays a role in protecting the cell against external proteases; its location in the periplasm
supports this (Chung et al., 1983). Studies by Ulmer et al. (1995) and Castro et al. (2006) have since
shown evidence that kallikrein and thrombin activity are affected by the presence of E. coli ecotin.
Ecotin forms homodimers via interactions at the C terminal and the ecotin dimer then forms a
heterotetramer complex with two proteases that it competitively inhibits. The crystal structure of
the tetramer reveals that each ecotin molecule forming the initial dimer interacts with one bound
enzyme via its primary binding site, and the other enzyme in the tetramer via its secondary binding
site, meaning that both ecotin monomers assist in the inhibition of both enzymes (Yang et al., 1998).
Ecotin has also been found in other Gram negative bacterial genomes such as Pseudomonas
aeruginosa and Yersinia pestis (Gillmor et al., 2000) and there are now many sequences available
in online databases. Using site directed mutagenesis it has been shown that the sequence of the
primary substrate binding site can be altered and still result in a functional inhibitor (Yang et al.,
1998; Pál et al., 1994).
E. coli ecotin has been shown by means of prothrombin time and activated partial thromboplastin
time tests to be a potent anticoagulant. It was found to be a potent inhibitor of Factors Xa and XIIa,
plasma kallikrein, human leukocyte elastase and bovine trypsin and chymotrypsin. It does not
inhibit thrombin, VIIa, Xia, activated protein C, plasmin and tissue plasminogen activator (Seymour
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et al., 1994; Ulmer et al., 1995). The anticoagulant effect seen in clotting time tests has been
explained as being due to the inhibition of Factor Xa, Factor XIIa and kallikrein (Ulmer et al., 1995).
Ecotin has been extensively studied in E. coli, but has not previously been studied in Fusobacterium
spp. F. necrophorum infections are known to spread via the bloodstream (Riordan, 2007), therefore
the ecotin protein could be an important protective measure for the bacteria as it is likely to
encounter neutrophils and their proteases while in the bloodstream. The aim of this chapter was
to investigate whether F. necrophorum produces a functional ecotin protein, and to test its activity
against host proteases.
It was hypothesised that F. necrophorum ecotin would be universal within the strain collection and
that protein model predictions would demonstrate a structure similar to that of E. coli, with both
primary and secondary binding sites present. PCR methods were used to determine the prevalence
of the ecotin gene within the strain collection and an analysis of the ecotin DNA and translated
protein sequences of the JCM 3718, JCM 3724 and ARU 01 strains was used to predict the protein
structure.
It was also hypothesised that a recombinant F. necrophorum ecotin protein would inhibit human
neutrophil elastase and human plasma kallikrein. This was tested using enzyme-substrate inhibition
tests. To assess the effect of the recombinant ecotin on clotting time in normal human donor
plasma, which could be affected due to the presence of serine proteases within the clotting




6.2.1 Ecotin gene locations
The ecotin gene was located by manually mining the annotations of the three genomes. In each
genome annotation the ecotin gene appeared once, as part of the BLASTp manual annotation, and
the locations were recorded in Table 41.
Table 41: Locations of ecotin genes found within the BLAST search results.
Isolate Assembly contig Base location Strand
JCM 3718 Contig00021 8696..9100 Complement
JCM 3724 Contig00015 77..733 Complement
ARU 01 Contig00099 125..604 Complement
Using the DNA sequence from the assembly contigs, a pair of custom PCR primers were designed
to amplify the putative gene in the three strains. The forward primer was located upstream of the
predicted ecotin start codon and the reverse primer was located downstream of the stop codon
(see Table 42).
Table 42: PCR primers used to amplify the ecotin genes in the three F. necrophorum genomes.
Primer Oligonucleotide sequence (5’ → 3’)
Ecotin_F GGCAACCAAAGACATGTAGGG
Ecotin_R GTACCACGAAACATGCATACTT
The PCR primers in Table 42 were used to test for the presence of the ecotin gene within the clinical
strain collection (methods section 2.8.2). Twenty five clinical strains, alongside strains JCM 3718,
JCM 3724 and ARU 01, were tested with the ecotin primers. Of these, a product of approximately
700 bp was amplified in 100 % of strains. See Figure 34 for an example gel image.
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Figure 34: Analysis of PCR products from Ecotin primers on a 1% agarose gel. Lane 1: 100 bp marker; 2: F. necrophorum
1; 3: F. necrophorum 5; 4: F. necrophorum 11; 5: F. necrophorum 21; 6: F. necrophorum 24; 7: F. necrophorum 30; 8:
Negative control (molecular grade water).
6.2.2 Gene sequence analysis
6.2.2.1 Clustal alignments
Amplified ecotin PCR products from strains JCM 3718, JCM 3724 and ARU 01 were run in a 1 %
agarose gel (methods section 2.8.3), excised and purified (methods section 2.8.5) before being sent
for commercial Sanger sequencing (methods section 2.8.7). The resulting sequences were aligned
using Clustal Omega (Figure 35) and show the three sequences are very highly conserved. The
sequences from the two Fnf strains are 100 % identical, however the sequence from the Fnn strain
differs in two locations, resulting in a 99.58 % identity. At position 189 there is a cytosine in place
of a thymine, and in position 250 there is an adenine in place of a guanine.
The DNA sequences of the first 12 strains from the clinical collection were also determined by
Sanger sequencing method and a Clustal alignment was performed (Appendix 21). The sequences
were shown to have percentage identities of 98.96 % or above.
700 bp
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JCM3718      ATGAAAAAATGTATTTATGCTATCGGCTTACTGTTTTCTTTTTCCGTCAGTGTTTTTGCA
JCM3724      ATGAAAAAATGTATTTATGCTATCGGCTTACTGTTTTCTTTTTCCGTCAGTGTTTTTGCA
ARU01        ATGAAAAAATGTATTTATGCTATCGGCTTACTGTTTTCTTTTTCCGTCAGTGTTTTTGCA
************************************************************
JCM3718      ATGCAGCATCCGGATATGAACTTGGAAATATATCCTAAGGCAAAACAAGGCATGAAGAAG
JCM3724      ATGCAGCATCCGGATATGAACTTGGAAATATATCCTAAGGCAAAACAAGGCATGAAGAAG
ARU01        ATGCAGCATCCGGATATGAACTTGGAAATATATCCTAAGGCAAAACAAGGCATGAAGAAG
************************************************************
JCM3718 GTTGTGTATCTTTTAGAGAAAAAAGAAAAAGAAGAAGACTATAAATTGGAAATAAAATTT
JCM3724      GTTGTGTATCTTTTAGAGAAAAAAGAAAAAGAAGAAGACTATAAATTGGAAATAAAATTT
ARU01        GTTGTGTATCTTTTAGAGAAAAAAGAAAAAGAAGAAGACTATAAATTGGAAATAAAATTT
************************************************************
JCM3718      GGAAAAGACCTTGTTGTAGATGATAATCTTCATCACTTTTTAGGAGGAAAGCTGGAAGAG
JCM3724      GGAAAAGATCTTGTTGTAGATGATAATCTTCATCACTTTTTAGGAGGAAAGCTGGAAGAG
ARU01        GGAAAAGATCTTGTTGTAGATGATAATCTTCATCACTTTTTAGGAGGAAAGCTGGAAGAG
******** ***************************************************
JCM3718      AAAGATGTAAAAGGTTGGGGCTATCCTTATTACATTTTTTCAGGAGATTCTCAAATGGCA
JCM3724      AAAGATGTAGAAGGTTGGGGCTATCCTTATTACATTTTTTCAGGAGATTCTCAAATGGCA
ARU01        AAAGATGTAGAAGGTTGGGGCTATCCTTATTACATTTTTTCAGGAGATTCTCAAATGGCA
********* **************************************************
JCM3718      CAAACTTTAATGGCGTTTCCTTTAGGAAGTGAACGAGAAAAAAGAGTATATTATCCCACA
JCM3724      CAAACTTTAATGGCGTTTCCTTTAGGAAGTGAACGAGAAAAAAGAGTATATTATCCCACA
ARU01        CAAACTTTAATGGCGTTTCCTTTAGGAAGTGAACGAGAAAAAAGAGTATATTATCCCACA
************************************************************
JCM3718      GCTACGAAAATATTGCCTTATCATTCAAAACTTCCTTTGGTTTTATATGTTCCGGAAGAT
JCM3724      GCTACGAAAATATTGCCTTATCATTCAAAACTTCCTTTGGTTTTATATGTTCCGGAAGAT
ARU01        GCTACGAAAATATTGCCTTATCATTCAAAACTTCCTTTGGTTTTATATGTTCCGGAAGAT
************************************************************
JCM3718      GTGAAGGTAGAAGTATCTCTTTGGAATCGAATGCAGGAAATCAAAGAAGTTTCTCGTTAA
JCM3724      GTGAAGGTAGAAGTATCTCTTTGGAATCGAATGCAGGAAATCAAAGAAGTTTCTCGTTAA
ARU01        GTGAAGGTAGAAGTATCTCTTTGGAATCGAATGCAGGAAATCAAAGAAGTTTCTCGTTAA
************************************************************
Figure 35: Clustal Omega alignment of the DNA sequence results from Sanger sequencing the three ecotin genes. Locations
where sequences are homologous are marked with ‘*’. Locations where bases do not match are marked in red.
The sequences were translated into protein using ExPASy translate (methods section 2.10.3), with
the first frame of the 5’ to 3’ sequence representing an open reading frame. The predicted protein
sequences were aligned using Clustal Omega (Figure 36). The protein alignment shows that of the
two substitutions highlighted in Figure 35, only one resulted in an amino acid substitution. The
difference at base number 189 caused no amino acid substitution as GAC and GAU both code for
aspartic acid. However the difference at base 250 resulted in a prediction of a lysine (AAA) in the
Fnn gene, compared to a glutamic acid (GAA) in the two Fnf genes. The location of this amino acid
variation in relation to the active site of the protein is discussed in section 6.2.2.3.
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JCM3718      MKKCIYAIGLLFSFSVSVFAMQHPDMNLEIYPKAKQGMKKVVYLLEKKEKEEDYKLEIKF
JCM3724      MKKCIYAIGLLFSFSVSVFAMQHPDMNLEIYPKAKQGMKKVVYLLEKKEKEEDYKLEIKF
ARU01        MKKCIYAIGLLFSFSVSVFAMQHPDMNLEIYPKAKQGMKKVVYLLEKKEKEEDYKLEIKF
************************************************************
JCM3718      GKDLVVDDNLHHFLGGKLEEKDVKGWGYPYYIFSGDSQMAQTLMAFPLGSEREKRVYYPT
JCM3724      GKDLVVDDNLHHFLGGKLEEKDVEGWGYPYYIFSGDSQMAQTLMAFPLGSEREKRVYYPT
ARU01        GKDLVVDDNLHHFLGGKLEEKDVEGWGYPYYIFSGDSQMAQTLMAFPLGSEREKRVYYPT
***********************:************************************
JCM3718      ATKILPYHSKLPLVLYVPEDVKVEVSLWNRMQEIKEVSR
JCM3724      ATKILPYHSKLPLVLYVPEDVKVEVSLWNRMQEIKEVSR
ARU01        ATKILPYHSKLPLVLYVPEDVKVEVSLWNRMQEIKEVSR
***************************************
Figure 36: Clustal Omega alignment of the predicted protein sequence results following the use of the ExPASy online
translation tool.
The ecotin gene sequences from strains JCM 3724 and ARU 01 were identical, therefore this Fnf
consensus sequence was used for the in vitro investigations as this subspecies is the one most
associated with humans and is therefore most relevant.
6.2.2.2 Signal peptide prediction
The Fnf ecotin protein sequencewas entered into the web-based tool SignalP (Petersen et al., 2011)
using Gram negative settings to predict the presence and location of signal peptide cleavage sites
(Figure 37). The results showed a predicted cleavage site between amino acid positions 20 and 21,
as shown by the first red and blue peak, suggesting that the mature protein begins on the second
methionine of the sequence. The D value weighted average score (see figure legend for definition)
was 0.777 with the cutoff being 0.570. The second, smaller peak in the red and blue lines was not
considered significant by the algorithm. It is not uncommon for there to be multiple high peaking C
scores when only one cleavage site is truly present (Petersen et al., 2011).
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Figure 37: SignalP prediction of signal peptide cleavage site. C scores are high at the position immediately after the
cleavage site, S scores distinguish between regions within the signal peptide and regions within the mature protein, and
Y scores are a combination of the C score average and S score slopes. A D score is then used to make a weighted average
of the mean S scores and the maximum Y scores which then determines whether a signal peptide is present.
6.2.2.3 Pfam search for conserved domains
The sequence was searched for conserved protein domains using Pfam, resulting in a match for
ecotin with an E value of 1.3e-32. A Clustal Omega alignment was carried out between the hidden
Markov model (HMM) consensus sequence for ecotin used by Pfam and the Fnf ecotin sequence,
resulting in a 42.62 % identity. Putative conserved domains were then predicted by BLASTp search.
The results of this were overlaid onto the sequence alignment (Figure 38). The four amino acids
highlighted in green are those predicted to be the primary substrate binding site. Three of the four
amino acids are conserved exactly, while the remaining position has been substituted for an amino
acid with weakly similar properties. The two segments highlighted in yellow are predicted to make
up the secondary substrate binding site. In the first of the two, four out of the five positions are
conserved, and in the second, four out of the six are conserved. The L and M in the primary
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substrate binding site are also predicted to form an inhibition loop and match the ecotin profile
exactly. The single variation between the Fnn and Fnf sequences occurs in the amino acid
immediately before part of the secondary substrate binding site. This may impact on substrate
specificity or binding efficiency, but without laboratory analysis it is not known.
HMM ------DLAPYPAPEEGQKRHVIKLPKLEDEADYKVELIIGKTLEVDCN-KQRLSGELEE
Fnf MQHPDMNLEIYPKAKQGMKKVVYLLEKKEKEEDYKLEIKFGKDLVVDDNLHHFLGGKLEE
:*  **  ::* *: *  * * *.* ***:*: :** * ** * :: *.*:***
HMM      KTLEGWGYEYYEVEKASEAASTLMACPDDEKKKEKFVSLEEGEKLLLRYNSKLPVVVYLP
Fnf KDVEGWGYPYYIFSGDSQMAQTLMAFPLGSEREKRVYY--PTATKILPYHSKLPLVLYVP
* :***** ** ..  *: *.**** *  .:::::.       . :* *.****:*:*:*
HMM      KDVELRYRVWK----------
Fnf EDVKVEVSLWNRMQEIKEVSR
:**::.  :*:
Figure 38: Clustal Omega alignment of the hidden Markov model consensus sequence of ecotin and the sequence of ecotin
from the Fnf genomes. Dashes represent where there is no corresponding sequence, ‘*’ represents an exact match,
‘:’represents amino acids with strongly similar properties and ‘.’ represents those with weakly similar properties. The
green highlighted sequence corresponds to the predicted primary substrate binding site and the yellow highlighted
sequence corresponds to the predicted secondary binding site regions. The amino acid in red shows the position where the
Fnn sequence differs.
6.2.2.4 Model of F. necrophorum ecotin
SWISS-MODEL and PyMol were used to create and visualise a protein prediction model of F.
necrophorum ecotin (Figure 39) using an E.coli ecotin reference (Figure 40). The two regions of the
protein sequence that make up the secondary binding site (highlighted in Figure 38) appear as one
region in the 3 dimensional protein model prediction, which was as expected in order for it to form
a single binding site. The primary (B1) and secondary (B2) binding sites were predicted to be
exposed on opposite sides of the protein. A computer graphic model, based on a crystallised
structure of E. coli ecotin shows a similar structure, with two ecotin monomers linked in such a way
that when the ecotin dimer binds to two target proteases, both monomers bind to both proteases
(Yang et al., 1998). The prediction that an F. necrophorum ecotin monomer has a similar structure
to an E. coli ecotin monomer suggests that there is a possibility that F. necrophorum ecotin is also
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a functional inhibitor. Laboratory tests are needed to confirm this hypothesis (sections 6.2.3 –
6.2.5).
Figure 39: Predicted protein model structure of F. necrophorum ecotin highlighting the primary binding site (B1) and
secondary binding site (B2).
Figure 40: Protein model structure of E. coli ecotin highlighting the primary binding site (B1) and secondary binding site
(B2). This model, visualised in PyMol, was the SWISS-MODEL reference used to predict the structure of F. necrophorum
ecotin in Figure 39 and is based on crystallised structures. The structures of E. coli and F. necrophorum ecotin appear






6.2.3 Cloning, expression and purification of recombinant ecotin
6.2.3.1 Plasmid design
A recombinant ecotin gene was designed to be inserted into a plasmid vector to enable expression
within E. coli cells and purification of the protein. A Novagen pET-16b plasmid was provided by Dr
Anatoliy Markiv, University of Westminster. This plasmid was chosen for its histidine tag, T7
promoter and ampicillin resistance gene. A plasmid map and sequence of the multiple cloning site
are shown in Appendix 22.
The cloning/expression region of the pET-16b plasmid includes a region cleaved by Factor Xa. Ecotin
is thought to inhibit Factor Xa, therefore due to concerns with the Factor Xa cleavage site interfering
with the ecotin assays this site was exchanged for an enterokinase site, making the pET-16b vector
sequence match that of the pET-19b vector sequence (see Appendix 23).
The restriction sites chosen were NcoI and XhoI. A sequence was designed to be synthesised which
included, in order, an NcoI restriction site, deca-histidine tag, enterokinase cleavage site, NdeI
restriction site, the F. necrophorum ecotin sequence matching that of the two subspecies
funduliforme strains, including the stop codon, and a XhoI restriction site. This allowed for the
section between the NcoI and XhoI restriction sites to be removed from the pET-16b vector and be
replaced by the equivalent sequence from the pET-19b sequence, with the addition of the ecotin
sequence between the NdeI and XhoI restriction sites.
The F. necrophorum ecotin sequence contains some codons that are known to be rarely used in E.
coli strains, therefore the codons were optimised to suit the codon bias of E. coli in order to facilitate
high and stable expression rates while still producing the same translated protein sequence. This
was carried out as part of the commercial synthesis package. An alignment of the original sequence
designed for the plasmid and the final optimised sequence was produced to ensure the restriction
sites had been conserved (Figure 41). These sites are where the DNA is cleaved during the cloning
process and would be non-functional if altered. When translated into protein, the original and
optimised sequences were 100 % congruent.
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Optimised    CCATGGGCCATCATCATCACCATCACCACCATCATCATAGCAGCGGTCATGATGATGATG
Original CCATGGGCCATCATCATCATCATCATCATCATCATCACAGCAGCGGCCATGACGACGACG
******************* ***** ** ******** ******** ***** ** ** *
Optimised    ATAAACATATGCAGCATCCGGATATGAACCTGGAAATTTATCCGAAAGCAAAACAGGGCA
Original ACAAGCATATGCAGCATCCGGATATGAACTTGGAAATATATCCTAAGGCAAAACAAGGCA
* **.************************ *******:***** **.********.****
Optimised    TGAAAAAAGTTGTTTATCTGCTGGAAAAAAAAGAAAAAGAAGAAGATTACAAACTGGAAA
Original     TGAAGAAGGTTGTGTATCTTTTAGAGAAAAAAGAAAAAGAAGAAGACTATAAATTGGAAA
****.**.***** *****  *.**.******************** ** *** ******
Optimised    TCAAATTTGGCAAAGATCTGGTGGTGGATGATAACCTGCATCATTTTCTGGGTGGTAAAC
Original     TAAAATTTGGAAAAGATCTTGTTGTAGATGATAATCTTCATCACTTTTTAGGAGGAAAGC
*.********.******** ** **.******** ** ***** *** *.**:**:**.*
Optimised    TGGAAGAAAAAGATGTTGAAGGTTGGGGCTATCCGTATTATATCTTTAGCGGTGATAGCC
Original     TGGAAGAGAAAGATGTAGAAGGTTGGGGCTATCCTTATTACATTTTTTCAGGAGATTCTC
*******.********:***************** ***** ** ***: .**:***: *
Optimised    AGATGGCACAGACCCTGATGGCATTTCCGCTGGGTAGCGAACGTGAAAAACGTGTTTATT
Original     AAATGGCACAAACTTTAATGGCGTTTCCTTTAGGAAGTGAACGAGAAAAAAGAGTATATT
*.********.**  *.*****.*****  *.**:** *****:******.*:**:****
Optimised    ATCCGACCGCAACCAAAATTCTGCCGTATCATAGCAAACTGCCGCTGGTTCTGTATGTTC
Original     ATCCCACAGCTACGAAAATATTGCCTTATCATTCAAAACTTCCTTTGGTTTTATATGTTC
**** **.**:** *****: **** ******: .***** **  ***** *.*******
Optimised    CGGAAGATGTTAAAGTTGAAGTTAGCCTGTGGAATCGCATGCAAGAAATTAAAGAAGTGA
Original     CGGAAGATGTGAAGGTAGAAGTATCTCTTTGGAATCGAATGCAGGAAATCAAAGAAGTTT
********** **.**:*****::  ** ********.*****.***** ******** :
Optimised    GCCGTTAACTCGAG
Original     CTCGTTAACTCGAG
************
Figure 41: Clustal Omega alignment showing the locations where DNA bases have been changed to suit the codon bias of
E. coli. Sequence highlighted in yellow shows the locations of restriction sites, which have the DNA sequence preserved in
order to retain the cleavage function. The section highlighted in green is the deca-histidine tag and the grey segment is
the enterokinase cleavage site. The sequence coding for the ecotin gene is between the second and third restriction sites.
The plasmid containing the ecotin insert was commercially synthesised (methods section 2.14.2)
and arrived as lyophilised DNA. After reconstitution (methods section 2.14.3), the plasmid was
transformed into chemically competent TOP10 E. coli cells (methods section 2.14.4) and grown
overnight at 37 °C on an LB agar plate with ampicillin. The next day, one colony was selected and
inoculated into LB broth with ampicillin and grown for 16 hours at 37 °C and 330 rpm. A plasmid
miniprep was carried out to extract plasmid DNA (methods section 2.14.5). Purified plasmid was
quantified using a Nanodrop (methods section 2.8.6) and then digested using restriction enzymes
to cleave the DNA at the NcoI and XhoI cloning sites (methods section 2.14.6). The pET-16b plasmid
was cleaved simultaneously using the same enzymes and all digestions were run in a 0.8 % agarose
gel. The resulting bands were excised and the DNA extracted using a DNA gel purification kit
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(methods section 2.8.5). The nucleic acid was quantified using a Nanodrop. The cut insert was
ligated into the pET-16b plasmid backbone (methods section 2.14.7) before being transformed into
chemically competent TOP10 E. coli cells and grown overnight at 37 °C. One colony was selected
and inoculated into LB broth with ampicillin and grown for 16 hours at 37 °C and 330 rpm. A plasmid
miniprep was carried out to extract plasmid DNA. The digest was repeated and cut plasmids were
run on a 0.8 % agarose gel to check for the presence of the insert. Successfully ligated plasmid DNA
was transformed into chemically competent BL21(DE3) E. coli cells (methods section 2.14.8) for
expression. A colony was selected from the LB agar with ampicillin, grown overnight in LB broth
with ampicillin, and a plasmid miniprep was carried out to extract plasmid DNA. This was quantified
using a Nanodrop before being sent for commercial Sanger sequencing using primers targeting the
T7 promoter in order to verify that the final plasmid contained the correct sequence.
6.2.3.2 Protein expression induced with IPTG
E. coli BL21(DE3) expression strain transformed with pET-16b+ecotin was induced with IPTG to
express the recombinant ecotin protein (methods section 2.15.1). BL21(DE3) containing no plasmid
was grown in parallel to be used as a negative control. 1 ml samples were taken from each culture
at IPTG induction (0 hours) and 1, 2 and 3 hours post-induction for analysis by SDS PAGE using the
Tricine method and a denaturing buffer (Figure 42) (see methods 2.15.3).
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Figure 42: SDS PAGE analysis of expression strain with (BL21(DE3)+) and without (BL21(DE3)-) plasmid. Lane 1:
NEB marker (11-190 kDa), 2: BL21(DE3)- 0 hours, 3: BL21(DE3)+ 0 hours, 4: BL21(DE3)- 1 hour, 5: BL21(DE3)+
1 hour 6: BL21(DE3)- 2 hours, 7: BL21(DE3)+ 2 hours, 8: BL21(DE3)- 3 hours, 9: BL21(DE3)+ 3 hours. Presumed
ecotin band highlighted with red arrow.
E. coli produces its own ecotin protein, so a band was expected in the 20 kDa region with or without
the plasmid present. At zero hours, both the plasmid-containing strain and the negative control
appeared the same. At one, two and three hours post-induction with IPTG, the plasmid-containing
strain contained a more pronounced band of the size equivalent to the presumptive ecotin protein.
This suggests that the IPTG has successfully induced production of the recombinant ecotin protein.
6.2.3.3 Purification of histidine-tagged protein by immobilised metal ion chromatography
(IMAC) under native conditions
The histidine-tagged protein was purified under native conditions by immobilised metal affinity
chromatography over a cross-linked agarose matrix charged with nickel ions (see methods 2.15.2).
Samples were analysed using the Tricine-SDS PAGE method using denaturing loading buffer; Figure




interest is present in the total lysate of the cell pellet, and has therefore not been secreted. Lane 3
demonstrates that the protein is present in the soluble fraction, as opposed to being maintained in
inclusion bodies, which would require purification under denaturing conditions. Lane 4 shows the
column flow through, containing proteins that have not bound to the column. Some protein of
interest did not bind to the column and can be seen in the flow through. Lanes 5 and 6 were samples
from the first and final wash fractions, respectively. The absence of any bands in lane 6 showed that
the column had been washed thoroughly enough to remove any protein not bound strongly to the
resin. Lanes 7 to 10 were samples of elution aliquots, and contained protein at the approximate
expected band size. There were also two high molecular weight bands faintly present, suggesting
the elution had not yielded a protein that was 100 % pure.
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Figure 43: SDS PAGE analysis of protein purification fractions. Lane 1: NEB marker (11-190 kDa), 2: Total lysate,
3: Soluble fraction, 4: Flow through, 5: Wash 1, 6: Wash 5, 7: Elution 1, 8: Elution 2, 9: Elution 3, 10: Elution 4.
Quantities loaded were: 5 µl of protein marker and 15 µl of each sample in 5 µl 4x Laemmli buffer.
6.2.3.4 Bradford assay to determine concentration of purified ecotin
A Bradford assay was carried out to measure the concentration of purified recombinant ecotin
protein (methods section 2.15.4). The standard curve generated fitted the linear equation y=0.029x
+ 0.0513 and had an R squared value of 0.995.
Table 43: Protein concentrations of eluted recombinant ecotin products, as measured by Bradford assay.










6.2.4 Human plasma kallikrein and human neutrophil elastase inhibition assays
The inhibitory effect of F. necrophorum ecotin, which has not previously been investigated, may
play a role in the virulence of the organism. The recombinant ecotin protein was therefore tested
for inhibitory activity against human plasma kallikrein, part of the intrinsic clotting cascade and
human neutrophil elastase, which functions as part of the immune response. These serine
proteases have previously been shown to be inhibited by E. coli ecotin (Seymour et al., 1994; Ulmer
et al., 1995).
6.2.4.1 Human plasma kallikrein inhibition assay
Human plasma kallikrein (HPK) was tested with a range of kallikrein substrate concentrations to
establish normal, uninhibited enzyme kinetics (methods section 2.16). HPK concentration was kept
constant at 10 nM throughout the experiment. Each concentration of substrate was added to the
enzyme in triplicate and relative fluorescence units were measured every minute for 30 minutes
(Figure 44). The kallikrein substrate contained a 7-Amino-4-(trifluoromethyl)coumarin (AFC)
terminus, which is cleaved by HPK, resulting in fluorescence. In order to establish rate of product
formation, a calibration curve was constructed with a concentration range of 0 – 0.5 mM AFC. The
resulting line had an equation of y=244626x and an R squared value of 0.9978 (Appendix 24).
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Figure 44: XY plot of relative fluorescence units (RFU) measured over 30 minutes from human plasma kallikrein. Substrate
concentrations ranged from 0.015 mM to 0.5 mM and inhibitor was at 0 nM. The graph shows the mean of three replicate
values and standard error of the mean is represented by bars.
The change in fluorescence at 5 minutes was used to calculate the rate of reaction (µmol min-1) for
each concentration of kallikrein substrate (see Table 44). The 5 minute time point was chosen for
the initial rate as this was within the initial linear section of the graph. [P] (concentration of product)
was calculated using the equation derived from the AFC calibration curve: y=244626x. Therefore
[P]=y/244626.
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Table 44: Calculations for the rate of reaction (µmol min-1) of HPK with substrate.









0 0.00 0.0000 0.0000 0.0000
0.015 169.61 0.0007 0.0693 0.0139
0.03 317.51 0.0013 0.1298 0.0260
0.06 649.48 0.0027 0.2655 0.0531
0.125 1136.03 0.0046 0.4644 0.0929
0.25 1949.89 0.0080 0.7971 0.1594
0.5 2303.78 0.0094 0.9418 0.1884
The values in Table 44 were used to make an XY plot of substrate concentration against rate of
reaction (Figure 45). Michaelis-Menten non-linear regression was applied to calculate the Vmax and
Km values (see Table 45).
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Figure 45: Michaelis-Menten HPK plot, showing the relationship between substrate concentration and rate of reaction.
The curve was fitted by nonlinear regression in GraphPad Prism using the Michaelis-Menten settings. R squared value =
0.9912.
Table 45: Results of nonlinear regression analysis of data in Table 44 and Figure 45.
Best fit values Standard error 95% Confidence
intervals
Vmax 0.293 0.026 0.226 to 0.360
Km 0.252 0.047 0.132 to 0.372
Using nonlinear regression analysis, the Km for kallikrein substrate with human plasma kallikrein
under the conditions specified (in methods section 2.16) was 252 µM. Vmax was 0.293 µmol min-1.
In order to confirm that autolysis of the substrate was not responsible for the increase in
fluorescence, relative fluorescence for the substrate range 0.015 – 0.5 mM was monitored for 30
minutes with no enzyme present. The change in fluorescence for each substrate concentration was
equal to less than 1 % of the fluorescence of the respective substrate standard.
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HPK was then tested with the addition of ecotin (Figure 46), with fluorescence monitored as above.
See Appendix 25 for RFU readings.
[I]=12.5 nM







































Figure 46: XY plots of RFUs monitored over 30 minutes in the presence of HPK (10 nM), substrate (0.015 – 0.5 mM) and
inhibitor (12.5 – 100 nM). Enzyme and inhibitor were incubated for an hour at room temperature to equilibrate before
addition of substrate.
In order to establish the type of inhibition caused by ecotin, a Lineweaver-Burk plot was produced
(see Appendix 26). The plot showed characteristics of competitive inhibition, such as increasing
slopes and Km for increasing inhibitor concentrations while Vmax remained stable.
Ecotin is thought to be a tight-binding inhibitor, so Morrison Ki nonlinear regression was applied.
The ratio of inhibited to uninhibited rate of reaction was plotted against the inhibitor concentration
for each substrate concentration (Figure 47). The Morrison equation was used as part of the
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GraphPad Prism package to determine the estimated concentrations required to produce half
maximal inhibition, known as the inhibition constant (Ki) (Table 46).
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Figure 47: Fractional activity of HPK derived using Morrison Ki nonlinear regression.
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Table 46: Ki values determined using Morrison tight binding kinetics within GraphPad Prism.
[S] µM Ki SE 95 % Confidence
Intervals
R squared
15 25.55 3.577 14.17 to 36.94 0.9815
30 24.1 3.779 12.08 to 36.13 0.9766
60 23.71 5.239 7.043 to 40.38 0.9526
125 34.81 8.511 7.733 to 61.90 0.9348
250 29.99 8.247 3.754 to 56.24 0.9073
500 34.55 13 -6.815 to 75.91 0.8054
The Morrison Ki of F. necrophorum ecotin with human plasma kallikrein had the highest R squared
value and the best visual fit at 15 µM, and was determined to be 26 nM.
6.2.4.2 Human neutrophil elastase inhibition assay
Human neutrophil elastase (HNE) was tested with a range of elastase substrate (Methoxysucinyl-
Ala-Ala-Pro-Val-p-nitroanilide) concentrations to establish normal, uninhibited enzyme kinetics
(methods section 2.16). Each concentration was added to the enzyme in triplicate and absorbance
was measured every minute for 30 minutes (Figure 48). HNE concentration was kept constant at 17
nM throughout the experiment. The chromogenic elastase substrate contained a p-nitroanilide
(pNA) terminus, which is cleaved by elastase, resulting in a shift in absorption spectrum. pNA has a
molar extinction coefficient (ε) of 8800 M-1 cm-1 at 410 nm, as stated in the product information
sheet provided by Merck, which when used with Beer-Lambert Law will establish concentration of
product (Equation 1 in methods section 2.16).
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Figure 48: XY plot of absorbance measured over 30 minutes from human neutrophil elastase and a range of substrate
concentrations (0.015 mM to 0.5 mM); no inhibitor was present. The graph shows the mean of three replicate values and
standard error of the mean is represented by bars.
The change in absorbance at 5 minutes was used to calculate the rate of reaction (µmol min-1) for
each concentration of elastase substrate (see Table 47). Five minutes was chosen as the time point,
as this was within the linear section of the graph. The concentration of product was calculated using
Beer-Lambert Law, as discussed above.
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Table 47: Calculations for the rate of reaction (µmol min-1) of HNE with substrate.









0 0 0.000 0.000 0.000
0.015 0.004 0.000 0.064 0.013
0.03 0.005 0.000 0.080 0.016
0.06 0.016 0.001 0.255 0.051
0.125 0.019 0.002 0.302 0.060
0.25 0.021 0.002 0.334 0.067
0.5 0.027 0.002 0.430 0.086
The values in Table 47 were used to make an XY plot of substrate concentration against rate of
reaction (Figure 49). Michaelis-Menten non-linear regression was applied to calculate the Vmax and
Km values (see Table 48).
Michaelis-Menten plot


















Figure 49: Michaelis-Menten HNE plot, showing the relationship between substrate concentration and rate of reaction.
The curve was fitted by nonlinear regression in GraphPad Prism using the Michaelis-Menten settings. R squared value =
0.9627.
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Table 48: Results of nonlinear regression analysis of data from Table 47 and Figure 49.
Best fit values Standard error 95% Confidence
intervals
Vmax 0.098 0.010 0.072 to 0.124
Km 0.089 0.026 0.019 to 0.151
Using nonlinear regression analysis, the Km for MeOSucc-AAPV-pNA with human neutrophil elastase
under the conditions specified (in methods section 2.16) was 89 µM. Vmax was 0.098 µmol min-1.
In order to confirm that autolysis of the substrate was not responsible for the increase in
absorbance, absorbance for the substrate range 0.015 – 0.5 mM was monitored for 30 minutes
with no enzyme present. The change in absorbance for each substrate concentration was equal to
less than 1 % of the absorbance of the respective substrate standard.
HNE was then tested with the addition of ecotin (Figure 50), with absorbance monitored as before.
See Appendix 27 for absorbance readings.
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[I]=12.5 nM























































Figure 50: XY plots of absorbance monitored over 30 minutes in the presence of HNE (17 nM), substrate (0.015 – 0.5 mM)
and inhibitor (12.5 – 100 nM). Enzyme and inhibitor were incubated for an hour at room temperature to equilibrate before
addition of substrate.
Morrison Ki nonlinear regression was applied to the data. The ratio of inhibited to uninhibited rate
of reaction was plotted against the inhibitor concentration for each substrate concentration (Figure
51). The Morrison equation was used as part of the GraphPad Prism package to determine the
estimated inhibition constant (Ki) (Table 49).
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Figure 51: Fractional activity of HNE derived using Morrison Ki nonlinear regression.
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Table 49: Ki values determined using Morrison tight binding kinetics equation
[S] µM Ki SE 95 % Confidence
Intervals
R squared
15 4.404 2.619 -3.930 to 12.74 0.9120
30 4.310 1.220 0.4290 to 8.192 0.9751
60 3.486 1.330 -0.7465 to 7.718 0.9560
125 4.042 1.721 -1.434 to 9.518 0.9241
250 2.818 1.912 -3.267 to 8.903 0.8269
500 1.932 1.250 -2.047 to 5.911 0.8285
The Morrison Ki of F. necrophorum ecotin with human neutrophil elastase had the highest R squared
value and the best visual fit at 30 µM, and was determined to be 4 nM. This demonstrates that the
recombinant F. necrophorum ecotin inhibits HNE to a greater extent than it inhibits HPK (Morrison
Ki of 4 nM compared to 26 nM, for HNE and HPK, respectively).
6.2.5 Plasma clotting assays
To test how the recombinant ecotin would affect the overall combination of clotting factors in
human blood, three assays were used to measure clotting times; ecotin final concentrations ranged
from 0 – 2 µM. Platelet-poor plasma was made from human donor blood (methods section 2.12.4).
Thrombin time (TT) assay was used to monitor the conversion of fibrinogen to fibrin. Prothrombin
time (PT) assay was used to monitor any abnormalities with the functioning of Factors II, V, VII, X
and fibrinogen; it measures the extrinsic and common pathways. The activated partial
thromboplastin time (APTT) assay measures the intrinsic and common pathways, and is sensitive
to Factors II, V, VIII, IX, X, XI, XII and fibrinogen. Using a combination of these tests can be very
suggestive to which factors are affected (Bain et al., 2012).
Blood was used from three different donors, with each experiment being carried out on a different
day. Platelet-poor plasma was separated and normal clotting times were established. The range of
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inhibitor concentrations were tested, with a follow up test of uninhibited clotting, to confirm that
the prolongation of clotting was not due to time bias. Each measurement was recorded in duplicate
and the mean taken. The results of the clotting prolongation are shown in Figure 52; points
represent the mean of the three sets of results. At 2 µM, ecotin caused a 1.1-fold increase in clotting
time for TT, 7-fold increase for PT and 40-fold increase for APTT. A process of elimination can be
used to determine the factors that may be inhibited, based on the factors measured in each test.
See Appendix 28 for full clotting prolongation results.






















Figure 52: Fold prolongation of human donor plasma clotting tested with a range of ecotin concentrations. The y axis is
shown as a log2 scale, however all data points have been unaltered.
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6.3 Discussion
Ecotin has not previously been described in F. necrophorum. Strains JCM 3718, JCM 3724 and ARU
01 were shown to contain the ecotin gene by mining the sequence data and by PCR. It was
hypothesised in section 6.1 that F. necrophorum ecotin would be universal within the strain
collection. When tested using PCR methods, there was amplification of the ecotin gene in the 25
strains in the clinical collection. The protein sequences of strains JCM 3718, JCM 3724 and ARU 01
were searched in the Pfam database and when compared to the ecotin consensus sequence they
had E values of 1.3e-32 and 2.3e-32 for Fnf and Fnn sequences, respectively, which indicate a very
small chance that the sequence matched that of ecotin by chance.
When the DNA sequences were aligned, the two Fnf strains had identical sequences, whereas the
Fnn sequence had two single point mutations. The predicted translated protein sequence resulted
in a single amino acid difference between the two subspecies. This single amino acid difference
occurs immediately before the region of the protein considered to be the secondary substrate
binding site. The Fnn gene contains a lysine in place of the glutamic acid present in the Fnf genes.
Lysine is a positively charged, basic amino acid, whereas glutamic acid is a negatively charged, acidic
amino acid. This could have an impact on the binding abilities of the two ecotin proteins, although
as demonstrated by Pál et al. (1994), the sequence can contain some variation and still be
functional. The hidden Markov model ecotin sequence used for the Pfam alignments contains a
glutamic acid in this position. As there was not sufficient funding to produce and test the activity of
two recombinant ecotins, only the activity of the Fnf ecotin was assessed.
The presence of the signal peptide at the start of the protein sequence is consistent with the
expectation that this gene is found in the periplasm of the bacteria, as opposed to the cytoplasm.
The location of the protein in the periplasm, as found with the E. coli ecotin by Chung et al. (1983),
is suggestive of the protein being a protective inhibitor. If the inhibitor was secreted then it would
appear more likely that the aim is to target clotting factors. It is therefore possible that the
inhibition of clotting is a coincidental by product of this serine protease inhibitor.
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It had been hypothesised that protein model predictions would demonstrate a structure similar to
that of E. coli, with both primary and secondary binding sites present. The Pfam domain results of
the protein locates the presence of the primary substrate binding site and the two secondary
substrate binding sites. While the substrate binding sites are not 100 % homologous, they are well
conserved. As discussed previously, the sequence of the primary binding site can include mutations
and still result in a functional inhibitor (Pál et al., 1994), therefore it is not essential that the
sequence is highly conserved and some sequence variation between species can be expected. The
protein model prediction shows the primary and secondary binding sites are located in the
expected positions, based on crystalised structures and in silico experiments. This therefore
satisfies the hypothesis.
Expression of the recombinant ecotin protein by E. coli BL21(DE3) cells was indicated by the
presence of a band at the expected molecular weight by Tricine-SDS PAGE analysis. At zero hours
post-induction with IPTG, the BL21(DE3) strain both with and without the plasmid appear the same
on the gel. At one, two and three hours post-induction there is a clear band for the strain containing
the plasmid that is lacking for the strain not transformed with the plasmid. The negative control
was chosen to be strain BL21(DE3) without the plasmid, as opposed to the strain with the plasmid
but without IPTG, since there is anecdotal evidence of the T7 promoter being ‘leaky’, and thus
inducing protein production in the absence of IPTG. As E. coli expresses an ecotin protein itself there
is already likely to be a band in the region, so the plasmid was not used in the negative control to
provide more clarity. The native E. coli ecotin does not contain a histidine tag, therefore was unlikely
to contaminate the final recombinant ecotin product during purification.
A Bradford assay was used for protein quantification, as opposed to Nanodrop technology, as the
Nanodrop is more reliable for proteins with a higher concentration. The Bradford assay works well
for lower concentrations of protein and appeared more reproducible during initial optimisation of
the assay. The Nanodrop was first used to provide an indication of the concentration before the
protein was diluted for use in the Bradford assay.
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The Tricine-SDS PAGE analysis of the purification steps (Figure 43) shows that native conditions
were suitable as opposed to denaturing conditions. Sample fractions were run on the gel to
demonstrate the location of the ecotin protein. If the protein had been present in the total fraction
but not in the soluble fraction, this would have indicated that the protein was present in inclusion
bodies within the cytoplasm, which would have required denaturing the protein and then refolding.
This often occurs if the protein is expressed in too high a concentration, or if it is toxic to the cell.
Under normal circumstances in E. coli, ecotin is expressed and the signal peptide causes the protein
to be transported to the periplasm. For the recombinant ecotin, the signal peptide was removed
and replaced with a histidine tag, therefore the protein would have remained in the cytoplasm.
Fortunately this was not problematic as the inhibitor is not toxic to E. coli, however, the protein
was not expressed in concentrations as high as had been anticipated.
A considerable amount of the recombinant protein appears to be present in the flow through
(Figure 43, lane 4). This unfortunately diminishes the final concentration. The tag was a deca-
histidine tag, as opposed to the frequently used hexa-histidine tag, and therefore should have
bound strongly. The tag may have been partially obscured by the folding of the protein, reducing
the strength of the interaction with the column, and this may be why some of the protein was lost
prior to elution.
The washing steps during the purification were continued until protein concentration within the
wash fraction was 0 mg/ml. The gel image supports this and the lane is clear for the final wash
fraction. Despite this there are two faint bands of a high molecular weight present within the elution
fractions, suggesting that the eluted protein isn’t completely pure. It is unlikely that the small
percentage of contaminating protein will inhibit serine proteases. It is likely, however, to have a
minimal effect on the measurement of the protein concentration, causing the Bradford assay to
measure a slightly higher concentration of inhibitor than is actually present.
The choice of methods used to assess the inhibitory properties of the F. necrophorum recombinant
ecotin were designed to include a variety of tests on a limited budget. Ecotin from E. coli has already
been shown to potently inhibit Factors Xa and XIIa, plasma kallikrein and human leukocyte elastase.
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Factors X and XII and their respective substrates are very expensive and as kallikrein is part of the
clotting cascade and was considered a likely target for ecotin, it was chosen due to the lower cost.
Human neutrophil elastase, a protease that degrades bacteria, was chosen as it was anticipated
that ecotin may act as a defence mechanism against this type of immune system protease released
at inflammation sites. It is not part of the clotting cascade. The thrombin time, prothrombin time
and activated partial thromboplastin time tests are standardised methods for testing clotting
pathways.
For the enzyme assays, Michaelis-Menten kinetics were established to assess the activity of the
enzymes under uninhibited conditions, to confirm appropriate concentrations of enzyme and
substrate had been chosen and to allow for different types of data analysis in the event that the
Morrison Ki for tight binding inhibitors had not been appropriate. Alternative options included non-
linear regression for competitive inhibition, or reciprocal plots, which tend to amplify any errors in
the data.
It had been hypothesised that the recombinant F. necrophorum ecotin protein would inhibit human
neutrophil elastase and human plasma kallikrein. The data in section 6.2.4 demonstrates this to be
the case. The set of four inhibition plots showing absorbance against time for HNE (Figure 50) shows
stronger inhibition than for the equivalent HPK graphs plotting RFU against time (Figure 46). This is
supported by the Morrison Ki values obtained for each enzyme, with 4 nM for HNE and 26 nM for
kallikrein. For comparison, E. coli ecotin was reported as having Morrison Ki values of 54 pM for
Factor Xa, 55 pM for human leukocyte elastase, 89 pM for Factor XIIa and 163 pM for plasma
kallikrein (Ulmer et al., 1995). This does appear to show E. coli ecotin as considerably more active
against these serine proteases (73X more active against HNE and 160X more active against HPK),
however without having performed the tests in the same laboratory under the same conditions it
is difficult to speculate. Differences in the accuracy of measuring the concentration of ecotin as well
as differences in the activity of the enzymes purchased could have an effect on the results. For
example, the Km values reported for kallikrein and human leukocyte elastase with their
corresponding substrates were 165 µM and 150µM, respectively (Ulmer et al., 1995), whereas
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under the conditions used in this work, they were 252 µM and 89 µM for kallikrein and HNE,
respectively. Variations in the results from this work compared to that of Ulmer et al. (1995) may
also be due to the use of different substrates. Ideally, E. coli ecotin would have been tested
alongside as a comparator, but due to the associated cost this was not possible.
The Morrison Ki data for the HPK assay (Figure 47) shows that the curve is flatter with more
substrate present, which suggests that with a high enough concentration of substrate the inhibition
can be overcome; this is typical of competitive inhibition. This supports the previous assumption
that ecotin is a competitive inhibitor and was further supported by a Lineweaver Burk plot
(Appendix 26) as discussed in section 6.2.4.1.
The Morrison Ki plots for the HNE data did not fit as closely as for the HPK data. This was reflected
in the lower R squared values of the curves. The HNE fractional activity ratios rapidly dropped to
zero, requiring a steep curve; a lower ecotin concentration range may have resolved this. The Ki
value with the best fit (as measured by the Rsquared value) was reported, however the mean of all
the Ki results were shown for comparison. The results did not vary greatly.
At the highest ecotin concentration tested (2 µM), the thrombin time clotting assay was prolonged
only 1.1-fold, suggesting that ecotin had very little effect on the conversion of fibrinogen to fibrin.
Prothrombin time was prolonged 7-fold, suggesting ecotin inhibited some of Factors II, V, VII and
X. APTT was prolonged up to 40-fold, suggesting that ecotin potently inhibited some or all of Factors
II, V, VIII, IX, X, XI and XII. Both PT and APTT are also measures of the conversion of fibrinogen to
fibrin as part of the common pathway, but as the TT was not prolonged this can be ruled out as
being a target for ecotin.
E. coli ecotin is known to be a potent inhibitor of Factors Xa, XIIa, kallikrein, human leukocyte
elastase, and bovine trypsin and chymotrypsin, but not thrombin, Factors VIIa and XIa, activated
protein C, plasmin, or tissue plasminogen activator (Seymour et al., 1994; Ulmer et al., 1995). E. coli
ecotin and F. necrophorum ecotin are likely to have similar binding sites, as suggested by the protein
model prediction in Figure 39, therefore information about E. coli ecotin inhibition can be used to
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hypothesise which factors are inhibited by F. necrophorum ecotin. Firstly, as Factors II and V are
present in both PT and APTT tests, these are not targets of potent inhibition by F. necrophorum
ecotin, due to the variation in prolongation times between the tests. Factor VIIa was found not to
be inhibited by E. coli ecotin, as discussed above, and no results were found regarding inhibition of
Factor VIII or IX. Factors Xa and XIIa have been shown to be potently inhibited by E. coli ecotin, as
also discussed above, while Factor XIa was not effectively inhibited. Consequently, it is likely that
PT was prolonged by F. necrophorum ecotin due to the potent inhibition of Factor X, while APTT
was prolonged to a much greater extent due to the combination of potent inhibition of Factor X,
Factor XII and kallikrein, which is also part of the intrinsic pathway and was inhibited in enzyme
assays. It is conceivable that F. necrophorum ecotin may also interfere with other factors in the
intrinsic pathway that were not the focus of investigation.
The role, if any, that F. necrophorum ecotin plays in disseminated intravascular coagulation during
cases of bacteraemia and Lemierre’s syndrome remains unclear. E. coli is present in the gut of
humans and is therefore highly likely to encounter many proteases against which it will need to
protect itself. The need for F. necrophorum to inhibit serine proteases is less obvious. While the
organism is present in the blood stream and at inflammatory sites it is likely to encounter
neutrophils and the elastases they secrete to degrade pathogens. Having ecotin present in the
periplasm may help protect the bacterial cell. It may also be released from dying F. necrophorum
cells and subsequently inhibit factors of the intrinsic clotting system, thereby inhibiting chemotaxis
of further neutrophils and blood clotting.
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Chapter 7:
Discussion, conclusions and future work
7.1 Discussion
The aim of this project was to use next generation sequencing and subsequent bioinformatic
analysis, and in vitro work to investigate the F. necrophorum genome and the virulence
determinants that it contains. The type strains of the two subspecies, along with a clinical strain
known to have caused Lemierre’s syndrome in a patient, were collected and commercially
sequenced and assembled. Draft genome sequences of JCM 3718 (Fnn), JCM 3724 (Fnf) and ARU
01 (Fnf) were found to have sizes of 2.3 Mb, 2.13 Mb, and 2.06 Mb, respectively. This is closely
aligned with the findings of Calcutt et al. (2014), who published the draft genome of Fnf strain B35
with a reported size of 2.09 Mb. The genome of F. nucleatum, the most closely-related completed
genome, was found to be 2.17 Mb (Kapatral et al., 2002).
At the start of this project, in 2011, there was no available F. necrophorum genome sequence,
therefore many of the genes the organism contained were unknown. With an increasing emphasis
on the use of genomic data, it was clear that F. necrophorum needed to be sequenced. Since then,
genome sequencing has dramatically increased in popularity and accessibility and the draft
genomes of eleven F. necrophorum strains have been deposited in the NCBI database. The tools
used for associated data analysis have also been rapidly changing over recent years. More extensive
genome sequencing projects are being carried out, such as the Human Microbiome Project and the
Genomics England 100,000 human genomes project. The increase in investment associated with
these projects leads to more cost effective technologies and more advanced data analysis. The
number of bacterial and archaeal genomes sequenced and submitted to the NCBI in 2011 was fewer
than 2000. In 2014, more than 14,000 genomes were sequenced and submitted. Not only are the
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number of genomes increasing, but also the diversity, due to projects such as the Genomic
Encyclopedia of Bacteria and Archaea, which aims to sequence organisms from diverse branches of
bacteria and archaea (Land et al., 2015).
The genomic data contributed by this project represents the most complete assembly for strain
JCM 3724/ATCC 51357 and the first genome sequence for strain JCM 3718/ATCC 25286. These
strains are important as they are the type strains for F. necrophorum subsp. funduliforme and F.
necrophorum subsp. necrophorum, respectively (Shinjo et al., 1991). These type strains are used as
references during various types of characterisation experiments and provide a method of external
quality control. Strain ARU 01, also sequenced as part of this project is the first to be recognised as
originating from human disease. This is important as there may be differences within genes that
lead to increased virulence in some strains. Comparison tools were used to investigate this. If the
genome is to be studied for virulence factors associated with disease, then isolates should therefore
be used from disease sources. It would be beneficial for the study of F. necrophorum infections in
humans if a type strain of Fnf isolated from human disease origin could be assigned as a type strain.
The F. necrophorum genome sequence data produced as part of this project provides a great deal
of information for researchers to investigate F. necrophorum further and make comparisons to
other organisms. With a greater availability of genomic data, more extensive phylogenetic analysis
can be carried out.
The genomes of strains JCM 3718, JCM 3724 and ARU 01 were annotated using a semi-automatic
approach. The use of the xBASE pipeline allowed for integration of various annotation packages, so
that open reading frames, tRNAs and rRNAs were all annotated. BLASTp was used to manually
investigate any ORFs that had not been assigned a function. This uncovered several interesting
genes, such as the leukotoxin, which was expected, and ecotin, which was not previously known to
be present in F. necrophorum. This appears to be the first F. necrophorum genome annotation to
have been thoroughly manually curated.
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The number of ORFs predicted in each draft genome in Table 28 ranges from 1,942 – 2,599. The
average contig size was plotted against the estimated number of genes and non-linear regression
was applied to demonstrate the trend of decreasing gene numbers with increasing average contig
size (Figure 8). The curve was estimated to plateau at 1,950, suggesting this could be a more
accurate prediction of the number of ORFs in the F. necrophorum genome.
The majority of the F. necrophorum genomes submitted to the NCBI database do not contain
information regarding the subspecies identification. This therefore means that the data cannot be
used for any subspecies comparisons. The use of a phylogenetic tree comprised of gyraseB
sequences in Figure 9 provided an effective tool for subspeciation where in vitro work was not
possible. The subspecies of the three strains sequenced during this project and two from the online
database were known. Strain JCM 3724/ATCC 51357 was included only once. The subspecies
identification of the remaining eight strains was deduced by the distinct grouping of the strains.
When the subspecies identification result was paired with the origin of the strain, the results
appeared to support the understanding that Fnn causes animal infections and that Fnf can be found
in both animals and humans.
While 454 sequencing was an appropriate choice for de novo genome sequencing in 2012, now a
more appropriate choice would be Pacific Biosciences for high quality de novo sequencing, or
Illumina for resequencing. There is still not a complete genome for F. necrophorum, however, the
sequence data for strain JCM 3724/ATCC 51357 contains only 35 contigs, which is a feasible number
of gaps to bridge by PCR and Sanger sequencing.
To build on the genomics work carried out in this project, future work would involve additional
bioinformatic analysis of the three genomes sequenced during this project as well as the sequence
data from the F. necrophorum genomes in Table 28. A pangenomic analysis would be carried out to
investigate the range of genes that are present within F. necrophorum genomes. The minimum core
genome would also be analysed to determine which genes are shared by all the isolates. These two
types of analyses would show which genes are shared and which are unique within F. necrophorum
strains. The sequence output from the minimum core genome analysis would also be used to
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produce a phylogenetic tree to reveal the diversity between the strains. This data set would also
allow for the investigation of single nucleotide polymorphisms. A comparison of F. necrophorum
core and accessory genes to those of related commensals and pathogens would be of great value,
and may reveal pathogenic mechanisms utilised by F. necrophorum.
As discussed above, the number of contigs for strain JCM 3724/ATCC 51357 has been reduced to
35, following the merging of data sets in section 4.2.4. The additional genomes available are likely
to contain information that may indicate the order of the contigs and the size of the gaps that need
to be sequenced by Sanger method.
An additional use for the genomic data available from online databases is that these sequences can
be used to design PCR primers for virulence determinants where the sequence wasn’t available in
the sequence data generated as part of this project. For example, the FadA gene, which is briefly
mentioned below.
Genes found within the genomes of strains JCM 3718, JCM 3724 and ARU 01 that are thought to be
associated with virulence potential include a leukotoxin, haemolysin, haemagglutinin, haemin
receptors and a serine protease inhibitor known as ecotin. The leukotoxin was expected to be
present due to the understanding that it is the organism’s primary virulence factor (Tan et al.,
1994a). Ecotin has not previously been described in F. necrophorum and was therefore a novel and
interesting find. It was unknown whether the FadA adhesin would be present, as this has been
found to be present in several Fusobacterium species (Han et al., 2005). It was not initially found
within the F. necrophorum genome data, and was not amplified by PCR targeting the gene. The
FadA adhesin gene was later found in Fnn genomes and would therefore be worth investigating as
part of future work as this could contribute to the varying levels of pathogenicity between Fnn and
Fnf strains.
The haemolysin and an adhesin that were annotated in the genomes contained motifs and domains
associated with type V secretion systems. These systems are known to be associated with
transporting large virulence proteins across the outer membrane of the bacterium, such as
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haemagglutinins (Hodak and Jacob-Dubuisson, 2007). Strains JCM 3718 and JCM 3724 contain
conserved motifs within the haemolysin gene that suggest the protein is secreted via a two-partner
secretion system (Figure 13). These TPS motifs have not previously been described in F.
necrophorum. Strain ARU 01 contains TPS motifs that are less well conserved and are in the reverse
order. Not all TPS proteins need both motifs (Jacob‐Dubuisson et al., 2001), so secretion by this
system may be unaffected. The YadA-like adhesin that was also found within the annotation data
has head, stalk and anchor regions that strongly suggest it acts as an autotransporter. Future work
on these secretion systems would include cloning the YadA adhesin gene and carrying out an
adhesion assay. Also, cloning the haemolysin gene, both with and without the TPS domain, would
be of interest, before carrying out a haemolysis assay with either human or animal whole blood.
There are limitations on what may be concluded by using bioinformatic tools alone, therefore to
investigate the leukotoxin and ecotin further, in vitro techniques were used. For the leukotoxin
chapter the aim was to investigate the leukotoxin sequence in strains JCM 3718, JCM 3724 and ARU
01 and also confirm cytotoxic activity of the strains. The HL-60 cell line was investigated to
determine whether it would be an appropriate substitute for human white blood cells. The
prevalence of the leukotoxin gene within the clinical strain collection was also tested using a range
of PCR primers.
One copy of the leukotoxin operon, containing genes lktB, lktA and lktC, was found in each of strains
JCM 3718, JCM 3724 and ARU 01. In order to ensure the sequence data was of a high quality, the
next generation sequence data for the genes was resequenced by Sanger sequencing to remove
the frameshift errors in the sequence that were causing the predicted protein sequence to
terminate prematurely.
The lktB protein sequences were found to be highly conserved between the Fnf strains, which had
a similarity of 99.8 %. The Fnn JCM 3718 lktB lacked this high level of similarity due to being shorter
than the Fnf strains. The protein is 336 amino acids long compared to 447 due to a later start codon
in the sequence. The lktB protein sequence contained several putative conserved domains,
including a polypeptide transport associated (POTRA) domain and a haemolysin
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activation/secretion protein. The POTRA domain was truncated at the N terminus in strains JCM
3724 and ARU 01 and was missing completely from strain JCM 3718. This domain has previously
been described by Tadepalli et al. (2008b) in relation to leukotoxin secretion, however the
haemolysin activation/secretion protein domain is present in all three strains and has a more
significant E value. The secretion mechanism of the leukotoxin remains unknown, however with
several domains within the lktB protein linked to secretion, it seems likely that this protein is
involved, although potentially not via the POTRA domain, which had been expected.
The lktA protein sequences of the bovine JCM strains were shown to have a greater level of
similarity than between the Fnf strains by using an Artemis Comparison Tool alignment (Figure 19).
This was unexpected as it was thought that the two Fnf strains would share the most homology. It
therefore seems that the leukotoxin sequence may be dependent on the source of the isolate more
so than the subspecies identification. Each sequence may have evolved to be more effective against
its host. The work by Narayanan et al. (2001b) discussed in section 5.1 implies that the active toxin
region is within the first 3.5 kb of the lktA gene. The ACT alignment demonstrates that this region
is well conserved between the two bovine strains, with similarities of 94 % between 1,000 bp and
4,000 bp. This not so well conserved between the two Fnf strains, which show several short regions
of similarity within this window of the coding sequences with similarities of approximately 80 – 90
%.
A phylogenetic tree of the three lktA gene sequences with a further nine lktA gene sequences
downloaded from the NCBI database (Figure 20) demonstrated how the sequences clustered with
those from the same origin more than with those of the same subspecies. For example, strains JCM
3724 and B35, both Fnf strains of bovine origin, clustered more closely with the remaining bovine
strains that were Fnn rather than with the human Fnf strains. The only animal strain to group with
the human isolates is one isolated from a rumen microbiome, rather than a disease source. This
suggests that this strain may be less virulent than the other animal strains, due to its grouping with
the human isolates and it being present as a commensal rather than a pathogen.
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The lktC protein sequences of the three sequenced strains were highly conserved. The top BLASTp
result for the lktC of each strain was Fusobacterium necrophorum histidine kinase for JCM 3718 and
JCM 3724, with E values of 2e-99 and 3e-94, respectively. For ARU 01 the top result was a sensory
transduction regulator, with an E value of 4e-96. Given that histidine kinases are signal transduction
enzymes (Wolanin et al., 2002), and that the result of the Pfam search also resulted in a putative
bacterial sensory transduction regulator domain, it seems that lktC has a signalling function.
The prevalence of the lktA gene within the clinical strain collection was shown to be 100 % by using
five sets of PCR primers targeting the gene. Two sets of primers, lkt1 and lkt2, custom designed for
this project, and Ludlam_LT1 (Ludlam et al., 2009a) all had a 100 % amplification rate. Ludlam_LT2
(Ludlam et al., 2009a) had amplification in 89 % of strains and lktA (Tadepalli et al., 2008b) amplified
product in 43 % of strains. The prevalence of the leukotoxin has been disputed in the literature
based on the results Ludlam et al. (2009a) found using their primers. Bennett et al. (2010) claimed
the leukotoxin was likely to be present in these cases but had been undetected. The reasons for the
low amplification rate found by Ludlam et al. (2009a) are difficult to speculate on, given that the
same primers amplified a product in all strains in this project. The sequences may have been more
varied than those included in this project and the genes simply weren’t detected, or the strain
identification was incorrect and the strains were not F. necrophorum. It seems unlikely that the
gene was absent in the strains. For future testing of leukotoxin prevalence, primer sets Ludlam_LT1,
lkt1 and lkt2 would be considered appropriate for use.
High molecular weight culture supernatant fractions, expected to contain the leukotoxin, from
strains JCM 3718, JCM 3724 and ARU 01 all demonstrated a cytotoxic effect against both the HL-60
cell line and human white blood cells (Figures 30 – 33), as measured by flow cytometry. For the HL-
60 cytotoxicity assay, a dose-dependent response was demonstrated with high statistical
significance between the negative control and the lowest concentration treatment group, as well
as varying levels of significance with higher treatment concentrations.
It was anticipated that JCM 3724 would have the weakest cytotoxic effect, due to the understanding
that the funduliforme subspecies is less virulent. However, this has been explained as being due to
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Fnf having a less efficient leukotoxin promoter (Tadepalli et al., 2008b). JCM 3718 and ARU 01 were
expected to have a stronger cytotoxic effect, as JCM 3718 is a Fnn strain, and ARU 01 exhibited high
virulence in a patient. The results showed that when the concentrations of the leukotoxin fraction
were standardised, JCM 3724 had the greatest cytotoxic effect, followed by that of JCM 3718, the
other bovine strain. Strain ARU 01, known to cause Lemierre’s syndrome in a patient, had the
weakest cytotoxic effect. However, the variations in promoter efficiency may change the order of
cytotoxicity. For example, the concentration of high molecular weight protein measured by
Bradford assay was higher for strain ARU 01 than for JCM 3724. The increase in production of
leukotoxin may therefore result in a greater cytotoxic effect for ARU 01 than for JCM 3724, despite
the differences in the standardised results. Given the lack of availability of an antibody for
immunoaffinity purification, it cannot be confirmed that the protein fractions contained pure
leukotoxin. Future work on the F. necrophorum leukotoxin would include carrying out qPCR on the
promoter region of these three strains, in order to characterise them more fully. This has been
carried out by Tadepalli et al. (2008b) on other strains in order to confirm that Fnn has a higher
transcript level of lktA than Fnf, although this has not been carried out on the type strains.
It was concluded that the HL-60 cell line was an appropriate choice to use in place of human donor
blood due the validation test using human donor blood as a comparison. For the concentration
tested (150 µg/ml), the HL-60 cells had a slightly lower percentage viability compared to the human
white blood cells, although there was no statistical significance (P>0.05). Using this cell line instead
of human WBCs provided more uniform cell samples, and would therefore be considered for use
again.
Increasing the understanding of the leukotoxin is an important aspect of studying F. necrophorum.
It is the primary virulence factor of the organism (Tan et al., 1994a) and has been used in an inactive
form as a vaccine for livestock (Saginala et al., 1997). The mode of action and secretion of the
leukotoxin are not yet understood. The POTRA and haemolysin activation/secretion protein domain
within the lktB protein and the signal peptide found at the start of the lktA protein are strong
indicators that this protein is secreted, rather than released upon cell death. The collection of a
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leukotoxic supernatant fraction from fresh cultures is further evidence of this. The protein
sequence was analysed for type V secretion systems, although none were found.
The leukotoxin work carried out on the JCM reference strains provides high quality sequence data
of the leukotoxins of both F. necrophorum type strains along with cytotoxicity data. These strains
have been well characterised in many other ways but have so far been lacking this data. This work
also provides characterisation of the leukotoxin of a clinically important strain of human origin. It
suggests that there is no mutation in the sequence that results in enhanced pathogenicity and that
if the leukotoxin is responsible for greater virulence, then the promoter region is likely to be
responsible, causing a greater rate of transcription.
The aim of the ecotin chapter was to determine the prevalence of the ecotin gene within the strain
collection, analyse the sequence using bioinformatic tools, and assess the function of a recombinant
ecotin against host serine proteases and the clotting cascade to assess the role of F. necrophorum
ecotin in the host.
The ecotin gene, which has not previously been described in F. necrophorum, was found in 100 %
of the strains. This was established by mining the BLASTp data of the three sequenced genomes
and by PCR of these strains and the 25 isolates in the clinical collection. The sequences obtained
from the genome data and by Sanger sequencing the first 12 strains of the clinical collection
demonstrate that the gene is highly conserved, with percentage identities of 98.96 % or above
between strains.
The sequence was searched for conserved domains by BLASTp and primary and secondary binding
sites of ecotin were located. A protein model (Figure 39) of the F. necrophorum ecotin monomer
predicted the primary and secondary binding sites were exposed on opposite sides of the protein.
The two conserved domains of the secondary binding site in the protein sequence were separated
by 36 amino acid residues, however the predicted folding of the protein results in those regions
forming one binding pocket. E. coli ecotin has previously been shown to dimerise in such a way that
when the ecotin dimer binds to two target proteases, both monomers bind to both proteases (Yang
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et al., 1998). This was not tested for F. necrophorum ecotin, however, the 3-dimensional models of
the F. necrophorum and E. coli ecotin monomers are similar, suggesting that the dimerised structure
would be similar also, and that the binding sites would be arranged in such a way that each ecotin
monomer would bind to each target protease.
The purified recombinant ecotin protein produced in section 6.2.3 acted as a potent inhibitor of
human neutrophil elastase during enzyme inhibition assays. Non-linear regression was used to
determine the inhibitor constants of ecotin, with a Morrison Ki of 4 nM for HNE. The inhibition was
less potent against human plasma kallikrein, with a Morrison Ki of 26 nM. This is consistent with the
findings of Ulmer et al. (1995), who reported that E. coli ecotin was a potent inhibitor of human
leukocyte elastase and human plasma kallikrein, with human leukocyte elastase inhibited more
strongly.
HNE is involved in bacterial degradation in phagosomes and at inflammatory sites (Korkmaz et al.,
2010). The ability for F. necrophorum to evade this enzyme would be advantageous for its survival.
As this enzyme was inhibited the most potently in this study and in the work by Ulmer et al. (1995),
it suggests that the primary function of ecotin may be as a defence mechanism. E. coli ecotin is
known to be located in the periplasm which also supports this idea. If the primary target was the
clotting cascade then the inhibitor would likely be secreted, however it is well placed in the
periplasm to protect the organism from host proteases. It was established by Chung et al. (1983)
that E. coli ecotin does not inhibit any of its own proteases.
HPK is part of the intrinsic pathway and therefore contributes to coagulation of blood plasma. Along
with Factor XIIa, it also attracts neutrophils by chemotaxis (Bain et al., 2012). While this serine
protease was not affected as strongly as HNE, it still was susceptible to inhibition by the
recombinant F. necrophorum ecotin. By inhibiting this enzyme, F. necrophorum may be able to
reduce the number of neutrophils attracted to the infection site and also have an effect on blood
clotting. It is unclear what the benefit of this may be as septic emboli are a mechanism the organism
uses to transport around the body of the host (Riordan, 2007). Mild disseminated intravascular
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coagulation has also been reported as a complication of Lemierre’s syndrome (Hagelskjaer
Kristensen and Prag, 2000), which again contradicts the inhibition of coagulation.
Human donor plasma treated with a range of ecotin concentrations was tested for clotting
prolongation using tests: thrombin time, prothrombin time and activated partial thromboplastin
time. At 2 µM, ecotin caused a 1.1-fold increase in clotting time for TT, 7-fold increase for PT and
40-fold increase for APTT. The thrombin time assay measures the effect of the conversion of
fibrinogen to fibrin. The prolongation of 1.1-fold suggests that ecotin had very little effect on this
reaction. Prothrombin time, which measures the effect on the extrinsic and common pathways was
prolonged 7-fold, suggesting that ecotin inhibits some of Factors II, V, VII and X, but not all. APTT,
which measures the effect on the intrinsic and common pathways, including kallikrein, high
molecular weight kininogen, and Factors II, V, VIII, IX, X, XI and XII was prolonged 40-fold, suggesting
that ecotin potently inhibits some or all of these factors. E. coli ecotin has been shown to be a
potent inhibitor of Factors Xa, XIIa, kallikrein, human leukocyte elastase, and bovine trypsin and
chymotrypsin, but not an effective inhibitor of thrombin, Factors VIIa and XIa, activated protein C,
plasmin, or tissue plasminogen activator (Seymour et al., 1994; Ulmer et al., 1995). E. coli ecotin
and F. necrophorum ecotin are likely to have similar binding sites, therefore information about E.
coli ecotin inhibition can be applied to F. necrophorum ecotin to hypothesise which individual
factors are inhibited in each test. Factors II and V are present in the both PT and APTT tests as part
of the common pathway. These are unlikely to be targets of potent inhibition, due to the variation
in prolongation times between the tests. Factor VIIa was found not to be inhibited by E. coli ecotin,
as discussed above. No results were found regarding inhibition of Factor VIII or IX. Factor XIa was
not effectively inhibited by E. coli ecotin, while Factors Xa and XIIa were potently inhibited, as also
discussed above. It is therefore likely that PT was prolonged due to the inhibition of Factor X, while
APTT was prolonged to a much greater extent due to inhibition of Factors X and XII and kallikrein.
While F. necrophorum ecotin is present in the host blood stream it is likely to encounter neutrophils
and the elastases they secrete to degrade pathogens. Having ecotin present in the periplasm can
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help protect the cell. It may possibly also be released from dying F. necrophorum cells and
subsequently inhibit factors of the clotting cascade.
This work has resulted in the production of a functional recombinant ecotin protein that can be
purified without the need to denature the protein. Future work on the F. necrophorum ecotin would
involve testing additional clotting factors, and using E.coli ecotin as a comparator. It would also be
of interest to determine the concentration of the F. necrophorum native inhibitor, to investigate
the levels of ecotin that occur naturally and the effect it has on plasma clotting time.
7.2 Conclusions
Projects such as this aim to decrease the bias in studies of microorganisms, and focus on researching
organisms that are not considered model strains. The leukotoxin and ecotin findings can be used to
build up an understanding of how the organism behaves during infection. The organism has been
reported to be increasing in incidence, thereby becoming more clinically relevant and important to
study. The genome sequence data will be added to the F. necrophorum data available online, and
enable further comparative study between strains. The data also provides genome sequence data
for the type strain of both subspecies of F. necrophorum. A greater understanding of the genome
of an organism can lead to more advanced diagnostic tests being introduced. Also, if human
microbiome testing is to be incorporated into the field of personalised medicine in order to treat
patients, then the genomes of organisms being tested for must be well understood. The major
findings of this project are as follows:
1. The F. necrophorum genome was found to be approximately 2.1 – 2.3 Mb in size, with an
estimated 1,950 ORFs and includes genes for a leukotoxin, ecotin, haemolysin,
haemagglutinin, haemin receptor, adhesin and type Vb and Vc secretion systems.
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2. The genomic data contributed by this project represents the most complete assembly for
strain JCM 3724/ATCC 51357, the first genome sequence for strain JCM 3718/ATCC 25286
and the first F. necrophorum genome of a strain recognised as originating from human
disease.
3. The subspeciation of the available F. necrophorum genomes online enables more
meaningful comparisons and conclusions to be made with the data and supports the
understanding that Fnn strains cause animal infections and that Fnf can be found in both
animals and humans.
4. The leukotoxin operon was found to be universal within the F. necrophorum strain
collection. Analysis of the sequence data found the lktB protein is highly conserved and
contains domains associated with secretion. The lktA protein, containing a signal peptide,
appears to be the most conserved among strains of the same host origin, and the lktC
protein may have a signalling function.
5. Strains JCM 3718, JCM 3724 and ARU 01 were cytotoxic to HL-60 cells in a dose-dependent
manner, and were shown to have a similar cytotoxic effect on human donor white blood
cells. The results suggest that variations in virulence are likely to be due to bovine origin
strains having a more efficient promoter for the leukotoxin. This hypothesis is based on the
findings of a Bradford assay and the cytotoxicity results being inconsistent with the
understanding that Fnn strains are more virulent.
6. The ecotin gene was found to be present in 100 % of the strain collection and had a highly
conserved sequence. A protein prediction model of the F. necrophorum ecotin resulted in
a structure very similar to that of E. coli ecotin.
7. A purified recombinant F. necrophorum ecotin protein inhibited human neutrophil elastase
and human plasma kallikrein in enzyme inhibition studies and prolonged human plasma
clotting times in both the intrinsic and extrinsic pathways.
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Appendices
Appendix 1: Preparation of reagents and solutions
A1.1 Ethylenediaminetetraacetic acid (EDTA)
0.5 M ETDA was made by dissolving 73 g EDTA in 350 ml deionised water. A magnetic stir bar was
used for stirring while the pH was adjusted to 8.0 with 10 M NaCl. The volume was then made up
to 500 ml using deionised water.
A1.2 50X Tris base, acetic acid and EDTA (TAE) buffer
50X TAE buffer was made by adding 121 g Tris base in 250 ml deionised water while stirring. 28.6
ml, acetic acid was added and 50 ml 0.5 M EDTA solution, pH 8.0. Deionised water was added to
bring the volume up to 500 ml. TAE buffer was diluted 50X in deionised water before use.
A1.3 6X Gel electrophoresis loading dye
6X Glycerol and bromophenol blue loading dye was made by adding 3 ml glycerol and 2.5 mg
bromophenol blue to a 20 ml container and adding deionised water to bring the volume up to 10
ml. The loading dye was diluted to 1X by mixing in a ratio of 1 part loading dye to 5 parts DNA
sample before samples were loaded into agarose gels.
A1.4 Laemmli buffer
6X Laemmli buffer was made as per Appendix Table for preparing and loading protein samples for
SDS PAGE analysis. Non-reducing Laemmli buffer was also separately made by replacing the
reducing agent β-mercaptoethanol with 1 ml of deionised water. Laemmli buffer was diluted to 1X
by mixing in a ratio of 1 part buffer to 5 parts protein sample before samples were boiled for 5
minutes and loaded into the gel.
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Appendix Table 1: Laemmli loading buffer components.
Component Quantity
1 M Tris-HCl pH 6.8 2.4 ml
SDS 0.8 g
Glycerol 4 ml
Deionised water 2.8 ml
Bromophenol blue Trace
β-mercaptoethanol 1 ml
A1.5 10X Tris-Glycine buffer
10X Tris-Glycine buffer was made by dissolving 30.29 g Tris base and 144.12 g glycine in 750 ml
deionised water. 100 ml 10 % (w/v) Sodium dodecyl sulfate was added and the pH adjusted to 8.3.
The volume was then brought up to 1 L with deionised water. The 10X buffer was diluted to 1X in
deionised water before use.
A1.6 Bradford reagent
1X Bradford reagent was made by dissolving 100 mg of Coomassie Brilliant Blue in 47 ml 100 %
methanol and stirring for an hour. 100 ml 85 % phosphoric acid was added and the volume was
brought up to 1 L with deionised water. The solution was filtered twice with Whatman paper filters
(Sigma, Gillingham) and stored at 4 °C in the dark.
A1.7 Phosphate buffered saline (PBS)
1X PBS was made by dissolving one PBS tablet (Sigma, Gillingham) in 200 ml deionised water and
sterilising the solution by autoclaving. Final concentrations of 1X PBS are: 0.01 M phosphate buffer,
0.0027 M potassium chloride and 0.137 M sodium chloride, pH 7.4.
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Appendix 2: Preparation of media and antibiotics
A2.1 LB agar and broth
LB agar and LB broth were obtained in powdered form from Fisher Scientific, Loughborough. LB
agar was made by suspending 40 g in 1 L deionised water before autoclaving, and LB broth was
made by suspending 25 g in 1 L deionised water before autoclaving, as per the manufacturer’s
instructions.
A2.2 Fastidious anaerobe agar (FAA) and fastidious anaerobe broth (FAB)
FAA and FAB were purchased from LabM, Heywood. FAA was made by suspending 46 g in 950 ml
deionised water before autoclaving. Following sterilisation, the agar was cooled to 50 °C and 50 ml
defibrinated horse blood (TCS Biosciences, Buckingham) was added asceptically. FAB was made by
suspending 29.7 g in 1 L of deionised water and autoclaving, as per the manufacturer’s instructions.
A2.3 Brain heart infusion (BHI) broth
BHI broth was purchased from Merck, Feltham and was made by suspending 37 g in 1 L deionised
water before autoclaving, as per the manufacturer’s instructions.
A2.4 Complete cell culture medium
IMDM with 2 mM L-glutamine and Foetal Bovine Serum (FBS) were purchased from Life
Technologies, Paisley. IMDM medium was supplemented with 20 % FBS. Complete cell culture
medium was stored at 4 °C for up to 4 weeks.
A2.5 SOC media
SOC media was made by adding the components from Appendix Table 2 to 90 ml deionised water.
The volume was then made up to 100 ml. All solutions were first filter sterilised with 0.2 µm syringe
filters (Millipore, Hertfordshire) and the final solution was autoclaved at 110 °C for 10 minutes.
Media was stored at -20 °C in 1 ml aliquots.
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Appendix Table 2: SOC media components.
Component Quantity
Tryptone 2 g
Yeast extract 0.5 g
5 M NaCl 0.2 ml
1 M KCl 0.25 ml
1 M MgCl2 1 ml
1 M MgSO4 1 ml
1 M glucose 2 ml
A2.6 Ampicillin
Ampicillin was obtained from Sigma, Gillingham and a stock solution of 100 mg/ml was prepared
by dissolving 1 g of ampicillin powder in 10 ml of deionised water. The solution was filter sterilised
with 0.2 µm syringe filters (Millipore, Hertfordshire) and stored at -20 °C in 500 µl aliquots.
A2.7 100X Penicillin-Streptomycin solution
100X Penicillin-Streptomycin solution was purchased from Sigma, Gillingham and stored at -20 °C
in 1 ml aliquots.
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Appendix 3: Methods for strain identification using biochemical tests
A3.1 Gram stain
1 or 2 colonies were smeared into a drop of deionised water on a glass slide and left to dry, then
heat fixed by passing through the flame upside down several times. The slide was covered with
crystal violet for 30 seconds, followed by iodine for 30 seconds before a brief rinse with tap water.
The slide was then quickly washed with acetone, followed immediately by a quick rinse with tap
water. The slide was then covered with safranin for 30 seconds, washed with tap water and blotted
dry. F. necrophorum should appear as a Gram negative pleomorphic rod, often with some long
filaments present.
A3.2 Oxidase test
A 1 % (w/v) solution of oxidase reagent (Sigma, Gillingham) was made in sterile deionised water.
This was poured onto filter paper in a petri dish until saturated. A cocktail stick was used to smear
several colonies onto the filter paper. Colonies changed to purple if positive for cytochrome
oxidase, or displayed no colour change if negative. F. necrophorum strains are oxidase negative.
A3.3 Catalase test
A drop of hydrogen peroxide (Sigma, Gillingham) was placed onto glass slide. A cocktail stick was
used to mix several colonies into the drop. Bubbles were produced if positive for catalase or
peroxidase. There was no bubble production if negative. F. necrophorum strains are catalase
negative.
A3.4 Indole production
A vial of Bactidrop Spot Indole test (Remel, Dartford) was broken open and poured onto filter paper
in a petri dish. A cocktail stick was used to smear several colonies onto the filter paper. Colonies
changed to green if positive for the production of indole from tryptophan. There was no colour
change if negative. F. necrophorum strains are indole positive.
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Appendix 4: Method for gel extraction of nucleic acid product
The GenElute Gel extraction kit was used for purification of DNA fragments from agarose gels
according to the manufacturer’s instructions. The DNA fragment was excised from the gel with a
clean, sharp scalpel under UV light and weighed in a microfuge tube. Three gel volumes of gel
solubilisation solution were added to the tube and the mixture was incubated at 55 °C for 10
minutes with occasional vortexing. One gel volume of 100 % isopropanol was added and the
solution was inverted several times. The binding column was then prepared by placing it into a 2 ml
collection tube and adding 500 µl column preparation solution before centrifuging at 12,000 x g in
an Eppendorf 5415 D benchtop centrifuge for 1 minute and discarding the flow through. The
solubilised gel solution was added to the binding column in 700 µl portions and centrifuged at
12,000 x g for 1 minute. The column was then washed with 700 µl wash solution, and centrifuged
again at 12,000 x g for 1 minute and the flow through discarded, followed by an additional spin at
12,000 x g for 1 minute. The binding column was transferred to a fresh collection tube and the DNA
was eluted by adding 30 µl elution solution, incubating for 1 minute and then centrifuging at 12,000
x g for 1 minute.
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Appendix 5: Methods for cell line culture, counting and storage
All sterile work involving the HL-60 cell line was carried out in a Bioair Safeflow microbiological
safety cabinet.
A5.1 Propagation from frozen
A vial of HL-60 cells, purchased from Sigma, Gillingham, was thawed in a 37 °C incubator and
decontaminated by spraying with ethanol. Thawed cells were added to a 15 ml conical based
centrifuge tube containing 9 ml of pre-warmed complete culture medium (IMDM with 2 mM L-
glutamine and 20 % foetal bovine serum). The cell suspension was centrifuged at 300 x g for 5
minutes. Culture medium was removed and the cells were resuspended in 5 ml of fresh medium. A
100 μl sample of the cell suspension was taken and the cells were counted and the concentration
calculated (see section A5.2). The cell suspension was added to a 75 cm2 cell culture flask and extra
medium was added to make the cell density 3 x 105 cells/ml. The flask was incubated horizontally
at 37 °C in 5 % CO2.
A5.2 Cell counting
Under sterile conditions 100 μl of cell suspension was removed and an equal volume of 0.4 % trypan
Blue was added and mixed by gentle pipetting. Approximately 5 – 10 μl of the mixture was added
to a clean haemocytometer under a coverslip and viewed under an inverted phase contrast
microscope using a x20 magnification lense. The number of viable cells, excluding the vital dye, in
0.1 mm3were counted and the concentration of viable cells was calculated using Appendix Equation
1.
Appendix Equation 1: Equation to calculate the concentration of viable HL-60 cells after addition of trypan blue in a 1:1
ratio.
C = N x DF x 104
Where C = Concentration of viable cells, N = Number of viable cells counted and DF = Dilution factor.
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A5.3 Serial passage
Cell line cultures were maintained between 1 – 9 x 105 cells/ml at 5 % CO2 in 37 °C by passaging
every 2 – 3 days in complete culture medium (IMDMwith 2 mM L-glutamine and 20 % foetal bovine
serum). Cultures were not passaged more than 20 times without thawing a new vial from the liquid
nitrogen storage bank.
To passage, the cell suspension was decanted into a centrifuge tube and centrifuged at 300 x g for
5 minutes at room temperature to form a pellet. The media was removed and the cells gently
resuspended in 5 ml warm fresh medium. Cells were counted, as described in section A5.2 and the
concentration of viable cells calculated.
Cell suspension and pre-warmed medium were added into 75 ml cell culture flasks to provide a cell
density of 1 X 105 cells/ml.
A5.4 Storage
After three weeks of propagating the cells, a portion of them were stored in a liquid nitrogen
storage bank. Freezing medium was prepared by supplementing complete growth medium (IMDM
with 2 mM L-glutamine and 20 % foetal bovine serum) with 5 % (v/v) DMSO. 50 ml of cell suspension
was transferred to each of two 50 ml centrifuge tubes and were centrifuged at 300 x g for 5 minutes
and the supernatant was discarded. 2.5 ml of freezing medium was added to each 50 ml centrifuge
tube and the cell pellets were gently resuspended and pooled into one tube. Cells were added to
cryovials in 1 ml aliquots in freezing medium before being put into aMr. Frosty™ Freezing Container
in a -80 °C freezer overnight. This ensured a cooling rate of approximately 1 °C per minute. The
following day, when freezing was completed, the cryovials were transferred to a liquid nitrogen
storage system.
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Appendix 6: Leukotoxin ethics approval and associated participant
information sheet and consent form
PARTICIPATION INFORMATION SHEET
Cytotoxic effects of Fusobacterium necrophorum leukotoxin on human white blood cells
Researcher: Katie Wright
Staff Supervisor: Dr Patrick Kimmitt and Dr Pamela Greenwell
What is the study about?
You are being invited to take part in a research study on the effects of a leukotoxin on human white
blood cells which involves taking a blood sample from you. Fusobacterium necrophorum is an
anaerobic bacterium with the ability to cause infections in humans. We are specifically investigating
the effects of the leukotoxin it produces on human white blood cells. There is evidence from other
studies that it causes cell death to bovine white blood cells and minimal research showing that this
happens to human white blood cells also. The aim of the research is to test a larger number of
Fusobacterium necrophorum strains, isolated from previous human infections, than has been
tested before to investigate the effect of this toxin on human white blood cells.
What is involved?
The study will involve you giving a small blood sample for us to extract your white blood cells from.
Blood samples will be taken by people experienced in the technique. Standard practice commonly
used in medical environments with be followed. A needle will be inserted into your arm and up to
40ml of blood will be taken, or about 3 tablespoons per collection.
With your consent, we may wish to use photographs of your sample material in academic
publications. This is most likely to be an image of a white blood cell before or after exposure to
leukotoxin.
Will I get paid?
No, there is no cash payment for participation in this research project.
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Please note:
 Participation is entirely voluntary.
 You have the right to withdraw at any time without giving a reason.
 You have the right to ask for your data to be withdrawn as long as this is practical, and for
personal information to be destroyed.
 Your data will be confidential. No individuals will be identifiable from any collated data,
written report of the research, or any publications arising from it.
 All personal data will be kept in a locked cupboard on University premises.
 Please notify us if any adverse symptoms arise during or after the research.
 If you wish you can receive information on the results of the research.
 The researcher can be contacted after participation by email
(Katie.wright@my.westminster.ac.uk) or by telephone (0207 911 5000 ext 64404).
CONSENT FORM
Title of Study:  Cytotoxic effects of Fusobacterium necrophorum leukotoxin on human white blood
cells
Lead researcher: Katie Wright
---------------------------------------------------------------------------------------------------
I have read the information in the Participation Information Sheet, and I am willing to act as a
participant in the above research study.
I also consent to the use of photographs of my sample material in academic publications.
Name:   _______________________________
Signature:  __________________________ Date:  _______________
This consent form will be stored separately from any data you provide so that your responses
remain anonymous.
I have provided an appropriate explanation of the study to the participant







Katie Wright: School of Life Sciences
Mode: MPhil/PhD
Supervisor:
Cytotoxic effects of Fusobacterium necrophorum leukotoxin on human white blood cells
 I am writing to inform you that your application was considered by the Research Ethics
Sub Committee (RESC) at its meeting of 22 November 2012, and the proposal was
approved.
 However, you must provide confirmation that your Supervisor supports this application.
Please ask your Supervisor to contact me by email and provide confirmation in electronic
format (a signature is not necessary).
 Also you will need to provide me with the name of your Supervisor, this was missing from
the Form.
 Please forward this letter to your Supervisor.
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Secretary, Research Ethics Sub Committee
cc. Dr. John Colwell (Chair, Research Ethics sub Committee)
Mike Fisher (Research Degrees Manager)
I am advised by the Committee to remind you of the following points:
1. Your responsibility to notify the Research Ethics sub Committee immediately of any information
received by you, or of which you become aware, which would cast doubt upon, or alter, any
information contained in the original application, or a later amendment, submitted to the Research
Ethics sub Committee and/or which would raise questions about the safety and/or continued
conduct of the research.
2. The need to comply with the Data Protection Act 1998
3. The need to comply, throughout the conduct of the study, with good research practice
standards
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4. The need to refer proposed amendments to the protocol to the Research Ethics sub Committee
for further review and to obtain Research Ethics sub Committee approval thereto prior to
implementation (except only in cases of emergency when the welfare of the subject is paramount).
5. You are authorised to present this University of Westminster Ethics Committee letter of
approval to outside bodies, e.g. NHS Research Ethics Committees, in support of any application for
further research clearance.
6. The requirement to furnish the Research Ethics sub Committee with details of the conclusion
and outcome of the project, and to inform the Research Ethics sub Committee should the research
be discontinued. The Committee would prefer a concise summary of the conclusion and outcome
of the project, which would fit no more than one side of A4 paper, please.
7. The desirability of including full details of the consent form in an appendix to your research,
and of addressing specifically ethical issues in your methodological discussion.
Academic Services Department
101 New Cavendish Street
Cavendish House, University of Westminster
London, W1W 6XH




Appendix 7: Ecotin ethics approval and associated participant
information sheet and consent form
PARTICIPANT INFORMATION SHEET
The anticoagulant effect of ecotin, a Fusobacterium necrophorum serine protease inhibitor
Researcher: Katie Wright
Staff Supervisor: Dr Patrick Kimmitt and Dr Pamela Greenwell
What is the study about?
You are being invited to take part in a research study on the effects of a serine protease inhibitor,
known as ecotin, on human blood plasma which involves taking a blood sample from you.
Fusobacterium necrophorum is an anaerobic bacterium with the ability to cause infections in
humans. We are specifically investigating the effects of the serine protease inhibitor it produces on
human blood clotting. There is evidence from other studies that a similar protein in E. coli binds to
and potently inhibits factors required for blood clotting. The aim of the research is to test the
activity of ecotin from Fusobacterium necrophorum in order to establish whether it has the
potential to cause an anticoagulant effect.
What is involved?
The study will involve you giving a small blood sample for us to extract your plasma from.
Blood samples will be taken by people experienced in the technique. Standard practice commonly
used in medical environments will be followed. A needle will be inserted into your arm and about
20-40ml of blood will be taken.
Will I get paid?
No, there is no cash payment for participation in this research project.
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Please note:
 Participation is entirely voluntary.
 You have the right to withdraw at any time without giving a reason.
 You have the right to ask for your data to be withdrawn as long as this is practical, and for
personal information to be destroyed.
 Your data will be confidential. No individuals will be identifiable from any collated data,
written report of the research, or any publications arising from it.
 All personal data will be kept in a locked cupboard on University premises.
 Please notify us if any adverse symptoms arise during or after the research.
 If you wish you can receive information on the results of the research.
 The researcher can be contacted after participation by email
(Katie.wright@my.westminster.ac.uk) or by telephone (0207 911 5000 ext 64404).
CONSENT FORM
Title of Study:  The anticoagulant effect of ecotin, a Fusobacterium necrophorum serine protease
inhibitor
Lead researcher: Katie Wright
---------------------------------------------------------------------------------------------------
I have read the information in the Participation Information Sheet, and I am willing to act as a
participant in the above research study.
Name:   _______________________________
Signature:  __________________________ Date:  _______________
This consent form will be stored separately from any data you provide so that your responses
remain anonymous.
I have provided an appropriate explanation of the study to the participant





Project title: Doctoral research project
Applicant: Miss Katie Wright
Thank you for providing the Committee with additional changes to protocol and a request for further
approval.
The revision to the protocol was considered by correspondence and approved by Chair's Action on
18 November 2014.
Once again, if your protocol changes significantly in the meantime, please contact me immediately,
in case of further ethical requirements.
Yours sincerely
Ms Mandy Walton
S&T Research Ethics Committee
I am advised by the Committee to remind you of the following points:
1. Your responsibility to notify the Research Ethics Committee immediately of any information
received by you, or of which you become aware, which would cast doubt upon, or alter, any
information contained in the original application, or a later amendment, submitted to the Research
Ethics Committee and/or which would raise questions about the safety and/or continued conduct of
the research.
2. The need to comply with the Data Protection Act 1998.
3. The need to comply, throughout the conduct of the study, with good research practice standards.
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4. The need to refer proposed amendments to the protocol to the Research Ethics Committee for
further review and to obtain Research Ethics Committee approval thereto prior to implementation
(except only in cases of emergency when the welfare of the subject is paramount).
5. The requirement to furnish the Research Ethics Committee with details of the conclusion and
outcome of the project, and to inform the Research Ethics Committee should the research be
discontinued. The Committee would prefer a concise summary of the conclusion and outcome of the
project, which would fit no more than one side of A4 paper, please.
6. The desirability of including full details of the consent form in an appendix to your research, and




Project title: Doctoral research project
Applicant: Miss Katie Wright
I am writing to inform you that your application was considered by the S&T Research Ethics
Committee at its meeting of 21 October 2014. The proposal was approved subject to the following:
1. The application omits to cite any specific source of ecotin for use in the proposed project. This
omission is further compounded by the attached (and unsigned) COSHH form entitled “Venous Blood
Sampling” that lists human blood as a culture type. The committee seeks clarification of the source
of ecotin to resolve any uncertainty regarding the potential of harm to the investigators through the
culture of pathogens, namely Fusobacterium necrophorum.
2. • Consent forms cannot be destroyed at the end of the study. The length of time that they must be
kept depends on the discipline, but the University directive is for at least two years after completion.
Please submit the above documentation or clarifications via the VRE no later than 27 November




S&T Research Ethics Committee
I am advised by the Committee to remind you of the following points:
1. Your responsibility to notify the Research Ethics Committee immediately of any information
received by you, or of which you become aware, which would cast doubt upon, or alter, any
information contained in the original application, or a later amendment, submitted to the Research
Ethics Committee and/or which would raise questions about the safety and/or continued conduct of
the research.
2. The need to comply with the Data Protection Act 1998.
3. The need to comply, throughout the conduct of the study, with good research practice standards.
4. The need to refer proposed amendments to the protocol to the Research Ethics Committee for
further review and to obtain Research Ethics Committee approval thereto prior to implementation
(except only in cases of emergency when the welfare of the subject is paramount).
5. The requirement to furnish the Research Ethics Committee with details of the conclusion and
outcome of the project, and to inform the Research Ethics Committee should the research be
discontinued. The Committee would prefer a concise summary of the conclusion and outcome of the
project, which would fit no more than one side of A4 paper, please.
6. The desirability of including full details of the consent form in an appendix to your research, and
of addressing specifically ethical issues in your methodological discussion.
Academic Services Department
101 New Cavendish Street
Cavendish House, University of Westminster
London, W1W 6XH




Appendix 8: Clustal alignments of gyrB sequences aligned to Fnf and
Fnn-specific TaqMan probe sequences
JCM3724 AGGATTGCATGGAGTAGGAATTTCCGTTGTAAATGCCCTTTCAGAGTGGACCGAAGTTAA
ARU01        AGGATTGCATGGAGTAGGAATTTCCGTTGTAAATGCCCTTTCAGAGTGGACTGAAGTTAA
D12          AGGATTGCATGGAGTAGGAATTTCCGTTGTAAATGCCCTTTCAGAGTGGACTGAAGTTAA
Fnf1007      AGGATTGCATGGAGTAGGAATTTCCGTTGTAAATGCCCTTTCAGAGTGGACTGAAGTTAA
B35          AGGATTGCATGGAGTAGGAATTTCCGTTGTAAATGCCCTTTCAGAGTGGACCGAAGTTAA
HUN048       AGGATTGCATGGAGTAGGAATTTCCGTTGTAAATGCCCTTTCAGAGTGGACCGAAGTTAA
*************************************************** ********
JCM3724      AGTAAAACGAGAAGGAAATGTATACTATCAAAAATATTTAAGAGGAAAACCGATAGAAGA
ARU01        AGTAAAACGAGAAGGAAATGTATACTATCAAAAATATTTAAGAGGAAAACCGATAGAAGA
D12          AGTAAAACGAGAAGGAAATGTATACTATCAAAAATATTTAAGAGGAAAACCGATAGAAGA
Fnf1007      AGTAAAACGAGAAGGAAATGTATACTATCAAAAATATTTAAGAGGAAAACCGATAGAAGA
B35          AGTAAAACGAGAAGGAAATGTATACTATCAAAAATATTTAAGAGGAAAACCGATAGAAGA
HUN048       AGTAAAACGAGAAGGAAATGTATACTATCAAAAATATTTAAGAGGAAAACCGATAGAAGA
************************************************************
JCM3724      TGTGAAAATAATTTCCGCTTTAGAGGCTGGAGAAACGACAGGAACCATTGTTACTTTTAA
ARU01        TGTGAAAATAATTTCCGCTTTAGAGGCTGGAGAAACGACAGGAACCATTGTTACTTTTAA
D12          TGTGAAAATAATTTCCGCTTTAGAGGCTGGAGAAACGACAGGAACCATTGTTACTTTTAA
Fnf1007      TGTGAAAATAATTTCCGCTTTAGAGGCTGGAGAAACGACAGGAACCATTGTTACTTTTAA
B35          TGTGAAAATAATTTCCGCTTTAGAGGCTGGAGAAACGACAGGAACCATTGTTACTTTTAA
HUN048       TGTGAAAATAATTTCCGCTTTAGAGGCTGGAGAAACGACAGGAACCATTGTTACTTTTAA
************************************************************
JCM3724      ACCGGATATAGAGATTTTTGAAACCGTTATTTTTGAATATGAGGTTTTACAACATCGTTT
ARU01        ACCGGATATAGAGATTTTTGAAACCGTTATTTTTGAATACGAGGTTTTACAACATCGTTT
D12          ACCGGATATAGAGATTTTTGAAACCGTTATTTTTGAATACGAGGTTTTACAACATCGTTT
Fnf1007      ACCGGATATAGAGATTTTTGAAACCGTTATTTTTGAATACGAGGTTTTACAACATCGTTT
B35          ACCGGATATAGAGATTTTTGAAACCGTTATTTTTGAATATGAGGTTTTACAACATCGTTT
HUN048       ACCGGATATAGAGATTTTTGAAACCATTATTTTTGAATACGAGGTTTTACAACATCGTTT
************************* ************* ********************
JCM3724      AAAAGAATTGGCATATTTAAATCGTGGACTGGAAATTAATTTATTGGATTGTCGAAATGA
ARU01        AAAAGAATTGGCATATTTAAATCGTGGACTGGAAATTAATTTATTGGATTGTCGAAATGA
D12          AAAAGAATTGGCATATTTAAATCGTGGACTGGAAATTAATTTATTGGATTGTCGAAATGA
Fnf1007      AAAAGAATTGGCATATTTAAATCGTGGACTGGAAATTAATTTATTGGATTGTCGAAATGA
B35          AAAAGAATTGGCATATTTAAATCGTGGACTGGAAATTAATTTATTGGATTGTCGAAATGA
HUN048       AAAAGAATTGGCATATTTAAATCGTGGACTGGAAATTAATTTATTGGATTGTCGAAATGA
************************************************************
JCM3724      AATAGG
ARU01        AATAGG
D12          AATAGG
Fnf1007      AATAGG
B35          AATAGG
HUN048       AATAGG
******
Appendix Figure 1: Fnf probe sequence alignment. All strains in the alignment were homologous to the Fnf probe sequence
region, highlighted in yellow.
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JCM3718      AGGATTGCATGGAGTAGGAATTTCCGTCGTGAATGCTCTTTCAGAGTGGACTGAAGTTAA
BL           AGGATTGCATGGAGTAGGAATTTCCGTCGTGAATGCTCTTTCAGAGTGGACTGAAGTTAA
DAB          AGGATTGCATGGAGTAGGAATTTCCGTCGTGAATGCTCTTTCAGAGTGGACTGAAGTTAA
BFTR-1       AGGATTGCATGGAGTAGGAATTTCCGTCGTGAATGCTCTTTCAGAGTGGACTGAAGTTAA
BFTR-2       AGGATTGCATGGAGTAGGAATTTCCGTCGTGAATGCTCTTTCAGAGTGGACTGAAGTTAA
DJ-1         AGGATTGCATGGAGTAGGAATTTCCGTCGTGAATGCTCTTTCAGAGTGGACTGAAGTTAA
DJ-2         AGGATTGCATGGAGTAGGAATTTCCGTCGTGAATGCTCTTTCAGAGTGGACTGAAGTTAA
************************************************************
JCM3718      AGTAAAACGAGAAGGAAATGTATACTATCAAAAATATTTAAGAGGAAAACCGGTAGAAGA
BL AGTAAAACGAGAAGGAAATGTATACTATCAAAAATATTTAAGAGGAAAACCGGTAGAAGA
DAB          AGTAAAACGAGAAGGAAATGTATACTATCAAAAATATTTAAGAGGAAAACCGGTAGAAGA
BFTR-1       AGTAAAACGAGAAGGAAATGTATACTATCAAAAATATTTAAGAGGAAAACCGGTAGAAGA
BFTR-2       AGTAAAACGAGAAGGAAATGTATACTATCAAAAATATTTAAGAGGAAAACCGGTAGAAGA
DJ-1         AGTAAAACGAGAAGGAAATGTATACTATCAAAAATATTTAAGAGGAAAACCGGTAGAAGA
DJ-2         AGTAAAACGAGAAGGAAATGTATACTATCAAAAATATTTAAGAGGAAAACCGGTAGAAGA
************************************************************
JCM3718      TGTGAAAATAATTtCTACTTTGGAGGTTGGAGAAACAACAGGAACCATTGTTACTTTTAA
BL           TGTGAAAATAATTTCTACTTTGGAGGTTGGAGAAACAACAGGAACCATTGTTACTTTTAA
DAB          TGTGAAAATAATTTCTACTTTGGAGGTTGGAGAAACAACAGGAACCATTGTTACTTTTAA
BFTR-1       TGTGAAAATAATTTCTACTTTGGAGGTTGGAGAAACAACAGGAACCATTGTTACTTTTAA
BFTR-2       TGTGAAAATAATTTCTACTTTGGAGGTTGGAGAAACAACAGGAACCATTGTTACTTTTAA
DJ-1         TGTGAAAATAATTTCTACTTTGGAGGTTGGAGAAACAACAGGAACCATTGTTACTTTTAA
DJ-2         TGTGAAAATAATTTCTACTTTGGAGGTTGGAGAAACAACAGGAACCATTGTTACTTTTAA
************************************************************
JCM3718      ACCGGATATAGAGATTTTTGAAACTGTTATTTTTGAATATGAAGTTTTACAGCATCGTTT
BL           ACCGGATATAGAGATTTTTGAAACTGTTATTTTTGAATATGAAGTTTTACAGCATCGTTT
DAB          ACCGGATATAGAGATTTTTGAAACTGTTATTTTTGAATATGAAGTTTTACAGCATCGTTT
BFTR-1       ACCGGATATAGAGATTTTTGAAACTGTTATTTTTGAATATGAAGTTTTACAGCATCGTTT
BFTR-2       ACCGGATATAGAGATTTTTGAAACTGTTATTTTTGAATATGAAGTTTTACAGCATCGTTT
DJ-1         ACCGGATATAGAGATTTTTGAAACTGTTATTTTTGAATATGAAGTTTTACAGCATCGTTT
DJ-2         ACCGGATATAGAGATTTTTGAAACTGTTATTTTTGAATATGAAGTTTTACAGCATCGTTT
************************************************************
JCM3718      AAAAGAACTGGCATATTTAAATCGTGGACTCGAAATTAATTTATTGGATTGTCGAAATGA
BL           AAAAGAACTGGCATATTTAAATCGTGGACTCGAAATTAATTTATTGGATTGTCGAAATGA
DAB          AAAAGAACTGGCATATTTAAATCGTGGACTCGAAATTAATTTATTGGATTGTCGAAATGA
BFTR-1       AAAAGAACTGGCATATTTAAATCGTGGACTCGAAATTAATTTATTGGATTGTCGAAATGA
BFTR-2       AAAAGAACTGGCATATTTAAATCGTGGACTCGAAATTAATTTATTGGATTGTCGAAATGA
DJ-1         AAAAGAACTGGCATATTTAAATCGTGGACTCGAAATTAATTTATTGGATTGTCGAAATGA
DJ-2         AAAAGAACTGGCATATTTAAATCGTGGACTCGAAATTAATTTATTGGATTGTCGAAATGA
************************************************************
JCM3718      AATAGG
BL           AATAGG
DAB          AATAGG
BFTR-1       AATAGG
BFTR-2       AATAGG
DJ-1         AATAGG
DJ-2         AATAGG
******
Appendix Figure 2: Fnn probe sequence alignment. All strains in the alignment were homologous to the Fnn probe
sequence region, highlighted in yellow.
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Appendix Figure 3: Gene lengths predicted by BASys in A) JCM 3718 genome data, and B) ARU 01 genome data.
244
Appendix 10: PCR primers for gap closing leukotoxin sequence
Appendix Table 3: Custom PCR primers for gap closing leukotoxin sequence.
















Appendix 11: PCR primers for Sanger sequencing the leukotoxin
operons of JCM 3718, JCM 3724 and ARU 01
Appendix Table 4: Custom PCR primers for Sanger sequencing the leukotoxin operons.
Primer 5’ – 3’ primer sequence Primer 5’ – 3’ primer sequence
op1_F a, b ACAAGAAATGGAAAGGATTTGGG op20_F b GGGGATGCCAATGTGAAGAG
op1_R a, b TCGGTAACAGTCCTTTGCCT op20_R b CAAGAAACAGCCCCTCCAAC
op2_F a, b, c TGGGATTGGAATAGTTCATCCTG op21_F b GCTTGGCTTTTACAGGAGTAGG
op2_R a, b, c TCCGATATCCTCTTCCGTGTC op21_R b ATCCCGTCTTCTGTTCCGTT
op3_F a GGGTAAGACAAAATGAGTGGCA op22_F b GAAAGCGATGGAACGGGAAT
op3_R a AGTTGAATTTTCTCCCACAGCT op22_R b GCTTCCACGTCATTGTCGAT
op4_F a TCATGCGGGATTAACTGGAGA op23_F b CAACAACTCAGGTGACGGC
op4_R a TCCTTCCGTCACCAATACTGA op23_R b TCCTCCGATTCCAACTTGCT
op5_F a TGATGCTTCTGTTTCTGTTGGA op24_F b GCCGGTTCTCTTTCTACTGC
op5_R a CCCTCTGAAGTCAACTCTGC op24_R b AACCGCTAACTCCAACTCCA
op6_F a, c GGCTGCACGAAAGGAAGAAA op25_F b TAGGAGCCGGAGTAGCAGTT
op6_R a, c TCCGGATGTACTGCTTCTCG op25_R b CGCCAACACCAAAGGAAGAA
op7_F a, c AGGAGCTAAACTTGCTGCAA op26_F b CGGAGCATTAAACGCAGGAA
op7_R a, c CCTTTATCGGGAGTGTGGGA op26_R b ATTCGCTCCAACAGAAACGC
op8_F a, c CCGAAATCAGAAGAAAGGCCA op27_F b GCAAGTGGAGTGGTTTCTGT
op8_R a, c CCTTTGATTGCCCTGCTTGT op27_R b CCCACAGAAGCTCCTTGAGA
op9_F a TCTGAAGATAAGAGAGCGGATGT op28_F c CGTAAGGATTTGGGAGCCC
op9_R a TTTTGACTGACAGCAAGCCC op28_R c GGCTTATTCCAATTCCCGCT
op10_F a AGCGGAAGTAATTGGTGAGGA op29_F c GCTGTTGAAGGCATCGGTTT
op10_R a CTTGCACAGAAGCCCCTTTT op29_R c GCAGAAATATATCCCGCTCCG
op11_F a AGCAACAGTCGCTCATACAA op30_F c GCCAAAGTCGAAGCAACAGA
op11_R a TCGGTTTCTTCTTTGGCTTCT op30_R c CCAATTCAGCATGATCGGCA
op12_F a GAAGTCATGCAGGGGTAGGA op31_F c GAGCAGGTTTGGAAGCAGTT
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op12_R a ATTCCAGCTCCTTTTGCAGC op31_R c CCACCTTTGCAATCGTGTCA
op13_F a, c TCAATTTGCAGGAAAGACGGA op32_F c GGAAGCAATAAGGAAGCCGG
op13_R a, c TCCTTCTCCCTGAGTATCTCCT op32_R c CTCCTACTGCAGCTTGTCCA
op14_F a, c TCTGAAGGAAAAGGAACGGAAG op33_F c ATAGCAGTCGGAGTTGGAGG
op14_R a, c TACCGCCCCTACAGAAACTC op33_R c CCACCAACACCAACAGAACC
op15_F a, b, c ATCGGAATTGACAGCGGAAG op34_F c TGGAGAAACAGAAGCTCTTGT
op15_R a, b, c GCTCCTCCAGTTCCTTTTACA op34_R c CTCGTGTTTGATTCATCTTTGGT
op16_F a, b, c TCAACTTCGTGCAAAAGCTTT op35_F c CGGATGCCAAAAGTCATGCT
op16_R a, b, c TCCCTTCCAATCTTGCCAGA op35_R c TCTGCAATGGAGGTTACACAAC
op17_F a ATGCCAAAAGTCATGCTGCA op36_F c TCGGATGCTGGAATGCTACT
op17_R a TCTTCTGCAATTGAGGTTATGCA op36_R c GCACGACAAACCAAATAGCC
op18_F b TCATGGAGAGAGTGCTTGGC op37_F b GAAGCAAAGGGTGTAGGAGC
op18_R b TCCGCTTCAATACTTCCCGA op37_R b ACAAACATCTGCATCCTCTGTC
op19_F b GCAAAGGTAGAGGAAGCAGG
op19_R b CCCTGCTCCGTTATCACTCA
a=Used for JCM 3724, b=Used for ARU 01, c=Used for JCM 3718
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Appendix 12: Clustal Omega DNA alignment of Sanger sequence data
from JCM 3718, JCM 3724 and ARU 01 leukotoxin operons
Contains genes of lktB, lktA and partial lktC:
3718_lkt       ATCGTAAGGatTTGGGAGCCCTATATAGAAAAAGAAGTTACCGTTGCAGATCTTTATACT 60
3724_lkt       ATGGAAAGGATTTGGGAATCCTATATAGAAAAAGAGATTACTATTACAGAGCTTTATACC 60
ARU01_lkt      ATGGAAAGGATTTGGGAATCCTATATAGAAAAAGAGATTACTATTACAGAGCTTTATACC 60
** * ************  ****************  ****  ** **** ********
3718_lkt       ATAGTTCAAAAAATCAATGAATTATATCAGGAAAAAGGCTATTTGGTTTGTCGTGCCGTA 120
3724_lkt       ATAGTTCAAAAAATCAATGAATTATATCAGGAAAAAGGCTATTTGGTTTGTCGTGCCGTA 120
ARU01_lkt      ATAGTTCAAAAAATCAATGAATTATATCAGGAAAAAGGCTATTTGGTTTGTCGTGCCGTA 120
************************************************************
3718_lkt       TTACCTGCACAAAAAATTCAAAATGGACTTGTGAATATTTTATTGATAGAAGGAAAAACA 180
3724_lkt       TTGCCTGCACAAAAAATTCAAAACGGGATCGTAAATATTTTATTGATAGAAGGAAAAACA 180
ARU01_lkt      TTGCCTGCACAAAAAATTCAAAACGGGATCGTAAATATTTTATTGATAGAAGGAAAAACA 180
** ******************** **  * ** ***************************
3718_lkt       GGAGATATTATAATTCAAGGAAATCATTCCACTCGAGAAAAATATATCAGAGAAAGAATT 240
3724_lkt       GGAGATATTACAATTCAAGGAAATCATTCCACTCGAGAAAAATACATCAAAGAAAGAATT 240
ARU01_lkt      GGAGATATTACAATTCAAGGAAATCATTCCACTCGAGAAAAATACATCAAAGAAAGAATT 240
********** ********************************* **** **********
3718_lkt       CCTTTAGAAAAAGACAGAGTTTCGAATTTTAAAGAATTAGATCGAAGTTTAACACGTTTT 300
3724_lkt       CCCTTAGAAAAAGGTAAAATTTCAAATTTTAAAGAATTGGATCGAAGTTTAACACGTTTT 300
ARU01_lkt      CCCTTAGAAAAAGGTAAAATTTCAAATTTTAAAGAATTGGATCGAAGTTTAACACGTTTT 300
** **********  * * **** ************** *********************
3718_lkt       AATCTTACAAATGACAGTCCTATACAGATCAATATGGCTTCCGGAAAAGTTCCGGGAACG 360
3724_lkt       AATCTTACAAATGACAGTCCTATACAGGTTAATATGACTTCCGGAAAAGTTCTCGGAACG 360
ARU01_lkt      AATCTTACAAATGACAGTCCTATACAGGTTAATATGACTTCCGGAAAAGTTCTCGGAACG 360
*************************** * ****** ***************  ******
3718_lkt       ACCGATTATTTTGTGCAAATCTATGAACCAAAAAGACAGCAGTTTTTTGTTTTTGCAGAT 420
3724_lkt       ACGGATTATTTTCTGCAAATCTACGAGCCAAAAAGGCAGCAATTTTTTACTTTTGCAGAT 420
ARU01_lkt      ACGGATTATTTTCTGCAAATCTACGAGCCAAAAAGGCAGCAATTTTTTACTTTTGCAGAT 420
** ********* ********** ** ******** ***** ******  **********
3718_lkt AATTTAGGACAAAAAAATACAGGAGAATTACGATGGGGGCTAAATTATATTAATAATAGT 480
3724_lkt       AATTTGGGACAAAAAAATACGGGAGAATTGCGATGGGGAATAAGTTATATCAATAATAGT 480
ARU01_lkt      AATTTGGGACAAAAAAATACGGGAGAATTGCGATGGGGAATAAGTTATATCAATAATAGT 480
***** ************** ******** ********  *** ****** *********
3718_lkt       GTTACAGGAAACAGAGATCAACTGTCTCTTACCTCTTTAGTAACAGAAGGAACGGCTTCT 540
3724_lkt       GTCACAGGAAATAGAGATCAGCTATCTCTGACTTCTTTATTAACGGAAGGAACGGCTTCT 540
ARU01_lkt      GTCACAGGAAATAGAGATCAGTTATCTCTGACTTCTTTAGTAACGGAAGGAACGGCTTCT 540
** ******** ********  * ***** ** ****** **** ***************
3718_lkt       CTATCTTCTTTTTATACTTTTCCTGTTTCTAAAAAAGGAACCAAAATATCACTACAACAT 600
3724_lkt       CTATCTTCTATTTATACTTTTCCTGTTTCTAAAAAAGGAACCAAAGTGTCATTACAACAT 600
ARU01_lkt      CTATCTTCTATTTATACTTTTCCTGTTTCTAAAAAAGGAACCAAAGTGTCATTACAACAT 600
********* *********************************** * *** ********
3718_lkt       TCTGTAGGAAAGTTGAAACATATACAAGGGGCTTTAAAGCATAAAATAACTGGAAACTCT 660
3724_lkt       TCTCTAGGAAAGTTGAAACATATACAAGGAGCTTTGAAACATAAAATAACCGGAAACTCT 660
ARU01_lkt      TCTCTAGGAAAGTTGAAACATATACAAGGAGCTTTGAAACATAAAATAACCGGAAACTCT 660
*** ************************* ***** ** *********** *********
3718_lkt       TATAGTTATGGGGTTGGAATAGTTCATCCTATTCTGGTTCATGAAAAAAATAAAGTAGAA 720
3724_lkt       TATAGTTATGGGATTGGAATAGTTCATCCTGTTTTGGTTGATGAAAAAAACAAAATAGAA 720
ARU01_lkt      TATAGTTATGGGATTGGAATAGTTCATCCTGTTTTGGTTGATGAAAAAAACAAAATAGAA 720
************ ***************** ** ***** ********** *** *****
3718_lkt       CTTTCCTTGGATTGGGTAAAACAAAGGACTGTTACAGATCTATTGAAATTGAAATGGGTA 780
3724_lkt       CTTTCCCTGGATTGGGGAAGGCAAAGGACTGTTACCGATTTATTGAAATTGAATTGGGTA 780
ARU01_lkt      CTTTCCCTGGATTGGGGAAGGCAAAGGACTGTTACCGATTTATTGAAATTGAATTGGGTA 780
****** ********* **  ************** *** ************* ******
3718_lkt       AATAATAGACTTTCTAAGTATACAGCGGGAATTGGAATAAGCCATTATGAGGAAGATAGT 840
3724_lkt       AATAATAGACTCTCTAAATATACAGCGGGAATTGGAATAAGTCATTATGAGGAAGACAGT 840
ARU01_lkt      AATAATAGACTCTCTAAATATACAGCGGGAATTGGAATAAGTCATTATGAGGAAGACAGT 840
*********** ***** *********************** ************** ***
3718_lkt       GTTTTCTATACAAAGCAAAATATTACAAAGGGAAAATTTATTCCAATTTCGGGAGATGCA 900
3724_lkt ATTTTCTATACAAAACAAAATATTACAAAGGGAAAATTTATTCCTATCTCAGGAGATGAA 900
ARU01_lkt      ATTTTCTATACAAAACAAAATATTACAAAGGGAAAATTTATTCCTATCTCAGGAGATGAA 900
************* ***************************** ** ** ******* *
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3718_lkt       AGAAATTATACAAAGTATGATATGTTTCTAATATATCAGAAAAACTTGAAATATAACACT 960
3724_lkt       AAAAAGTATACAAAGTATGATATGTTTCTAATGTATCAGAAAAACTTGAAATACCATACC 960
ARU01_lkt      AAAAAGTATACAAAGTATGATATGTTTCTAATGTATCAGAAAAACTTGAAATACCATACC 960
* *** ************************** ********************  * **
3718_lkt       TTAGTAACACTAAAGATGGCAGGGCAATATTCTCTGAGTAAAAAATTACCCTCTGTCGAG 1020
3724_lkt       TTGGCAACACTAAGGATGACAGGGCAGTATTCTTTGAGTAAAAAATTGCCCTCTGTAGAA 1020
ARU01_lkt      TTGGCAACACTAAGGATGACAGGGCAGTATTCTTTGAGTAAAAAATTGCCCTCTGTAGAA 1020
** * ******** **** ******* ****** ************* ******** **
3718_lkt       CAAATTTATGCAGGAGGAGCCTATAATGTTCGTGGTTATCCGGAAAATTTTATGGGAGCT 1080
3724_lkt       CAAATTTATGCGGGAGGAGCTTATAATGTTCGCGGTTATCCGGAAAGTTTTATGGGAGCT 1080
ARU01_lkt      CAAATTTATGCGGGAGGAGCTTATAATGTTCGCGGTTATCCGGAAAGTTTTATGGGAGCT 1080
*********** ******** *********** ************* *************
3718_lkt       GAACACGGAGTTTTTTTCAATGCTGAATTATCAAAATTAGTAGAGAATAAAGGAGAATTT 1140
3724_lkt       GAACATGGAATCTTTTTTAATATTGAATTATCAAAATTAGTAGAGAATAAAGGAGAATTT 1140
ARU01_lkt      GAACATGGAATCTTTTTTAATATTGAATTATCAAAATTAGTAGAGAATAAAGGAGAATTT 1140
***** *** * ***** ***  *************************************
3718_lkt       TTTGTTTTTTTAGATGGGGCTTCTCTTCATGGAGAGAGTGCTTGGCAGGAAAATAGAATT 1200
3724_lkt       TTTGTTTTTCTGGATGGAGCTTCTCTTCATGGAGAGAGTGCTTGGCAGGAAAATAGAATC 1200
ARU01_lkt      TTTGTTTTTCTGGATGGAGCTTCTCTTCATGGAGAGAGTGCTTGGCAGGAAAATAGAATC 1200
********* * ***** *****************************************
3718_lkt       TTTAGCTCAGGTTTTGGATATAAAATAAGGTTTTTAGAAAAAAATAATATTGCTGTTAGC 1260
3724_lkt       TTCAGTTCAGGTTTTGGATATAGACTGAGGTTTTTAGAAAAGAATAATATTGCTGTTAGC 1260
ARU01_lkt      TTCAGTTCAGGTTTTGGATATAGACTGAGGTTTTTAGAAAAGAATAATATTGCTGTTAGC 1260
** ** **************** * * ************** ******************
3718_lkt       ATGGCATTTCCATGGAAGAAAAAAATAAATAGTATTTCAGTAGATTCTAATCGAATCTAT 1320
3724_lkt       ATGGCATTTCCATGGAAGAAAACAATAAATAGTATTTCAGTAGATTCCAATCGAATCTAT 1320
ARU01_lkt      ATGGCATTTCCATGGAAGAAAACAATAAATAGTATTTCAGTAGATTCCAATCGAATCTAT 1320
********************** ************************ ************
3718_lkt       ATTACAATAAATCATGAATTTTAAAGGGGGTAAGACAAAATGAGCGGCATCAAAAATAAC 1380
3724_lkt       ATTACAATAAATCATGAATTTTAAAGGGGGTAAGACAAAATGAGTGGCATCAAAAATAAT 1380
ARU01_lkt      ATTACAATAAATCATGAATTTTAAAGGGGGTAAGACAAAATGAGTGGCATCAAAAATAAT 1380
******************************************** **************
3718_lkt       GTTCAGAGGACAAGGAAGAGGATATCAGATTCTAAAAAAGTTTTAATGATTTTGGGATTG 1440
3724_lkt       GTTAGGAGGACACGGAAGAGGATATCGGATTCCAAAAAAGTGTTAATGATTCTGGGATTG 1440
ARU01_lkt      GTTAGGAGGACACGGAAGAGGATATCGGATTCCAAAAAAGTGTTAATGATTCTGGGATTG 1440
***  ******* ************* ***** ******** ********* ********
3718_lkt       TTGATTAACACTATGACGGTGAGGGCTAATGATACAATCACCGCGACTGAGAATTTTGGA 1500
3724_lkt       TTGATTAATACTATGACGGCAGTTGCCGACGATAGTATTAAAGAAACGCAAGGTTTTGGA 1500
ARU01_lkt      TTGATTAATACTATGACGGCAGTTGCCGACGATAGTATTAAAGAAACGCAAGGTTTTGGA 1500
******** **********     **  * ****  ** *  *  **  *   *******
3718_lkt       ACAAAAATAGAAAAAAAGGATAATGTTTATGACATTACTACAAACAAGATTCAAGGGGAG 1560
3724_lkt       ACAAAAGTAGAAAAGCAGGGAAATGTTTATGATATTACTACAAATAAGATTAAAGATAAG 1560
ARU01_lkt      ACAAAAGTAGAAAAGCAGGGAAATGTTTATGATATTACTACAAATAAGATTAAAGATAAG 1560
****** *******  ***  *********** *********** ****** ***   **
3718_lkt       AACGCTTTTAACAGTTTTAATAGATTTGCTTTAACAGAAAATAATATAGCAAATCTATAT 1620
3724_lkt       AATGCCTTTAATAGCTTTGATAAGTTTCATTTGGAACAAAATAATATAGCAAACATGCAC 1620
ARU01_lkt      AATGCCTTTAATAGCTTTGATAAGTTTCATTTGGAACAAAATAATATAGCAAACATGCAC 1620
** ** ***** ** *** ***  ***  ***   * ****************  *  *
3718_lkt       TTTGGGGAAAAGAATAGTACGGGGGTAAATAATCTTTTTAACTTTGTCAATGGAAAAATT 1680
3724_lkt       TTTGGAAGTAAAGGTGGGAAAGAGGCAGAAAATCTTTTTAACTTTGTTAAAGGGAAAATT 1680
ARU01_lkt      TTTGGAAGTAAAGGTGGGAAAGAGGCAGAAAATCTTTTTAACTTTGTTAAAGGGAAAATT 1680
*****    **   * * *  * ** * * ***************** ** ** ******
3718_lkt       GAAGTAGATGGGATTATCAACGGAATTCGAGAAAATAAAATTGGAGGAAATTTATATTTC 1740
3724_lkt       GAAGTAAATGGAGTTATCAATGGAATCCGTGACAATAAAATAGGAGGAAATTTGTATTTC 1740
ARU01_lkt      GAAGTAAATGGAGTTATCAATGGAATCCGTGACAATAAAATAGGAGGAAATTTGTATTTC 1740
****** ****  ******* ***** ** ** ******** *********** ******
3718_lkt       TTAAGCTCGGAAGGGATGGCAGTAGGAAAAAATGGAGTTATCAATGCTGGTTCTTTTCAT 1800
3724_lkt       CTAAGTTCTGAAGGATTGCTTGTCGGAAAAACCGGGGTTATCAATGCCGGGACTTTCCAT 1800
ARU01_lkt      CTAAGTTCTGAAGGATTGCTTGTCGGAAAAACCGGGGTTATCAATGCCGGGACTTTCCGT 1800
**** ** *****  **   ** *******  ** *********** **  **** * *
3718_lkt       TCTATTATTCCAAAACAAGATGATTTTAAGAAGGCTTTGGAAGAAGCCAAACATGGTAAA 1860
3724_lkt       GCTATTAGTCCGAAAAAGGAGGAATATGAAAAAGCTTTTAAAGACGCTCAAAATAGCAAA 1860
ARU01_lkt      GCTATTAGTCCGAAAAAGGAGGAATATGAAAAAGCTTTTAAAGACGCTCAAAATAGCAAA 1860
****** *** *** * ** ** * * * ** *****  **** **  ** ** * ***
3718_lkt       GTTTTTAATGGAATCATTCCAGT---AGATGGAAAAGTAAAAATTCCATTGAATCCGAAT 1917
3724_lkt       GTTTTTGATGGAATTGTTCCACAACAGGATGGGAGTATCAAGATTCCGTTGAATCCAAAT 1920
ARU01_lkt      GTTTTTGATGGAATTGTTCCACAACAGGATGGGAGTATCAAGATTCCGTTGAATCCAAAT 1920
****** *******  *****      ***** *   * ** ***** ******** ***
3718_lkt       GGAAGCATTACGGTAGAAGGAAAAATCAATGCTGTTGAAGGCATCGGTTTATATGCGGCG 1977
3724_lkt       GGAAGTATTACGGTAGAAGGAAAAATCAATGCTGTTGAAGATATCGGTTTATATGCCGCA 1980
ARU01_lkt      GGAAGTATTACGGTAGAAGGAAAAATCAATGCGGTGGATGAAATTGGTTTGTATGCAGCA 1980
***** ************************** ** ** *  ** ***** ***** **
249
3718_lkt       GATATTAGATTGAAAGATACTGCAATACTAAAGACAGGAATTACAGATTTTAAAAATTTA 2037
3724_lkt       GATATTAGATTGAAGGATACTGCAAGACTAAAGACAGGAATTACAGAATTTAAAAATTTA 2040
ARU01_lkt      GATATTAAACTGCCTGAAACAGGAGCTTTGAAAACCGGGGTAACAGATTTTCATCAATTG 2040
******* * **   ** ** * *    * ** ** **  * ***** *** *  * **
3718_lkt       GTCAATATTAGTGATC---GAATAAATTCTGGTCTGACCGGAGATTTAAAAGCTACCAAG 2094
3724_lkt       GTAAATATTAATGAAA---CTATTCATGCGGGATTAACTGGAGATTTAACAGCTGTTAAA 2097
ARU01_lkt      GTAAATATAAAAGATTCTAATGTAAATGCAGGATTGTCTGGGGACCTGAAAGCTACTAAG 2100
** ***** *  **        *  ** * **  *  * ** **  * * ****   **
3718_lkt       ACAAAATCTGGAGATATTATTCTTTCAGCTCACATAGATTCTCCTCAAAAAGCTATGGGA 2154
3724_lkt       ACAAAGTCGGGAGATATTATTCTTTCAGCTCATGTAGATTCTCCTCAAAAAGCTGTGGGA 2157
ARU01_lkt      ACCGGAACGGGAGATATTATTCTTTCTGCAAAGGTAGAGGAAGCAGGACATGAATTGGAA 2160
**     * ***************** **  * ****     *   * * *   *** *
3718_lkt       AAAAATTCAACTGTTGGAAAGAGAATAGAAGAATATGTAAAAGGAAATACCAAAGCAAAT 2214
3724_lkt       GAAAATTCAACTGTTGGAAAGAGAATAGAAGAATATGTAAAAGGAAATACCAAAGCAAAT 2217
ARU01_lkt      AGTTCTACCATTT---ATGAACAGATAGGGCGTAACTTCAAAGGAAAAATTAAGGCAAAC 2217
* * * *       *    ****      *  * ******** *  ** *****
3718_lkt       ATTGAATCTGATGCTGTATTGGAAGCAGATGGAAATATAAAAATTAGTGCGAAAGCTACA 2274
3724_lkt       ATTGAATCCGATGCCGTGTTGGAAGCAGATGGAAATATAAAAATTAGTGCGAGAGCTACA 2277
ARU01_lkt      ATTGAAACCTCGGGAAGTATTGAAGCGGAAGGGCATGCAAAAATTCATGCAGAAGCAAGC 2277
****** *    *      * ***** ** **  **  *******  ***   *** *
3718_lkt       AATGGGAGATTTATAAAGAAAGAAGGGGAAAAAGAAACTTATAACACTCCTTTAAGTTTA 2334
3724_lkt       AATGGGACATTTGTAAAGAAAGAAGGGGAAAAAGAAATTTACAATACTCCTTTAAGTTTA 2337
ARU01_lkt      AATGGAAAGTTGACTAAAAAAGACGGAGAAAAAGAAGTATACGCTCCGGAATTCAGTTTG 2337
***** *  **    ** ***** ** *********   **     *    ** *****
3718_lkt       TCAGATGTGGAAGCTTCCGTAAGAGTAAATAAAGGAAAAGTCATAGGAAAGAATGTTGAC 2394
3724_lkt       TCAGATGTAGAAGCTTCCGTAAGAGTAAATAAAGGAAAAGTCATAGGAAAGAATGTTAGT 2397
ARU01_lkt      GCAGAGGTAGAGGCTAGCGTCAAAGTGAATAAAGGAAAGATCAAAGGAAAAAAGGTAGAT 2397
**** ** ** ***  *** * *** ***********  *** ****** ** **
3718_lkt       ATTACAGCTGAAGCAAAGAATTTCTATGATGCAACTTTAGTTACTAAGCTTGCAAAGCAC 2454
3724_lkt       ATTACAGCTGAAGCAAAGAATTTCTATGATGCAACTTTAGTTACTAAGCTTGCAAAGCAC 2457
ARU01_lkt      ATCAGTGCAGAAGCAAAAAATTATTATGACACCCCCATCCTTACAAAAGTTGGAAAAATA 2457
** *  ** ******** ****  *****  *  *  *  **** **  *** ***
3718_lkt       TCTTTTAGCTTTGTTACAGGTTCTATTTCTCCTATCAATTTAAATGGATTTTTAGGTTTA 2514
3724_lkt       TCTTTCAGCTTTGTTACAGGTTCGCTTTCTCCTATCAATTTAAATGGATTTTTAGGTTTA 2517
ARU01_lkt      GCTTTTTCTGTCGGGACAGGCTCTTTATCTCCTATCAATATGAACGGGGCCTTAGGTTTA 2517
****     * *  ***** **  * ************ * ** **    *********
3718_lkt       TTGACAAGTAAGTCCAGTGTCGTTATTGGAAAAGATGCCAAAGTCGAAGCAACAGAAGGA 2574
3724_lkt       TTGACAAGTAAATCCAGTGTCGTTATTGGAAAAGATGCCAAAGTGGAGGCAAGGGAAGGA 2577
ARU01_lkt      TTAAAAAGTAAGGCGAGTGTTTTTATTGGAAAAGATGCAACAGTAGAGTCAACGGAGGGA 2577
** * ******  * *****  **************** * *** **  ***  ** ***
3718_lkt       AAGGCAAATATTCATTCTTACAGTGGAGTAAGAGCAACTATGGGAGCAGCTACTTCTCCA 2634
3724_lkt       AGTGCAAATATTCATTCTTATAGTGGAGTAAGAGCGACTATGGGAGCAGCTACTTCTCCA 2637
ARU01_lkt      GAAGCGAATATTCGTTCTTATAGCGGAGTAAGAGCTTCAATGGGAGCCTCTACTTCTCCT 2637
** ******* ****** ** ***********  * ********  **********
3718_lkt       TTAAAAATTACCAATTTATATTTGGAGAAAGCCAATGGAAAACTTCCTAGTATCGGAGCG 2694
3724_lkt       TTAAAAATTACTAATTTATATTTGGAGAATGCTGATGGAAAACTTCCCAGCATCGGAGCA 2697
ARU01_lkt      ATAAAACTTACTGACCTTTATTTGAAAACATTGGAGGGAAAATTACCTAGCGTTGGAGCT 2697
***** ****  *  * ****** * *      * ****** * ** **  * *****
3718_lkt       GGATATATTTCTGCAAAAAGTAATTCCAATGTAACTATTGAAGGAGAAGTAAAATCGAAG 2754
3724_lkt       GGGTATATTTCTGCAAAAAGTGACTCCAATGTAACCATTGAAGGAGAAGTAAAATCGAAG 2757
ARU01_lkt      GCATATATTTCTACTTCCAGTGAGTCTGATGTCACTGTGGAAGGAAAGGTGAGCTCAAAA 2757
*  ********* *    *** * **  **** **  * ****** * ** *  ** **
3718_lkt       GGAAGAGCAGATATTACTTCAAAATCTGAAAATACTATTGATGCTTCTGTTTCTGTTGGA 2814
3724_lkt       GAAAGAGCAGATATTACTTCAAAATCTGAAAATACTATTGATGCTTCTGTTTCTGTTGGA 2817
ARU01_lkt      GAAAAGGCAAATATTACTTCTAAATCAGAAAATACGATTGATGCTTCTGTTTCAGTCGGA 2817
* **  *** ********** ***** ******** ***************** ** ***
3718_lkt       ACGATGAGAGATTCCAATAAAGTAGCTCTTTCAGTATTGGTGACGGAAGGAGAAAATAAA 2874
3724_lkt       ACGATGAGAGATTCCAATAAAGTAGCTCTTTCAGTATTGGTGACGGAAGGAGAAAATAAA 2877
ARU01_lkt      ACTATAAGAGATTCAAATAAAGTAGGAATTTCTGTTTTGGTTACAGAGGGAAAAAATCAT 2877
** ** ******** **********   **** ** ***** ** ** *** ***** *
3718_lkt       TCTTCCGTCAAGATTGCTAAAGGAGCAAAAGTAGAATCAGAAACGGATGATGTAAATGTG 2934
3724_lkt       TCTTCCGTCAAGATTGCTAAAGGAGCAAAAGTAGAATCAGAAACGGATGATGTAAATGTG 2937
ARU01_lkt      TCTTCTGTCAAAATCGCTGAGGGAGCCAAAGTGGAATCAGACGGGG---ATGCCAATGTG 2934
***** ***** ** *** * ***** ***** ********   **   ***  ******
3718_lkt       AGAAGTGAAGCGATTAATTCCATTCGAGCTGCTGTAAAAGGTGGATTGGGGGATAGTGGT 2994
3724_lkt       AGAAGTGAAGCGATTAACTCCGTTCGAGCTACTGTAAAAGGTGGATTGGGGGATAGCGGT 2997
ARU01_lkt      AAGAGTGAAGCCGTTAACTCTATTCGAGCAGCTGTTAAAAGCGGTTTGAGTGATAACGGA 2994
*  ********  **** **  *******  **** *** * ** *** * ****  **
3718_lkt       AATGGGGTTGTGGCTGCAAATATTTCTAACTATAATGCTTCCTCCCGTATAGATGTAGAT 3054
3724_lkt       AATGGGGTTGTGGCTGCAAATATTTCTAATTATAATGCTTCCTCCCGTGTAGATGTAGAT 3057
ARU01_lkt      GCAGGGGTTGTTGCAGCCAATATCTCCAATTATAACAGTTCTTCAAAGGTTGTAGTGGAT 3054
******** ** ** ***** ** ** *****   *** **     * *  ** ***
250
3718_lkt       GGATATCTACATGCCAAGAAGCGACTAAATGTGGAGGCTCATAACATTACTAAAAATAGT 3114
3724_lkt       GGATATCTACATGCCAAGAAGCGACTAAATGTGGAGGCTCATAACATTACTAAAAATAGT 3117
ARU01_lkt      GGAGAAGTCCATGCAAAGAAGAGACTAAACACGGAAGCATATAATATTACGAAGCAAAAT 3114
*** *  * ***** ****** ******* *** **  **** ***** **  * * *
3718_lkt       GTTCTGCAAACAGGATCTGATTTGGGAACTTCCAAGTTTATGAATGATCACGTTTATGAA 3174
3724_lkt       GTTCTACAAACAGGAACTAATTTGGGAACTTCCAAGTTTATGAATGATCACGTTTATGAA 3177
ARU01_lkt      GTTTTACAAACGGGAACGAAAACAGGGACTTCGAAACTGATGAATGAACTTGTTTTTGAA 3174
*** * ***** *** *  *    ** ***** **  * ******** *  **** ****
3718_lkt       TCAGGTCATCTAAAATCAATTTTAGATGCAATAAAACAGCGGTTTGGAGGAGACAGTGTC 3234
3724_lkt       TCAGGTCATCTAAAATCAATTTTAGATGCAATAAAACAGCGGTTTGGAGGGGACAGTGTC 3237
ARU01_lkt      TCCAGTCATACCAAAGCTTTGATAGATGCTTTACAATATCGATTTGGCGGAG-------- 3226
**  *****   *** *  *  *******  ** ** * ** ***** ** *
3718_lkt       AATGAGGAAATAAAGAATAAGCTAACAGACTTATTTAGTGTCGGTGTGTCTGCAACCATA 3294
3724_lkt AATGAGGAAATAAAGAATAAGCTAACAGACTTATTTAGTGTCGGTGTGTCTGCAACCATA 3297
ARU01_lkt -ATGAAAAAATCAAATCTAAGTTGACTGATTTATTCAGTGTTGGAGCTTCTGCAACCGTA 3285
****  **** **   **** * ** ** ***** ***** ** *  ********* **
3718_lkt       GCAAATCATAATAATTCTGCTTCTGTGGCAATAGGAGAGAGTGGAAGACTTTCTTcaGGA 3354
3724_lkt       GCAAATCATAATAATTCTGCTTCTGTGGCAATAGGAGAGAGTGGAAGACTTTCTTCAGGA 3357
ARU01_lkt      GCAAATCACAATAATACTTCTTCTGTTAGCCTGGGGCAAAAATCCAAGTTAGTTTCCGGA 3345
******** ****** ** ******* * **  * *     *   *   *** ***
3718_lkt       GTGGAAGGGAGTAATGTAAGGGCATTAAATGAAGCTCAAAATCTTCGAGCGACtacGTca 3414
3724_lkt       GTGGAAGGGAGTAATGTAAGGGCATTAAATGAAGTTCAAAATCTTCGAGCGACTACGTCA 3417
ARU01_lkt      GTCGAAGGAACGAATATAAAAGCTTTGACAGAAACCCAACAACTTCGTTCTACCACAACA 3405
** ***** *  *** ***  ** ** *  ***   *** * *****  * ** **  **
3718_lkt       aGTGGAAGTGTGGCTGTACGAAAGGAAGAAAAAAAGAAACTTATTGGAAATGCAGCAGTT 3474
3724_lkt       AGTGGAAGTGTGGCTGCACGAAAGGAAGAAAAAAAGAAATTTATTGGAAATGCAGCAGTT 3477
ARU01_lkt      AGTGGAAGCTTGGCAACAAGAGGAGAAGAAAAGAAAAAGTTGGTTGGAAATGCAGCTGTT 3465
********  ****   * **   ******** ** **  *  ************* ***
3718_lkt       TTTTATGGAAACTATAAAAATAATGCTTCTGTGACAATTGCCGATCATGCTGAATTGGTA 3534
3724_lkt TTTTATGGAAACTATAAAAATAACGCTTCTGTAACTATCGCAGATCAAGCAGAGTTGACT 3537
ARU01_lkt      TTCTATGGAAACTATAAAAATGATGCTTCCGTAACAATTGCGGACGATGCTCAAGTCGTA 3525
** ****************** * ***** ** ** ** ** **  * **  *  *
3718_lkt       TCGGAAGGAAAAATTGATATCAACAGTGAAAATAAAATTGAATATAAAAATCCTTCAAAA 3594
3724_lkt       TCAGAGGGTAAAATTGATACAATCAGTGAAAATAAAACTGAATATAAAAATCCTTCAAAA 3597
ARU01_lkt      TCGGAAGGAAAGATTGATACGATCAGTGAAAATAAGCTCGAGTACAAAAATCCGTCGAAA 3585
** ** ** ** *******  * ************    ** ** ******** ** ***
3718_lkt       ATGGCAAAGTCTGTTATTGATAAATTAGAACTTTTAAAGAGAGCTTTTGGAAAAGAAACG 3654
3724_lkt       ATGGCAAAGTCTGTTATTGAAAAATTAGAACTTTTAAAGAGAGCTTTTGGAAAAGAAACG 3657
ARU01_lkt      ATGGCGGAAGAAGTTGTGGAAAAATTAGAAATTTTAAAAAGAGCCTTTGAAAAAGAGAAG 3645
*****  *    *** * ** ********* ******* ***** **** ****** * *
3718_lkt       AAAAC---TCCAGAATATGATCCGAAAGATATTGAATCTATTGAAAAATTATTGAATGCA 3711
3724_lkt       AAAAC---TCCAGAATATGATCCGAAAGATATTGAATCTATTGAAAAATTATTGAATGCA 3714
ARU01_lkt      AAAGATGAAACGACATTTGATCCGAAAGACATTGATTCCATGAAAAAATTATTGACAGAA 3705
***       *   ** ************ ***** ** **  ************  * *
3718_lkt       TTTTCAGAAAAATTGGATGGAAAACCGGAGCTTTTACTAAATGGTGAAAGAATGACAATT 3771
3724_lkt TTTTCAGAAAAATTGGATGGAAAACCGGAGCTTTTACTAAATGGTGAAAGAATGACAATT 3774
ARU01_lkt      TTTTCTAAAAAATTGGATGATAAGCCTGAAATTTTATTGAACGGAGAAAAAATAACGATT 3765
*****  ************  ** ** **  ***** * ** ** **** *** ** ***
3718_lkt       ATTCTTCCGGATGGAACTTCAAAAACAGGAACTGCTATAGAAATTGCAAACTATGTTCAG 3831
3724_lkt       ATTCTTCCGGATGGAACTTCAAAAACAGGAACTGCTATAGAAATTGCAAACTATGTTCAG 3834
ARU01_lkt      GTTCTTCCAGATGGAACTTCTAAAACAGGAACGGTTCCGGAACTTGCAGAATATGTGAAA 3825
******* *********** *********** * *   *** ***** * *****  *
3718_lkt       GGAGAAATGAAAAAATTAGAGGAAAAATTACCGAAAGGATTTAAAGCTTTTTCAGAAGGA 3891
3724_lkt       GGAGAAATGAAAAAATTAGAGGAAAAATTACCGAAAGGATTTAAAGCTTTTTCAGAAGGA 3894
ARU01_lkt      GAGGAAATGAAAAAACTGGAAGCAAAATTACCGACAGGATTTAAAGCTTTTTCTGAAGGA 3885
*  ************ * ** * *********** ****************** ******
3718_lkt       TTGAGTGGACTGATTAAAGAAACTTTGAATTTTACAGGAGTAGGAAATTATGCAAATTTT 3951
3724_lkt       TTGAGTGGACTGATTAAAGAAACTTTGAATTTTACAGGAGTAGGAAATTATGCAAATTTT 3954
ARU01_lkt      TTAAGCGGATTGTTAAAAGAAAGCTTGGCTTTTACAGGAGTAGGAAATTATGCAAATTTC 3945
** ** *** ** * *******  ***  ******************************
3718_lkt       CACACTTTTACCTCTTCCGGAGCTAATGGAGAAAGAGATGTTTCTTCTGTGGGAGGAGCT 4011
3724_lkt CACACTTTTACCTCTTCCGGAGCTAATGGAGAAAGAGATGTCTCTTCTGTGGGAGGAGCT 4014
ARU01_lkt      CATACATTTACCTCGGCAGGAACCAATGCAAAAAGAGATACTTCTTCTGTTGGAGGGGCT 4005
** ** ********  * *** * **** * ********   ******** ***** ***
3718_lkt       GTTTCGTGGGTAGAACAGGAGAATTATagcaaGGTATCCGTTGGAAAAGGAGCTAAACTT 4071
3724_lkt       GTTTCGTGGGTAGAACAGGAGAATTATAGCAAGGTATCCATTGGAAAAGGAGCTAAACTT 4074
ARU01_lkt      GTTTCTTGGGTAGAAATGGATAATCACAGTAAGGTTTCTATTGGAAGAGGAAGCAAAATT 4065
***** *********  *** *** * ** ***** **  ****** ****   *** **
3718_lkt       GCTGCAAAAAAAGATTTAAATATAAAAGCTATCAATAAAGCAGAAACAGTGAATTTAGTT 4131
3724_lkt       GCTGCAAAAAAAGATTTAAATATAAAAGCTATCAATAAAGCAGAAACAGTGAATTTAGTT 4134
ARU01_lkt      ACTGCAAAGGGAGATTTGAATGTAAAGGCAATCAATAAAACGGAAACTGTAAATCTGGTT 4125
*******   ****** *** **** ** ********* * ***** ** *** * ***
251
3718_lkt       GGAAATATTGGACTTGCGAGAAGCAGTACATCCGGAAGTGCAGTCGGAGGAAGATTAAAT 4191
3724_lkt       GGAAATATTGGACTTGCGAGAAGCAGTACATCCGGAAGTGCAGTCGGAGGAAGATTAAAT 4194
ARU01_lkt      GGAAAATTAGGTCTTTCAAAGAGTAGTGATTCGGCAACCGCAGTCGGTGGAGGATTGAAT 4185
*****  * ** *** * *  ** ***   ** * **  ******** *** **** ***
3718_lkt       GTTCAAAGATCGAAAAATTCAGCTATCGTAGAAGCTAAAGAAAAAGCTGAATTATCAGGA 4251
3724_lkt GTTCAAAGAACGAAAAATTCTGCTATTGTAGAAGCTAAAGAAAAAGCTGAATTATCAGGA 4254
ARU01_lkt      GTTCAAAAATCAAATACTTCCTCTATTGTAGTGACAAAAGAGAAAGCCGAGTTATCCGGG 4245
******* * * ** * ***  **** ****   * ***** ***** ** ***** **
3718_lkt       GAAAATATTAATGCAGATGCATTGAACAGACTTTTTCATGTAGCGGGATCTTTTAATGGT 4311
3724_lkt       GAAAATATTAATGCAGATGCATTGAACAGTCTTTTTCATGTAGCAGGATCTTTTAATGGT 4314
ARU01_lkt      GAAAATATTCATACAAATGCTTTCAATAATGTCTTCCATGTAGCGGCTTCTTTGAATGCC 4305
********* ** ** **** ** ** * * ** ******** *  ***** ****
3718_lkt       GGCTCAGGTGGGAATGCAATCAATGGAATGGGAAGTTATAGTGGAGGTATCAGTAAGGCA 4371
3724_lkt       GGCTCAGGTGGGAATGCAATCAATGGAATGGGAAGTTATAGTGGAGGTATCAGTAAGGCA 4374
ARU01_lkt      GGAACGGGTGGAAACGGTATCAATGGAATGGGAAGCTATAGCGGAGGAAGCAGTAAGTCG 4365
**  * ***** ** *  ***************** ***** ***** * ******* *
3718_lkt       AGAGTTTCCATTGATGACGAAGCATATTTGAAAGCTAATAAAAAAATTGCTTTAAACAGT 4431
3724_lkt       AGAGTTTCCATTGATGACGAAACATATTTGACAGCTAATAAAAAAATTGCTTTAAACAGT 4434
ARU01_lkt      AGAGTTTCCATTGATGATGAAACACACTTAAAGGCGAAGAAAAAAATATATTTAGACAGT 4425
***************** *** ** * ** *  ** ** ********   **** *****
3718_lkt       AAGAATGATACTTCTGTTTGGAATGCTGCCGGTTCAGCGGGAATCGGAACGAAAAATGCG 4491
3724_lkt AAGAATGATACTTCTGTTTGGAATGTTGCCGGTTCAGCGGGAATCGGAACGAAAAATGCG 4494
ARU01_lkt      GAAAATAATACCTCTGTAACCAATGTTGCCGGAGCCGTAGCAATCGGAAGCAAAAATGCA 4485
* *** **** *****    **** ******  * *  * ********  ********
3718_lkt       GCGGTCGGGGTTGCTGTTGCGGTAAATGATTATGATATTTCAAACAAAGCTTCCATTGAA 4551
3724_lkt       GCAGTCGGGGTTGCTGTTGCGGTAAATGATTATGATATTTCAAACAAAGCTTCCATTGAA 4554
ARU01_lkt      GCAGTGGGAGCTGCTGTGGCAATCAATGATTACGATATTTCAAACAAAGTTTCTATCGAA 4545
** ** ** * ****** **  * ******** **************** *** ** ***
3718_lkt       GATAATGACGAAG---------GACAAAGTAAATATGATAAGAATAAAGATGAAGTAACA 4602
3724_lkt       GATAATGACGAAG---------GACAAAGTAAATATGATAAGAATAAAGATGAAGTAACA 4605
ARU01_lkt      GACAATGATACCGAAGATGGAGGTAAAAGTAAGTACGATAAAAATAAAGAGGAAGTAACC 4605
** *****    *         *  ******* ** ***** ******** ********
3718_lkt       GTAACTGCGGAATCTTTAGAAGTAGATGCAAAAACGACCGGAACAATCAACAGTATTTCT 4662
3724_lkt       GTAACTGCGGAATCTTTAGAAGTAGATGCAAAAACGACCGGAACAATCAACAGTATTTCT 4665
ARU01_lkt      GTTACAGCAGAGGATTTACATGCAAATGCAAAAACGACAGGAACCATTAATGCTGTTTCC 4665
** ** ** **   **** * * * ************* ***** ** **   * ****
3718_lkt       GTTGCCGGAGGAATTAATAAGGTTGGAAGTAAACCGAGTGAAGAAAAACCGAAATCAGAA 4722
3724_lkt GTTGCCGGAGGAATCAATAAGGTTGGAAGTAAACCAAGTGAAGAAAAACCGAAATCAGAA 4725
ARU01_lkt      GTTGCCGGTGGAATTAGCAAGGTTGGAGAAGCGGAAAGCGA------------------- 4706
******** ***** *  *********         ** **
3718_lkt       GAAAGACCAGAGGGATTTTTTGGCAAAATCGGAAACAAAGTGGACTCTGTAAAAAATAAA 4782
3724_lkt       GAAAGGCCAGAGGGATTTTTTGACAAAATCGGAAATAAAGTGGATTCTGTAAAAAATAAA 4785
ARU01_lkt -----TGGAACGGGAATTTTTAGTAAAATTGGGAACAAGGTGGATTCTGTCAAAGGGAAA 4761
*  **** *****   ***** ** ** ** ***** ***** ***   ***
3718_lkt       ATTACGGATAGTATGGATTCATTAACAGAAAAAATTACaAAtTAcATTTCTGAAGGAGTA 4842
3724_lkt       ATTACGGATAGTATGGATTCACTAACAGAAAAAATTACAAATTACATTTCTGAAGGAGTA 4845
ARU01_lkt      ATTACAGATGCTATCGGGTTTGTTACAGATCAAGTGACAAATTATGTCTATAGAGGAAGT 4821
***** ***  *** *  *   * *****  ** * ********  * * *  ****
3718_lkt       AAAAAAGCGGGGAATCTTCCTTCGAACGTTTCTCATACTCCCGATAAAGGACCGTCTTTC 4902
3724_lkt       AAAAAAGCGGGAAATCTTCCTTCGAACGTTTCCCACACTCCCGATAAAGGACCGTCTTTC 4905
ARU01_lkt      AACGGAACAGAAGACGGGATTCCAAATATTTCGAAAGAATCTTCTAAATTGCCTTCTTTC 4881
**   * * *   *      * * **  ****  *     *   ****   ** ******
3718_lkt       AGTTTGGGAGCTTCTGGAAGTGTTTCTTTCAATAATATTAAAAAGGAAACATCTGCTGTC 4962
3724_lkt AGTTTAGGGGCTGCCGGCAGTGTTTCTGTTAATAATATAAAGAAAGAAACTTCCGCAGTG 4965
ARU01_lkt      AGTTTAGGAGCTTCCGGAAGTGTTTCCGTGAATAATATTAAAAAGGAAACTTCTGCTGTT 4941
***** ** *** * ** ********  * ******** ** ** ***** ** ** **
3718_lkt       GTAGATGGAGTAAAGATAAATTTGAAGGGAGCAAATAAAAAGGTAGAGGTGACTTCTTCT 5022
3724_lkt       GTTGACGGAGTGAAAGTAAACTTAAAAGGAGATAATAAAAAGGCGGAAGTTATTGCTTCA 5025
ARU01_lkt      ATGGATGGAGTGAAGATAAGTCTAAGCGGGGCAAATAAAGAGGTAGGAGTGACTTCTTCC 5001
* ** ***** **  ***   * *  ** *  ****** ***  *  ** * * ****
3718_lkt       GATTCTACTTTTGTTGGAGCATGGGGCGGATCTGCTGCACTTCAGTGGAATCATATTGGA 5082
3724_lkt       GATTCAGCTTTTATTGGTGCTTGGAGTGGAGCAGCAGCACTTCAATGGAATCATGTCGGA 5085
ARU01_lkt      GACTCCACTTTCGTTGGAGCATGGAGTGGATCTGCCGCACTTCAATGGAATCATATCGGA 5061
** **  ****  **** ** *** * *** * ** ******** ********* * ***
3718_lkt       AGTGGAAATAGCAACATCAGTGCTGGTTTAGCTGGAGCGGCTGCTGTAAATAATATTCAA 5142
3724_lkt       AGTGGAGAGAGTAATACGACGGTTGGATTGGCTGGAGCGGCAGCTGTAAATAATGTTCAA 5145
ARU01_lkt      AGCGGAAATAGTAATTTCAGTGCTAGTTTAGCCGGAGCGGCTGCTGCAAATAACATTCAA 5121
** *** * ** **    *  * * * ** ** ******** **** ******  *****
3718_lkt       AGTAAAACAAGTGCTTTGGTTAAAAATAGTGATATTCGAAATGCCAATAAATTTAAAGTA 5202
3724_lkt AGTAAAACAAAGGCTTTTGTGAAAGACAGTAGTATTACCAATGCCAATAAGTTTAAGGTA 5205
ARU01_lkt      AGTAAAACAAATGCGGTGGTTAAAAATAGTAGTATTCAAAATGCCAATAAATTTAAAGTA 5181
**********  **  * ** *** * ***  ****   *********** ***** ***
252
3718_lkt       AATGCTTTGAGTGGAGGAACTCAAGTAGCAGCAGGAGCAGGTTTGGAAGCAGTTAAAGAA 5262
3724_lkt       AATGCAGTGAGTGGAGGAACACAGGTAGCAGCCGGTATGGGATTAGAAGCTGTTAAAGAA 5265
ARU01_lkt      AATGCTTTGAGTGGAGGAACTCAAGTAGCGGCGGGAGCAGGTTTGGAAGCAGCCAAAGAA 5241
*****  ************* ** ***** ** **    ** ** ***** *  ******
3718_lkt       AGTGGAGGACAAGGAAAAAGTTATCTATTGGGAACTTCTGCTTCTATCAACTTAGTGAAC 5322
3724_lkt       AGTGGAGGACAAGGAAGAAGTTATTTATTAGGAACTTCAGCTTCTATGAACTTTATTGAT 5325
ARU01_lkt      AGTGGAGGTCAAGGAAAAAGTTATCTATTGGGAACATCCGCTTCTATCAACTTAGTGGAC 5301
******** ******* ******* **** ***** ** ******** *****  *  *
3718_lkt       AATGAAGTTTCTGCAAAATCAGAAAATAATACAGTAGCAGGAGAATCTGAAAGCCAAAAA 5382
3724_lkt       AATGAAGTGTCTTCAGAATCTGAAAACAATATTATCACCGGAGAATCTGAAGATAAGAGA 5385
ARU01_lkt      AATGAAGTTTCTGCAAAATCAGAAAATAATATAGTAGAAGGTGAATCTGAAAACAAAAAA 5361
******** *** ** **** ***** ****   *    ** *********    * * *
3718_lkt       ATGGATGTTGATGTCACTGCTTATCAAGCGGACACCCAAGTGACAGGAGCTTTAAATTTA 5442
3724_lkt GCGGATGTAGATGTTACAGCTTATGAAAGTGATACTCAAGTGACGGGAGGATTCAATTTA 5445
ARU01_lkt      ATGAATGTTGATGTCACTGCTTATGAAGCAGATACTCAAGTGACAGGAGCCTTGGATTTA 5421
* **** ***** ** ****** **   ** ** ******** ****  **  *****
3718_lkt       CAAGCTGGAAAGTCAAATGGAACTGTAGGGGCTACTGTGACTGTTGCCAAATTAAACAAC 5502
3724_lkt       CAAGCAGGGCAATCAAAGGGAACAGTAGGAGCCGCCGTTACGGTTGCGAAATTAAATAAT 5505
ARU01_lkt      CAAGCCGGAAAATCATCAGGAACTGCAGGAGCTGCTATCACTGTTGCTAAGTTAAACAAC 5481
***** **  * ***   ***** * *** **  *  * ** ***** ** ***** **
3718_lkt       AAAGTAAATGCTTCTATTAGTGGTGGGAGATATACTAACGTTAATCGAGCGGACGCAAAA 5562
3724_lkt       AAGGTAAAAGCAGGTATTAAAGGAGGAAATTATACAAACATAAATCGGGCAGACACAAAA 5565
ARU01_lkt      AAGGTAAATGCTTCTATTAGTGGAGGAAAATATACCAAGGTCAATCGAGCGGATGCAAAA 5541
** ***** **   *****  ** ** *  ***** **  * ***** ** **  *****
3718_lkt       GCTCTTTTAGCAACCACTCAAGTGACTGCTGCAGTGACGACGGGAGGGACAATTAGTTCT 5622
3724_lkt       GCACTTTTGGCGACAACACAAGTGACTTCTGCTTTATCTGTGGGAGGGACTAATAGTTTC 5625
ARU01_lkt      GCTCTTTTAGCAACAACTCAGGTGACGGCTGCTGTGGCAACAGGAGGAACAATTAGTTCC 5601
** ***** ** ** ** ** *****  ****  *  *    ***** ** * *****
3718_lkt       GGAGCGGGATTAGGAAATTATCAAGGGGCTGTTTCTGTCAATAAGATTGACAATGACGTG 5682
3724_lkt GGTTCTGGATTAGGAAATTATCAGGGAGCTGTTTCTGTCAATAACATCAATAATGATGTA 5685
ARU01_lkt      GGAGCGGGATTAGGAAATTATCAAGGAGTTGTTTCCGTCAATAAGATCGACAATGACGTG 5661
**  * ***************** ** * ****** ******** **  * ***** **
3718_lkt       GAAGCTAGCGTTGATAAATCTTCCATCGAAGGAGCTAATGAAATCAATGTCATTGCCAAA 5742
3724_lkt       TCAGCCACTGTAGATAAGTCTTCGATTAAAAATGCAAAAGAATTGAATGTAATTGCGAAA 5745
ARU01_lkt      GAAGCCGGCATTGATAAGTCTTCCATCGAAGGAGCTGATGAAGTTAATGTCATTGCAAAA 5721
***     * ***** ***** ** **   **  * *** * ***** ***** ***
3718_lkt       GATGTCAAAGGAAGTTCTGATCTAGCAAAAGAATATCAGGCTTTACTAAATGGAAAAGAT 5802
3724_lkt       GATATCAAAGGGAGTTCTGAATTAGCAAAAGAATATCAATCCTTATTAAACGGGAAAGAT 5805
ARU01_lkt      GATGTCAAAGGAAGTTCTAATCTGGCAAAAGAGTATCAAGCTTTACTGAACGGAAAAGAT 5781
*** ******* ****** *  * ******** *****  * *** * ** ** ******
3718_lkt       AAAAAATATTTAGAAGATCGTGGTATTAATACGACTGGAAATGGTTATTATACGAAGGAA 5862
3724_lkt       AGAGAATACTTGGAAGCACATGGTATTGATACTACAGGAAAAAATTACTATACTGAAGAA 5865
ARU01_lkt      GAAAAATATTTAAAAGATCGTGGAATTGATACGACCGGAAATGGTTATTATACAAAAGAA 5841
* **** **  ***  * *** *** **** ** *****   *** *****  * ***
3718_lkt       CAACTAGAAAAAGCAAAGAAAAAAGAAGGAGCGGTCATTGTAAATGCTGCTTTATCGGTT 5922
3724_lkt CAATTAAAAGAAGCAGCAAAGCGGGATGGAGCTGTAATTGTCAATGCGGCAGCATCTATA 5925
ARU01_lkt      CAATTGGAAGAAGCAAAGAAAAAAGAAGGAGCGGTCATTGTAAATGCTGCTTTATCGGTT 5901
*** *  ** *****   **    ** ***** ** ***** ***** **   ***  *
3718_lkt       GCTGGAACGGATAAATCCGCTGGAGGAGTAGCTATTGCAGTCAATACTGTTAAAAATAAA 5982
3724_lkt       GCGGGAAGTGATAAATCTTCCGGAGGAGCCGGAGTTGCGGTGAATCTTGTAAAAAATAAA 5985
ARU01_lkt      GCCGGAACGGATAAATCCGCCGGAGGAGTAGCTATTGCAGTCAATACTGTTAAAAATAAA 5961
** ****  ********  * *******  *   **** ** ***  *** *********
3718_lkt       TTTAAAGCAGAATTGAGTGGAAGCAATAAGGAAGCCGGAGAGGATAAAATTCATGCGAAA 6042
3724_lkt       TTTAAAGCGGAAGTAATTGGTGAGGATAAGGTTGATAAAACAAAGGATATTGCTGCAGAA 6045
ARU01_lkt      TTTAAAGCGGAATTGAATGGAAAAGATAAGGAAGTTGAAGAGGGTAAAATTCGTGCGAAG 6021
******** *** * * ***     ******  *    *       * ***  ***  *
3718_lkt       CATGTAAATGTGGAGGCAAAATCATCTACTGTTGTTGTGAATGCGGCTTCTGGACTTGCT 6102
3724_lkt       AAAATAAATGTGGATGCAAAATCATCTACAGTTATTGTAAACACAGCTGCAGGGCTTGCT 6105
ARU01_lkt      CATGTAAATGTCGAAGCTAAATCGTCCACTGTCGTTGTAAATGCGGCTTCCGGACTTGCT 6081
*  ******* ** ** ***** ** ** **  **** **  * *** * ** ******
3718_lkt       ATCAGCAAAGATGCTTTTTCAGGAATGGGATCTGGAGCATGGCAAGACTTATCAAATGAC 6162
3724_lkt GTCAGTCAAAATAGTTTTGCAGGATTGGGTTCTTTCGCATGGCAAGAGTTGAACAATGAA 6165
ARU01_lkt      GTCAGCAAAGACGCTTTTTCAGGAATGGGATCCGGAGCATGGCAAGATTTATCGAATGAA 6141
****  ** *   **** ***** **** **    *********** **    *****
3718_lkt       ACGATTGCAAAGGTGGATAAAGGAAGAATTTCTGCTGATTCCTTAAATGTGAACGCAAAT 6222
3724_lkt       GTAAGTACAAAGGTAGAGAATATAAAAGCGGAAACCGATCGGTTAAATGTCGTTGCTAGA 6225
ARU01_lkt      ACCGTTGCAAAGGTCAATAAAGGAAGAATTTCTACCGATTCCTTGAATGTGACTGCAAAT 6201
* *******  * **   ** *       * ***   ** *****    ** *
3718_lkt       AATTCCATTCTTGGGGTGAATGTTGCGGGAACCATTGCCGGTTCTCTTTCTACGGCGGTA 6282
3724_lkt       AACAATACTTTAGGAGTTAATATAGCAGGAAATATTGCCGGAACAGGTTCTGCTGCAGTG 6285
ARU01_lkt      AATTCCGTTCTTGGAGTGAATGTTGCTGGAACCATTGCCGGTTCTCTTTCTACTGCAGTA 6261
**      * * ** ** *** * ** ****  ********  *   **** * ** **
253
3718_lkt       GGAGCTGCTTTTGCGAATAATACTCTTCATAATAAAACCTCTGCTTTGATTACAGGAACG 6342
3724_lkt       GGAGCTGCTTTAGCTCATAATTCTCTGAAAAATAAAGCATCATCTTCTGTGACCGCTTCT 6345
ARU01_lkt      GGAGCTGCTTTTGCGAATAATACTCTTCATAATAAAACCTCTGCTTTGATTACGGAAACA 6321
*********** **  ***** ****  * ****** * **  ***   * ** *   *
3718_lkt       AAGGTAAATCCTTTTAGTGGAAAG------AATACAAAAGTCAATGTACAAGCTTTGAAT 6396
3724_lkt AATTTTAAGCCTTTTTCAAAAACAAATGCTAAGATGGGTATCAATGTACAGGCATTGAAT 6405
ARU01_lkt      AAGGTAAATTCTTTTAGTGGAAAG------GATACAAAAATCAATGCACAAGCTTTGAAT 6375
**  * **  *****     **         * *      ****** *** ** ******
3718_lkt       GATTCTCATATTACAAACGTTTCTGCTGGAGGCGCTGCAAGTATTAAGCAGGCTGGAATC 6456
3724_lkt       GATTCTCATATCACGAATGTGTCTGCGGGAGTTGTTGCCAGTGCAAAAGCTTCCGGAATT 6465
ARU01_lkt      GATTCTCATATTACAAATGTTTCTGCCGGAGTCGCTGCAAGTGTTAAGCAAGTTGGAATC 6435
*********** ** ** ** ***** ****  * *** ***   **       *****
3718_lkt       GGAGGAATGGTATCTGTCAATCGTGGTTCTGATGAAACGGAAGCTTTAGTTAGTGATTCT 6516
3724_lkt       TCCGGAATGGCATCTATTAATCGAGGTTCTGATGAAACGGAAGCTTTAGTCAGTGATTCT 6525
ARU01_lkt      GGAGGAATGGTATCTGTCAATCGCGGTTCTGATGAAACAGAAGCTTTGGTCAGTGATTCT 6495
******* **** * ***** ************** ******** ** *********
3718_lkt       GAGTTTGAAGGAGTAAGTTCTTTCAATGTAGATGCAAAAGATCAAAAAACAATAAATACA 6576
3724_lkt       GAATTTGAAGGAGTAAATTCTTTCAATGTAGATGCAAAAGATCAAAAAATAGTAAATACA 6585
ARU01_lkt      GAGTTTGATGGAGTAAATTCTGTCGATGTAAGAGCTGAAGATAAAAAAGTATTGAATACC 6555
** ***** ******* **** ** *****   **  ***** *****  * * *****
3718_lkt       ATTGCCGGAAATGCAAATGGAGGAAAAGCGGCTGGAGTTGGAGCAACAGTTGCTCATACA 6636
3724_lkt ATTGCCGGGAACATAAATGGAGGAAAAGCAGCCGGAGTTGGAGCAACAGTCGCTCATACA 6645
ARU01_lkt      ATTGCCGGAAATATCAATGGAGGGCAAGCAGCCGGAGTTGGAGCGACAGTTGCTCATACC 6615
******** **    ********  **** ** *********** ***** ********
3718_lkt       AATATTGGAAAACAATCAGTTATAGCTATTGTAAAAAACAGTAAAATTACAACGGCGAAT 6696
3724_lkt       AATATTGGAAAACAATCTGTTACAGCTATTGTAAAAAATAGTAAAATTAAAACAGCAAAT 6705
ARU01_lkt      AATATCGGAAAGCAATCTGTTACAGCTGCTATAAAAAATAGTAAAATTACAACGGCTAAG 6675
***** ***** ***** **** ****  * ******* ********** *** ** **
3718_lkt       GATCAAGATAGAAAAAATATCAATGTGACTGCAAAAGATTATACTATGACTAATACTATA 6756
3724_lkt       AATCAAGATAAAAAAAaTATCCATGTTACTGCGAAAGATAGTGTTATTATGAATACAGTG 6765
ARU01_lkt      AATCAAGACAAGAAAAATATAAATGTTACTGCAAAAGACAGTGTTGTTATGAATACAGTG 6735
******* *  ********  **** ***** *****   *  * * *  *****  *
3718_lkt       GCAGTCGGAGTTGGAGGAGCAAAAGGAGCCTCTGTGCAAGGAGCTTCTGCAAGTACTACC 6816
3724_lkt       GCAGCCGGAGTTGGAGGAGCAAAAGGGGCTTCTGTGCAAGGAGCTTCTGCAAGTACCGCT 6825
ARU01_lkt      GCAGCCGGAGTCGGAGGGGCAAAAGGAGCTTCTGTGCAAGGATCTTCTGCAAGTACCACT 6795
**** ****** ***** ******** ** ************ *************  *
3718_lkt       TTGAATAAGACAGTTTCTTCTCATGTTGATCAAACTGATATTGaCAAAGATTTAGAGGAA 6876
3724_lkt TTCAATAAAACAGTTGCTTCTCATGTCGAGCATACTGATATTGACAAAGATTTAGAAAAA 6885
ARU01_lkt      TTGAATAAAACGGTTTCCGCTCATGTTGAGAAAACTGATATTGATAA------------A 6843
** ***** ** *** *  ******* **  * *********** **            *
3718_lkt       GAAAATAATGGAAATAAGGAAAAGGCAAATGTTAATGTTCTAGCTGAAAATACGAGTCAA 6936
3724_lkt       GAAAATGATGAAAATAAAGAAAAAGCAAATTTCAATATTCTGGCTGAGAACACAAGTCAA 6945
ARU01_lkt      GAAAATCATGAAAGTAAAGAAAAAGCAGATTTCAACGTTCTGGCTGAAAATACAAGTCAA 6903
****** *** ** *** ***** *** ** * **  **** ***** ** ** ******
3718_lkt       GTGGTCACAAATGCGACAGTGCTTTCCGGAGCAAGTGGACAAGCTGCAGTAGGAGCTGGA 6996
3724_lkt       GTAGTCACAAATGCGACAGTGCTTTCCGGAGCGAGTGGACAAGCCGCAGTAGGAGCCGGA 7005
ARU01_lkt      GTAGTAACAAATGCGACAGTACTTGCCGGAGCGAGCGGACAAGCTGCGGTAGGAGCCGGA 6963
** ** ************** *** ******* ** ******** ** ******** ***
3718_lkt       GTAGCAGTTAATAAAATTACACAAAATACTTCTGCACATATAAAAAATAGTACTCAAAAT 7056
3724_lkt       GTAGCAGTTAATAAAATTACACAAAATACTTCTGCACATATAAAAAACAGTACTCAAAAT 7065
ARU01_lkt      GTAGCAGTTAATAAAATTACACAAAATACTTCTGCACATATAAAAAATAGTACCCAAAAT 7023
*********************************************** ***** ******
3718_lkt       GTACGAAATGCTTTGGTAAAAAGCAAATCTCATTCATCTATTAAAACAATTGGAATTGGA 7116
3724_lkt GTACGAAATGCTTTAGTAAAAAGTAAAGCGAATTCCTCTATTAAAACGATCGGAATTGGA 7125
ARU01_lkt      GTACGAAATGCTTTGCTAAAAAGTAAAGCTAATTCTTCCATTAAAACAATTGGAATTGGA 7083
**************  ******* *** *  **** ** ******** ** *********
3718_lkt       GCTGGAGTTGGAGCTGGAGGAGCTGGAGTGACAGGTTCTGTAGCAGTGAATAAGATTGTA 7176
3724_lkt       GCGGGAATTGGAGCTGGAGGAGTTGGATCCAGCGGTTCTGTAGCTGTGAATAAAATTACA 7185
ARU01_lkt      GCAGGAGTCGGAGTAGGTGGAGTTGGAGTTAGCGGTTCTGTAGCTGTAAATAAAATCACA 7143
** *** * ****  ** **** ****   *  *********** ** ***** **   *
3718_lkt       AATAATACGATAGCAGAATTAAATCATGCAAAAATCACTGCGAAGGGAAATGTCGGAGTT 7236
3724_lkt       AATAATAATACAGCTTCTGTTGAACATTCTAATATTTTTGCAAGAGGAAATGTAGGAGTT 7245
ARU01_lkt      AATAATAACACAGCTGTTGTTGAACATTCTGATATTTTTGCAAAAGGAAATATAGGAGTA 7203
*******  * ***     *  * *** *  * **   *** *  ****** * *****
3718_lkt       ATTACAGAGTCTGATGCGGTAATTGCTAATTATGCAGGAACAGTGTCTGGAGGGGCCCGT 7296
3724_lkt       ATTACAGAATCTGATGCGGTCATTGCTAATTATGCCGGAACAGTTTCCGGAGGAAGTCAT 7305
ARU01_lkt      ATTGCAGAATCCGATGCAGTCATTGCTAATTATGCCGGAACAGTTTCCGGAGGAGGTCAT 7263
*** **** ** ***** ** ************** ******** ** *****    * *
3718_lkt       GCAGCAATAGGAGCCTCAACCAGTGTGAATGAAATTACAGGATCTACAAAAGCATATGTA 7356
3724_lkt GCAGGGGTAGGAGGATCCACCAGTGTCAATGAAATCCAAGGAGATACGATTGCTTCTGTT 7365
ARU01_lkt      GTAGGGGTAGGAGGATCTACCGGTGTCAATGAAATCGAAGGAGATACGATTGCTTCCGTT 7323
* **   ******  ** *** **** ********   ****  *** *  ** *  **
254
3718_lkt       AAAGATTCTACAGTGATTGCTAAAGAAGAAACAGATGATTATATTACTACTCAAGGGCAA 7416
3724_lkt       AAACATTCAAAAATAGAAGCCAAAGAAGAAACCGAAGATGTCATTGAAACACAGGGGAAA 7425
ARU01_lkt      AAAAAATCAAAACTGGAGGCAAAAGAAGAAACGGAAGATGTTATTGAAACGCAAGGGAAA 7383
*** * ** * * *    ** *********** ** ***   ***   ** ** *** **
3718_lkt       GTAGATAAAGTGGTAGATAAAGTATTCAAAAATCTTAATATTAACGAAGACTTATCACAA 7476
3724_lkt       GTAAAAGAAGTTGTAGAAAAGGTATTTCAAGATATAGGAATTAATGAGGATTTGAGCAAG 7485
ARU01_lkt      GTAAAAGAAGTTGTAGAAAACGTACTTCAAGATATAGGAATCAATGATGATTTGAGTAAG 7443
*** *  **** ***** ** *** *  ** ** *    ** ** ** ** **     *
3718_lkt       AAAAGAAAaatAagtAATAAAAAAGGATTTGTTaccAATAGTTCAGCTACTCATACTTTA 7536
3724_lkt       AAAAGAGAAAAATCAAAGAAAAGAGGATTTGTTGTAAACAGCTCCTCTACTCATACTTTA 7545
ARU01_lkt      AAAAGAGAAAAATCAAATAAAAAAGGATTTGTTGTAAACAGCTCTTCCACTCACACGATA 7503
****** *** *   ** **** **********   ** ** **  * ***** **  **
3718_lkt       AAATCTTTATTGGCAAATGCCGCTGGTTCaggAcaaGCCGGAGTGGCAGGAACTGttaAT 7596
3724_lkt       AAATCCTTATTGGCAAATGCAGCCGGTTCAGGACAAGCCGGAGTGGCAGGAACTGTCAAT 7605
ARU01_lkt      AAATCATTGTTGGCAAATGCTGCAGGAGCAGGTAAAGCTGCAGTGGCAGGAACTGTAAAT 7563
***** ** *********** ** **  ****  **** * *************** ***
3718_lkt       ATCAacaaGGTTTatgGAGAAacAGAAGCTCTTGTAGAAAATTCTATATTAAATGCAAAA 7656
3724_lkt       ATCAACAAGGTTTATGGAGCAACAGAAGCTCTTGTAGAAGATTCCATATTGAATGCAAAA 7665
ARU01_lkt      GTAAATAAAATTACAGGAGAAACAAAAGCCCTTGTAGAAAGTTCCGTATTAAATGTAAAA 7623
* ** **  **   **** **** **** *********  ***  **** **** ****
3718_lkt       CATTATTCTGTAAAATCAGGAGATTACACGAATTCAATCGGAGTAGTAGGTTCTGTTGGT 7716
3724_lkt       CATTACTCTGTGAAATCGGGAGATTACACAAACTCGATCGGAGCAGTAGGCTCTGTTGGT 7725
ARU01_lkt      AATTCTTCGATACATGCAGGAGATTATACTAACAGTATTGGAGCGGTAGGATCCGCTTCC 7683
***  **  *  *  * ******** ** **    ** ****  ***** ** * *
3718_lkt       GTTGGTGGAAATGTAGGAGTAGGAGCTTCTTCTGATACCAATATTATAAAAAGAAATACC 7776
3724_lkt       GTTGGTGGAAATGTAGGAGCAGGAGCTTCTTCTGATACCAATATTATAAAAAGAAATACC 7785
ARU01_lkt      GGAGCATTAAACGCAGGAATAGGAGCTTCTTCCAATACAAATCTTTTCAGTAGAAATACA 7743
*  *    *** * ****  ************  **** *** ** * *  ********
3718_lkt       AAGACAAGAGTTGGAAAAACTACAATGTCTGATGAAGGTTTCGGAGAAGAAGCTGAAATT 7836
3724_lkt       AAGACAAGAGTTGGAAAAACTACAATGTCTGATGAAGGTTTCGGAGAAGAAGCTGAAATT 7845
ARU01_lkt      AAAACAATAGTGCACGATACGAAAATATCTACAGAAAAAGAAGGACAATCTTCAGAAATT 7803
** **** ***     * ** * *** ***   ***      *** **    * ******
3718_lkt       ACAGCAGATTCTAAGCAAGGAATTTCCTCTTTTGGAGTCGGAGTCGCAGCAGCCGGGGTA 7896
3724_lkt       ACAGCAGATTCTAAGCAAGGAATTTCCTCTTTTGGAGTCGGAGTCGCAGCAGCCGGGGTA 7905
ARU01_lkt      ACAGCGGATTCTAAACAAGGAATTTCTTCCTTTGGTGTTGGCGTTGGAGCTGGAGTAGTC 7863
***** ******** *********** ** ***** ** ** ** * *** *  *  **
3718_lkt       GGAGCCGGAGTGGCAGGAACCGTTTCCGTAAATCAATTTGCAGGAAAGACGGAAGTAGAT 7956
3724_lkt       GGAGCCGGAGTGGCAGGAACCGTTTCCGTAAATCAATTTGCAGGAAAGACGGAAGTAGAT 7965
ARU01_lkt      GGAGCCGGAGTGGCAGGAACGGTTTCTGTCAATAAATTATCTGGAAAAACCGAAGTAGAT 7923
******************** ***** ** *** ****  * ***** ** *********
3718_lkt       GTGGAAGAAGCAAAGATTTTGGTAAAAAAAGCTGAGATTACAGCAAAACGTTATAGTTCT 8016
3724_lkt       GTGGAAGAAGCAAAGATTTTTGTAAAAAAAGCTGAGATTACAGCAAAACGTTATAGTTCG 8025
ARU01_lkt      ATTCAAAAATCTGATATTTCTACAAAATCAGCAGATATTTCCGCAAAACATTATGGAGTG 7983
*  ** ** *  * ****    ****  *** ** *** * ******* **** *
3718_lkt       GTTGCAATtGGAAATGCCGCAGTCGGAGTGGCTGCAAAAGGAGCTGGAATTGGAGCAGCA 8076
3724_lkt       GTTGCAATTGGAAATGCCGCAGTCGGAGTGGCTGCAAAAGGAGCTGGAATTGGAGCAGCA 8085
ARU01_lkt      CTTTCTACAGGAAACGGATCTGTTGGGGCGGCAGTAAAGGGAGCCGGAGTCGGAGCAGCG 8043
** * *  ***** *   * ** ** * *** * *** ***** *** * ********
3718_lkt       GTGGCAGTTACCAAAGATGAATCAAACACGAGAGCAAGAGTGAAAAATTCTAAAATTATG 8136
3724_lkt       GTGGCAGTTACCAAAGATGAATCAAACACGAGAGCAAGAGTGAAAAATTCTAAAATTATG 8145
ARU01_lkt      GTTGCCGTGACGAAAGATTTGACAAATACAAATGTAAGAATTAAAGATTCTAAAATTGTC 8103
** ** ** ** ****** **** ** *  * **** * *** *********** *
3718_lkt       ACTCGAAACAAGTTAGATGTAATAGCAGAAAATGAGATAAAATCAGGTACTGGAATCGGT 8196
3724_lkt       ACTCGAAACAAGTTAGATGTAATAGCAGAAAATGAGATAAAATCAGGTACTGGAATCGGT 8205
ARU01_lkt      ACAAAAACAAAATTAGATGTCATTGCACAAAATCATACTAAAGTAAATGGAGGAATGGTA 8163
**   **  ** ******** ** *** ***** * *  ***  *  *   ***** *
3718_lkt       TCAGCCGGAGCTGGAATTCTTGCAGCCGGAGTATCTGGAGTTGTTTCTGTCAATAATATT 8256
3724_lkt       TCAGCCGGAGCTGGAATTCTTGCAGCCGGAGTATCTGGAGTTGTTTCTGTCAATAATATT 8265
ARU01_lkt      GGAATTGGAGCAGCCGGAGTTGGAGCCGGATTAGCAGGAACCGTTTCTGTCAATAATATC 8223
*   ***** *      *** ******* ** * ***   *****************
3718_lkt       GCAAATAAGGTAGAAACAGATATCGATCATAGTACTTTACACTCTTCTACTGATGTAAAT 8316
3724_lkt       GCAAATAAGGTAGAAACAGATATCGATCATAGTACTTTACACTCTTCTACTGATGTAAAT 8325
ARU01_lkt      ACCAGCAAAGTAGGAACAGAAATAGATCATAGTGAATTGCTGTCTGAAGAAGATGTAAAT 8283
* *  ** **** ****** ** *********   ** *  ***      *********
3718_lkt       GTAAAAGCTCTTAATAAAATTTCGAATTCCTTGACAGCCGGTGGAGGAGCCGCAGGTCTT 8376
3724_lkt       GTAAAAGCTCTTAATAAAATTTCAAATTCCTTGACAGCCGGTGGAGGAGCCGCAGGTCTT 8385
ARU01_lkt      GTGAAAGCTTTGAATAAAGTTGATAGTTCTATGATGGCTGCCGGAGGAGCTGCAGGTCTT 8343
** ****** * ****** ** * ***  ***  ** *  ******** *********
3718_lkt       GCAGCAGTTACCGGAGTGGTTTCTGTTAACACTATAAATAGTTCTGTGATAGCTCGAGTT 8436
3724_lkt       GCGGCAGTTACCGGAGTGGTTTCTGTTAACACTATAAATAGTTCTGTGATAGCTCGAGTT 8445
ARU01_lkt      GGTGCAGCAAGTGGAGTGGTTTCTGTGAATACTGTCAATACTTCCGTAGTAACCAGAGTT 8403
*  ****  *  ************** ** *** * **** *** **  ** *  *****
255
3718_lkt       CACAATAACTCTGATTTGACTTCCGTACGAGAAAAAGTAAATGTAACGGCAAAAGAGGAA 8496
3724_lkt       CACAATAACTCTGATTTGACTTCCGTACGAGAAAAAGTAAATGTAACGGCAAAAGAGGAA 8505
ARU01_lkt      CATAATAATTCAAAAATAACTTCATCCAAAGGAAGCACCAATGTAAAAGCAGAAGAAGAA 8463
** ***** **  *  * *****      ** **     *******  *** **** ***
3718_lkt       AAAAATATTAAGCAAACAGCAGCAAATGCAGGAATCGGAGGAGCAGCAATCGGAGCCAAT 8556
3724_lkt       AAAAATATTAAGCAAACGGCAGCAAATGCAGGAATCGGAGGAGCAGCAATCGGAGCCAAT 8565
ARU01_lkt      AAAAATATAAAACAAGTAGTTGCAAATGCAGTGGCAGGGGGCGTTTCTGTTGGAGCGAAT 8523
******** ** ***   *  **********     ** ** *   *  * ***** ***
3718_lkt       GTCTTGGTAAATAATTTTGGAACAGCTGTAGAAGATAGAAAAAATTCTGAAGGAAAAGGA 8616
3724_lkt       GTCTTGGTAAATAATTTTGGAACAGCTGTAGAAGATAGAAAAAATTCTGAAGGAAAAGGA 8625
ARU01_lkt      GTCTTGGTTAATAATTTTGGAACTGCTGTAGAAGATAAGGCAGCTGAAACAGGAAAAGGA 8583
******** ************** *************    *  *     **********
3718_lkt       ACAGAAGTTTTAAAAACTTTAGACGAAGTTAACAAAGAACAAGATAAAAAAGTAAATGAT 8676
3724_lkt       ACGGAAGTTTTGAAAACTTTAGACGAAGTTAACAAAGAACAAGATAAAAAAGTAAATGAT 8685
ARU01_lkt      ACTGAAATCTTAAAAACTTTAGAAGAAATCAATAAAGATCAAGATCAAAAAATCAGTGAA 8643
** *** * ** *********** *** * ** ***** ****** ***** * * ***
3718_lkt       GCTACGAAAAAAATCTTACAATCAGCAGGTATTTCTACAGAAGATACTTCTGTAAAAGCG 8736
3724_lkt       GCTACGAAAAAAATCTTACAATCAGCAGGTATTTCTACAGAAGATACTTCTGTAAAAGCG 8745
ARU01_lkt      GATGCCGCTAAAATATTAAAGTCAAATGGAATTGATACAAAAGACTATGCTGTCAAGGCG 8703
* * *    ***** *** * ***   ** ***  **** ****   * **** ** ***
3718_lkt       GATAGAGGAGATACTCAGGGAGAAGGAATTAAAGCCATTGTGAAGACTTCTGATATTATT 8796
3724_lkt       GATAGAGGAGATACTCAGGGAGAAGGAATTAAAGCCATTGTGAAGACTTCTGATATTATT 8805
ARU01_lkt      GATCGTGGAGAAACACAAGCAGAAGGAATTAAAGTATTTGTAGAAAATTCTTCGATAAAA 8763
*** * ***** ** ** * **************   ****  * * ****   ** *
3718_lkt       GGAAAAAATGTAGATATTACAACAGAGGACAAGAATAATATCACTTCTACTGGTGGTTTG 8856
3724_lkt       GGAAAAAATGTAGATATTACAACAGAGGACAAGAATAATATCACTTCTACTGGTGGTTTG 8865
ARU01_lkt      GGAAAAAATACGAATATTGCAGCAAATCAAACGGATAATGTGACTTCCACCGGTGGAGCA 8823
*********    ***** ** ** *  * * * ***** * ***** ** *****
3718_lkt       GGAACTGCAGGTCTTGCTTCCGCATCAGGAACAGTGGCAGTTACAAATATTAAAAGAAAT 8916
3724_lkt       GGAACTGCAGGTCTTGCTTCCGCATCAGGAACAGTGGCAGTTACAAATATTAAAAGAAAT 8925
ARU01_lkt      GGAAGTGCAGGAGTGGCGTCCGCATTGGGAACTGTAGGAGTAACAAATATCAAAAGAAAC 8883
**** ******  * ** *******  ***** ** * *** ******** ********
3718_lkt       TCCGGAGTTACTGTTGAAAATTCTTTTGTGAAAGCAGCTGAAAAAGTAAATGTTAGATCG 8976
3724_lkt       TCCGGAGTTACTGTTGAAAATTCTTTTGTGAAAGCGATTGAAAAACTAAATGTTAGATCG 8985
ARU01_lkt      ATAGGAGTTTTCATAAATAATGCGGATGTGAAAGCGGATGAGAAACTAAGTGTACGATCC 8943
******    *  * *** *   *********   *** *** *** ***  ****
3718_lkt       GATATTACAGGAAATGTTGCTTTAACAGCATATCAAGGTTCTGTAGGAGCATTGGGAATA 9036
3724_lkt       GATATTACAGGAAATGTCGCTTTAACAGCATACCAAGGTTCCGTAGGAGCATTGGGAATA 9045
ARU01_lkt      GATATTTCAGGAAACGTATCCCTAACTTCTTATCAAGGAACTGTTGGAGCTTTGGGATTA 9003
****** ******* **  *  ****  * ** *****  * ** ***** ****** **
3718_lkt       GGAGCTGCCTATGCAGAATTAAATTCTAATGGAAGATCAAATATCAGTATTAAAAATTCT 9096
3724_lkt       GGAGCTGCCTATACAGAATTAAATTCTAATGGAAGATCAAATATCAACATTAGAAATTCT 9105
ARU01_lkt      GGAGCGGCTTATTCACAAATAAATGCTAACGGACAATCGAATATTACTATTAAAAACTCT 9063
***** ** *** ** ** ***** **** ***  *** ***** *  **** *** ***
3718_lkt       AAGCTATTAGGAAAAAATATTGATGTTATTGTAAAAGATAAATCGGAATTGAGAGCGGAA 9156
3724_lkt       AAGCTATTAGGAAAAAATATTGATGTTATTGTAAAAGATAAATCGGAATTGACAGCGGAA 9165
ARU01_lkt      AGATTTGCAGCAAAACATATTGATGTTATTGCAAAAGATAAATCTCAATTGAAGGCGGAA 9123
*   *   ** **** *************** ************  ******  ******
3718_lkt       GCAAAAGGATTAACCGTAGGAGCGGTAGCTGCCGGAGCCATTATCTCAAAAGCAAAGAAT 9216
3724_lkt       GCAAAAGGATTAACCGCCGGAGCGGTAGCCGCCGGAGCTATTATCTCAAAAGCAAAGAAT 9225
ARU01_lkt      GCAAAAGGATTAACCGTAGGAGCGGTAGCTGCCGGAGCTATTATCTCAAAAGCAAACAAT 9183
****************  *********** ******** ***************** ***
3718_lkt       GAAATGAATTCAGAGGTTGAAATTGAGAAGAGTATTTTCAATGAAGAAAATAGAGTAACT 9276
3724_lkt       GAAATGAATTCAGAGATTGAAATCGAGAAGAGTATTTTCAATGAAGAAAATAGAGTAAAC 9285
ARU01_lkt      GAAATGAATTCAGAAATTGAAATTGAGAAGAGCATTTTCAATGAAGAAAATAGAGTAAGC 9243
**************  ******* ******** *************************
3718_lkt       AGCCCTTCTAAAGGAATTGGAAGAGAAATCAATGTCAAAGTGGAAAAAGAAAACAGAGTG 9336
3724_lkt       AGCCCTTCTAAAGGAATTGGAAGAGAAATCAATGTCAAAGTGGAAAAAGAAAATAGAGTG 9345
ARU01_lkt      AGCCCTTCTAAGGGAATTGGAAGAGAAATCAATGTTAAAGTGGAAAAAGAAAACAGAGTG 9303
*********** *********************** ***************** ******
3718_lkt       ACTGCTGAATCTCAAGGAGCTTCTGTAGGAGCAGTAGCAGGGGCAGGAATTATTTCCGAA 9396
3724_lkt       ACTGCTGAATCTCAGGGAGTTTCTGTAGGGGCGGTAGCAGGGGCAGGAATCATTTCCGAT 9405
ARU01_lkt      ACTGCTGAATCTCAAGGAGCTTCTGTGGGAGCAGTAGCGGGGGCAGGAATTATTTCCGAT 9363
************** **** ****** ** ** ***** *********** ********
3718_lkt       GCAAAAGATGCCGGAAGCTCTTATTTGAAAGTTAGTACAAAATCCGGAAGAAGTATTTTT 9456
3724_lkt       GCAAAAGATGCGGGAAGTTCTTATTTAAAAGTTAGTACAAAATCCGGAAGAAGTATTTTC 9465
ARU01_lkt      GCAAAAGATGCGGGAAATTCTTATTTAAAAGTTAGTACAAAATCCGGAAGAAGTATTTTC 9423
*********** ****  ******** ********************************
3718_lkt       CATGCAGATAATGTGAATATGGAAGCAACACATAAAATGAAAGTAACAGCAGTTTCTAAA 9516
3724_lkt       CATGCAGATAATGTGAATATGGAAGCAACACATAAAATGAAAGTAACTGCAGCTTCTAAA 9525
ARU01_lkt      CATGCAGATAATGTGAATATGGAAGCAACACATAAAATGAAAGTAACTGCAGGTTCTAAA 9483
*********************************************** **** *******
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3718_lkt       GCAGTAACAGGTTCTGTATTGGGAGGAGTTGGAGTCACCAAGGCAGAAGCTACTGCTGCA 9576
3724_lkt       GCGGTAACGGGTTCTGTATTGGGAGGAGTTGGAGTCACCAAAGCGGAAGCTGTTGCTGCC 9585
ARU01_lkt      GCGGTAACAGGTTCTGTATTGGGAGGAGTTGGAGTTACAAAGGCGGAAGCAACTTCTGCA 9543
** ***** ************************** ** ** ** *****   * ****
3718_lkt       GGTAAAACTATGGTAGAAGTTGAGGAAGGAAATTTGTTCAGAACAAATCGATTGAATGCA 9636
3724_lkt       GGTAAAACTATGATAGAAGTTGAAGAAGGAAATTTGTTCAGAACAAATCGATTGAATACA 9645
ARU01_lkt      GGAAAAGTAATGGTAGAGATTGAGGAAGGAAATTTGTTCAGAACAAATCGATTGAATGCA 9603
** ***   *** ****  **** ********************************* **
3718_lkt       ATTTCTAAAGTAGAAGGTTTGGATGAAGATAAAGTAACTGCTAAATCTTCTGTAGTATCA 9696
3724_lkt       ATTTCCAAAGTAGAAGGTTTGGATGAAGATAAAGTAACTGCTAAATCTTCTGCAATATCA 9705
ARU01_lkt      ATTTCTAAAGTAGAAGGATTGGATGAAGATAAAGTAACTGCGAAATCTTTTGTAGTATCA 9663
***** *********** *********************** ******* ** * *****
3718_lkt       GGAAATGGAGGAGGAATTGCCGGAGCAGGAGTGAATACTTCTACAGCACAAAGTAATACT 9756
3724_lkt       GGAAATGGAGGAGGAATTTCTGGAGCGGGAGTGAATACTTCTACAGCACAAAGTAATACC 9765
ARU01_lkt      GGAAATGGAGGAGGAATTGCCGGAGCGGGAGTGAATACTTCTACAGCACAAAGTAATACG 9723
****************** * ***** ********************************
3718_lkt       GAATCCGTAGTTCGTTTACGAAAGCAAGATTATGAAAATAATGATTACACAAAAAAATAT 9816
3724_lkt       GAATCCGTAGTTCATTTACAAAGACAAGACTATGAAAATAATGATTATACAAAAAAATAT 9825
ARU01_lkt      GAATCCGTCGTTCGTTTACGAAAGCAAGACTACGAAAATAACGACAGTACGAAAAAATAT 9783
******** **** ***** **  ***** ** ******** **    ** *********
3718_lkt       ATTTCAGAAGTCAATGCTCTTGCTTTAAATGATACAAAGAATGAAGCGAATATAGAATCT 9876
3724_lkt       ATTTCAGAAGTCAATGCTCTTGCTTTAAATGATACAAAGAATGAAGCGAATATAGAATCT 9885
ARU01_lkt      ATTTCAGAAGTGAATGCTCTTGCTGTAAATGACACAAAGAATGAAGCAAATATAGAATCT 9843
*********** ************ ******* ************** ************
3718_lkt       TTAGCGGTAGCCGGTGTGCATGCACAAGGAACAAACAAAGCATTTacGAGATCAAACAAG 9936
3724_lkt       TTAGCGGTAGCCGGTGTGCATACACAAGGAACAAACAAAGCATTTACGAGATCAAACAAG 9945
ARU01_lkt      TTAGAGGTAGCGGGAGTATACGCACAAGGAACAAACAAAGCATTTACGAAATCGGATAAG 9903
**** ****** ** **  *  *************************** ***  * ***
3718_lkt       TTAACTTCTACAACTGTAAATGGAGGaAACGTAtCtCAACTTCGTGCAAAAgCTTTGGCT 9996
3724_lkt       TTAACTTCTACAACTGTAAATGGAGGAAACGTATATCAACTTCGTGCAAAAGCTTTGGCT 10005
ARU01_lkt      TTAACTTCTACAACTGTAAATGGAGGAAAAGTATATCAACTTCGTGCAAAAGCTTTGGCT 9963
***************************** **** *************************
3718_lkt       AAAAATGAAAATTATggaAaTGTAAAAggAACTGGAGGAGCcttAGTCGGAGCGGAAACA 10056
3724_lkt       AAAAATGAAAATTATGGAAATGTAAAAGGAACTGGAGGAGCCTTAGTCGGAGCGGAAACA 10065
ARU01_lkt      AAAAATGAAAATTACGGAAATGTAAAAGGAAGCGGAGGAGCCTTAGTCGGAGCGGAAACA 10023
************** ****************  ***************************
3718_lkt       GCAGCCGTTGAAAATTATACAAAGAGTACTACAGGAGCATTGGTTGCAGGAAATTGGGAA 10116
3724_lkt       GCAGCCGTTGAAAATTATACAAAGAGTACTACAGGAGCATTGGTTGCAGGAAATTGGGAA 10125
ARU01_lkt      GCAGCTGTTGAGAATTATGTAAAGAGTACTACAGGAGCATCTGTTGCAGGAGAATGGGAA 10083
***** ***** ******  ********************  ********* * ******
3718_lkt       ATTGGAGATAAATTAGAAACGATTGCAAGAGATAATACGATTGTAAGAGTCAACGGAGAC 10176
3724_lkt       ATTGGAGATAAATTAGAAACGATTGCAAGAGATAATACGATTGTAAGAGTCAACGGAGAC 10185
ARU01_lkt      ATTGGAGATAAATTAGAAACGATTGCAAAAGATAATACGATTGTAAAAGTTAACGGAGAC 10143
**************************** ***************** *** *********
3718_lkt       GGAACCAAAGGAGGTCTTGTCGGAAAGAATGGTATTTCTGTGAAAAATACAATTTCAGGG 10236
3724_lkt       GGAACCAAAGGAGGTCTTGTCGGAAAGAATGGTATTTCTGTGAAAAATACAATTTCAGGG 10245
ARU01_lkt      GGAACAAAAGGAGGTCTTGTCGGAAAGAATGGTATTTCTGTGAAAAATACAATTTTAGGA 10203
***** ************************************************* ***
3718_lkt       GAAACAAAATCATCCATTGAAGATAAAGCCAGAATTGTTGGAACCGGAAGTGTAAATGTA 10296
3724_lkt       GAAACAAAATCATCCATTGAAGATAAAGCCAGAATTGTTGGAACCGGAAGTGTAAATGTA 10305
ARU01_lkt      GAAACAAAATCATTTATTGACGATAAGGCTAAAATCGCCGGAACCGGAAGCGTAAATGTA 10263
*************  ***** ***** ** * *** *  *********** *********
3718_lkt       GATGCTTTGAATGAACTTGATGTAGATCTACAAGGAAAAAGTGGTGGCTATGGTGGAATT 10356
3724_lkt       GATGCTTTGAATGAACTTGATGTAGATCTACAAGGAAAAAGTGGTGGTTATGGTGGAATT 10365
ARU01_lkt      GAGGCTCTGAATGAACTTGATGTAGATTTACAAGGAAAAAGTGGTGGATATGGTGGAATT 10323
** *** ******************** ******************* ************
3718_lkt       GGTATTGGAAATGTTGATGTAAATAATGTGATTAAGAAAAATGTAGAAGCCAAAATCGGA 10416
3724_lkt       GGTATTGGAAATGTTGATGTAAATAATGTGATTAAGAAAAATGTAGAAGCCAAAATCGGA 10425
ARU01_lkt      GGTGTTGGAAATGTCGATATAAGCAATGTTATTAAAAAAGATACAGAAGCAAAAATAGGA 10383
*** ********** *** ***  ***** ***** *** **  ****** ***** ***
3718_lkt       AGACATGCTATTGTAGAAACTACTGGAAAACAAGAATATCAAGCATTTACAAGAGCAAAA 10476
3724_lkt       AGACATGCTATTGTAGAAACTACTGGAAAACAAGAATATCAAGCATTTACAAGAGCAAAA 10485
ARU01_lkt      CAACATGCTGTTGTAGAAACCACCGGAAAACAAGAATATCAAGCATTTACAAAAGCGAAA 10443
******* ********** ** **************************** *** ***
3718_lkt       GTAAATATTCTTGGAAAAGGAGACGCTGCAGCTGCAGCTGCAATATCGAATGTACACATT 10536
3724_lkt       GTAAATATTCTTGGAAAAGGAGACGCTGCAGCTGCAGCTGCAATATCGAATGTACACATT 10545
ARU01_lkt      GTAAACATTCTTGGAAAAGGAGATGCTGCAGCTGCAGCTGCGATATCCAATGTACATGTT 10503
***** ***************** ***************** ***** ********  **
3718_lkt       TCCAATGAGATGGATATTAAAAATTTGGCAAAGCAGTATGCATCTTCTCAATTAATAACC 10596
3724_lkt       TCCAATGAGATGGATATTAAAAATTTGGCAAAGCAGTATGCATCTTCTCAATTAATAACC 10605
ARU01_lkt      TCTAATGAGATGGATATTAAAAATTTAGCAAAGCAGTATGCATATTCTCAATTAACAACA 10563
** *********************** **************** *********** ***
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3718_lkt       AAAAATTCAAAAAATAATATTACTTTAGCATCAAGTAGTGAATCGAATGTGAATGTTCAT 10656
3724_lkt       AAAAATTCAAAAAATAATATTACTTTAGCATCAAGTAGTGAATCGAATGTGAATGTTCAT 10665
ARU01_lkt      AAAAATTCAAAAAATGATATTACTTTAGCTTCAAGTAGTGAGTTGGATGTGAATGTTCAC 10623
*************** ************* *********** * * *************
3718_lkt       GGGGTGGCTGAAGCAAGAGGTGCAGGAGCCAAAGCGACAGTTAGTGTAAAGAATCAAATA 10716
3724_lkt       GGGGTGGCTGAAGCAAGAGGTGCAGGAGCCAAAGCGACAGTTAGTGTAAAGAATCAAATA 10725
ARU01_lkt      GGAGTGGCTGAAGCAAAGGGTGTAGGAGCCAAAGCGACGTCTAGTGTAAAAAATCAAATA 10683
** *************  **** ***************   ********* *********
3718_lkt       AATAGAACTAATAATGTTGATTTAGCAGGAAAAATTAAAAcaGAGGGAAACATCAATGTA 10776
3724_lkt       AATAGAACTAATAATGTTGATTTAGCAGGAAAAATTAAAACAGAGGGAAACATCAATGTA 10785
ARU01_lkt      AATAGAGCGAATAATGTTGATTTGGCAGGAAAAATTAAGACAGAAGGAAACATTAATGTA 10743
****** * ************** ************** ***** ******** ******
3718_lkt       TATGCCGGATATGATAAAAATTATAATATAAGTAAGACAAATTCTAAGGCTATTGCGGAT 10836
3724_lkt       TATGCCGGATATGATAAAAATTATAATATAAGTAAGACAAATTCTAAGGCTATTGCGGAT 10845
ARU01_lkt      TATGCCGGATATGATAAAAATTATAATATAAGTAAGACAAATTCTAAGGCCATTGCGGAT 10803
************************************************** *********
3718_lkt       GCCAAAAGTCATGCTGCAGCTGCTTCGGCAACTGCCACTGTTGAAAAAAATGAAGTAAAA 10896
3724_lkt       GCCAAAAGTCATGCTGCAGCTGCTTCAGCAACTGCCACTATTGAAAAAAATGAAGTAAAA 10905
ARU01_lkt      GCTAAAAGTCATGCTGCAGCTGCTTCTGCAACTGCTACCATTGAAAAAAATGAAGTGAAA 10863
** *********************** ******** **  **************** ***
3718_lkt       TTTAATAATGCGATCCGAGAATTTAAAAATAATCTGGCAAGATTGGAAGGGAAAGCTAAT 10956
3724_lkt       TTTAATAATGCGATCCGAGAATTTAAAAATAATCTGGCAAGATTGGAAGGGAAAGCTAAT 10965
ARU01_lkt      TTCAATAACGCGATCCGAGAGTTTAAAAATAATCTGGCAAAATTGGAAGGTAAAGTTAAT 10923
** ***** *********** ******************* ********* **** ****
3718_lkt       AAAAAAACGTCGGTAGGATCTAATCAGGTAGACTGGTATACGGATAAATATACATGGCAT 11016
3724_lkt       AAAAAAACGTCGGTAGGATCTAATCAGGTAGACTGGTATACGGATAAATATACATGGCAT 11025
ARU01_lkt      AAAGAAGTGTCAACTGGATTGAATCAGGTAGATTGGTATACAGATAAATATACATGGCAT 10983
*** **  ***    ****  *********** ******** ******************
3718_lkt       TCTTCTGAAAAAGCATACAAAAAATTGACATATCAATCAAAGAGAGGAGAAAAAGGGAAA 11076
3724_lkt       TCTTCTGAAAAAGCATACAAAAAATTGACATATCAATCAAAGAGAGGAGAAAAAGGGAAA 11085
ARU01_lkt      TCTTCTGAAAAAGCATATAAAAAATTGACATATCAATCAAAGAAAGGGGAAAAAAATAAA 11043
***************** ************************* *** ******   ***
3718_lkt       AAATGAATTTAAGAGAGAGTAAATTTAGTGAGTTTTTAAAAAATTCAAACATAACTTGTT 11136
3724_lkt AAATGAATTTAAGAGAGAGTAAATTTAGTGAGTTTTTAAAAAATTCAAACATAACTTGTT 11145
ARU01_lkt      AAATGAATTTAAGAGAGAGTAAATTTAATGATTTTTTAAAAAATTCAAACATAACTTGTT 11103
*************************** *** ****************************
3718_lkt       TTGAAAGAGAAGAAGTGAAAGATGAGTTAGAAACAGTTGTATATCGAAGTTTTATGGAAG 11196
3724_lkt       TTGAAAGAGAAGAAGTGAAAGATGAGTTGGAAACGGTTGTATATCGAAGTTTTATGGAAG 11205
ARU01_lkt      TTGAAAGAGAAGAAGTGAAAGATGAATTGGAAACAGTGGTATATCGAAGTTTTATGGAAG 11163
************************* ** ***** ** **********************
3718_lkt       TAGAGGGACAAAATTTACCTATGGTAATTGTGATGGATAACAGTATTTATACGAATATCC 11256
3724_lkt       TAGAGGGACAAAATTTACCTATGGTAATTGTGATGGATAATAGTATCTATACGAATATTC 11265
ARU01_lkt      TAGAGGGACAAAATTTACCTATGGTAATTGTGCTGGATAACAGTATCTATACAAATATTC 11223
******************************** ******* ***** ***** ***** *
3718_lkt       GAGTGCAAATTGCTCCAAAAGTCATAAAAGATACTAATAAAGAAGCGGTACTTTCCTATA 11316
3724_lkt       GAGTGCAAATTGCCCCAAAAGTTATAAAAGATAGTAACAGGGAAGCAGTACTTTCCTATA 11325
ARU01_lkt      GAGTACAAATTGCCTCAAAAGTCATAAAAGATAGCAACAAAGAAGCAGTACTTTCCTATA 11283
**** ********  ******* **********  ** *  ***** *************
3718_lkt       TCAATGAATTGAACCGAGAATACAAAGTATTTAAATATTATGTGACAGAGGATG 11370
3724_lkt       TCAATGAATTGAACCGAGAATACAAAGTATTTAAATATTATGTAACAGAGGATG 11379
ARU01_lkt      TCAATGAATTGAACCGAGAATACAAAGTATTTAAATACTATGTGACAGAGGATG 11337
************************************* ***** **********
Appendix Figure 4: Clustal Omega DNA alignment of Sanger sequence data from JCM 3718, JCM 3724 and ARU 01
leukotoxin operons. Contains genes of lktB, lktA and partial lktC.
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Appendix 13: Clustal Omega protein sequence alignment of JCM
3718, JCM 3724 and ARU 01 leukotoxinA
3718_lktA       MSGIKNNVQRTRKRISDSKKVLMILGLLINTMTVRANDTITATENFGTKIEKKDNVYDIT 60
3724_lktA       MSGIKNNVRRTRKRISDSKKVLMILGLLINTMTAVADDSIKETQGFGTKVEKQGNVYDIT 60
ARU01_lktA      MSGIKNNVRRTRKRISDSKKVLMILGLLINTMTAVADDSIKETQGFGTKVEKQGNVYDIT 60
********:************************. *:*:*. *: ****:**: ******
3718_lktA       TNKIQGENAFNSFNRFALTENNIANLYFGEKNSTGVNNLFNFVNGKIEVDGIINGIRENK 120
3724_lktA       TNKIKDKNAFNSFDKFHLEQNNIANMHFGSKGGKEAENLFNFVKGKIEVNGVINGIRDNK 120
ARU01_lktA      TNKIKDKNAFNSFDKFHLEQNNIANMHFGSKGGKEAENLFNFVKGKIEVNGVINGIRDNK 120
****: :******::* * :*****::**.* .. .:******:*****:*:*****:**
3718_lktA       IGGNLYFLSSEGMAVGKNGVINAGSFHSIIPKQDDFKKALEEAKHGKVFNGIIPV-DGKV 179
3724_lktA       IGGNLYFLSSEGLLVGKTGVINAGTFHAISPKKEEYEKAFKDAQNSKVFDGIVPQQDGSI 180
ARU01_lktA      IGGNLYFLSSEGLLVGKTGVINAGTFRAISPKKEEYEKAFKDAQNSKVFDGIVPQQDGSI 180
************: ***.******:*::* **:::::**:::*:..***:**:*  **.:
3718_lktA       KIPLNPNGSITVEGKINAVEGIGLYAADIRLKDTAILKTGITDFKNLVNISD-RINSGLT 238
3724_lktA       KIPLNPNGSITVEGKINAVEDIGLYAADIRLKDTARLKTGITEFKNLVNINE-TIHAGLT 239
ARU01_lktA      KIPLNPNGSITVEGKINAVDEIGLYAADIKLPETGALKTGVTDFHQLVNIKDSNVNAGLS 240
*******************: ********:* :*. ****:*:*::****.: :.:**:
3718_lktA       GDLKATKTKSGDIILSAHIDSPQKAMGKNSTVGKRIEEYVKGNTKANIESDAVLEADGNI 298
3724_lktA       GDLTAVKTKSGDIILSAHVDSPQKAVGENSTVGKRIEEYVKGNTKANIESDAVLEADGNI 299
ARU01_lktA      GDLKATKTGTGDIILSAKVEEAGHELE-SSTIYEQIGRNFKGKIKANIETSGSIEAEGHA 299
***.*.** :*******:::.  : :  .**: ::* . .**: *****:.. :**:*.
3718_lktA       KISAKATNGRFIKKEGEKETYNTPLSLSDVEASVRVNKGKVIGKNVDITAEAKNFYDATL 358
3724_lktA       KISARATNGTFVKKEGEKEIYNTPLSLSDVEASVRVNKGKVIGKNVSITAEAKNFYDATL 359
ARU01_lktA      KIHAEASNGKLTKKDGEKEVYAPEFSLAEVEASVKVNKGKIKGKKVDISAEAKNYYDTPI 359
** *.*:** : **:**** *   :**::*****:*****: **:*.*:*****:**: :
3718_lktA       VTKLAKHSFSFVTGSISPINLNGFLGLLTSKSSVVIGKDAKVEATEGKANIHSYSGVRAT 418
3724_lktA       VTKLAKHSFSFVTGSLSPINLNGFLGLLTSKSSVVIGKDAKVEAREGSANIHSYSGVRAT 419
ARU01_lktA      LTKVGKIAFSVGTGSLSPINMNGALGLLKSKASVFIGKDATVESTEGEANIRSYSGVRAS 419
:**:.* :**. ***:****:** ****.**:**.*****.**: **.***:*******:
3718_lktA       MGAATSPLKITNLYLEKANGKLPSIGAGYISAKSNSNVTIEGEVKSKGRADITSKSENTI 478
3724_lktA       MGAATSPLKITNLYLENADGKLPSIGAGYISAKSDSNVTIEGEVKSKERADITSKSENTI 479
ARU01_lktA      MGASTSPIKLTDLYLKTLEGKLPSVGAAYISTSSESDVTVEGKVSSKEKANITSKSENTI 479
***:***:*:*:***:. :*****:**.***:.*:*:**:**:*.** :*:*********
3718_lktA       DASVSVGTMRDSNKVALSVLVTEGENKSSVKIAKGAKVESETDDVNVRSEAINSIRAAVK 538
3724_lktA       DASVSVGTMRDSNKVALSVLVTEGENKSSVKIAKGAKVESETDDVNVRSEAINSVRATVK 539
ARU01_lktA      DASVSVGTIRDSNKVGISVLVTEGKNHSSVKIAEGAKVESDG-DANVKSEAVNSIRAAVK 538
********:******.:*******:*:******:******:  *.**:***:**:**:**
3718_lktA       GGLGDSGNGVVAANISNYNASSRIDVDGYLHAKKRLNVEAHNITKNSVLQTGSDLGTSKF 598
3724_lktA       GGLGDSGNGVVAANISNYNASSRVDVDGYLHAKKRLNVEAHNITKNSVLQTGTNLGTSKF 599
ARU01_lktA SGLSDNGAGVVAANISNYNSSSKVVVDGEVHAKKRLNTEAYNITKQNVLQTGTKTGTSKL 598
.**.*.* ***********:**:: *** :*******.**:****:.*****:. ****:
3718_lktA       MNDHVYESGHLKSILDAIKQRFGGDSVNEEIKNKLTDLFSVGVSATIANHNNSASVAIGE 658
3724_lktA       MNDHVYESGHLKSILDAIKQRFGGDSVNEEIKNKLTDLFSVGVSATIANHNNSASVAIGE 659
ARU01_lktA      MNELVFESSHTKALIDALQYRFGGD---EKIKSKLTDLFSVGASATVANHNNTSSVSLGQ 655
**: *:**.* *:::**:: *****   *:**.*********.***:*****::**::*:
3718_lktA       SGRLSSGVEGSNVRALNEAQNLRATTSSGSVAVRKEEKKKLIGNAAVFYGNYKNNASVTI 718
3724_lktA       SGRLSSGVEGSNVRALNEVQNLRATTSSGSVAARKEEKKKFIGNAAVFYGNYKNNASVTI 719
ARU01_lktA      KSKLVSGVEGTNIKALTETQQLRSTTTSGSLATRGEEKKKLVGNAAVFYGNYKNDASVTI 715
..:* *****:*::**.*.*:**:**:***:*.* *****::************:*****
3718_lktA       ADHAELVSEGKIDINSENKIEYKNPSKMAKSVIDKLELLKRAFGKETK-TPEYDPKDIES 777
3724_lktA       ADQAELTSEGKIDTISENKTEYKNPSKMAKSVIEKLELLKRAFGKETK-TPEYDPKDIES 778
ARU01_lktA      ADDAQVVSEGKIDTISENKLEYKNPSKMAEEVVEKLEILKRAFEKEKKDETTFDPKDIDS 775
**.*::.******  **** *********:.*::***:***** **.*    :*****:*
3718_lktA       IEKLLNAFSEKLDGKPELLLNGERMTIILPDGTSKTGTAIEIANYVQGEMKKLEEKLPKG 837
3724_lktA       IEKLLNAFSEKLDGKPELLLNGERMTIILPDGTSKTGTAIEIANYVQGEMKKLEEKLPKG 838
ARU01_lktA MKKLLTEFSKKLDDKPEILLNGEKITIVLPDGTSKTGTVPELAEYVKEEMKKLEAKLPTG 835
::***. **:*** ***:*****::**:**********. *:*:**: ****** ***.*
3718_lktA       FKAFSEGLSGLIKETLNFTGVGNYANFHTFTSSGANGERDVSSVGGAVSWVEQENYSKVS 897
3724_lktA       FKAFSEGLSGLIKETLNFTGVGNYANFHTFTSSGANGERDVSSVGGAVSWVEQENYSKVS 898
ARU01_lktA      FKAFSEGLSGLLKESLAFTGVGNYANFHTFTSAGTNAKRDTSSVGGAVSWVEMDNHSKVS 895
***********:**:* ***************:*:*.:**.*********** :*:****
3718_lktA       VGKGAKLAAKKDLNIKAINKAETVNLVGNIGLARSSTSGSAVGGRLNVQRSKNSAIVEAK 957
3724_lktA       IGKGAKLAAKKDLNIKAINKAETVNLVGNIGLARSSTSGSAVGGRLNVQRTKNSAIVEAK 958
ARU01_lktA      IGRGSKITAKGDLNVKAINKTETVNLVGKLGLSKSSDSATAVGGGLNVQKSNTSSIVVTK 955
:*:*:*::** ***:*****:*******::**::** *.:**** ****:::.*:** :*
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3718_lktA       EKAELSGENINADALNRLFHVAGSFNGGSGGNAINGMGSYSGGISKARVSIDDEAYLKAN 1017
3724_lktA       EKAELSGENINADALNSLFHVAGSFNGGSGGNAINGMGSYSGGISKARVSIDDETYLTAN 1018
ARU01_lktA      EKAELSGENIHTNAFNNVFHVAASLNAGTGGNGINGMGSYSGGSSKSRVSIDDETHLKAK 1015
**********.::*:* :****.*:*.*:***.********** **:*******::*.*:
3718_lktA       KKIALNSKNDTSVWNAAGSAGIGTKNAAVGVAVAVNDYDISNKASIEDND---EGQSKYD 1074
3724_lktA       KKIALNSKNDTSVWNVAGSAGIGTKNAAVGVAVAVNDYDISNKASIEDND---EGQSKYD 1075
ARU01_lktA      KKIYLDSENNTSVTNVAGAVAIGSKNAAVGAAVAINDYDISNKVSIEDNDTEDGGKSKYD 1075
*** *:*:*:*** *.**:..**:******.***:********.******    *:****
3718_lktA       KNKDEVTVTAESLEVDAKTTGTINSISVAGGINKVGSKPSEEKPKSEERPEGFFGKIGNK 1134
3724_lktA KNKDEVTVTAESLEVDAKTTGTINSISVAGGINKVGSKPSEEKPKSEERPEGFFDKIGNK 1135
ARU01_lktA      KNKEEVTVTAEDLHANAKTTGTINAVSVAGGISKVGEAE--------SDGTGIFSKIGNK 1127
***:*******.*..:********::******.***.          .   *:* *****
3718_lktA       VDSVKNKITDSMDSLTEKITNYISEGVKKAGNLPSNVSHTPDKGPSFSLGASGSVSFNNI 1194
3724_lktA       VDSVKNKITDSMDSLTEKITNYISEGVKKAGNLPSNVSHTPDKGPSFSLGAAGSVSVNNI 1195
ARU01_lktA      VDSVKGKITDAIGFVTDQVTNYVYRGSNGTEDGIPNISKESSKLPSFSLGASGSVSVNNI 1187
***** ****::  :*:::***: .* : : :   *:*:  .* *******:****.***
3718_lktA       KKETSAVVDGVKINLKGANKKVEVTSSDSTFVGAWGGSAALQWNHIGSGNSNISAGLAGA 1254
3724_lktA       KKETSAVVDGVKVNLKGDNKKAEVIASDSAFIGAWSGAAALQWNHVGSGESNTTVGLAGA 1255
ARU01_lktA      KKETSAVMDGVKISLSGANKEVGVTSSDSTFVGAWSGSAALQWNHIGSGNSNFSASLAGA 1247
*******:****:.*.* **:. * :***:*:***.*:*******:***:** :..****
3718_lktA       AAVNNIQSKTSALVKNSDIRNANKFKVNALSGGTQVAAGAGLEAVKESGGQGKSYLLGTS 1314
3724_lktA       AAVNNVQSKTKAFVKDSSITNANKFKVNAVSGGTQVAAGMGLEAVKESGGQGRSYLLGTS 1315
ARU01_lktA      AAANNIQSKTNAVVKNSSIQNANKFKVNALSGGTQVAAGAGLEAAKESGGQGKSYLLGTS 1307
**.**:****.*.**:*.* *********:********* ****.*******:*******
3718_lktA       ASINLVNNEVSAKSENNTVAGESESQKMDVDVTAYQADTQVTGALNLQAGKSNGTVGATV 1374
3724_lktA       ASMNFIDNEVSSESENNIITGESEDKRADVDVTAYESDTQVTGGFNLQAGQSKGTVGAAV 1375
ARU01_lktA      ASINLVDNEVSAKSENNIVEGESENKKMNVDVTAYEADTQVTGALDLQAGKSSGTAGAAI 1367
**:*:::****::**** : ****.:: :******::******.::****:*.**.**::
3718_lktA TVAKLNNKVNASISGGRYTNVNRADAKALLATTQVTAAVTTGGTISSGAGLGNYQGAVSV 1434
3724_lktA       TVAKLNNKVKAGIKGGNYTNINRADTKALLATTQVTSALSVGGTNSFGSGLGNYQGAVSV 1435
ARU01_lktA      TVAKLNNKVNASISGGKYTKVNRADAKALLATTQVTAAVATGGTISSGAGLGNYQGVVSV 1427
*********:*.*.**.**::****:**********:*::.*** * *:*******.***
3718_lktA       NKIDNDVEASVDKSSIEGANEINVIAKDVKGSSDLAKEYQALLNGKDKKYLEDRGINTTG 1494
3724_lktA       NNINNDVSATVDKSSIKNAKELNVIAKDIKGSSELAKEYQSLLNGKDREYLEAHGIDTTG 1495
ARU01_lktA      NKIDNDVEAGIDKSSIEGADEVNVIAKDVKGSSNLAKEYQALLNGKDEKYLKDRGIDTTG 1487
*:*:***.* :*****: *.*:******:****:******:******.:**: :**:***
3718_lktA       NGYYTKEQLEKAKKKEGAVIVNAALSVAGTDKSAGGVAIAVNTVKNKFKAELSGSNKEAG 1554
3724_lktA       KNYYTEEQLKEAAKRDGAVIVNAAASIAGSDKSSGGAGVAVNLVKNKFKAEVIGEDKVDK 1555
ARU01_lktA      NGYYTKEQLEEAKKKEGAVIVNAALSVAGTDKSAGGVAIAVNTVKNKFKAELNGKDKEVE 1547
: ***:***::* *::******** *:**:***:**..:*** ********: *.:*
3718_lktA       EDKIHAKHVNVEAKSSTVVVNAASGLAISKDAFSGMGSGAWQDLSNDTIAKVDKGRISAD 1614
3724_lktA       TKDIAAEKINVDAKSSTVIVNTAAGLAVSQNSFAGLGSFAWQELNNEVSTKVENIKAETD 1615
ARU01_lktA      EGKIRAKHVNVEAKSSTVVVNAASGLAVSKDAFSGMGSGAWQDLSNETVAKVNKGRISTD 1607
.* *:::**:******:**:*:***:*:::*:*:** ***:*.*:. :**:: : .:*
3718_lktA       SLNVNANNSILGVNVAGTIAGSLSTAVGAAFANNTLHNKTSALITGTKVNPFSGKNTK-- 1672
3724_lktA       RLNVVARNNTLGVNIAGNIAGTGSAAVGAALAHNSLKNKASSSVTASNFKPFSKTNAKMG 1675
ARU01_lktA      SLNVTANNSVLGVNVAGTIAGSLSTAVGAAFANNTLHNKTSALITETKVNSFSGKDTK-- 1665
*** *.*. ****:**.***: *:*****:*.*:*:**:*: :* ::.: ** .::*
3718_lktA       VNVQALNDSHITNVSAGGAASIKQAGIGGMVSVNRGSDETEALVSDSEFEGVSSFNVDAK 1732
3724_lktA       INVQALNDSHITNVSAGVVASAKASGISGMASINRGSDETEALVSDSEFEGVNSFNVDAK 1735
ARU01_lktA      INAQALNDSHITNVSAGVAASVKQVGIGGMVSVNRGSDETEALVSDSEFDGVNSVDVRAE 1725
:*.************** .** *  **.**.*:****************:**.*.:* *:
3718_lktA       DQKTINTIAGNANGGKAAGVGATVAHTNIGKQSVIAIVKNSKITTANDQDRKNINVTAKD 1792
3724_lktA       DQKIVNTIAGNINGGKAAGVGATVAHTNIGKQSVTAIVKNSKIKTANNQDKKNIHVTAKD 1795
ARU01_lktA      DKKVLNTIAGNINGGQAAGVGATVAHTNIGKQSVTAAIKNSKITTAKNQDKKNINVTAKD 1785
*:* :****** ***:****************** * :*****.**::**:***.*****
3718_lktA       YTMTNTIAVGVGGAKGASVQGASASTTLNKTVSSHVDQTDIDKDLEEENNGNKEKANVNV 1852
3724_lktA       SVIMNTVAAGVGGAKGASVQGASASTAFNKTVASHVEHTDIDKDLEKENDENKEKANFNI 1855
ARU01_lktA      SVVMNTVAAGVGGAKGASVQGSSASTTLNKTVSAHVEKTDIDK----ENHESKEKADFNV 1841
.: **:*.************:****::****::**::*****    **. .****:.*:
3718_lktA       LAENTSQVVTNATVLSGASGQAAVGAGVAVNKITQNTSAHIKNSTQNVRNALVKSKSHSS 1912
3724_lktA       LAENTSQVVTNATVLSGASGQAAVGAGVAVNKITQNTSAHIKNSTQNVRNALVKSKANSS 1915
ARU01_lktA      LAENTSQVVTNATVLAGASGQAAVGAGVAVNKITQNTSAHIKNSTQNVRNALLKSKANSS 1901
***************:************************************:***:.**
3718_lktA       IKTIGIGAGVGAGGAGVTGSVAVNKIVNNTIAELNHAKITAKGNVGVITESDAVIANYAG 1972
3724_lktA       IKTIGIGAGIGAGGVGSSGSVAVNKITNNNTASVEHSNIFARGNVGVITESDAVIANYAG 1975
ARU01_lktA      IKTIGIGAGVGVGGVGVSGSVAVNKITNNNTAVVEHSDIFAKGNIGVIAESDAVIANYAG 1961
*********:*.**.* :********.**. * ::*:.* *:**:***:***********
3718_lktA       TVSGGARAAIGASTSVNEITGSTKAYVKDSTVIAKEETDDYITTQGQVDKVVDKVFKNLN 2032
3724_lktA       TVSGGSHAGVGGSTSVNEIQGDTIASVKHSKIEAKEETEDVIETQGKVKEVVEKVFQDIG 2035
ARU01_lktA      TVSGGGHVGVGGSTGVNEIEGDTIASVKKSKLEAKEETEDVIETQGKVKEVVENVLQDIG 2021
*****.:..:*.**.**** *.* * **.*.: *****:* * ***:*.:**::*::::
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3718_lktA       INEDLSQKRKISNKKGFVTNSSATHTLKSLLANAAGSGQAGVAGTVNINKVYGETEALVE 2092
3724_lktA       INEDLSKKREKSKKRGFVVNSSSTHTLKSLLANAAGSGQAGVAGTVNINKVYGATEALVE 2095
ARU01_lktA      INDDLSKKREKSNKKGFVVNSSSTHTIKSLLANAAGAGKAAVAGTVNVNKITGETKALVE 2081
**:***:**: *:*:***.***:***:*********:*:*.******:**: * *:****
3718_lktA       NSILNAKHYSVKSGDYTNSIGVVGSVGVGGNVGVGASSDTNIIKRNTKTRVGKTTMSDEG 2152
3724_lktA       DSILNAKHYSVKSGDYTNSIGAVGSVGVGGNVGAGASSDTNIIKRNTKTRVGKTTMSDEG 2155
ARU01_lktA      SSVLNVKNSSIHAGDYTNSIGAVGSASGALNAGIGASSNTNLFSRNTKTIVHDTKISTEK 2141
.*:**.*. *:::********.***.. . *.* ****:**::.***** * .*.:* *
3718_lktA       FGEEAEITADSKQGISSFGVGVAAAGVGAGVAGTVSVNQFAGKTEVDVEEAKILVKKAEI 2212
3724_lktA       FGEEAEITADSKQGISSFGVGVAAAGVGAGVAGTVSVNQFAGKTEVDVEEAKIFVKKAEI 2215
ARU01_lktA      EGQSSEITADSKQGISSFGVGVGAGVVGAGVAGTVSVNKLSGKTEVDIQKSDISTKSADI 2201
*:.:*****************.*. ************:::******::::.* .*.*:*
3718_lktA       TAKRYSSVAIGNAAVGVAAKGAGIGAAVAVTKDESNTRARVKNSKIMTRNKLDVIAENEI 2272
3724_lktA       TAKRYSSVAIGNAAVGVAAKGAGIGAAVAVTKDESNTRARVKNSKIMTRNKLDVIAENEI 2275
ARU01_lktA      SAKHYGVLSTGNGSVGAAVKGAGVGAAVAVTKDLTNTNVRIKDSKIVTKTKLDVIAQNHT 2261
:**:*. :: **.:**.*.****:********* :**..*:*:***:*:.******:*.
3718_lktA KSGTGIGSAGAGILAAGVSGVVSVNNIANKVETDIDHSTLHSSTDVNVKALNKISNSLTA 2332
3724_lktA       KSGTGIGSAGAGILAAGVSGVVSVNNIANKVETDIDHSTLHSSTDVNVKALNKISNSLTA 2335
ARU01_lktA      KVNGGMVGIGAAGVGAGLAGTVSVNNITSKVGTEIDHSELLSEEDVNVKALNKVDSSMMA 2321
*   *: . **. :.**::*.******:.** *:**** * *. *********:..*: *
3718_lktA       GGGAAGLAAVTGVVSVNTINSSVIARVHNNSDLTSVREKVNVTAKEEKNIKQTAANAGIG 2392
3724_lktA       GGGAAGLAAVTGVVSVNTINSSVIARVHNNSDLTSVREKVNVTAKEEKNIKQTAANAGIG 2395
ARU01_lktA      AGGAAGLGAASGVVSVNTVNTSVVTRVHNNSKITSSKGSTNVKAEEEKNIKQVVANAVAG 2381
.******.*.:*******:*:**::******.:** : ..**.*:*******..***  *
3718_lktA       GAAIGANVLVNNFGTAVEDRKNSEGKGTEVLKTLDEVNKEQDKKVNDATKKILQSAGIST 2452
3724_lktA       GAAIGANVLVNNFGTAVEDRKNSEGKGTEVLKTLDEVNKEQDKKVNDATKKILQSAGIST 2455
ARU01_lktA      GVSVGANVLVNNFGTAVEDKAAETGKGTEILKTLEEINKDQDQKISEDAAKILKSNGIDT 2441
*.::***************:  . *****:****:*:**:**:*:.: : ***:* **.*
3718_lktA       EDTSVKADRGDTQGEGIKAIVKTSDIIGKNVDITTEDKNNITSTGGLGTAGLASASGTVA 2512
3724_lktA       EDTSVKADRGDTQGEGIKAIVKTSDIIGKNVDITTEDKNNITSTGGLGTAGLASASGTVA 2515
ARU01_lktA      KDYAVKADRGETQAEGIKVFVENSSIKGKNTNIAANQTDNVTSTGGAGSAGVASALGTVG 2501
:* :******:**.****.:*:.*.* ***.:*::::.:*:***** *:**:*** ***.
3718_lktA       VTNIKRNSGVTVENSFVKAAEKVNVRSDITGNVALTAYQGSVGALGIGAAYAELNSNGRS 2572
3724_lktA       VTNIKRNSGVTVENSFVKAIEKLNVRSDITGNVALTAYQGSVGALGIGAAYTELNSNGRS 2575
ARU01_lktA      VTNIKRNIGVFINNADVKADEKLSVRSDISGNVSLTSYQGTVGALGLGAAYSQINANGQS 2561
******* ** ::*: *** **:.*****:***:**:***:*****:****:::*:**:*
3718_lktA       NISIKNSKLLGKNIDVIVKDKSELRAEAKGLTVGAVAAGAIISKAKNEMNSEVEIEKSIF 2632
3724_lktA       NINIRNSKLLGKNIDVIVKDKSELTAEAKGLTAGAVAAGAIISKAKNEMNSEIEIEKSIF 2635
ARU01_lktA      NITIKNSRFAAKHIDVIAKDKSQLKAEAKGLTVGAVAAGAIISKANNEMNSEIEIEKSIF 2621
**.*:**:: .*.****.****:* *******.************:******:*******
3718_lktA       NEENRVTSPSKGIGREINVKVEKENRVTAESQGASVGAVAGAGIISEAKDAGSSYLKVST 2692
3724_lktA       NEENRVNSPSKGIGREINVKVEKENRVTAESQGVSVGAVAGAGIISDAKDAGSSYLKVST 2695
ARU01_lktA      NEENRVSSPSKGIGREINVKVEKENRVTAESQGASVGAVAGAGIISDAKDAGNSYLKVST 2681
******.**************************.************:*****.*******
3718_lktA       KSGRSIFHADNVNMEATHKMKVTAVSKAVTGSVLGGVGVTKAEATAAGKTMVEVEEGNLF 2752
3724_lktA       KSGRSIFHADNVNMEATHKMKVTAASKAVTGSVLGGVGVTKAEAVAAGKTMIEVEEGNLF 2755
ARU01_lktA      KSGRSIFHADNVNMEATHKMKVTAGSKAVTGSVLGGVGVTKAEATSAGKVMVEIEEGNLF 2741
************************ *******************.:***.*:*:******
3718_lktA       RTNRLNAISKVEGLDEDKVTAKSSVVSGNGGGIAGAGVNTSTAQSNTESVVRLRKQDYEN 2812
3724_lktA       RTNRLNTISKVEGLDEDKVTAKSSAISGNGGGISGAGVNTSTAQSNTESVVHLQRQDYEN 2815
ARU01_lktA      RTNRLNAISKVEGLDEDKVTAKSFVVSGNGGGIAGAGVNTSTAQSNTESVVRLRKQDYEN 2801
******:**************** .:*******:*****************:*::*****
3718_lktA       NDYTKKYISEVNALALNDTKNEANIESLAVAGVHAQGTNKAFTRSNKLTSTTVNGGNVSQ 2872
3724_lktA       NDYTKKYISEVNALALNDTKNEANIESLAVAGVHTQGTNKAFTRSNKLTSTTVNGGNVYQ 2875
ARU01_lktA      NDSTKKYISEVNALAVNDTKNEANIESLEVAGVYAQGTNKAFTKSDKLTSTTVNGGKVYQ 2861
** ************:************ ****::********:*:**********:* *
3718_lktA       LRAKALAKNENYGNVKGTGGALVGAETAAVENYTKSTTGALVAGNWEIGDKLETIARDNT 2932
3724_lktA       LRAKALAKNENYGNVKGTGGALVGAETAAVENYTKSTTGALVAGNWEIGDKLETIARDNT 2935
ARU01_lktA      LRAKALAKNENYGNVKGSGGALVGAETAAVENYVKSTTGASVAGEWEIGDKLETIAKDNT 2921
*****************:***************.****** ***:***********:***
3718_lktA       IVRVNGDGTKGGLVGKNGISVKNTISGETKSSIEDKARIVGTGSVNVDALNELDVDLQGK 2992
3724_lktA       IVRVNGDGTKGGLVGKNGISVKNTISGETKSSIEDKARIVGTGSVNVDALNELDVDLQGK 2995
ARU01_lktA      IVKVNGDGTKGGLVGKNGISVKNTILGETKSFIDDKAKIAGTGSVNVEALNELDVDLQGK 2981
**:********************** ***** *:***:*.*******:************
3718_lktA       SGGYGGIGIGNVDVNNVIKKNVEAKIGRHAIVETTGKQEYQAFTRAKVNILGKGDAAAAA 3052
3724_lktA       SGGYGGIGIGNVDVNNVIKKNVEAKIGRHAIVETTGKQEYQAFTRAKVNILGKGDAAAAA 3055
ARU01_lktA      SGGYGGIGVGNVDISNVIKKDTEAKIGQHAVVETTGKQEYQAFTKAKVNILGKGDAAAAA 3041
********:****:.*****:.*****:**:*************:***************
3718_lktA       AISNVHISNEMDIKNLAKQYASSQLITKNSKNNITLASSSESNVNVHGVAEARGAGAKAT 3112
3724_lktA       AISNVHISNEMDIKNLAKQYASSQLITKNSKNNITLASSSESNVNVHGVAEARGAGAKAT 3115
ARU01_lktA      AISNVHVSNEMDIKNLAKQYAYSQLTTKNSKNDITLASSSELDVNVHGVAEAKGVGAKAT 3101
******:************** *** ******:******** :*********:*.*****
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3718_lktA       VSVKNQINRTNNVDLAGKIKTEGNINVYAGYDKNYNISKTNSKAIADAKSHAAAASATAT 3172
3724_lktA       VSVKNQINRTNNVDLAGKIKTEGNINVYAGYDKNYNISKTNSKAIADAKSHAAAASATAT 3175
ARU01_lktA      SSVKNQINRANNVDLAGKIKTEGNINVYAGYDKNYNISKTNSKAIADAKSHAAAASATAT 3161
********:**************************************************
3718_lktA VEKNEVKFNNAIREFKNNLARLEGKANKKTSVGSNQVDWYTDKYTWHSSEKAYKKLTYQS 3232
3724_lktA       IEKNEVKFNNAIREFKNNLARLEGKANKKTSVGSNQVDWYTDKYTWHSSEKAYKKLTYQS 3235
ARU01_lktA      IEKNEVKFNNAIREFKNNLAKLEGKVNKEVSTGLNQVDWYTDKYTWHSSEKAYKKLTYQS 3221
:*******************:****.**:.*.* **************************
3718_lktA       KRGEKGKK 3240
3724_lktA       KRGEKGKK 3243
ARU01_lktA      KKGEKNKK 3229
*:*** **
Appendix Figure 5: Clustal Omega protein sequence alignment of JCM 3718, JCM 3724 and ARU 01 leukotoxinA
.
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Appendix 14: PCR primers for lktA detection within the clinical strain
collection
Appendix Table 5: PCR primers for lktA detection within the clinical strain collection.












Appendix 15: Full leukotoxin PCR results




lktA Ludlam_LT1 Ludlam_LT2 lkt1 lkt2
1 + + + + +
5 - + + + +
11 - + - + +
21 + + + + +
24 - + + + +
30 - + + + +
39 + + + + +
40 + + + + +
41 - + - + +
42 - + + + +
52 - + - + +
59 - + + + +
62 + + + + +
70 + + + + +
80 - + + + +
82 - + + + +
86 - + + + +
87 - + + + +
89 - + + + +
90 + + + + +
91 + + + + +
92 + + + + +
93 - + + + +
94 - + + + +
95 - + + + +
JCM 3718 + + + + +
JCM 3724 + + + + +
ARU 01 + + + + +
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Appendix 16: Alignment of Ludlam_LT1 amplicon Sanger sequences
LT1_1       AAATTGGATGGAAAACCGGAGCTTTTACTAAATGGTGAAAGAATGACAATTATTCTTCCG 60
LT1_5       AAATTGGATGATAAGCCTGAAATTTTATTGAACGGAGAAAAAATAACGATTGTTCTTCCA 60
LT1_11      AAATTGGATGATAAGCCTGAAATTTTATTGAACGGAGAAAAAATAACGATTGTTCTTCCA 60
LT1_21      AAATTGGATGGAAAACCGGAGCTTTTACTAAATGGTGAAAGAATGACAATTATTCTTCCG 60
LT1_24      AAATTGGATGATAAGCCTGAAATTTTATTGAACGGAGAAAAAATAACGATTGTTCTTCCA 60
LT1_30      AAATTGGATGATAAGCCTGAAATTTTATTGAACGGAGAAAAAATAACGATTGTTCTTCCA 60
LT1_39      AAATTGGATGGAAAACCGGAGCTTTTACTAAATGGTGAAAGAATGACAATTATTCTTCCG 60
LT1_40      AAATTGGATGGAAAACCGGAGCTTTTACTAAATGGTGAAAGAATGACAATTATTCTTCCG 60
LT1_41      AAATTGGATGATAAGCCTGAAATTTTATTGAACGGAGAAAAAATAACGATTGTTCTTCCA 60
LT1_42      AAATTGGATGATAAGCCTGAAATTTTATTGAACGGAGAAAAAATAACGATTGTTCTTCCA 60
LT1_52      AAATTGGATGATAAGCCTGAAATTTTATTGAACGGAGAAAAAATAACGATTGTTCTTCCA 60
LT1_59      AAATTGGATGATAAGCCTGAAATTTTATTGAACGGAGAAAAAATAACGATTGTTCTTCCA 60
**********  ** ** **  ***** * ** ** **** *** ** *** *******
LT1_1       GATGGAACTTCAAAAACAGGAACTGCTATAGAAATTGCAAACTATGTTCAGGGAGAAATG 120
LT1_5       GATGGAACTTCTAAAACAGGAACGGTTCCGGAACTTGCAGAATATGTGAAAGAGGAAATG 120
LT1_11      GATGGAACTTCTAAAACAGGAACGGTTCCGGAACTTGCAGAATATGTGAAAGAGGAAATG 120
LT1_21      GATGGAACTTCAAAAACAGGAACTGCTATAGAAATTGCAAACTATGTTCAGGGAGAAATG 120
LT1_24      GATGGAACTTCTAAAACAGGAACGGTTCCGGAACTTGCAGAATATGTGAAAGAGGAAATG 120
LT1_30      GATGGAACTTCTAAAACAGGAACGGTTCCGGAACTTGCAGAATATGTGAAAGAGGAAATG 120
LT1_39      GATGGAACTTCAAAAACAGGAACTGCTATAGAAATTGCAAACTATGTTCAGGGAGAAATG 120
LT1_40      GATGGAACTTCAAAAACAGGAACTGCTATAGAAATTGCAAACTATGTTCAGGGAGAAATG 120
LT1_41      GATGGAACTTCTAAAACAGGAACGGTTCCGGAACTTGCAGAATATGTGAAAGAGGAAATG 120
LT1_42      GATGGAACTTCTAAAACAGGAACGGTTCCGGAACTTGCAGAATATGTGAAAGAGGAAATG 120
LT1_52      GATGGAACTTCTAAAACAGGAACGGTTCCGGAACTTGCAGAATATGTGAAAGAGGAAATG 120
LT1_59      GATGGAACTTCTAAAACAGGAACGGTTCCGGAACTTGCAGAATATGTGAAAGAGGAAATG 120
*********** *********** * *   *** ***** * *****  * *  ******
LT1_1       AAAAAATTAGAGGAAAAATTACCGAAAGGATTTAAAGCTTTTTCAGAAGGATTGAGTGGA 180
LT1_5       AAAAAACTGGAAGCAAAATTACCGACAGGATTTAAAGCTTTTTCTGAAGGATTAAGCGGA 180
LT1_11      AAAAAACTGGAAGCAAAATTACCGACAGGATTTAAAGCTTTTTCTGAAGGATTAAGCGGA 180
LT1_21      AAAAAATTAGAGGAAAAATTACCGAAAGGATTTAAAGCTTTTTCAGAAGGATTGAGTGGA 180
LT1_24      AAAAAACTGGAAGCAAAATTACCGACAGGATTTAAAGCTTTTTCTGAAGGATTAAGCGGA 180
LT1_30      AAAAAACTGGAAGCAAAATTACCGACAGGATTTAAAGCTTTTTCTGAAGGATTAAGCGGA 180
LT1_39      AAAAAATTAGAGGAAAAATTACCGAAAGGATTTAAAGCTTTTTCAGAAGGATTGAGTGGA 180
LT1_40      AAAAAATTAGAGGAAAAATTACCGAAAGGATTTAAAGCTTTTTCAGAAGGATTGAGTGGA 180
LT1_41      AAAAAACTGGAAGCAAAATTACCGACAGGATTTAAAGCTTTTTCTGAAGGATTAAGCGGA 180
LT1_42      AAAAAACTGGAAGCAAAATTACCGACAGGATTTAAAGCTTTTTCTGAAGGATTAAGCGGA 180
LT1_52      AAAAAACTGGAAGCAAAATTACCGACAGGATTTAAAGCTTTTTCTGAAGGATTAAGCGGA 180
LT1_59      AAAAAACTGGAAGCAAAATTACCGACAGGATTTAAAGCTTTTTCTGAAGGATTAAGCGGA 180
****** * ** * *********** ****************** ******** ** ***
LT1_1       CTGATTAAAGAAACTTTGAATTTTACAGGAGTAGGAAATTATGCAAATTTTCACACTTTT 240
LT1_5       TTGTTAAAAGAAAGCTTGGCTTTTACAGGAGTAGGAAATTATGCAAATTTCCATACATTT 240
LT1_11      TTGTTAAAAGAAAGCTTGGCTTTTACAGGAGTAGGAAATTATGCAAATTTCCATACATTT 240
LT1_21      CTGATTAAAGAAACTTTGAATTTTACAGGAGTAGGAAATTATGCAAATTTTCACACTTTT 240
LT1_24      TTGTTAAAAGAAAGCTTGGCTTTTACAGGAGTAGGAAATTATGCAAATTTCCATACATTT 240
LT1_30      TTGTTAAAAGAAAGCTTGGCTTTTACAGGAGTAGGAAATTATGCAAATTTCCATACATTT 240
LT1_39      CTGATTAAAGAAACTTTGAATTTTACAGGAGTAGGAAATTATGCAAATTTTCACACTTTT 240
LT1_40      CTGATTAAAGAAACTTTGAATTTTACAGGAGTAGGAAATTATGCAAATTTTCACACTTTT 240
LT1_41      TTGTTAAAAGAAAGCTTGGCTTTTACAGGAGTAGGAAATTATGCAAATTTCCATACATTT 240
LT1_42      TTGTTAAAAGAAAGCTTGGCTTTTACAGGAGTAGGAAATTATGCAAATTTCCATACATTT 240
LT1_52      TTGTTAAAAGAAAGCTTGGCTTTTACAGGAGTAGGAAATTATGCAAATTTCCATACATTT 240
LT1_59      TTGTTAAAAGAAAGCTTGGCTTTTACAGGAGTAGGAAATTATGCAAATTTCCATACATTT 240
** * *******  ***  ****************************** ** ** ***
LT1_1       ACCTCTTCCGGAGCTAATGGAGAAAGAGATGTCTCTTCTGTGGGAGGAGCT 291
LT1_5       ACCTCGGCAGGAACCAATGCAAAAAGAGATACTTCTTCTGTGGGAGGAGCT 291
LT1_11      ACCTCGGCAGGAACCAATGCAAAAAGAGATACTTCTTCTGTGGGAGGAGCT 291
LT1_21      ACCTCTTCCGGAGCTAATGGAGAAAGAGATGTCTCTTCTGTGGGAGGAGCT 291
LT1_24      ACCTCGGCAGGAACCAATGCAAAAAGAGATACTTCTTCTGTGGGAGGAGCT 291
LT1_30      ACCTCGGCAGGAACCAATGCAAAAAGAGATACTTCTTCTGTGGGAGGAGCT 291
LT1_39      ACCTCTTCCGGAGCTAATGGAGAAAGAGATGTCTCTTCTGTGGGAGGAGCT 291
LT1_40      ACCTCTTCCGGAGCTAATGGAGAAAGAGATGTCTCTTCTGTGGGAGGAGCT 291
LT1_41      ACCTCGGCAGGAACCAATGCAAAAAGAGATACTTCTTCTGTGGGAGGAGCT 291
LT1_42      ACCTCGGCAGGAACCAATGCAAAAAGAGATACTTCTTCTGTGGGAGGAGCT 291
LT1_52      ACCTCGGCAGGAACCAATGCAAAAAGAGATACTTCTTCTGTGGGAGGAGCT 291
LT1_59      ACCTCGGCAGGAACCAATGCAAAAAGAGATACTTCTTCTGTGGGAGGAGCT 291
*****  * *** * **** * ********   ******************
Appendix Figure 6: Clustal Omega alignment of Ludlam_LT1 amplicon Sanger sequence data. lktA forward and reverse
PCR primer binding positions are highlighted in yellow. Those not highlighted in yellow lack homology and did not amplify
lktA product.
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Appendix 17: Full results of the HL-60 cell line cytotoxicity assay
Appendix Table 7: Full results of the HL-60 cell line cytotoxicity assay. All viabilities are expressed as a percentage of the
negative control.

















100.00 86.79 81.77 76.39 64.82 86.49 98.28
100.00 86.72 84.96 81.02 61.71 85.13 97.86
100.00 87.82 84.83 83.07 63.33 86.82 99.14
JCM
3724
100.00 79.60 66.12 55.74 NT 90.34 96.25
100.00 80.87 74.03 60.30 NT 80.27 94.15
100.00 77.27 73.56 62.49 NT 82.46 95.19
ARU 01
100.00 91.61 88.76 86.06 74.09 90.49 98.64
100.00 92.46 91.22 87.75 74.26 84.49 97.71
100.00 92.18 87.32 85.82 70.55 80.05 99.07
NT= Not Tested
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Appendix 18: Full statistical analysis of the HL-60 cell line cytotoxicity
assay, using Fisher’s least significant differences test








125 µg/ml 150 µg/ml 0.029
150 µg/ml 175 µg/ml 0.016
175 µg/ml 250 µg/ml 0.000






125 µg/ml 150 µg/ml 0.011
150 µg/ml 175 µg/ml 0.001






125 µg/ml 150 µg/ml 0.137
150 µg/ml 175 µg/ml 0.197
175 µg/ml 250 µg/ml 0.000
Positive control Flow through 0.000
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Appendix 19: Full results of the cytotoxicity assay with human donor
white blood cells
Appendix Table 9: Full results of the cytotoxicity assay with human donor white blood cells. All viabilities are expressed as























100.00 81.77 85.87 66.12 73.40 88.76 91.22 91.77
100.00 84.96 89.83 74.03 77.46 91.22 92.21 77.82
100.00 84.83 92.84 73.56 74.56 87.32 92.26 80.33
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Appendix 20: Statistical analysis of the cytotoxicity assay with human
donor white blood cells, using Fisher’s least significant differences
test
Appendix Table 10: Statistical analysis of the cytotoxicity assay with human donor white blood cells, using Fisher’s least
significant differences test.
Treatment groups Significance
JCM 3718 HL-60 JCM 3718 WBCs 0.067
JCM 3724 HL-60 JCM 3724 WBCs 0.193
ARU 01 HL-60 ARU 01 WBCs 0.345
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Appendix 21. Clustal Omega alignment of ecotin DNA sequences
Eco_42      ATGAAAAAATGTATTTATGCTATCGGCTTACTGTTTTCTTTTTCCGTCAGTGTTTTTGCA 60
Eco_11      ATGAAAAAATGTATTTATGCTATCGGCTTACTGTTTTCTTTTTCCGTCAGTGTTTTTGCA 60
Eco_41      ATGAAAAAATGTATTTATGCTATCGGCTTACTGTTTTCTTTTTCCGTCAGTGTTTTTGCA 60
Eco_52      ATGAAAAAATGTATTTATGCTATCGGCTTACTGTTTTCTTTTTCCGTCAGTGTTTTTGCA 60
JCM3718     ATGAAAAAATGTATTTATGCTATCGGCTTACTGTTTTCTTTTTCCGTCAGTGTTTTTGCA 60
Eco_01      ATGAAAAAATGTATTTATGCTATCGGCTTACTGTTTTCTTTTTCCGTCAGTGTTTTTGCA 60
Eco_05      ATGAAAAAATGTATTTATGCTATCGGCTTACTGTTTTCTTTTTCCGTCAGTGTTTTTGCA 60
Eco_21      ATGAAAAAATGTATTTATGCTATCGGCTTACTGTTTTCTTTTTCCGTCAGTGTTTTTGCA 60
Eco_24      ATGAAAAAATGTATTTATGCTATCGGCTTACTGTTTTCTTTTTCCGTCAGTGTTTTTGCA 60
Eco_30      ATGAAAAAATGTATTTATGCTATCGGCTTACTGTTTTCTTTTTCCGTCAGTGTTTTTGCA 60
Eco_39      ATGAAAAAATGTATTTATGCTATCGGCTTACTGTTTTCTTTTTCCGTCAGTGTTTTTGCA 60
Eco_40      ATGAAAAAATGTATTTATGCTATCGGCTTACTGTTTTCTTTTTCCGTCAGTGTTTTTGCA 60
JCM3724     ATGAAAAAATGTATTTATGCTATCGGCTTACTGTTTTCTTTTTCCGTCAGTGTTTTTGCA 60
ARU01 ATGAAAAAATGTATTTATGCTATCGGCTTACTGTTTTCTTTTTCCGTCAGTGTTTTTGCA 60
Eco_59      ATGAAAAAATGTATTTATGCTATCGGCTTACTGTTTTCTTTTTCCGTCAGTGTTTTTGCA 60
************************************************************
Eco_42      ATGCAGCATCCGGATATGAACTTGGAAATATATCCTAAGGCAAAACAAGGCATGAAGANG 120
Eco_11      ATGCAGCATCCGGATATGAACTTGGAAATATATCCTAAGGCAAAACAAGGCATGAAGAAG 120
Eco_41      ATGCAGCATCCGGATATGAACTTGGAAATATATCCTAAGGCAAAACAAGGCATGAAGAAG 120
Eco_52      ATGCAGCATCCGGATATGAACTTGGAAATATATCCTAAGGCAAAACAAGGCATGAAGAAG 120
JCM3718     ATGCAGCATCCGGATATGAACTTGGAAATATATCCTAAGGCAAAACAAGGCATGAAGAAG 120
Eco_01      ATGCAGCATCCGGATATGAACTTGGAAATATATCCTAAGGCAAAACAAGGCATGAAGAAG 120
Eco_05      ATGCAGCATCCGGATATGAACTTGGAAATATATCCTAAGGCAAAACAAGGCATGAAGAAG 120
Eco_21      ATGCAGCATCCGGATATGAACTTGGAAATATATCCTAAGGCAAAACAAGGCATGAAGAAG 120
Eco_24      ATGCAGCATCCGGATATGAACTTGGAAATATATCCTAAGGCAAAACAAGGCATGAAGAAG 120
Eco_30      ATGCAGCATCCGGATATGAACTTGGAAATATATCCTAAGGCAAAACAAGGCATGAAGAAG 120
Eco_39      ATGCAGCATCCGGATATGAACTTGGAAATATATCCTAAGGCAAAACAAGGCATGAAGAAG 120
Eco_40      ATGCAGCATCCGGATATGAACTTGGAAATATATCCTAAGGCAAAACAAGGCATGAAGAAG 120
JCM3724     ATGCAGCATCCGGATATGAACTTGGAAATATATCCTAAGGCAAAACAAGGCATGAAGAAG 120
ARU01 ATGCAGCATCCGGATATGAACTTGGAAATATATCCTAAGGCAAAACAAGGCATGAAGAAG 120
Eco_59      ATGCAGCATCCGGATATGAACTTGGAAATATATCCTAAGGCAAAACAAGGCATGAAGAAG 120
********************************************************** *
Eco_42      GTTGTGTATCTTTTAGAGAAAAAAGAAAAAGAAGAAGACTATAAATTGGAAATAAAATTT 180
Eco_11      GTTGTGTATCTTTTAGAGAAAAAAGAAAAAGAAGAAGACTATAAATTGGAAATAAAATTT 180
Eco_41      GTTGTGTATCTTTTAGAGAAAAAAGAAAAAGAAGAAGACTATAAATTGGAAATAAAATTT 180
Eco_52      GTTGTGTATCTTTTAGAGAAAAAAGAAAAAGAAGAAGACTATAAATTGGAAATAAAATTT 180
JCM3718     GTTGTGTATCTTTTAGAGAAAAAAGAAAAAGAAGAAGACTATAAATTGGAAATAAAATTT 180
Eco_01      GTTGTGTATCTTTTAGAGAAAAAAGAAAAAGAAGAAGACTATAAATTGGAAATAAAATTT 180
Eco_05      GTTGTGTATCTTTTAGAGAAAAAAGAAAAAGAAGAAGACTATAAATTGGAAATAAAATTT 180
Eco_21      GTTGTGTATCTTTTAGAGAAAAAAGAAAAAGAAGAAGACTATAAATTGGAAATAAAATTT 180
Eco_24      GTTGTGTATCTTTTAGAGAAAAAAGAAAAAGAAGAAGACTATAAATTGGAAATAAAATTT 180
Eco_30      GTTGTGTATCTTTTAGAGAAAAAAGAAAAAGAAGAAGACTATAAATTGGAAATAAAATTT 180
Eco_39      GTTGTGTATCTTTTAGAGAAAAAAGAAAAAGAAGAAGACTATAAATTGGAAATAAAATTT 180
Eco_40      GTTGTGTATCTTTTAGAGAAAAAAGAAAAAGAAGAAGACTATAAATTGGAAATAAAATTT 180
JCM3724     GTTGTGTATCTTTTAGAGAAAAAAGAAAAAGAAGAAGACTATAAATTGGAAATAAAATTT 180
ARU01 GTTGTGTATCTTTTAGAGAAAAAAGAAAAAGAAGAAGACTATAAATTGGAAATAAAATTT 180
Eco_59      GTTGTGTATCTTTTAGAGAAAAAAGAAAAAGAAGAAGACTATAAATTGGAAATAAAATTT 180
************************************************************
Eco_42      GGAAAAGATCTTGTTGTAGATGATAATCTTCNTCACTTTTTAGGAGGAAAGCTGGAAGAG 240
Eco_11      GGAAAAGACCTTGTTGTAGATGATAATCTTCATCACTTTTTAGGAGGAAAGCTGGAAGAG 240
Eco_41      GGAAAAGACCTTGTTGTAGATGATAATCTTCATCACTTTTTAGGAGGAAAGCTGGAAGAG 240
Eco_52      GGAAAAGACCTTGTTGTAGATGATAATCTTCATCACTTTTTAGGAGGAAAGCTGGAAGAG 240
JCM3718     GGAAAAGACCTTGTTGTAGATGATAATCTTCATCACTTTTTAGGAGGAAAGCTGGAAGAG 240
Eco_01      GGAAAAGATCTTGTTGTAGATGATAATCTTCATCACTTTTTAGGAGGAAAGCTGGAAGAG 240
Eco_05      GGAAAAGATCTTGTTGTAGATGATAATCTTCATCACTTTTTAGGAGGAAAGCTGGAAGAG 240
Eco_21      GGAAAAGATCTTGTTGTAGATGATAATCTTCATCACTTTTTAGGAGGAAAGCTGGAAGAG 240
Eco_24      GGAAAAGATCTTGTTGTAGATGATAATCTTCATCACTTTTTAGGAGGAAAGCTGGAAGAG 240
Eco_30      GGAAAAGATCTTGTTGTAGATGATAATCTTCATCACTTTTTAGGAGGAAAGCTGGAAGAG 240
Eco_39      GGAAAAGATCTTGTTGTAGATGATAATCTTCATCACTTTTTAGGAGGAAAGCTGGAAGAG 240
Eco_40      GGAAAAGATCTTGTTGTAGATGATAATCTTCATCACTTTTTAGGAGGAAAGCTGGAAGAG 240
JCM3724     GGAAAAGATCTTGTTGTAGATGATAATCTTCATCACTTTTTAGGAGGAAAGCTGGAAGAG 240
ARU01 GGAAAAGATCTTGTTGTAGATGATAATCTTCATCACTTTTTAGGAGGAAAGCTGGAAGAG 240
Eco_59      GGAAAAGATCTTGTTGTAGATGATAATCTTCATCACTTTTTAGGAGGAAAGCTGGAAGAG 240
******** ********************** ****************************
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Eco_42      AAAGATGTAGAAGGTTGGGGCTATCCTTATTACATTTTTTCAGGAGATTCTCAAATGGCA 300
Eco_11      AAAGATGTAAAAGGTTGGGGCTATCCTTATTACATTTTTTCAGGAGATTCTCAAATGGCA 300
Eco_41      AAAGATGTAAAAGGTTGGGGCTATCCTTATTACATTTTTTCAGGAGATTCTCAAATGGCA 300
Eco_52      AAAGATGTAAAAGGTTGGGGCTATCCTTATTACATTTTTTCAGGAGATTCTCAAATGGCA 300
JCM3718     AAAGATGTAAAAGGTTGGGGCTATCCTTATTACATTTTTTCAGGAGATTCTCAAATGGCA 300
Eco_01      AAAGATGTAGAAGGTTGGGGCTATCCTTATTACATTTTTTCAGGAGATTCTCAAATGGCA 300
Eco_05      AAAGATGTAGAAGGTTGGGGCTATCCTTATTACATTTTTTCAGGAGATTCTCAAATGGCA 300
Eco_21      AAAGATGTAGAAGGTTGGGGCTATCCTTATTACATTTTTTCAGGAGATTCTCAAATGGCA 300
Eco_24      AAAGATGTAGAAGGTTGGGGCTATCCTTATTACATTTTTTCAGGAGATTCTCAAATGGCA 300
Eco_30      AAAGATGTAGAAGGTTGGGGCTATCCTTATTACATTTTTTCAGGAGATTCTCAAATGGCA 300
Eco_39      AAAGATGTAGAAGGTTGGGGCTATCCTTATTACATTTTTTCAGGAGATTCTCAAATGGCA 300
Eco_40      AAAGATGTAGAAGGTTGGGGCTATCCTTATTACATTTTTTCAGGAGATTCTCAAATGGCA 300
JCM3724     AAAGATGTAGAAGGTTGGGGCTATCCTTATTACATTTTTTCAGGAGATTCTCAAATGGCA 300
ARU01 AAAGATGTAGAAGGTTGGGGCTATCCTTATTACATTTTTTCAGGAGATTCTCAAATGGCA 300
Eco_59      AAAGATGTAGAAGGTTGGGGCTATCCTTATTACATTTTTTCAGGAGATTCTCAAATGGCA 300
********* **************************************************
Eco_42      CAAACTTTAANGGCGTTTCCTTTAGGAAGTGAACGAGAAAAAAGAGTATATTATCCCACA 360
Eco_11      CAAACTTTAATGGCGTTTCCTTTAGGAAGTGAACGAGAAAAAAGAGTATATTATCCCACA 360
Eco_41      CAAACTTTAATGGCGTTTCCTTTAGGAAGTGAACGAGAAAAAAGAGTATATTATCCCACA 360
Eco_52      CAAACTTTAATGGCGTTTCCTTTAGGAAGTGAACGAGAAAAAAGAGTATATTATCCCACA 360
JCM3718     CAAACTTTAATGGCGTTTCCTTTAGGAAGTGAACGAGAAAAAAGAGTATATTATCCCACA 360
Eco_01      CAAACTTTAATGGCGTTTCCTTTAGGAAGTGAACGAGAAAAAAGAGTATATTATCCCACA 360
Eco_05      CAAACTTTAATGGCGTTTCCTTTAGGAAGTGAACGAGAAAAAAGAGTATATTATCCCACA 360
Eco_21      CAAACTTTAATGGCGTTTCCTTTAGGAAGTGAACGAGAAAAAAGAGTATATTATCCCACA 360
Eco_24      CAAACTTTAATGGCGTTTCCTTTAGGAAGTGAACGAGAAAAAAGAGTATATTATCCCACA 360
Eco_30      CAAACTTTAATGGCGTTTCCTTTAGGAAGTGAACGAGAAAAAAGAGTATATTATCCCACA 360
Eco_39      CAAACTTTAATGGCGTTTCCTTTAGGAAGTGAACGAGAAAAAAGAGTATATTATCCCACA 360
Eco_40      CAAACTTTAATGGCGTTTCCTTTAGGAAGTGAACGAGAAAAAAGAGTATATTATCCCACA 360
JCM3724     CAAACTTTAATGGCGTTTCCTTTAGGAAGTGAACGAGAAAAAAGAGTATATTATCCCACA 360
ARU01 CAAACTTTAATGGCGTTTCCTTTAGGAAGTGAACGAGAAAAAAGAGTATATTATCCCACA 360
Eco_59      CAAACTTTAATGGCGTTTCCTTTAGGAAGTGAACGAGAAAAAAGAGTATATTATCCCACA 360
********** *************************************************
Eco_42      GCTACGAAAATATTGCCTTATCATTCAAAACTTCCTTTGGTTTTATATGTTCCGGAAGAT 420
Eco_11      GCTACGAAAATATTGCCTTATCATTCAAAACTTCCTTTGGTTTTATATGTTCCGGAAGAT 420
Eco_41      GCTACGAAAATATTGCCTTATCATTCAAAACTTCCTTTGGTTTTATATGTTCCGGAAGAT 420
Eco_52      GCTACGAAAATATTGCCTTATCATTCAAAACTTCCTTTGGTTTTATATGTTCCGGAAGAT 420
JCM3718     GCTACGAAAATATTGCCTTATCATTCAAAACTTCCTTTGGTTTTATATGTTCCGGAAGAT 420
Eco_01      GCTACGAAAATATTGCCTTATCATTCAAAACTTCCTTTGGTTTTATATGTTCCGGAAGAT 420
Eco_05      GCTACGAAAATATTGCCTTATCATTCAAAACTTCCTTTGGTTTTATATGTTCCGGAAGAT 420
Eco_21      GCTACGAAAATATTGCCTTATCATTCAAAACTTCCTTTGGTTTTATATGTTCCGGAAGAT 420
Eco_24      GCTACGAAAATATTGCCTTATCATTCAAAACTTCCTTTGGTTTTATATGTTCCGGAAGAT 420
Eco_30      GCTACGAAAATATTGCCTTATCATTCAAAACTTCCTTTGGTTTTATATGTTCCGGAAGAT 420
Eco_39      GCTACGAAAATATTGCCTTATCATTCAAAACTTCCTTTGGTTTTATATGTTCCGGAAGAT 420
Eco_40      GCTACGAAAATATTGCCTTATCATTCAAAACTTCCTTTGGTTTTATATGTTCCGGAAGAT 420
JCM3724     GCTACGAAAATATTGCCTTATCATTCAAAACTTCCTTTGGTTTTATATGTTCCGGAAGAT 420
ARU01 GCTACGAAAATATTGCCTTATCATTCAAAACTTCCTTTGGTTTTATATGTTCCGGAAGAT 420
Eco_59      GCTACGAAAATATTGCCTTATCATTCAAAACTTCCTTTGGTTTTATATGTTCCGGAAGAT 420
************************************************************
Eco_42      GTGAAGGTAGAAGTATCTCTTTGGAATCGAATGCAGGAAATCAAAGAAGTTTCTCGTTAA 480
Eco_11      GTGAAGGTAGAAGTATCTCTTTGGAATCGAATGCAGGAAATCAAAGAAGTTTCTCGTTAA 480
Eco_41      GTGAAGGTAGAAGTATCTCTTTGGAATCGAATGCAGGAAATCAAAGAAGTTTCTCGTTAA 480
Eco_52      GTGAAGGTAGAAGTATCTCTTTGGAATCGAATGCAGGAAATCAAAGAAGTTTCTCGTTAA 480
JCM3718     GTGAAGGTAGAAGTATCTCTTTGGAATCGAATGCAGGAAATCAAAGAAGTTTCTCGTTAA 480
Eco_01      GTGAAGGTAGAAGTATCTCTTTGGAATCGAATGCAGGAAATCAAAGAAGTTTCTCGTTAA 480
Eco_05      GTGAAGGTAGAAGTATCTCTTTGGAATCGAATGCAGGAAATCAAAGAAGTTTCTCGTTAA 480
Eco_21      GTGAAGGTAGAAGTATCTCTTTGGAATCGAATGCAGGAAATCAAAGAAGTTTCTCGTTAA 480
Eco_24      GTGAAGGTAGAAGTATCTCTTTGGAATCGAATGCAGGAAATCAAAGAAGTTTCTCGTTAA 480
Eco_30      GTGAAGGTAGAAGTATCTCTTTGGAATCGAATGCAGGAAATCAAAGAAGTTTCTCGTTAA 480
Eco_39      GTGAAGGTAGAAGTATCTCTTTGGAATCGAATGCAGGAAATCAAAGAAGTTTCTCGTTAA 480
Eco_40      GTGAAGGTAGAAGTATCTCTTTGGAATCGAATGCAGGAAATCAAAGAAGTTTCTCGTTAA 480
JCM3724     GTGAAGGTAGAAGTATCTCTTTGGAATCGAATGCAGGAAATCAAAGAAGTTTCTCGTTAA 480
ARU01 GTGAAGGTAGAAGTATCTCTTTGGAATCGAATGCAGGAAATCAAAGAAGTTTCTCGTTAA 480
Eco_59      GTGAAGGTAGAAGTATCTCTTTGGAATCGAATGTAGGAAATCAAAGAAGTTTCTCGTTAA 480
********************************* **************************
Appendix Figure 7: Clustal Omega alignment of ecotin DNA sequences of the first 12 strains from the clinical collection,
and strains JCM 3718, JCM 3724 and ARU 01.
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Appendix 22. Plasmid map and sequence of pET-16b
Appendix Figure 8: Plasmid map of pET-16b vector.
Appendix Figure 9: DNA sequence of the cloning/expression region of vector pET-16b.
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Appendix 23. Plasmid sequence of pET-19b
Appendix Figure 10: DNA sequence of the cloning/expression region of vector pET-19b, including an enterokinase cleavage
site in place of the Factor Xa cleavage site present in pET-16b.
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Appendix 24. Callibration curve for AFC
AFC calibration curve










Appendix Figure 11: Calibration curve for 7-Amino-4-(trifluoromethyl)coumarin (AFC). Ten concentrations were tested,
covering the full range of fluorescence generated from the substrate standard curves. The AFC calibration curve has an
equation of y=244626x and an R squared value of 0.9978.
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Appendix 25. Human plasma kallikrein (HPK) RFU readings




0.5 mM 0.25 mM 0.125 mM 0.06 mM 0.03 mM 0.015 mM
0 0.00 0.00 0.00 0.00 0.00 0.00
1 502.23 387.95 187.82 124.54 53.08 28.88
2 944.47 758.78 400.45 239.76 116.66 63.83
3 1402.98 1152.92 615.32 369.83 183.12 100.69
4 1857.98 1559.57 861.20 511.80 251.62 135.66
5 2303.78 1949.89 1136.03 649.48 317.51 169.61
6 2738.23 2319.86 1399.72 782.38 382.08 203.93
7 3159.66 2671.34 1634.09 908.09 443.43 237.48
8 3565.63 3013.27 1853.90 1029.18 502.89 270.04
9 3961.50 3343.21 2064.39 1144.81 559.98 301.45
10 4344.97 3661.04 2267.55 1257.16 615.23 332.13
11 4713.54 3968.56 2462.09 1364.66 668.57 361.83
12 5062.98 4263.88 2650.69 1468.97 720.07 390.53
13 5396.19 4547.22 2830.15 1569.18 769.01 418.32
14 5711.41 4820.72 3005.64 1665.34 816.78 445.27
15 6012.46 5084.33 3173.68 1758.52 862.95 471.71
16 6303.00 5339.29 3336.28 1847.57 907.04 496.82
17 6584.13 5581.94 3492.45 1934.72 949.70 521.39
18 6859.10 5820.54 3643.40 2017.69 990.75 545.04
19 7125.29 6048.48 3790.46 2098.67 1030.10 567.83
20 7388.89 6266.99 3931.15 2175.66 1068.32 590.09
21 7664.26 6482.32 4068.33 2250.93 1104.45 611.45
22 7970.73 6686.01 4199.11 2322.75 1140.45 632.27
23 8320.06 6885.34 4327.26 2392.58 1174.28 652.38
24 8694.00 7075.54 4449.47 2459.20 1206.63 671.70
25 9052.66 7264.36 4569.30 2523.85 1238.86 690.39
26 9423.72 7444.28 4683.51 2586.06 1268.61 708.58
27 9772.61 7615.70 4794.83 2646.39 1297.71 726.28
28 10120.45 7783.29 4901.07 2702.78 1325.62 743.17
29 10449.32 7945.26 5004.14 2758.69 1352.98 759.48
30 10729.96 8102.58 5104.08 2813.27 1378.90 775.74
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0.5 mM 0.25 mM 0.125 mM 0.06 mM 0.03 mM 0.015 mM
0 0.00 0.00 0.00 0.00 0.00 0.00
1 331.83 265.46 192.19 71.63 35.26 17.87
2 622.00 523.49 384.72 146.64 73.15 35.91
3 968.13 799.20 591.10 228.48 113.75 57.10
4 1324.57 1078.84 797.32 310.38 154.29 81.86
5 1681.06 1355.95 997.55 390.52 194.53 105.86
6 2037.81 1629.45 1184.39 470.93 235.95 128.27
7 2384.17 1895.97 1361.22 556.42 280.42 149.58
8 2727.80 2158.91 1535.18 652.31 329.82 170.36
9 3064.03 2409.28 1706.46 758.25 384.62 190.86
10 3403.49 2652.79 1875.42 865.02 436.59 211.14
11 3735.09 2894.18 2040.24 962.95 483.37 231.10
12 4071.56 3132.03 2193.77 1051.75 527.47 250.77
13 4404.29 3372.88 2342.74 1135.76 569.78 269.79
14 4740.37 3624.79 2490.91 1217.90 611.27 288.55
15 5079.19 3886.08 2655.59 1297.90 651.63 306.85
16 5416.13 4145.69 2856.14 1374.52 691.25 324.87
17 5741.61 4405.22 3072.92 1448.87 729.58 342.40
18 6060.54 4660.25 3258.29 1520.83 767.06 359.62
19 6369.85 4928.92 3413.98 1591.04 803.51 376.29
20 6667.65 5200.94 3556.98 1659.41 838.81 392.63
21 6956.42 5438.80 3694.17 1726.09 873.29 408.52
22 7227.91 5650.54 3827.47 1789.88 906.48 424.22
23 7489.04 5851.10 3954.29 1852.42 938.86 439.40
24 7739.52 6047.85 4078.88 1913.06 970.74 454.37
25 7994.61 6236.61 4200.27 1971.42 1001.40 468.89
26 8269.29 6418.94 4316.19 2028.71 1030.85 483.20
27 8574.05 6600.43 4427.28 2084.30 1059.86 497.09
28 8904.51 6775.53 4536.72 2138.10 1088.17 510.60
29 9228.53 6944.67 4639.93 2190.65 1115.22 523.64
30 9623.73 7109.77 4742.09 2241.79 1141.75 536.82
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0.5 mM 0.25 mM 0.125 mM 0.06 mM 0.03 mM 0.015 mM
0 0.00 0.00 0.00 0.00 0.00 0.00
1 247.78 210.31 105.65 48.58 23.77 14.33
2 545.81 440.03 227.82 111.80 53.04 30.09
3 882.66 696.43 371.43 180.44 87.34 47.33
4 1220.36 957.55 520.62 249.34 121.45 66.35
5 1547.42 1213.92 668.07 318.27 156.52 84.85
6 1870.10 1465.82 810.34 388.60 195.64 103.12
7 2194.28 1711.14 946.16 464.30 236.09 120.93
8 2520.36 1947.73 1079.44 547.87 278.60 138.60
9 2849.26 2178.70 1210.68 637.96 320.08 155.84
10 3178.82 2403.95 1340.97 728.63 360.07 173.05
11 3502.90 2625.16 1473.19 813.21 398.87 189.88
12 3820.65 2842.65 1601.64 891.34 436.97 206.55
13 4125.77 3066.18 1726.52 966.27 474.40 222.74
14 4416.60 3309.53 1845.80 1039.60 511.09 238.69
15 4691.26 3575.51 1952.26 1111.18 547.06 254.58
16 4956.32 3837.39 2068.64 1180.91 582.35 269.99
17 5216.88 4081.89 2217.86 1249.38 616.86 285.11
18 5476.87 4303.45 2412.92 1315.61 650.47 299.90
19 5733.93 4531.40 2604.15 1380.04 683.55 314.52
20 5992.10 4775.17 2755.68 1443.07 715.91 328.86
21 6245.98 5025.01 2886.14 1504.89 747.28 342.85
22 6495.13 5248.30 3009.67 1564.61 777.89 356.51
23 6719.52 5453.04 3128.95 1623.09 808.19 369.91
24 6980.46 5647.13 3246.33 1680.15 837.33 383.11
25 7288.28 5826.39 3362.78 1735.16 866.39 396.13
26 7687.97 6007.56 3474.29 1789.62 894.18 408.85
27 8127.55 6186.91 3583.64 1842.26 921.19 421.20
28 8511.51 6358.33 3689.45 1893.45 947.90 433.59
29 8817.79 6527.27 3792.43 1944.27 973.91 445.41
30 9083.76 6689.05 3893.47 1993.14 999.16 457.12
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0.5 mM 0.25 mM 0.125 mM 0.06 mM 0.03 mM 0.015 mM
0 0.00 0.00 0.00 0.00 0.00 0.00
1 202.43 154.67 79.30 36.82 17.18 9.64
2 463.75 348.54 183.29 86.32 35.83 20.60
3 760.39 568.23 305.41 146.57 58.83 32.62
4 1074.00 790.59 434.21 210.32 85.63 45.35
5 1397.19 1008.16 562.80 276.55 116.73 60.37
6 1715.18 1222.78 687.34 349.35 150.04 77.21
7 2026.16 1434.39 807.67 423.34 183.43 94.12
8 2333.56 1638.34 925.47 493.59 215.93 109.47
9 2642.48 1842.56 1042.20 560.26 247.62 123.77
10 2950.82 2044.10 1157.87 625.53 278.47 137.98
11 3254.70 2244.31 1271.79 689.46 309.02 151.86
12 3547.80 2443.81 1379.69 752.90 339.07 165.48
13 3828.88 2640.12 1479.47 814.62 368.43 178.93
14 4097.39 2840.22 1579.40 875.56 397.42 192.24
15 4352.25 3055.42 1696.40 934.95 425.63 205.31
16 4607.17 3278.92 1848.94 993.60 453.55 218.43
17 4865.00 3501.04 2008.86 1050.86 480.94 231.12
18 5125.84 3711.56 2142.51 1107.10 507.78 243.56
19 5390.52 3924.93 2260.82 1161.99 534.49 256.09
20 5645.85 4152.75 2373.65 1215.71 560.61 268.23
21 5902.94 4372.95 2484.00 1268.38 586.03 280.22
22 6159.61 4570.75 2592.72 1320.10 611.08 292.10
23 6404.48 4756.17 2698.37 1370.62 635.75 303.66
24 6674.53 4936.11 2802.78 1420.01 659.94 315.20
25 6986.83 5112.00 2904.60 1468.64 683.69 326.56
26 7341.09 5282.84 3004.18 1515.73 707.12 337.53
27 7702.85 5451.83 3101.15 1562.32 729.94 348.48
28 8036.73 5613.82 3197.01 1607.81 752.38 359.22
29 8322.44 5774.86 3289.94 1652.13 774.37 369.80
30 8581.79 5932.68 3380.86 1696.00 796.22 380.22
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0.5 mM 0.25 mM 0.125 mM 0.06 mM 0.03 mM 0.015 mM
0 0.00 0.00 0.00 0.00 0.00 0.00
1 167.02 119.55 57.49 22.69 11.68 6.31
2 417.13 282.96 145.48 58.20 27.81 15.41
3 688.72 463.79 249.90 95.71 46.03 25.52
4 963.02 649.11 356.08 134.09 64.62 35.43
5 1242.05 834.77 460.35 170.57 83.85 45.18
6 1520.16 1018.79 561.46 207.16 102.74 54.83
7 1791.33 1199.73 661.19 248.47 121.51 64.96
8 2056.43 1378.24 760.45 297.65 140.45 75.45
9 2321.45 1555.13 858.76 356.14 159.94 86.74
10 2588.51 1732.40 953.58 418.31 179.56 98.19
11 2851.47 1908.75 1047.21 476.89 201.65 109.79
12 3113.07 2083.12 1142.79 529.61 225.31 120.42
13 3371.30 2258.64 1239.89 576.43 250.67 130.41
14 3623.59 2432.75 1337.31 621.77 276.20 140.22
15 3874.34 2611.00 1433.08 666.21 299.33 150.00
16 4122.95 2789.16 1527.63 709.97 320.15 159.67
17 4372.27 2969.23 1619.98 753.81 340.19 169.30
18 4618.95 3155.34 1711.88 796.48 359.71 178.70
19 4867.30 3341.62 1801.22 838.36 379.00 188.14
20 5119.24 3515.02 1889.27 880.24 397.89 197.45
21 5370.87 3681.81 1976.50 921.06 416.61 206.70
22 5623.93 3844.16 2061.75 961.45 435.14 215.75
23 5873.34 4003.88 2144.98 1000.95 453.48 224.79
24 6119.88 4160.65 2227.53 1039.80 471.54 233.65
25 6381.72 4311.81 2309.21 1078.29 489.84 242.52
26 6658.18 4460.37 2388.24 1116.21 507.25 251.17
27 6956.29 4607.23 2465.93 1153.46 524.64 259.81
28 7244.23 4749.82 2542.92 1190.19 541.88 268.20
29 7497.64 4889.30 2618.25 1226.57 558.90 276.42
30 7733.40 5028.88 2692.92 1262.11 575.64 284.61
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Appendix 26. Lineweaver-Burk plot for kallikrein data
Lineweaver-Burk plot













Appendix Figure 12: A Lineweaver-Burk plot showing characteristics of competitive inhibition. Y intercept was set at 0.466
resulting in a shared Vmax of 0.406 µmol min-1. The x intercept is equal to -1/Km and the y intercept is equal to 1/Vmax.
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Appendix 27. Human neutrophil elastase (HNE) absorbance readings




0.5 mM 0.25 mM 0.125 mM 0.06 mM 0.03 mM 0.015 mM
0 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000
1 0.0060 0.0047 0.0040 0.0027 0.0010 0.0010
2 0.0120 0.0090 0.0083 0.0060 0.0023 0.0017
3 0.0167 0.0130 0.0120 0.0097 0.0040 0.0023
4 0.0227 0.0170 0.0157 0.0127 0.0047 0.0033
5 0.0270 0.0207 0.0187 0.0157 0.0050 0.0043
6 0.0320 0.0250 0.0227 0.0183 0.0060 0.0043
7 0.0370 0.0287 0.0260 0.0207 0.0070 0.0057
8 0.0423 0.0323 0.0290 0.0230 0.0080 0.0060
9 0.0470 0.0360 0.0320 0.0253 0.0090 0.0070
10 0.0507 0.0397 0.0347 0.0280 0.0100 0.0077
11 0.0550 0.0427 0.0377 0.0303 0.0110 0.0080
12 0.0587 0.0457 0.0400 0.0323 0.0117 0.0087
13 0.0627 0.0490 0.0423 0.0347 0.0127 0.0093
14 0.0663 0.0527 0.0447 0.0367 0.0133 0.0097
15 0.0697 0.0563 0.0470 0.0380 0.0137 0.0107
16 0.0730 0.0577 0.0493 0.0400 0.0147 0.0107
17 0.0763 0.0607 0.0513 0.0413 0.0153 0.0117
18 0.0800 0.0643 0.0540 0.0430 0.0157 0.0117
19 0.0823 0.0660 0.0560 0.0450 0.0167 0.0123
20 0.0853 0.0683 0.0577 0.0460 0.0173 0.0127
21 0.0883 0.0707 0.0597 0.0473 0.0177 0.0127
22 0.0913 0.0727 0.0613 0.0493 0.0183 0.0133
23 0.0943 0.0757 0.0633 0.0507 0.0187 0.0137
24 0.0967 0.0773 0.0650 0.0517 0.0193 0.0140
25 0.1000 0.0800 0.0667 0.0530 0.0197 0.0140
26 0.1020 0.0823 0.0680 0.0547 0.0203 0.0147
27 0.1043 0.0847 0.0697 0.0557 0.0207 0.0150
28 0.1067 0.0863 0.0713 0.0563 0.0213 0.0150
29 0.1090 0.0883 0.0727 0.0577 0.0213 0.0153
30 0.1117 0.0900 0.0740 0.0590 0.0220 0.0160
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0.5 mM 0.25 mM 0.125 mM 0.06 mM 0.03 mM 0.015 mM
0 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000
1 0.0047 0.0030 0.0020 0.0017 0.0003 0.0010
2 0.0100 0.0063 0.0047 0.0030 0.0010 0.0003
3 0.0133 0.0093 0.0070 0.0047 0.0013 0.0013
4 0.0180 0.0130 0.0093 0.0057 0.0013 0.0013
5 0.0220 0.0160 0.0110 0.0067 0.0013 0.0017
6 0.0267 0.0187 0.0130 0.0083 0.0020 0.0017
7 0.0303 0.0217 0.0157 0.0093 0.0023 0.0020
8 0.0343 0.0240 0.0173 0.0107 0.0030 0.0027
9 0.0383 0.0267 0.0187 0.0120 0.0037 0.0027
10 0.0417 0.0297 0.0203 0.0130 0.0033 0.0030
11 0.0453 0.0323 0.0217 0.0137 0.0040 0.0027
12 0.0490 0.0347 0.0233 0.0147 0.0040 0.0030
13 0.0520 0.0370 0.0247 0.0160 0.0043 0.0033
14 0.0553 0.0393 0.0263 0.0180 0.0047 0.0033
15 0.0583 0.0420 0.0280 0.0193 0.0050 0.0037
16 0.0610 0.0440 0.0297 0.0183 0.0050 0.0037
17 0.0640 0.0460 0.0307 0.0190 0.0050 0.0040
18 0.0670 0.0483 0.0320 0.0197 0.0050 0.0040
19 0.0697 0.0503 0.0330 0.0203 0.0053 0.0040
20 0.0720 0.0523 0.0343 0.0210 0.0057 0.0047
21 0.0750 0.0543 0.0387 0.0217 0.0057 0.0043
22 0.0773 0.0563 0.0367 0.0220 0.0060 0.0047
23 0.0797 0.0583 0.0377 0.0230 0.0060 0.0047
24 0.0817 0.0603 0.0380 0.0237 0.0060 0.0050
25 0.0843 0.0617 0.0393 0.0240 0.0060 0.0050
26 0.0863 0.0637 0.0420 0.0250 0.0060 0.0053
27 0.0883 0.0657 0.0413 0.0253 0.0060 0.0053
28 0.0907 0.0673 0.0417 0.0270 0.0060 0.0057
29 0.0927 0.0690 0.0423 0.0263 0.0063 0.0053
30 0.0943 0.0710 0.0437 0.0267 0.0060 0.0057
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0.5 mM 0.25 mM 0.125 mM 0.06 mM 0.03 mM 0.015 mM
0 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000
1 0.0013 0.0003 0.0013 0.0007 0.0000 0.0000
2 0.0033 0.0013 0.0027 0.0010 0.0007 0.0000
3 0.0037 0.0017 0.0033 0.0013 0.0007 0.0000
4 0.0053 0.0023 0.0043 0.0020 0.0007 0.0000
5 0.0063 0.0027 0.0050 0.0020 0.0007 0.0000
6 0.0070 0.0037 0.0060 0.0020 0.0020 0.0000
7 0.0087 0.0040 0.0067 0.0020 0.0027 0.0000
8 0.0097 0.0043 0.0070 0.0023 0.0020 0.0000
9 0.0107 0.0050 0.0077 0.0023 0.0010 0.0000
10 0.0113 0.0053 0.0080 0.0023 0.0013 0.0000
11 0.0120 0.0057 0.0083 0.0023 0.0017 0.0000
12 0.0130 0.0060 0.0087 0.0027 0.0013 0.0000
13 0.0137 0.0067 0.0090 0.0027 0.0007 0.0000
14 0.0143 0.0073 0.0093 0.0023 0.0007 0.0000
15 0.0150 0.0077 0.0097 0.0023 0.0007 0.0000
16 0.0153 0.0077 0.0097 0.0027 0.0007 0.0000
17 0.0163 0.0083 0.0103 0.0027 0.0007 0.0000
18 0.0167 0.0087 0.0103 0.0027 0.0007 0.0000
19 0.0173 0.0090 0.0107 0.0030 0.0007 0.0003
20 0.0177 0.0097 0.0107 0.0030 0.0007 0.0000
21 0.0183 0.0097 0.0107 0.0030 0.0007 0.0000
22 0.0190 0.0100 0.0107 0.0030 0.0007 0.0000
23 0.0197 0.0107 0.0110 0.0033 0.0010 0.0000
24 0.0197 0.0107 0.0117 0.0033 0.0007 0.0000
25 0.0203 0.0113 0.0117 0.0030 0.0007 0.0000
26 0.0207 0.0117 0.0117 0.0033 0.0007 0.0000
27 0.0207 0.0120 0.0117 0.0033 0.0010 0.0000
28 0.0213 0.0120 0.0117 0.0033 0.0007 0.0000
29 0.0217 0.0123 0.0120 0.0033 0.0007 0.0000
30 0.0223 0.0130 0.0123 0.0033 0.0007 0.0000
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0.5 mM 0.25 mM 0.125 mM 0.06 mM 0.03 mM 0.015 mM
0 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000
1 0.0000 0.0000 0.0000 0.0000 -0.0003 0.0000
2 0.0000 0.0000 0.0000 0.0000 0.0000 0.0003
3 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000
4 0.0003 0.0000 0.0000 0.0000 0.0000 0.0000
5 0.0007 0.0000 -0.0003 0.0000 0.0000 0.0000
6 0.0003 0.0000 0.0000 0.0000 0.0000 0.0000
7 0.0010 0.0000 0.0000 0.0000 0.0000 0.0000
8 0.0010 0.0003 0.0000 0.0000 0.0000 0.0000
9 0.0010 0.0000 0.0000 0.0000 0.0000 0.0000
10 0.0010 0.0000 0.0000 0.0000 0.0000 0.0000
11 0.0010 0.0003 0.0000 0.0000 0.0000 0.0000
12 0.0010 0.0007 0.0000 0.0003 0.0000 0.0000
13 0.0010 0.0007 0.0000 0.0000 0.0000 0.0000
14 0.0013 0.0010 0.0000 0.0003 0.0000 0.0000
15 0.0020 0.0007 0.0000 0.0003 0.0000 0.0000
16 0.0020 0.0013 0.0000 0.0003 0.0000 0.0000
17 0.0020 0.0010 0.0000 0.0003 0.0000 0.0000
18 0.0020 0.0010 0.0003 0.0003 0.0000 0.0000
19 0.0023 0.0007 0.0010 0.0003 0.0000 0.0000
20 0.0027 0.0013 0.0010 0.0003 0.0000 0.0000
21 0.0030 0.0010 0.0010 0.0003 0.0000 0.0000
22 0.0030 0.0010 0.0010 0.0003 0.0000 0.0000
23 0.0030 0.0010 0.0010 0.0003 0.0000 0.0000
24 0.0037 0.0020 0.0010 0.0010 0.0000 0.0000
25 0.0037 0.0020 0.0010 0.0010 0.0000 0.0000
26 0.0040 0.0020 0.0010 0.0010 0.0000 0.0000
27 0.0040 0.0020 0.0010 0.0010 0.0000 0.0000
28 0.0040 0.0020 0.0010 0.0010 0.0000 0.0000
29 0.0047 0.0020 0.0010 0.0010 0.0000 0.0000
30 0.0050 0.0020 0.0010 0.0010 0.0000 0.0000
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0.5 mM 0.25 mM 0.125 mM 0.06 mM 0.03 mM 0.015 mM
0 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000
1 0.0000 0.0000 0.0000 -0.0010 -0.0010 0.0000
2 0.0000 0.0000 0.0000 0.0000 0.0000 -0.0003
3 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000
4 0.0000 0.0000 0.0000 0.0000 0.0000 -0.0003
5 0.0003 0.0000 0.0000 0.0000 0.0000 0.0000
6 0.0007 0.0000 0.0000 0.0000 0.0000 -0.0003
7 0.0010 0.0000 0.0000 0.0000 0.0000 -0.0003
8 0.0010 0.0000 0.0000 0.0000 0.0000 -0.0003
9 0.0013 0.0007 0.0000 0.0000 0.0000 -0.0003
10 0.0010 0.0007 0.0000 0.0000 0.0000 -0.0003
11 0.0010 0.0007 0.0003 0.0003 0.0003 0.0000
12 0.0010 0.0007 0.0003 0.0000 0.0000 -0.0003
13 0.0017 0.0007 0.0003 0.0000 0.0000 -0.0003
14 0.0020 0.0007 0.0007 0.0000 0.0000 -0.0003
15 0.0020 0.0007 0.0000 0.0000 0.0000 0.0000
16 0.0020 0.0013 0.0007 0.0000 0.0000 -0.0003
17 0.0027 0.0010 0.0007 0.0000 0.0000 -0.0003
18 0.0030 0.0010 0.0007 0.0000 0.0000 -0.0003
19 0.0030 0.0010 0.0007 0.0003 0.0003 0.0000
20 0.0030 0.0013 0.0007 0.0000 0.0000 -0.0003
21 0.0030 0.0017 0.0007 0.0000 0.0000 -0.0003
22 0.0030 0.0017 0.0007 0.0003 0.0003 0.0000
23 0.0030 0.0017 0.0007 0.0003 0.0003 -0.0003
24 0.0030 0.0017 0.0007 0.0003 0.0003 -0.0003
25 0.0030 0.0017 0.0007 0.0000 0.0000 -0.0003
26 0.0030 0.0017 0.0007 0.0003 0.0003 -0.0003
27 0.0030 0.0017 0.0007 0.0003 0.0003 0.0000
28 0.0033 0.0020 0.0007 0.0003 0.0003 0.0000
29 0.0030 0.0017 0.0007 0.0000 0.0000 -0.0003
30 0.0033 0.0017 0.0007 0.0003 0.0003 -0.0003
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Appendix 28. Thrombin time, prothrombin time and activated partial
thromboplastin time results
Appendix Table 21: Fold prolongation values of thrombin time, prothrombin time and activated partial thromboplastin









0 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00
0.06 NT NT NT NT NT NT 2.06 1.71 1.45
0.125 NT NT NT NT NT NT 4.72 7.39 2.24
0.25 1.02 1.00 0.98 1.94 1.84 1.98 7.93 8.69 7.14
0.5 1.08 0.98 1.02 2.89 3.34 3.17 38.48 14.48 13.18
0.75 1.09 1.02 1.07 3.77 4.00 3.66 45.93 15.84 19.61
1 1.11 1.02 1.16 4.51 4.72 4.57 59.17 28.20 28.14
2 1.13 1.04 1.18 6.92 6.28 6.49 66.21 22.19 32.28
